


List of Eligible Studies and Literature Flow Diagram

Systematic Review – Diagnosis of Attention-Deficit/Hyperactivity Disorder in Adults

| | |
|--|-----|
| Literature Flow Diagram..... | 2 |
| Eligibility Criteria | 3 |
| List of Included Studies | 4 |
| Background Papers | 15 |
| List of Excluded Publications with Reasons for Exclusion | 37 |
| On Order/Not Retrieved Yet..... | 241 |

Literature Flow Diagram



Eligibility Criteria

| | Inclusion Criteria | Exclusion Criteria |
|---------------------|---|--|
| Population | Adults 18 years and older with symptoms of ADHD and without the diagnosis of ADHD | Individuals 17 years of age or younger unless findings are reported separately for older participants |
| Intervention | Any ADHD diagnostic tool used for the diagnosis of ADHD in adults | Studies not reporting on diagnostic performance; non-English language questionnaires and interview guides |
| Comparator | Confirmation of diagnosis by a specialist (reference standard), such as a psychologist, psychiatrist or other healthcare provider using a well validated and reliable process of confirming a clinical diagnosis of ADHD | Comparison to diagnosis with another diagnostic instrument |
| Outcome | Diagnostic accuracy (e.g., sensitivity, specificity, accuracy, area under the curve, positive predictive value, negative predictive value, likelihood ratios, false positives, false negatives) or impact associated with diagnosing ADHD | Provider opinion of tests, cost without performance measures |
| Timing | Diagnostic follow-up must be completed before treatment is initiated | Any other timing |
| Setting | Primary or specialty care settings, including telehealth | Settings where diagnosis is for nonclinical or not research purposes |
| Study Design | • Diagnostic accuracy studies | <ul style="list-style-type: none"> • Editorials, nonsystematic reviews, letters, case series, pre-post studies, case reports. • Systematic reviews are not eligible for inclusion but will be retained for reference mining. |

Commented [MOU1]: What is your definition of a diagnostic tool? Some tools claim to measure only part of the ADHD diagnosis (i.e., the symptom count criteria, the impairment criteria, the age of onset criteria). Some like the DIVA or SCID would claim to be assessing the entirety of the diagnosis. Still others are claiming to make a diagnosis based on non-DSM criteria (i.e., they aren't actually assessing ADHD criteria but some sort of proxy for it like on a cognitive task). This definition and fleshing out these issues with specificity is critical to the success of this review.

Commented [MOU2]: Research team or can a community diagnosis count? Should only be research team because community are known to be inaccurate.

Commented [MOU3]: This is being made into an artificial monolith. An impairment tool should not predict the diagnosis. Most diagnoses of ADHD are made by a collection of measures put together for their various purposes. It should be accuracy of measuring the part of the diagnosis the tool is supposed to measure.

Commented [MOU4]: This might need to be clarified if a research setting validating the scale that is not conducted in a real world primary or specialty care clinic can be included.

Included Studies

List of Included Studies

Key Question 1: What is the comparative diagnostic accuracy, unintended consequences, and impact of tools that can be used in the primary care practice setting or by specialists to diagnose ADHD among adults?

- a. How does the comparative diagnostic accuracy of these tools vary by clinical setting, including primary care or specialty clinic, or patient characteristics, including, age, gender, or other risk factors associated with ADHD?

Studies meeting eligibility criteria for key question 1.

1. Abramson DA, White DJ, Rhoads T, et al. Cross-validating the Dot Counting Test Among an Adult ADHD Clinical Sample and Analyzing the Effect of ADHD Subtype and Comorbid Psychopathology. *Assessment*. 2023 Mar;30(2):264-73. doi: 10.1177/10731911211050895. PMID: 34643101.
2. Adamou M, Jones SL, Marks L, et al. Efficacy of Continuous Performance Testing in Adult ADHD in a Clinical Sample Using QbTest. *J Atten Disord*. 2022 Sep;26(11):1483-91. doi: 10.1177/10870547221079798. PMID: 35255743.
3. Aita SL, Sofko CA, Hill BD, et al. Utility of the Personality Assessment Inventory in detecting feigned Attention-Deficit/Hyperactivity Disorder (ADHD): The Feigned Adult ADHD index. *Arch Clin Neuropsychol*. 2018 Nov 1;33(7):832-44. doi: 10.1093/arclin/acx113. PMID: 29186287.
4. Amen DG, Henderson TA, Newberg A. SPECT Functional Neuroimaging Distinguishes Adult Attention Deficit Hyperactivity Disorder From Healthy Controls in Big Data Imaging Cohorts. *Front Psychiatry*. 2021;12:725788. doi: 10.3389/fpsy.2021.725788. PMID: 34899414.
5. Andrikopoulos D, Vassiliou G, Fatouros P, et al. Machine learning-enabled detection of attention-deficit/hyperactivity disorder with multimodal physiological data: a case-control study. *BMC Psychiatry*. 2024;24(1). doi: 10.1186/s12888-024-05987-7.
6. Bakare B, Jordanova V. Psychometric Properties of a Brief Screening Measure for ADHD in Adults. *Int J Psychol Res (Medellin)*. 2020 Jul-Dec;13(2):78-88. doi: 10.21500/20112084.4511. PMID: 33329880.
7. Bastiaens L, Galus J. Comparison of the Adult ADHD Self Report Scale Screener for DSM-IV and DSM-5 in a Dually Diagnosed Correctional Population. *Psychiatr Q*. 2018 Jun;89(2):505-10. doi: 10.1007/s11126-017-9553-4. PMID: 29270886.
8. Becke M, Tucha L, Butzbach M, et al. Feigning Adult ADHD on a Comprehensive Neuropsychological Test Battery: An Analogue Study. *Int J Environ Res Public Health*. 2023 Feb 24;20(5). doi: 10.3390/ijerph20054070. PMID: 36901080.
9. Berger C, Lev A, Braw Y, et al. Detection of Feigned ADHD Using the MOXO-d-CPT. *J Atten Disord*. 2021 May;25(7):1032-47. doi: 10.1177/1087054719864656. PMID: 31364437.

Commented [MOU5]: It looks like you excluded all of the work in the MTA follow-up because of "Exclude Intervention." This is odd. This study in particular:

Sibley MH, Swanson JM, Arnold LE, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. *J Child Psychol Psychiatry*. 2017 Jun;58(6):655-62. doi: 10.1111/jcpp.12620. PMID: 27642116. *Exclude-Intervention*

Is exactly what you are looking for? There is no intervention component to the MTA follow-up study. It was just recruited from the original MTA study. The data was 16 years after treatment and the research had nothing to do with the treatment the kids had received as part of the MTA acute study 16 years ago. By this definition you would need to exclude a lot of the longitudinal follow-up samples that have done key work in this area (like Barkley's) that originally started out as clinical samples that were then followed. What is the point of that inclusion criteria? How are you envisioning it is invalidating your findings? Instead it is kicking out a large portion of the literature.

Much of the important work here is on self vs. informant reports, retrospective reporting, and chronicity of symptoms over time, and our ability to measure them. You are going to have a very incomplete review if you exclude that entire literature...Pittsburgh ADHD longitudinal study, MTA, Barkley, BGals, Biederman, and more all came from initially treated samples as children that then grew up into adults and were studied decades later in a different context....

Included Studies

10. Biederman J, Hammerness P, Sadeh B, et al. Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder. *Psychol Med*. 2017 May;47(7):1259-70. doi: 10.1017/s0033291716003329. PMID: 28065167.
11. Brunkhorst-Kanaan N, Verdenhalven M, Kittel-Schneider S, et al. The Quantified Behavioral Test-A Confirmatory Test in the Diagnostic Process of Adult ADHD? *Front Psychiatry*. 2020;11:216. doi: 10.3389/fpsyt.2020.00216. PMID: 32265761.
12. Brunkhorst-Kanaan N, Verdenhalven M, Kittel-Schneider S, et al. The Quantified Behavioral Test—A Confirmatory Test in the Diagnostic Process of Adult ADHD? *Frontiers in Psychiatry*. 2020;11. doi: 10.3389/fpsyt.2020.00216.
13. Chaim-Avancini TM, Doshi J, Zanetti MV, et al. Neurobiological support to the diagnosis of ADHD in stimulant-naïve adults: pattern recognition analyses of MRI data. *Acta Psychiatr Scand*. 2017 Dec;136(6):623-36. doi: 10.1111/acps.12824. PMID: 29080396.
14. Chen T, Antoniou G, Adamou M, et al. Automatic diagnosis of attention deficit hyperactivity disorder using machine learning. *Applied Artificial Intelligence*. 2021;35(9):657-69. doi: 10.1080/08839514.2021.1933761.
15. Chiasson JP, Stavro K, Rizkallah É, et al. Questioning the specificity of ASRS-v1.1 to accurately detect ADHD in substance abusing populations. *J Atten Disord*. 2012 Nov;16(8):661-3. doi: 10.1177/1087054711425768. PMID: 22049481.
16. Cohen AL, Shapiro SK. Exploring the performance differences on the flicker task and the conners' continuous performance test in adults with ADHD. *J Atten Disord*. 2007 Jul;11(1):49-63. doi: 10.1177/1087054706292162. PMID: 17606772.
17. Cook CM, Bolinger E, Suhr J. Further Validation of the Conner's Adult Attention Deficit/Hyperactivity Rating Scale Infrequency Index (CII) for Detection of Non-Credible Report of Attention Deficit/Hyperactivity Disorder Symptoms. *Arch Clin Neuropsychol*. 2016 Jun;31(4):358-64. doi: 10.1093/arclin/acw015. PMID: 27193367.
18. Courrégé SC, Skeel RL, Feder AH, et al. The ADHD Symptom Infrequency Scale (ASIS): A novel measure designed to detect adult ADHD simulators. *Psychol Assess*. 2019 Jul;31(7):851-60. doi: 10.1037/pas0000706. PMID: 30802120.
19. Dakwar E, Mahony A, Pavlicova M, et al. The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders. *J Clin Psychiatry*. 2012 Nov;73(11):e1372-8. doi: 10.4088/JCP.12m07895. PMID: 23218166.
20. Dunlop BW, Wu R, Helms K. Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder. *Behav Sci (Basel)*. 2018 Mar 29;8(4). doi: 10.3390/bs8040037. PMID: 29596328.
21. Edebol H, Helldin L, Norlander T. Objective Measures of Behavior Manifestations in Adult ADHD and Differentiation from Participants with Bipolar II Disorder, Borderline Personality Disorder, Participants with Disconfirmed ADHD as Well as Normative Participants. *Clin Pract Epidemiol Ment Health*. 2012;8:134-43. doi: 10.2174/1745017901208010134. PMID: 23166565.

Included Studies

22. Edebol H, Helldin L, Norlander T. Measuring adult Attention Deficit Hyperactivity Disorder using the Quantified Behavior Test Plus. *Psych J*. 2013 Apr;2(1):48-62. doi: 10.1002/pchj.17. PMID: 24294490.
23. Eich D, Angst J, Frei A, et al. A new rating scale for adult ADHD based on the Symptom Checklist 90 (SCL-90-R). *Eur Arch Psychiatry Clin Neurosci*. 2012 Sep;262(6):519-28. doi: 10.1007/s00406-011-0288-1. PMID: 22212725.
24. Elbaum T, Braw Y, Lev A, et al. Attention-Deficit/Hyperactivity Disorder (ADHD): Integrating the MOXO-dCPT with an Eye Tracker Enhances Diagnostic Precision. *Sensors (Basel)*. 2020 Nov 9;20(21). doi: 10.3390/s20216386. PMID: 33182303.
25. Emser TS, Johnston BA, Steele JD, et al. Assessing ADHD symptoms in children and adults: evaluating the role of objective measures. *Behav Brain Funct*. 2018 May 18;14(1):11. doi: 10.1186/s12993-018-0143-x. PMID: 29776429.
26. Erhardt D, Epstein JN, Conners CK, et al. Self-ratings of ADHD symptoms in adults: II. Reliability, validity, and diagnostic sensitivity. *Journal of Attention Disorders*. 1999;3(3):153-8. doi: 10.1177/108705479900300304.
27. Faraone SV, Biederman J, Feighner JA, et al. Assessing symptoms of attention deficit hyperactivity disorder in children and adults: which is more valid? *J Consult Clin Psychol*. 2000 Oct;68(5):830-42. PMID: 11068969.
28. Finley JA, Brooks JM, Nili AN, et al. Multivariate examination of embedded indicators of performance validity for ADHD evaluations: A targeted approach. *Appl Neuropsychol Adult*. 2023 Sep 13:1-14. doi: 10.1080/23279095.2023.2256440. PMID: 37703401.
29. Finley JA, Cerny BM, Brooks JM, et al. Cross-validating the Clinical Assessment of Attention Deficit-Adult symptom validity scales for assessment of attention deficit/hyperactivity disorder in adults. *J Clin Exp Neuropsychol*. 2024 Mar;46(2):111-23. doi: 10.1080/13803395.2023.2283940. PMID: 37994688.
30. Fuermaier ABM, Tucha O, Koerts J, et al. The development of an embedded figures test for the detection of feigned attention deficit hyperactivity disorder in adulthood. *PLoS ONE*. 2016;11(10). doi: 10.1371/journal.pone.0164297.
31. Gift TE, Reimherr ML, Marchant BK, et al. Wender Utah Rating Scale: Psychometrics, clinical utility and implications regarding the elements of ADHD. *J Psychiatr Res*. 2021 Mar;135:181-8. doi: 10.1016/j.jpsychires.2021.01.013. PMID: 33493947.
32. Gillen WG. *The tova: Discriminant validity for adhd and depression*. US: ProQuest Information & Learning; 2003.
33. Grogan K, Gormley CI, Rooney B, et al. Differential diagnosis and comorbidity of ADHD and anxiety in adults. *Br J Clin Psychol*. 2018 Mar;57(1):99-115. doi: 10.1111/bjc.12156. PMID: 28895146.
34. Groom MJ, Young Z, Hall CL, et al. The incremental validity of a computerised assessment added to clinical rating scales to differentiate adult ADHD from autism spectrum disorder.

Included Studies

- Psychiatry Res. 2016 Sep 30;243:168-73. doi: 10.1016/j.psychres.2016.06.042. PMID: 27400220.
35. Grünblatt E, Geissler J, Jacob CP, et al. Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood. *Atten Defic Hyperact Disord*. 2012 Jun;4(2):77-84. doi: 10.1007/s12402-012-0074-6. PMID: 22562805.
36. Hadas I, Hadar A, Lazarovits A, et al. Right prefrontal activation predicts ADHD and its severity: A TMS-EEG study in young adults. *Prog Neuropsychopharmacol Biol Psychiatry*. 2021 Dec 20;111:110340. doi: 10.1016/j.pnpbp.2021.110340. PMID: 33957168.
37. Harrison AG, Armstrong IT. Development of a symptom validity index to assist in identifying ADHD symptom exaggeration or feigning. *Clin Neuropsychol*. 2016 Feb;30(2):265-83. doi: 10.1080/13854046.2016.1154188. PMID: 26954905.
38. Harrison AG, Armstrong IT. Differences in performance on the test of variables of attention between credible vs. noncredible individuals being screened for attention deficit hyperactivity disorder. *Appl Neuropsychol Child*. 2020 Oct-Dec;9(4):314-22. doi: 10.1080/21622965.2020.1750115. PMID: 32301339.
39. Harrison AG, Edwards MJ, Parker KC. Identifying students faking ADHD: Preliminary findings and strategies for detection. *Arch Clin Neuropsychol*. 2007 Jun;22(5):577-88. doi: 10.1016/j.acn.2007.03.008. PMID: 17507198.
40. Harrison AG, Harrison KA, Armstrong IT. Discriminating malingered attention Deficit Hyperactivity Disorder from genuine symptom reporting using novel Personality Assessment Inventory validity measures. *Appl Neuropsychol Adult*. 2022 Jan-Feb;29(1):10-22. doi: 10.1080/23279095.2019.1702043. PMID: 31852281.
41. Harrison AG, Nay S, Armstrong IT. Diagnostic Accuracy of the Conners' Adult ADHD Rating Scale in a Postsecondary Population. *J Atten Disord*. 2019 Dec;23(14):1829-37. doi: 10.1177/1087054715625299. PMID: 26794674.
42. Houston JP, Kroenke K, Faries DE, et al. A provisional screening instrument for four common mental disorders in adult primary care patients. *Psychosomatics*. 2011 Jan-Feb;52(1):48-55. doi: 10.1016/j.psych.2010.11.011. PMID: 21300195.
43. Jiménez EC, Avella-García C, Kustow J, et al. Eye Vergence Responses During an Attention Task in Adults With ADHD and Clinical Controls. *J Atten Disord*. 2021 Jul;25(9):1302-10. doi: 10.1177/1087054719897806. PMID: 31959011.
44. Juselius Baghdassarian E, Nilsson Markhed M, Lindström E, et al. Auditory brainstem response (ABR) profiling tests as diagnostic support for schizophrenia and adult attention-deficit hyperactivity disorder (ADHD). *Acta Neuropsychiatr*. 2018 Jun;30(3):137-47. doi: 10.1017/neu.2017.24. PMID: 28803577.
45. Kaur S, Singh S, Arun P, et al. Phase Space Reconstruction of EEG Signals for Classification of ADHD and Control Adults. *Clin EEG Neurosci*. 2020 Mar;51(2):102-13. doi: 10.1177/1550059419876525. PMID: 31533446.

Included Studies

46. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. *Arch Gen Psychiatry*. 2010 Nov;67(11):1168-78. doi: 10.1001/archgenpsychiatry.2010.146. PMID: 21041618.
47. Khan H, Rauch AA, Obolsky MA, et al. A comparison of embedded validity indicators from the Stroop Color and Word Test among adults referred for clinical evaluation of suspected or confirmed attention-deficit/hyperactivity disorder. *Psychol Assess*. 2022 Jul;34(7):697-703. doi: 10.1037/pas0001137. PMID: 35357873.
48. Kiiski H, Rueda-Delgado LM, Bennett M, et al. Functional EEG connectivity is a neuromarker for adult attention deficit hyperactivity disorder symptoms. *Clin Neurophysiol*. 2020 Jan;131(1):330-42. doi: 10.1016/j.clinph.2019.08.010. PMID: 31506235.
49. Kim S, Baek JH, Kwon YJ, et al. Machine-learning-based diagnosis of drug-naive adult patients with attention-deficit hyperactivity disorder using mismatch negativity. *Transl Psychiatry*. 2021 Sep 18;11(1):484. doi: 10.1038/s41398-021-01604-3. PMID: 34537812.
50. Kingston DA, Ahmed AG, Gray J, et al. The assessment and diagnosis of attention deficit hyperactivity disorder in adult forensic psychiatric outpatients. *Journal of Psychopathology and Behavioral Assessment*. 2013;35(3):293-300. doi: 10.1007/s10862-013-9346-5.
51. Kovner R, Budman C, Frank Y, et al. Neuropsychological testing in adult attention deficit hyperactivity disorder: a pilot study. *Int J Neurosci*. 1998 Dec;96(3-4):225-35. doi: 10.3109/00207459808986470. PMID: 10069622.
52. Kumar G, Faden J, Steer RA. Screening for attention-deficit/hyperactivity disorder in adult inpatients with psychiatric disorders. *Psychol Rep*. 2011 Jun;108(3):815-24. doi: 10.2466/03.05.09.13.15.Pr0.108.3.815-824. PMID: 21879629.
53. Kwan D, Davin N, Harrison AG, et al. Determining cutoff scores on the Conners' adult ADHD rating scales that can definitively rule out the presence of ADHD in a clinical sample. *Appl Neuropsychol Adult*. 2024 Apr 3:1-11. doi: 10.1080/23279095.2024.2336204. PMID: 38569190.
54. Lancaster A, Liljequist L. Cross-validation of PAI scales for the detection of suspected ADHD in adults. *J Clin Psychol*. 2018 Oct;74(10):1710-8. doi: 10.1002/jclp.22620. PMID: 29574728.
55. Lee Booksh R, Pella RD, Singh AN, et al. Ability of college students to simulate ADHD on objective measures of attention. *J Atten Disord*. 2010 Jan;13(4):325-38. doi: 10.1177/1087054708329927. PMID: 19439760.
56. Lev A, Braw Y, Elbaum T, et al. Eye Tracking During a Continuous Performance Test: Utility for Assessing ADHD Patients. *J Atten Disord*. 2022 Jan;26(2):245-55. doi: 10.1177/1087054720972786. PMID: 33238787.
57. Lewandowski LJ, Lovett BJ, Coddling RS, et al. Symptoms of ADHD and academic concerns in college students with and without ADHD diagnoses. *J Atten Disord*. 2008 Sep;12(2):156-61. doi: 10.1177/1087054707310882. PMID: 18192625.

Included Studies

58. Liu YS, Cao B, Chokka PR. Screening for Adulthood ADHD and Comorbidities in a Tertiary Mental Health Center Using EarlyDetect: A Machine Learning-Based Pilot Study. *J Atten Disord*. 2023 Feb;27(3):324-31. doi: 10.1177/10870547221136228. PMID: 36367134.
59. Lovejoy DW, Ball JD, Keats M, et al. Neuropsychological performance of adults with attention deficit hyperactivity disorder (ADHD): diagnostic classification estimates for measures of frontal lobe/executive functioning. *J Int Neuropsychol Soc*. 1999 Mar;5(3):222-33. doi: 10.1017/s1355617799533055. PMID: 10217922.
60. Luderer M, Kaplan-Wickel N, Richter A, et al. Screening for adult attention-deficit/hyperactivity disorder in alcohol dependent patients: Underreporting of ADHD symptoms in self-report scales. *Drug Alcohol Depend*. 2019 Feb 1;195:52-8. doi: 10.1016/j.drugalcdep.2018.11.020. PMID: 30583265.
61. Luty J, Rajagopal Arokiadass SM, Sarkhel A, et al. Validation of self-report instruments to assess attention deficit hyperactivity disorder symptoms in adults attending community drug and alcohol services. *J Addict Med*. 2009 Sep;3(3):151-4. doi: 10.1097/ADM.0b013e31819343d0. PMID: 21769011.
62. Marchant BK, Reimherr FW, Wender PH, et al. Psychometric properties of the Self-Report Wender-Reimherr Adult Attention Deficit Disorder Scale. *Ann Clin Psychiatry*. 2015 Nov;27(4):267-77; quiz 78-82. PMID: 26554368.
63. Marshall P, Schroeder R, O'Brien J, et al. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. *Clin Neuropsychol*. 2010 Oct;24(7):1204-37. doi: 10.1080/13854046.2010.514290. PMID: 20845231.
64. Matte B, Rohde LA, Turner JB, et al. Reliability and Validity of Proposed DSM-5 ADHD Symptoms in a Clinical Sample of Adults. *J Neuropsychiatry Clin Neurosci*. 2015 Summer;27(3):228-36. doi: 10.1176/appi.neuropsych.13060137. PMID: 26067434.
65. Mattos P, Nazar BP, Tannock R. By the book: ADHD prevalence in medical students varies with analogous methods of addressing DSM items. *Braz J Psychiatry*. 2018 Oct-Dec;40(4):382-7. doi: 10.1590/1516-4446-2017-2429. PMID: 29451590.
66. McCann BS, Roy-Byrne P. Screening and diagnostic utility of self-report attention deficit hyperactivity disorder scales in adults. *Compr Psychiatry*. 2004 May-Jun;45(3):175-83. doi: 10.1016/j.comppsy.2004.02.006. PMID: 15124147.
67. Mehringer AM, Downey KK, Schuh LM, et al. The Assessment of Hyperactivity and Attention (AHA): development and preliminary validation of a brief self-assessment of adult ADHD. *J Atten Disord*. 2002 Mar;5(4):223-31. doi: 10.1177/108705470100500404. PMID: 11967478.
68. Morey LC. Examining a novel performance validity task for the detection of feigned attentional problems. *Appl Neuropsychol Adult*. 2019 May-Jun;26(3):255-67. doi: 10.1080/23279095.2017.1409749. PMID: 29251998.

Included Studies

69. Mostert JC, Onnink AMH, Klein M, et al. Cognitive heterogeneity in adult attention deficit/hyperactivity disorder: A systematic analysis of neuropsychological measurements. *Eur Neuropsychopharmacol*. 2015 Nov;25(11):2062-74. doi: 10.1016/j.euroneuro.2015.08.010. PMID: 26336867.
70. Mueller A, Candrian G, Grane VA, et al. Discriminating between ADHD adults and controls using independent ERP components and a support vector machine: a validation study. *Nonlinear Biomed Phys*. 2011 Jul 19;5:5. doi: 10.1186/1753-4631-5-5. PMID: 21771289.
71. Müller A, Vetsch S, Pershin I, et al. EEG/ERP-based biomarker/neuroalgorithms in adults with ADHD: Development, reliability, and application in clinical practice. *World J Biol Psychiatry*. 2020 Mar;21(3):172-82. doi: 10.1080/15622975.2019.1605198. PMID: 30990349.
72. Musso MW, Hill BD, Barker AA, et al. Utility of the Personality Assessment Inventory for Detecting Malingered ADHD in College Students. *J Atten Disord*. 2016 Sep;20(9):763-74. doi: 10.1177/1087054714548031. PMID: 25204276.
73. Nielsen NP, Wiig EH. AQT cognitive speed and processing efficiency differentiate adults with and without ADHD: a preliminary study. *Int J Psychiatry Clin Pract*. 2011 Sep;15(3):219-27. doi: 10.3109/13651501.2011.582538. PMID: 22121933.
74. Notzon DP, Pavlicova M, Glass A, et al. ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders. *J Atten Disord*. 2020 Sep;24(11):1487-92. doi: 10.1177/1087054716640109. PMID: 27033880.
75. Palma-Álvarez RF, Barta C, Carpentier PJ, et al. Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. *Revista de Psiquiatria y Salud Mental*. 2020. doi: 10.1016/j.rpsm.2020.04.013.
76. Palma-Álvarez RF, Barta C, Carpentier PJ, et al. Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. *Span J Psychiatry Ment Health*. 2023 Jan-Mar;16(1):11-5. doi: 10.1016/j.rpsm.2020.04.013. PMID: 32561156.
77. Palmer M, Fang Z, Hollocks MJ, et al. Screening for Attention Deficit Hyperactivity Disorder in Young Autistic Adults: The Diagnostic Accuracy of Three Commonly Used Questionnaires. *J Autism Dev Disord*. 2023 Oct 28. doi: 10.1007/s10803-023-06146-9. PMID: 37898580.
78. Paucke M, Stibbe T, Huang J, et al. Differentiation of ADHD and Depression Based on Cognitive Performance. *J Atten Disord*. 2021 May;25(7):920-32. doi: 10.1177/1087054719865780. PMID: 31409195.
79. Pettersson R, Söderström S, Nilsson KW. Diagnosing ADHD in Adults: An Examination of the Discriminative Validity of Neuropsychological Tests and Diagnostic Assessment Instruments. *J Atten Disord*. 2018 Sep;22(11):1019-31. doi: 10.1177/1087054715618788. PMID: 26681530.

Included Studies

80. Phillips MS, Wisinger AM, Lapitan-Moore FT, et al. Cross-validation of multiple embedded performance validity indices in the Rey Auditory Verbal Learning Test and Brief Visuospatial Memory Test-Revised in an adult attention deficit/hyperactivity disorder clinical sample. *Psychological Injury and Law*. 2023;16(1):27-35. doi: 10.1007/s12207-022-09443-3.
81. Poil SS, Bollmann S, Ghisleni C, et al. Age dependent electroencephalographic changes in attention-deficit/hyperactivity disorder (ADHD). *Clin Neurophysiol*. 2014 Aug;125(8):1626-38. doi: 10.1016/j.clinph.2013.12.118. PMID: 24582383.
82. Ponomarev VA, Mueller A, Candrian G, et al. Group Independent Component Analysis (gICA) and Current Source Density (CSD) in the study of EEG in ADHD adults. *Clin Neurophysiol*. 2014 Jan;125(1):83-97. doi: 10.1016/j.clinph.2013.06.015. PMID: 23871197.
83. Potts HE, Lewandowski LJ, Lovett BJ. Identifying Feigned ADHD in College Students: Comparing the Multidimensional ADHD Rating Scale to Established Validity Measures. *J Atten Disord*. 2022 Oct;26(12):1622-30. doi: 10.1177/10870547221092095. PMID: 35466735.
84. Quinn CA. Detection of malingering in assessment of adult ADHD. *Arch Clin Neuropsychol*. 2003 May;18(4):379-95. PMID: 14591453.
85. Ramachandran S, Holmes ER, Rosenthal M, et al. Development of the Subtle ADHD Malingering Screener. *Assessment*. 2019 Apr;26(3):524-34. doi: 10.1177/1073191118773881. PMID: 29749255.
86. Reimherr FW, Marchant BK, Gift TE, et al. Psychometric data and versions of the Wender Utah Rating Scale including the WURS-25 & WURS-45. *Data Brief*. 2021 Aug;37:107232. doi: 10.1016/j.dib.2021.107232. PMID: 34235235.
87. Reyes MM, Schneekloth TD, Hitschfeld MJ, et al. The Clinical Utility of ASRS-v1.1 for Identifying ADHD in Alcoholics Using PRISM as the Reference Standard. *J Atten Disord*. 2019 Aug;23(10):1119-25. doi: 10.1177/1087054716646450. PMID: 27138328.
88. Robinson A, Reed C, Davis K, et al. Settling the Score: Can CPT-3 Embedded Validity Indicators Distinguish Between Credible and Non-Credible Responders Referred for ADHD and/or SLD? *J Atten Disord*. 2023 Jan;27(1):80-8. doi: 10.1177/10870547221121781. PMID: 36113024.
89. Rogers R, Velsor SF, Donnelly JW, 2nd, et al. Embedded WAIS-IV Detection Strategies and Feigned Cognitive Impairment: An Investigation of Malingered ADHD. *Assessment*. 2021 Jan;28(1):44-56. doi: 10.1177/1073191120927788. PMID: 32495690.
90. Schneider H, Thornton JF, Freeman MA, et al. Conventional SPECT Versus 3D Thresholded SPECT Imaging in the Diagnosis of ADHD: A Retrospective Study. *J Neuropsychiatry Clin Neurosci*. 2014 Fall;26(4):335-43. doi: 10.1176/appi.neuropsych.12110280. PMID: 26037855.
91. Schreiber HE, Javorsky DJ, Robinson JE, et al. Rey-Osterrieth Complex Figure performance in adults with attention deficit hyperactivity disorder: a validation study of the Boston Qualitative Scoring System. *Clin Neuropsychol*. 1999 Nov;13(4):509-20. doi: 10.1076/1385-4046(199911)13:04;1-y;ft509. PMID: 10806464.

Included Studies

92. Selek S, Bulut M, Ocak AR, et al. Evaluation of total oxidative status in adult attention deficit hyperactivity disorder and its diagnostic implications. *J Psychiatr Res.* 2012 Apr;46(4):451-5. doi: 10.1016/j.jpsychires.2011.12.007. PMID: 22257388.
93. Shahaf G, Reches A, Pinchuk N, et al. Introducing a novel approach of network oriented analysis of ERPs, demonstrated on adult attention deficit hyperactivity disorder. *Clin Neurophysiol.* 2012 Aug;123(8):1568-80. doi: 10.1016/j.clinph.2011.12.010. PMID: 22261156.
94. Shepler DK, Callan PD. Differences in executive functioning between adults with ADHD and those diagnosed with other psychiatric diagnoses: Utility of the CTMT and the WAIS-IV. *Appl Neuropsychol Adult.* 2024 Sep-Oct;31(5):984-93. doi: 10.1080/23279095.2022.2102923. PMID: 35894662.
95. Singh P, White S, Saleem K, et al. Identifying ADHD in adults using the international personality disorder examination screening questionnaire. *J Ment Health.* 2015 Aug;24(4):236-41. doi: 10.3109/09638237.2015.1057331. PMID: 26445014.
96. Smith ST, Cox J, Mowle EN, et al. Intentional inattention: Detecting feigned attention-deficit/hyperactivity disorder on the Personality Assessment Inventory. *Psychol Assess.* 2017 Dec;29(12):1447-57. doi: 10.1037/pas0000435. PMID: 29227126.
97. Söderström S, Pettersson R, Nilsson KW. Quantitative and subjective behavioural aspects in the assessment of attention-deficit hyperactivity disorder (ADHD) in adults. *Nord J Psychiatry.* 2014 Jan;68(1):30-7. doi: 10.3109/08039488.2012.762940. PMID: 23527787.
98. Solanto MV, Etefia K, Marks DJ. The utility of self-report measures and the continuous performance test in the diagnosis of ADHD in adults. *CNS Spectr.* 2004 Sep;9(9):649-59. doi: 10.1017/s1092852900001929. PMID: 15337862.
99. Sollman MJ, Ranseen JD, Berry DT. Detection of feigned ADHD in college students. *Psychol Assess.* 2010 Jun;22(2):325-35. doi: 10.1037/a0018857. PMID: 20528060.
100. Spenceley LM, Wood WLM, Lovett BJ. Using the Woodcock-Johnson IV tests of cognitive abilities to detect feigned ADHD. *Appl Neuropsychol Adult.* 2022 May-Jun;29(3):324-32. doi: 10.1080/23279095.2020.1748631. PMID: 32320323.
101. Udal ABH, Stray LL, Pripp AH, et al. The Utility of Neuromuscular Assessment to Identify ADHD Among Patients with a Complex Symptom Picture. *Journal of attention disorders.* 2024;28(12):1577-88. doi: 10.1177/10870547241273102.
102. Unal M, O'Mahony E, Dunne C, et al. The clinical utility of three visual attention tests to distinguish adults with ADHD from normal controls. *Riv Psichiatr.* 2019 Sep-Oct;54(5):211-7. doi: 10.1708/3249.32185. PMID: 31657805.
103. Ustun B, Adler LA, Rudin C, et al. The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5. *JAMA Psychiatry.* 2017 May 1;74(5):520-7. doi: 10.1001/jamapsychiatry.2017.0298. PMID: 28384801.
104. van de Glind G, van den Brink W, Koeter MW, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder

Included Studies

- patients. *Drug Alcohol Depend.* 2013 Oct 1;132(3):587-96. doi: 10.1016/j.drugalcdep.2013.04.010. PMID: 23660242.
105. Van Voorhees EE, Hardy KK, Kollins SH. Reliability and validity of self- and other-ratings of symptoms of ADHD in adults. *J Atten Disord.* 2011 Apr;15(3):224-34. doi: 10.1177/1087054709356163. PMID: 20424007.
106. Vitola ES, Bau CH, Salum GA, et al. Exploring DSM-5 ADHD criteria beyond young adulthood: phenomenology, psychometric properties and prevalence in a large three-decade birth cohort. *Psychol Med.* 2017 Mar;47(4):744-54. doi: 10.1017/s0033291716002853. PMID: 27866484.
107. Vizgaitis AL, Bottini S, Polizzi CP, et al. Self-Reported Adult ADHD Symptoms: Evidence Supporting Cautious Use in an Assessment-Seeking Sample. *J Atten Disord.* 2023 Aug;27(10):1156-66. doi: 10.1177/10870547231172764. PMID: 37158158.
108. Wang D, Hong D, Wu Q. Attention Deficit Hyperactivity Disorder Classification Based on Deep Learning. *IEEE/ACM Trans Comput Biol Bioinform.* 2023 Mar-Apr;20(2):1581-6. doi: 10.1109/tcbb.2022.3170527. PMID: 35471884.
109. Wang X, Jiao Y, Tang T, et al. Altered regional homogeneity patterns in adults with attention-deficit hyperactivity disorder. *Eur J Radiol.* 2013 Sep;82(9):1552-7. doi: 10.1016/j.ejrad.2013.04.009. PMID: 23684384.
110. Wiig EH, Nielsen NP. A quick test of cognitive speed for comparing processing speed to differentiate adult psychiatric referrals with and without attention-deficit/hyperactivity disorders. *Prim Care Companion CNS Disord.* 2012;14(2). doi: 10.4088/PCC.11m01273. PMID: 22943032.
111. Williamson KD, Combs HL, Berry DT, et al. Discriminating among ADHD alone, ADHD with a comorbid psychological disorder, and feigned ADHD in a college sample. *Clin Neuropsychol.* 2014;28(7):1182-96. doi: 10.1080/13854046.2014.956674. PMID: 25225947.
112. Wolfers T, van Rooij D, Oosterlaan J, et al. Quantifying patterns of brain activity: Distinguishing unaffected siblings from participants with ADHD and healthy individuals. *Neuroimage Clin.* 2016;12:227-33. doi: 10.1016/j.nicl.2016.06.020. PMID: 27489770.
113. Woodruff DB, El-Mallakh RS, Thiruvengadam AP. A potential diagnostic blood test for attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord.* 2011 Sep;3(3):265-9. doi: 10.1007/s12402-011-0057-z. PMID: 21523444.
114. Woods SP, Lovejoy DW, Stutts ML, et al. Comparative efficiency of a discrepancy analysis for the classification of Attention-Deficit/Hyperactivity Disorder in adults. *Arch Clin Neuropsychol.* 2002 May;17(4):351-69. PMID: 14589720.
115. Yao D, Guo X, Zhao Q, et al. Discriminating ADHD From Healthy Controls Using a Novel Feature Selection Method Based on Relative Importance and Ensemble Learning. *Annu Int Conf IEEE Eng Med Biol Soc.* 2018 Jul;2018:4632-5. doi: 10.1109/embs.2018.8513155. PMID: 30441383.

Included Studies

116. Young JC, Gross AM. Detection of response bias and noncredible performance in adult attention-deficit/hyperactivity disorder. *Arch Clin Neuropsychol*. 2011 Apr;26(3):165-75. doi: 10.1093/arclin/acr013. PMID: 21441258.
117. Young JL, Powell RN, Zabel C, et al. Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations. *BMC Psychiatry*. 2023 Nov 6;23(1):806. doi: 10.1186/s12888-023-05295-6. PMID: 37932675.
118. Young S, González RA, Mutch L, et al. Diagnostic accuracy of a brief screening tool for attention deficit hyperactivity disorder in UK prison inmates. *Psychol Med*. 2016 May;46(7):1449-58. doi: 10.1017/s0033291716000039. PMID: 26867860.
119. Young S, Gudjonsson GH. Neuropsychological correlates of the YAQ-S and YAQ-I self- and informant-reported ADHD symptomatology, emotional and social problems and delinquent behaviour. *Br J Clin Psychol*. 2005 Mar;44(Pt 1):47-57. doi: 10.1348/014466504x197769. PMID: 15826343.

Background Papers

Background Papers

Publications retained to identify additional studies (e.g., systematic reviews, protocols of upcoming studies) and papers to cite (including to answer the context question)

1. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consensus Statement. 1998 Nov 16-18;16(2):1-37. PMID: 10868163.
2. Effectiveness of attention-deficit/hyperactivity treatment and diagnosis methods tested. Rep Med Guidel Outcomes Res. 2000 Feb 17;11(4):1-2, 5-7. PMID: 11768409.
3. Dimensional approaches in diagnostic classification: Refining the research agenda for DSM-V. Arlington, VA, US: American Psychiatric Association; 2008.
4. "Meta-analysis of cognitive-behavioral treatments for adult ADHD": Correction to Knouse, Teller, and Brooks (2017). J Consult Clin Psychol. 2017 Sep;85(9):882. doi: 10.1037/ccp0000240. PMID: 28857594.
5. A Phase 3, Dose-Optimized, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate). In: Rho I, editor; 2022.
6. EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo. 2022.
7. Guided ADHD Therapy for Managing the Extent and Severity of Symptoms - A Randomized, Controlled, Parallel-group, Intervention Study to Assess an At-home, Game-based Digital Therapy for Treating Adult Patients With Attention-Deficit/Hyperactivity Disorder. 2022.
8. Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder. 2023.
9. A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults. 2023.
10. Benefits of In-prison OROS-methylphenidate Vs. Placebo Treatment in Detained People with Attention-deficit/hyperactivity Disorder: a Randomized Controlled Trial. In: University of L, University of Geneva S, Netherlands Institute for the Study of C, School of Health Sciences F, eds.; 2023.
11. Abelson RP. A Variance Explanation Paradox: When a Little is a Lot. Psychological Bulletin. 1985;97:129-33.
12. Achenbach TM, Rescorla LA. Manual for the ASEBA School-age Forms & Profiles: An Integrated System of Multi-informant Assessment: ASEBA; 2001.
13. Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):429-39. doi: 10.1097/jcp.0000000000001575. PMID: 35652746.

Background Papers

14. Adler LA, Faraone SV, Spencer TJ, et al. The reliability and validity of self- and investigator ratings of ADHD in adults. *J Atten Disord*. 2008 May;11(6):711-9. doi: 10.1177/1087054707308503. PMID: 18025250.
15. Adler LA, Robertson B, Chen J, et al. Post hoc Responder and Remission Analyses from Two Studies of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2020 Sep;30(7):427-38. doi: 10.1089/cap.2020.0012. PMID: 32423239.
16. Adler LA, Wilens T, Zhang S, et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. *Clin Ther*. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. PMID: 22285724.
17. Alexander LM, Salum GA, Swanson JM, et al. Measuring strengths and weaknesses in dimensional psychiatry. *Journal of Child Psychology and Psychiatry*. 2020;61(1):40-50. doi: 10.1111/jcpp.13104. PMID: 31423596.
18. American Psychiatric Association. Attention-Deficit/Hyperactivity Disorder. Diagnostic and statistical manual of mental disorders. 5th ed.; 2013.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text rev. ed; 2022.
20. APSARD. U.S. Based Guidelines for Adults with ADHD. n.d. <https://apsard.org/us-guidelines-for-adults-with-adhd/>. Accessed on November 10, 2024.
21. Arnold LE, Hodgkins P, Caci H, et al. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. *PLoS One*. 2015;10(2):e0116407. doi: 10.1371/journal.pone.0116407. PMID: 25714373.
22. Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. *J Psychopharmacol*. 2014 Sep;28(9):837-46. doi: 10.1177/0269881114542453. PMID: 25035246.
23. Asherson P, Doyle A. SWAN rating scale, adapted for adults by Philip Asherson and Alysa Doyle for use in the UK Biobank social interactions and focus questionnaire. June 2023.
24. Asherson P, Stes S, Nilsson Markhed M, et al. The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. *Eur Psychiatry*. 2015 Jun;30(4):511-20. doi: 10.1016/j.eurpsy.2014.12.002. PMID: 25649490.
25. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. *Arch Dis Child*. 2005 Feb;90 Suppl 1(Suppl 1):i26-9. doi: 10.1136/adc.2004.059386. PMID: 15665154.
26. Becker P, Rask M, Safipour J, et al. Selfcare Strategies Shown to Be Useful in Daily Life for Adults Diagnosed with Attention Deficit Hyperactivity Disorder - A Systematic Review. *Issues Ment Health Nurs*. 2023 Sep;44(9):825-33. doi: 10.1080/01612840.2023.2234477. PMID: 37669505.
27. Bellato A, Perrott NJ, Marzulli L, et al. Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. *J*

Background Papers

- Am Acad Child Adolesc Psychiatry. 2024 May 30. doi: 10.1016/j.jaac.2024.05.023. PMID: 38823477.
28. Benkert D, Krause KH, Wasem J, et al. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment. *GMS Health Technol Assess*. 2010 Sep 7;6:Doc13. doi: 10.3205/hta000091. PMID: 21289886.
29. Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. *BMC Psychiatry*. 2007 Sep 14;7:49. doi: 10.1186/1471-244x-7-49. PMID: 17868455.
30. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. *Int J Neuropsychopharmacol*. 2004 Mar;7(1):77-97. doi: 10.1017/s1461145703003973. PMID: 14733627.
31. Bieś R, Fojcik J, Warchala A, et al. The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. *Pharmaceuticals (Basel)*. 2023 Sep 13;16(9). doi: 10.3390/ph16091292. PMID: 37765100.
32. Boesen K, Paludan-Müller AS, Gøtzsche PC, et al. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2022 Feb 24;2(2):Cd012857. doi: 10.1002/14651858.CD012857.pub2. PMID: 35201607.
33. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2014 Mar;28(3):179-203. doi: 10.1177/0269881113519509. PMID: 24526134.
34. Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. *Curr Med Res Opin*. 2010 Aug;26(8):1809-25. doi: 10.1185/03007995.2010.488553. PMID: 20491612.
35. Brauer H, Breitling-Ziegler C, Moliadze V, et al. Transcranial direct current stimulation in attention-deficit/hyperactivity disorder: A meta-analysis of clinical efficacy outcomes. *Prog Brain Res*. 2021;264:91-116. doi: 10.1016/bs.pbr.2021.01.013. PMID: 34167666.
36. Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. *Postgrad Med*. 2010 Sep;122(5):42-51. doi: 10.3810/pgm.2010.09.2200. PMID: 20861587.
37. Buitelaar J, Asherson P, Soutullo C, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. *Eur Neuropsychopharmacol*. 2015 Oct;25(10):1611-21. doi: 10.1016/j.euroneuro.2015.06.003. PMID: 26169574.
38. Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. *Expert Rev Neurother*. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. PMID: 26693882.
39. Bushe C, Day K, Reed V, et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult

Background Papers

patients. *J Psychopharmacol*. 2016 May;30(5):444-58. doi: 10.1177/0269881116636105. PMID: 27005307.

40. Byrne C, Guenter D. Treatments for ADHD in adults in jails, prisons and correctional settings: a scoping review of the literature. *Health Justice*. 2023 Sep 7;11(1):36. doi: 10.1186/s40352-023-00234-9. PMID: 37676388.

41. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. *Clin Ther*. 2003 Dec;25(12):3065-83. doi: 10.1016/s0149-2918(03)90092-0. PMID: 14749146.

42. Caisley H, Müller U. Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. *Eur Psychiatry*. 2012 Jul;27(5):343-9. doi: 10.1016/j.eurpsy.2012.01.002. PMID: 22521805.

43. Callan PD, Swanberg S, Weber SK, et al. Diagnostic Utility of Conners Continuous Performance Test-3 for Attention Deficit/Hyperactivity Disorder: A Systematic Review. *J Atten Disord*. 2024 Apr;28(6):992-1007. doi: 10.1177/10870547231223727. PMID: 38317541.

44. Camporeale A, Porsdal V, De Bruyckere K, et al. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. *J Psychopharmacol*. 2015 Jan;29(1):3-14. doi: 10.1177/0269881114560183. PMID: 25424623.

45. Cândido RCF, Menezes de Padua CA, Golder S, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2021 Jan 18;1(1):Cd013011. doi: 10.1002/14651858.CD013011.pub2. PMID: 33460048.

46. Caroline SS, Sudhir PM, Mehta UM, et al. Assessing Adult ADHD: An Updated Review of Rating Scales for Adult Attention Deficit Hyperactivity Disorder (ADHD). *J Atten Disord*. 2024 May;28(7):1045-62. doi: 10.1177/10870547241226654. PMID: 38369740.

47. Carpentier PJ, Levin FR. Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us? *Harv Rev Psychiatry*. 2017 Mar/Apr;25(2):50-64. doi: 10.1097/hrp.000000000000122. PMID: 28272130.

48. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2018 Aug 9;8(8):Cd007813. doi: 10.1002/14651858.CD007813.pub3. PMID: 30091808.

49. Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. *Eur J Clin Pharmacol*. 2013 Mar;69(3):347-56. doi: 10.1007/s00228-012-1390-7. PMID: 22983311.

50. Castells X, Ramos-Quiroga JA, Bosch R, et al. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2011 Jun 15(6):Cd007813. doi: 10.1002/14651858.CD007813.pub2. PMID: 21678370.

51. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. *CNS Drugs*. 2011 Feb;25(2):157-69. doi: 10.2165/11539440-000000000-00000. PMID: 21254791.

52. Castells X, Saez M, Barcheni M, et al. Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and

Background Papers

MetaForest. *Int J Neuropsychopharmacol*. 2022 Jan 12;25(1):26-35. doi: 10.1093/ijnp/pyab054. PMID: 34355753.

53. Chandler ML. Psychotherapy for adult attention deficit/hyperactivity disorder: a comparison with cognitive behaviour therapy. *J Psychiatr Ment Health Nurs*. 2013 Nov;20(9):814-20. doi: 10.1111/jpm.12023. PMID: 23506050.

54. Chang Z, Ghirardi L, Quinn PD, et al. Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. *Biol Psychiatry*. 2019 Sep 1;86(5):335-43. doi: 10.1016/j.biopsych.2019.04.009. PMID: 31155139.

55. Chen YH, Liang SC, Sun CK, et al. A meta-analysis on the therapeutic efficacy of repetitive transcranial magnetic stimulation for cognitive functions in attention-deficit/hyperactivity disorders. *BMC Psychiatry*. 2023 Oct 17;23(1):756. doi: 10.1186/s12888-023-05261-2. PMID: 37845676.

56. Chierrito de Oliveira D, Guerrero de Sousa P, Borges Dos Reis C, et al. Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses. *J Atten Disord*. 2019 Jan;23(2):111-20. doi: 10.1177/1087054717696773. PMID: 28366111.

57. Christopher H-B, Maria Fiatarone S, Michael I, et al. Exercise and Physical Activity in adults with Attention Deficit Hyperactivity Disorder (ADHD): A systematic review. 2020. PMID: CRD42020215375.

58. Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. *J Psychopharmacol*. 2015 Dec;29(12):1221-30. doi: 10.1177/0269881115602489. PMID: 26349559.

59. Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. *CNS Drugs*. 2010 Oct;24(10):843-66. doi: 10.2165/11537450-000000000-00000. PMID: 20839896.

60. Coghill D, Banaschewski T, Zuddas A, et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. *BMC Psychiatry*. 2013 Sep 27;13:237. doi: 10.1186/1471-244x-13-237. PMID: 24074240.

61. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. *Expert Opin Pharmacother*. 2006 Oct;7(15):2119-38. doi: 10.1517/14656566.7.15.2119. PMID: 17020437.

62. Coghill DR, Banaschewski T, Soutullo C, et al. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry*. 2017 Nov;26(11):1283-307. doi: 10.1007/s00787-017-0986-y. PMID: 28429134.

63. Coghill DR, Caballero B, Sorooshian S, et al. A systematic review of the safety of lisdexamfetamine dimesylate. *CNS Drugs*. 2014 Jun;28(6):497-511. doi: 10.1007/s40263-014-0166-2. PMID: 24788672.

Background Papers

64. Conners CK. Chapter 6: Interpretation. Conners 3rd Edition: Manual. Canada: Multi-Health Systems, Inc.; 2008.
65. Conners CK. Chapter 10: Standardization. Conners 3rd Edition: Manual. Canada: Multi-Health Systems, Inc.; 2008.
66. Contini V, Rovaris DL, Victor MM, et al. Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review. *Eur Neuropsychopharmacol*. 2013 Jun;23(6):555-60. doi: 10.1016/j.euroneuro.2012.05.006. PMID: 22709890.
67. Cooper RE, Tye C, Kuntsi J, et al. Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis. *J Psychopharmacol*. 2015 Jul;29(7):753-63. doi: 10.1177/0269881115587958. PMID: 26040902.
68. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. *Am J Health Syst Pharm*. 2004 Nov 15;61(22):2391-9. doi: 10.1093/ajhp/61.22.2391. PMID: 15581262.
69. Cornforth C, Sonuga-Barke E, Coghill D. Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. *Curr Pharm Des*. 2010;16(22):2424-33. doi: 10.2174/138161210791959827. PMID: 20513225.
70. Correll CU, Starling BR, Huss M. Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. *CNS Spectr*. 2021 Apr 12;1-13. doi: 10.1017/s1092852921000341. PMID: 33843531.
71. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2018 Sep;5(9):727-38. doi: 10.1016/s2215-0366(18)30269-4. PMID: 30097390.
72. Cortese S, Del Giovane C, Chamberlain S, et al. Pharmacological and non-pharmacological interventions for adults with ADHD: protocol for a systematic review and network meta-analysis. *BMJ Open*. 2022 Mar 11;12(3):e058102. doi: 10.1136/bmjopen-2021-058102. PMID: 35277411.
73. Cotton J, Baker ST. A data mining and item response mixture modeling method to retrospectively measure Diagnostic and Statistical Manual of Mental Disorders-5 attention deficit hyperactivity disorder in the 1970 British Cohort Study. *Int J Methods Psychiatr Res*. 2019 Mar;28(1):e1753. doi: 10.1002/mpr.1753. PMID: 30402897.
74. Coulter MK, Dean ME. Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. *Cochrane Database Syst Rev*. 2007 Oct 17(4):Cd005648. doi: 10.1002/14651858.CD005648.pub2. PMID: 17943868.
75. Cunill R, Castells X, Tobias A, et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoevidenciol Drug Saf*. 2013 Sep;22(9):961-9. doi: 10.1002/pds.3473. PMID: 23813665.
76. Cunill R, Castells X, Tobias A, et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over

Background Papers

- 9000 patients. *Psychopharmacology (Berl)*. 2016 Jan;233(2):187-97. doi: 10.1007/s00213-015-4099-3. PMID: 26446868.
77. Currie J, Stabile M, Jones L. Do stimulant medications improve educational and behavioral outcomes for children with ADHD? *J Health Econ*. 2014 Sep;37:58-69. doi: 10.1016/j.jhealeco.2014.05.002. PMID: 24954077.
78. De Bruyckere K, Bushe C, Bartel C, et al. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database. *CNS Drugs*. 2016 Jun;30(6):541-58. doi: 10.1007/s40263-016-0346-3. PMID: 27224994.
79. De Crescenzo F, Cortese S, Adamo N, et al. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. *Evid Based Ment Health*. 2017 Feb;20(1):4-11. doi: 10.1136/eb-2016-102415. PMID: 27993933.
80. Dekkers TJ, Groenman AP, Cuijpers P, et al. Commentary: Why treatment is the best choice for childhood mental disorders – a commentary on Roest et al. (2022). *Journal of Child Psychology and Psychiatry*. 2023;64(3):470-3. doi: <https://doi.org/10.1111/jcpp.13715>.
81. Den Heijer AE, Groen Y, Tucha L, et al. Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review. *J Neural Transm (Vienna)*. 2017 Feb;124(Suppl 1):3-26. doi: 10.1007/s00702-016-1593-7. PMID: 27400928.
82. Dijk HH, Wessels LM, Constanti M, et al. Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. *J Child Adolesc Psychopharmacol*. 2021 Nov;31(9):578-96. doi: 10.1089/cap.2021.0068. PMID: 34705525.
83. Eaton C, Yong K, Walter V, et al. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy. *Cochrane Database Syst Rev*. 2022 Jul 13;7(7):Cd013136. doi: 10.1002/14651858.CD013136.pub2. PMID: 35844168.
84. Elbe P, Bäcklund C, Vega-Mendoza M, et al. Computerized cognitive interventions for adults with ADHD: A systematic review and meta-analysis. *Neuropsychology*. 2023 Jul;37(5):519-30. doi: 10.1037/neu0000890. PMID: 36892894.
85. Elliott J, Johnston A, Husereau D, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. *PLoS One*. 2020;15(10):e0240584. doi: 10.1371/journal.pone.0240584. PMID: 33085721.
86. Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2014 Sep 18(9):Cd005041. doi: 10.1002/14651858.CD005041.pub2. PMID: 25230710.
87. Fan HY, Sun CK, Cheng YS, et al. A pilot meta-analysis on self-reported efficacy of neurofeedback for adolescents and adults with ADHD. *Sci Rep*. 2022 Jun 15;12(1):9958. doi: 10.1038/s41598-022-14220-y. PMID: 35705685.
88. Faraone SV. Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release). *Expert Opin Pharmacother*. 2007 Sep;8(13):2127-34. doi: 10.1517/14656566.8.13.2127. PMID: 17714065.

Background Papers

89. Faraone SV. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. *J Atten Disord*. 2012 Feb;16(2):128-37. doi: 10.1177/1087054710379738. PMID: 20837983.
90. Faraone SV, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. *Behav Brain Funct*. 2005 Oct 3;1:16. doi: 10.1186/1744-9081-1-16. PMID: 16202140.
91. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2005 Aug;15(4):664-70. doi: 10.1089/cap.2005.15.664. PMID: 16190797.
92. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *J Clin Psychiatry*. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. PMID: 20051220.
93. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2004 Feb;24(1):24-9. doi: 10.1097/01.jcp.0000108984.11879.95. PMID: 14709943.
94. Farhat LC, Flores JM, Avila-Quintero VJ, et al. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. *JAMA Psychiatry*. 2024 Feb 1;81(2):157-66. doi: 10.1001/jamapsychiatry.2023.3985. PMID: 37878348.
95. Fredriksen M, Halmøy A, Faraone SV, et al. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. *Eur Neuropsychopharmacol*. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. PMID: 22917983.
96. Fridman M, Hodgkins PS, Kahle JS, et al. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis. *Eur Psychiatry*. 2015 Jun;30(4):521-7. doi: 10.1016/j.eurpsy.2015.01.001. PMID: 25725594.
97. Funder DC, Ozer DJ. "Evaluating effect size in psychological research: Sense and nonsense": Corrigendum. *Advances in Methods and Practices in Psychological Science*. 2020;3(4):509-. doi: 10.1177/2515245920979282.
98. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. *Neuropsychiatr Dis Treat*. 2014;10:1543-69. doi: 10.2147/ndt.S65721. PMID: 25187718.
99. Geraets CNW, Wallinius M, Sygel K. Use of Virtual Reality in Psychiatric Diagnostic Assessments: A Systematic Review. *Front Psychiatry*. 2022;13:828410. doi: 10.3389/fpsy.2022.828410. PMID: 35295778.
100. Gobbo MA, Louzã MR. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review. *Eur Neuropsychopharmacol*. 2014 Sep;24(9):1425-43. doi: 10.1016/j.euroneuro.2014.06.006. PMID: 25044052.

Background Papers

101. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. *J Psychopharmacol*. 2009 Mar;23(2):194-205. doi: 10.1177/0269881108089809. PMID: 18515459.
102. Goodman David W, Mattingly G. Practice Guidelines Development: The APSARD United States Guidelines for the Diagnosis and Treatment of ADHD in Adults. *Psychiatric Annals*. 2023 10/01;53(10):449-54. doi: 10.3928/00485713-20230911-05.
103. Goodman DW. Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies. *Ther Clin Risk Manag*. 2013;9:121-30. doi: 10.2147/term.S30762. PMID: 23576871.
104. Guo C, Assumpcao L, Hu Z. Efficacy of Non-pharmacological Treatments on Emotional Symptoms of Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis. *J Atten Disord*. 2022 Feb;26(4):508-24. doi: 10.1177/10870547211001953. PMID: 33759605.
105. Hamatani S, Matsumoto K, Kunisato Y, et al. Dismantling cognitive-behavioural therapy components for attention-deficit hyperactivity disorder in adolescents and adults: protocol for a network meta-analysis. *BMJ Open*. 2023 Apr 19;13(4):e068547. doi: 10.1136/bmjopen-2022-068547. PMID: 37076162.
106. Hammerness PG, Karampahtsis C, Babalola R, et al. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? *Expert Opin Drug Saf*. 2015 Apr;14(4):543-51. doi: 10.1517/14740338.2015.1011620. PMID: 25648243.
107. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. *Curr Psychiatry Rep*. 2011 Oct;13(5):357-63. doi: 10.1007/s11920-011-0213-3. PMID: 21698412.
108. Harpin V, Mazzone L, Raynaud JP, et al. Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function. *J Atten Disord*. 2016 Apr;20(4):295-305. doi: 10.1177/1087054713486516. PMID: 23698916.
109. Harrison AG, Edwards MJ. The Ability of Self-Report Methods to Accurately Diagnose Attention Deficit Hyperactivity Disorder: A Systematic Review. *J Atten Disord*. 2023 Oct;27(12):1343-59. doi: 10.1177/10870547231177470. PMID: 37366274.
110. Helzer JE, Wittchen H-U, Krueger RF, et al. Dimensional Options for DSM-V: The Way Forward. In: Helzer JE, Kraemer HC, Krueger RF, Wittchen H-U, Sirovatka PJ, Regier DA, eds. *Dimensional approaches in diagnostic classification: Refining the research agenda for DSM-V*. Arlington, VA, US: American Psychiatric Association; 2008:116-27.
111. Hodgkins P, Shaw M, McCarthy S, et al. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? *CNS Drugs*. 2012 Mar 1;26(3):245-68. doi: 10.2165/11599630-000000000-00000. PMID: 22329564.
112. Hopkins SC, Sunkaraneni S, Skende E, et al. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. *Clin Drug Investig*. 2016 Feb;36(2):137-46. doi: 10.1007/s40261-015-0358-7. PMID: 26597180.

Background Papers

113. Huss M, Duhan P, Gandhi P, et al. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. *Neuropsychiatr Dis Treat*. 2017;13:1741-51. doi: 10.2147/ndt.S130444. PMID: 28740389.
114. Hutchison SL, Ghuman JK, Ghuman HS, et al. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. *Ther Adv Psychopharmacol*. 2016 Oct;6(5):317-34. doi: 10.1177/2045125316647686. PMID: 27721971.
115. Jadad AR, Booker L, Gault M, et al. The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. *Can J Psychiatry*. 1999 Dec;44(10):1025-35. doi: 10.1177/070674379904401009. PMID: 10637682.
116. Jaeschke RR, Sujkowska E, Sowa-Kućma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. *Psychopharmacology (Berl)*. 2021 Oct;238(10):2667-91. doi: 10.1007/s00213-021-05946-0. PMID: 34436651.
117. Jain R, Katic A. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder. *Prim Care Companion CNS Disord*. 2016 Aug 18;18(4). doi: 10.4088/PCC.16r01979. PMID: 27828696.
118. Jensen CM, Amdisen BL, Jørgensen KJ, et al. Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. *Atten Defic Hyperact Disord*. 2016 Mar;8(1):3-11. doi: 10.1007/s12402-016-0188-3. PMID: 26801998.
119. Jin C, Schachar R. Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies. *CNS Spectr*. 2004 Mar;9(3):217-26. doi: 10.1017/s1092852900009019. PMID: 14999162.
120. Kanodia J, Lo A, Baldwin RM, et al. Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. *Clin Pharmacokinet*. 2021 Jan;60(1):121-31. doi: 10.1007/s40262-020-00918-7. PMID: 32856281.
121. Knouse LE, Teller J, Brooks MA. Meta-analysis of cognitive-behavioral treatments for adult ADHD. *J Consult Clin Psychol*. 2017 Jul;85(7):737-50. doi: 10.1037/ccp0000216. PMID: 28504540.
122. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. *J Psychopharmacol*. 2009 Sep;23(7):733-44. doi: 10.1177/0269881108092338. PMID: 18562416.
123. Kofler MJ, Rapport MD, Sarver DE, et al. Reaction time variability in ADHD: a meta-analytic review of 319 studies. *Clin Psychol Rev*. 2013 Aug;33(6):795-811. doi: 10.1016/j.cpr.2013.06.001. PMID: 23872284.
124. Kok FM, Groen Y, Fuermaier ABM, et al. The female side of pharmacotherapy for ADHD-A systematic literature review. *PLoS One*. 2020;15(9):e0239257. doi: 10.1371/journal.pone.0239257. PMID: 32946507.

Background Papers

125. Krisanaprakornkit T, Ngamjarus C, Witoonchart C, et al. Meditation therapies for attention-deficit/hyperactivity disorder (ADHD). *Cochrane Database Syst Rev*. 2010 Jun 16;2010(6):Cd006507. doi: 10.1002/14651858.CD006507.pub2. PMID: 20556767.
126. Lauder K, McDowall A, Tenenbaum HR. A systematic review of interventions to support adults with ADHD at work-Implications from the paucity of context-specific research for theory and practice. *Front Psychol*. 2022;13:893469. doi: 10.3389/fpsyg.2022.893469. PMID: 36072032.
127. Lee CSC, Ma MT, Ho HY, et al. The Effectiveness of Mindfulness-Based Intervention in Attention on Individuals with ADHD: A Systematic Review. *Hong Kong J Occup Ther*. 2017 Dec;30(1):33-41. doi: 10.1016/j.hkjot.2017.05.001. PMID: 30186078.
128. Lenzi F, Cortese S, Harris J, et al. Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2018 Jan;84:359-67. doi: 10.1016/j.neubiorev.2017.08.010. PMID: 28837827.
129. Li Y, Zhang L. Efficacy of Cognitive Behavioral Therapy Combined with Pharmacotherapy Versus Pharmacotherapy Alone in Adult ADHD: A Systematic Review and Meta-Analysis. *J Atten Disord*. 2024 Feb;28(3):279-92. doi: 10.1177/10870547231214969. PMID: 38084075.
130. Liang EF, Lim SZ, Tam WW, et al. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. *Int J Environ Res Public Health*. 2018 Aug 20;15(8). doi: 10.3390/ijerph15081789. PMID: 30127314.
131. Liu CI, Hua MH, Lu ML, et al. Effectiveness of cognitive behavioural-based interventions for adults with attention-deficit/hyperactivity disorder extends beyond core symptoms: A meta-analysis of randomized controlled trials. *Psychol Psychother*. 2023 Sep;96(3):543-59. doi: 10.1111/papt.12455. PMID: 36794797.
132. López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. *Atten Defic Hyperact Disord*. 2013 Sep;5(3):249-65. doi: 10.1007/s12402-013-0106-x. PMID: 23564273.
133. Lopez PL, Torrente FM, Ciapponi A, et al. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2018 Mar 23;3(3):Cd010840. doi: 10.1002/14651858.CD010840.pub2. PMID: 29566425.
134. Lopez PL, Torrente FM, Ciapponi A, et al. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database of Systematic Reviews*. 2018(3). doi: 10.1002/14651858.CD010840.pub2. PMID: CD010840.
135. López-Pinar C, Martínez-Sanchis S, Carbonell-Vayá E, et al. Long-Term Efficacy of Psychosocial Treatments for Adults With Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. *Front Psychol*. 2018;9:638. doi: 10.3389/fpsyg.2018.00638. PMID: 29780342.
136. López-Pinar C, Martínez-Sanchis S, Carbonell-Vayá E, et al. Efficacy of Nonpharmacological Treatments on Comorbid Internalizing Symptoms of Adults With Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. *J Atten Disord*. 2020 Feb;24(3):456-78. doi: 10.1177/1087054719855685. PMID: 31189374.

Background Papers

137. Maiti R, Mishra A, Jena M, et al. Efficacy and safety of dasotraline in attention-deficit hyperactivity disorder: A systematic review and meta-analysis. *Indian J Psychiatry*. 2024 Apr;66(4):326-35. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_3_24. PMID: 38778858.
138. Man KKC, Ip P, Chan EW, et al. Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies. *CNS Drugs*. 2017 Dec;31(12):1043-55. doi: 10.1007/s40263-017-0485-1. PMID: 29255995.
139. Maneeton N, Maneeton B, Intaprasert S, et al. A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat*. 2014;10:1439-49. doi: 10.2147/ndt.S62714. PMID: 25120365.
140. Maneeton N, Maneeton B, Srisurapanont M, et al. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. *Psychiatry Clin Neurosci*. 2011 Dec;65(7):611-7. doi: 10.1111/j.1440-1819.2011.02264.x. PMID: 22176279.
141. Maneeton N, Maneeton B, Suttajit S, et al. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. *Drug Des Devel Ther*. 2014;8:1685-93. doi: 10.2147/dddt.S68393. PMID: 25336914.
142. Marshall P, Hoelzle J, Nikolas M. Diagnosing Attention-Deficit/Hyperactivity Disorder (ADHD) in young adults: A qualitative review of the utility of assessment measures and recommendations for improving the diagnostic process. *Clin Neuropsychol*. 2021 Jan;35(1):165-98. doi: 10.1080/13854046.2019.1696409. PMID: 31791193.
143. Martinez-Raga J, Knecht C, Szerman N, et al. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. *CNS Drugs*. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. PMID: 23160939.
144. Matsui Y, Matsunaga S, Matsuda Y, et al. Azapirones for Attention Deficit Hyperactivity Disorder: A Systematic Review. *Pharmacopsychiatry*. 2016 May;49(3):97-106. doi: 10.1055/s-0042-102457. PMID: 27074948.
145. Matza LS, Stoeckl MN, Shorr JM, et al. Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. *Expert Rev Pharmacoecon Outcomes Res*. 2006 Aug;6(4):379-90. doi: 10.1586/14737167.6.4.379. PMID: 20528508.
146. Mayer K, Wyckoff SN, Strehl U. One size fits all? Slow cortical potentials neurofeedback: a review. *J Atten Disord*. 2013 Jul;17(5):393-409. doi: 10.1177/1087054712468053. PMID: 23264371.
147. McCleary R, Schuck S, Swanson JM. Ecological Correlates of ADHD. In press.
148. McDonagh MS, Peterson K, Thakurta S, et al. Drug Class Reviews. Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report. Portland (OR): Oregon Health & Science University
- Copyright © 2011 by Oregon Health & Science University.; 2011.

Background Papers

149. Melzer D, Tom BD, Brugh TS, et al. Common mental disorder symptom counts in populations: are there distinct case groups above epidemiological cut-offs? *Psychol Med*. 2002 Oct;32(7):1195-201. doi: 10.1017/s0033291702006049. PMID: 12420889.
150. Mészáros A, Czobor P, Bálint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. *Int J Neuropsychopharmacol*. 2009 Sep;12(8):1137-47. doi: 10.1017/s1461145709990198. PMID: 19580697.
151. Mongia M, Hechtman L. Cognitive behavior therapy for adults with attention-deficit/hyperactivity disorder: a review of recent randomized controlled trials. *Curr Psychiatry Rep*. 2012 Oct;14(5):561-7. doi: 10.1007/s11920-012-0303-x. PMID: 22878974.
152. Moriyama TS, Polanczyk GV, Terzi FS, et al. Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses. *CNS Spectr*. 2013 Dec;18(6):296-306. doi: 10.1017/s109285291300031x. PMID: 23739183.
153. Moukhtarian TR, Cooper RE, Vassos E, et al. Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis. *Eur Psychiatry*. 2017 Jul;44:198-207. doi: 10.1016/j.eurpsy.2017.05.021. PMID: 28646732.
154. Mowlem FD, Skirrow C, Reid P, et al. Validation of the Mind Excessively Wandering Scale and the Relationship of Mind Wandering to Impairment in Adult ADHD. *J Atten Disord*. 2019 Apr;23(6):624-34. doi: 10.1177/1087054716651927. PMID: 27255536.
155. Mucci F, Avella MT, Marazziti D. ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan. *Curr Med Chem*. 2019;26(38):6942-69. doi: 10.2174/0929867326666190805153610. PMID: 31385763.
156. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. *Clin Ther*. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. PMID: 19243715.
157. Najib J, Wimer D, Zeng J, et al. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. *J Cent Nerv Syst Dis*. 2017;9:1179573517728090. doi: 10.1177/1179573517728090. PMID: 28855799.
158. Narrow W. Editorial: The Enigma of "Real World" Mental Health Care. *J Am Acad Child Adolesc Psychiatry*. 2022 Aug;61(8):980-1. doi: 10.1016/j.jaac.2022.04.003. PMID: 35452783.
159. National Institute for Health and Care Excellence: (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline, no. 87. London; 2019.
160. Nigg JT, Bruton A, Kozlowski MB, et al. Systematic Review and Meta-Analysis: Do White Noise or Pink Noise Help With Task Performance in Youth With Attention-Deficit/Hyperactivity Disorder or With Elevated Attention Problems? *J Am Acad Child Adolesc Psychiatry*. 2024 Aug;63(8):778-88. doi: 10.1016/j.jaac.2023.12.014. PMID: 38428577.
161. Nimmo-Smith V, Merwood A, Hank D, et al. Non-pharmacological interventions for adult ADHD: a systematic review. *Psychol Med*. 2020 Mar;50(4):529-41. doi: 10.1017/s0033291720000069. PMID: 32036811.
162. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults:

Background Papers

- recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2007 Jan;21(1):10-41. doi: 10.1177/0269881106073219. PMID: 17092962.
163. Oliva F, Malandrone F, di Girolamo G, et al. The efficacy of mindfulness-based interventions in attention-deficit/hyperactivity disorder beyond core symptoms: A systematic review, meta-analysis, and meta-regression. *J Affect Disord*. 2021 Sep 1;292:475-86. doi: 10.1016/j.jad.2021.05.068. PMID: 34146899.
164. Owens J. Relationships between an ADHD Diagnosis and Future School Behaviors among Children with Mild Behavioral Problems. *Sociology of Education*. 2020;93(3):191-214. doi: 10.1177/0038040720909296.
165. Owens J, Jackson H. Attention-deficit/hyperactivity disorder severity, diagnosis, & later academic achievement in a national sample. *Soc Sci Res*. 2017 Jan;61:251-65. doi: 10.1016/j.ssresearch.2016.06.018. PMID: 27886732.
166. Pablo Luis L, Fernando Manuel T, Agustín C, et al. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane Protocol]. 2015. PMID: CRD42015016294.
167. Pagán AF, Huizar YP, Schmidt AT. Conner's Continuous Performance Test and Adult ADHD: A Systematic Literature Review. *J Atten Disord*. 2023 Feb;27(3):231-49. doi: 10.1177/10870547221142455. PMID: 36495125.
168. Păsărelu CR, Andersson G, Dobrea A. Attention-deficit/ hyperactivity disorder mobile apps: A systematic review. *Int J Med Inform*. 2020 Jun;138:104133. doi: 10.1016/j.ijmedinf.2020.104133. PMID: 32283479.
169. Penberthy JK, Cox D, Breton M, et al. Calibration of ADHD assessments across studies: a meta-analysis tool. *Appl Psychophysiol Biofeedback*. 2005 Mar;30(1):31-51. doi: 10.1007/s10484-005-2172-0. PMID: 15889584.
170. Pereira-Sanchez V, Franco AR, Vieira D, et al. Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2021 Feb;60(2):222-35. doi: 10.1016/j.jaac.2020.10.013. PMID: 33137412.
171. Pérez de los Cobos J, Siñol N, Pérez V, et al. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. *Br J Clin Pharmacol*. 2014 Feb;77(2):337-56. doi: 10.1111/bcp.12045. PMID: 23216449.
172. Perugi G, Pallucchini A, Rizzato S, et al. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD). *Expert Opin Pharmacother*. 2019 Aug;20(12):1457-70. doi: 10.1080/14656566.2019.1618270. PMID: 31112441.
173. Peterson BS, Trampush J, Brown M, et al. Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review. *Pediatrics*. 2024 Apr 1;153(4). doi: 10.1542/peds.2024-065854. PMID: 38523599.
174. Peterson BS, Trampush J, Maglione M, et al. Treatments for ADHD in Children and Adolescents: A Systematic Review. *Pediatrics*. 2024 Apr 1;153(4). doi: 10.1542/peds.2024-065787. PMID: 38523592.

Background Papers

175. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. *Psychopharmacology (Berl)*. 2008 Mar;197(1):1-11. doi: 10.1007/s00213-007-0996-4. PMID: 18026719.
176. Pia E, Mariana Vega M, Daniel Eriksson S, et al. Cognitive interventions for adults with ADHD: A systematic review and meta-analysis. 2020. PMID: CRD42020190142.
177. Pievsky MA, McGrath RE. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis. *Neurosci Biobehav Rev*. 2018 Jul;90:447-55. doi: 10.1016/j.neubiorev.2018.05.012. PMID: 29751051.
178. Poissant H, Mendrek A, Talbot N, et al. Behavioral and Cognitive Impacts of Mindfulness-Based Interventions on Adults with Attention-Deficit Hyperactivity Disorder: A Systematic Review. *Behav Neurol*. 2019;2019:5682050. doi: 10.1155/2019/5682050. PMID: 31093302.
179. Polanczyk G, Faraone SV, Bau CH, et al. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. *Am J Med Genet B Neuropsychiatr Genet*. 2008 Dec 5;147b(8):1419-24. doi: 10.1002/ajmg.b.30855. PMID: 18802923.
180. Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. *Biol Psychiatry*. 2007 Mar 1;61(5):713-9. doi: 10.1016/j.biopsych.2006.05.044. PMID: 16996485.
181. Power HA, Shivak SM, Kim J, et al. A systematic review of attention-deficit/hyperactivity disorder in people living with cystic fibrosis. *Pediatr Pulmonol*. 2024 Apr;59(4):825-33. doi: 10.1002/ppul.26843. PMID: 38197494.
182. Radonjić NV, Bellato A, Khoury NM, et al. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. *CNS Drugs*. 2023 May;37(5):381-97. doi: 10.1007/s40263-023-01005-8. PMID: 37166701.
183. Ramos-Quiroga JA, Montoya A, Kutzelnigg A, et al. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines. *Curr Med Res Opin*. 2013 Sep;29(9):1093-104. doi: 10.1185/03007995.2013.812961. PMID: 23742051.
184. Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. *Fam Pract*. 2018 Mar 27;35(2):142-50. doi: 10.1093/fampra/cmx088. PMID: 28973393.
185. Ravishankar V, Chowdappa SV, Benegal V, et al. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials. *Asian J Psychiatr*. 2016 Dec;24:53-8. doi: 10.1016/j.ajp.2016.08.017. PMID: 27931908.
186. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. *Biol Psychiatry*. 2005 Jul 15;58(2):125-31. doi: 10.1016/j.biopsych.2005.04.040. PMID: 16038683.
187. Retz W, Retz-Junginger P, Thome J, et al. Pharmacological treatment of adult ADHD in Europe. *World J Biol Psychiatry*. 2011 Sep;12 Suppl 1:89-94. doi: 10.3109/15622975.2011.603229. PMID: 21906003.

Background Papers

188. Riccioni A, Radua J, Ashaye FO, et al. Systematic Review and Meta-Analysis: Reporting and Representation of Race/Ethnicity in 310 Randomized Controlled Trials of Attention-Deficit/Hyperactivity Disorder Medications. *J Am Acad Child Adolesc Psychiatry*. 2024 Jul;63(7):698-707. doi: 10.1016/j.jaac.2023.09.544. PMID: 37890665.
189. Rodrigo-Yanguas M, González-Tardón C, Bella-Fernández M, et al. Serious Video Games: Angels or Demons in Patients With Attention-Deficit Hyperactivity Disorder? A Quasi-Systematic Review. *Front Psychiatry*. 2022;13:798480. doi: 10.3389/fpsyt.2022.798480. PMID: 35573357.
190. Roest AM, de Vries YA, Wienen AW, et al. Editorial Perspective: Are treatments for childhood mental disorders helpful in the long run? An overview of systematic reviews. *Journal of Child Psychology and Psychiatry*. 2023;64(3):464-9. doi: <https://doi.org/10.1111/jcpp.13677>.
191. Rösler M, Casas M, Konofal E, et al. Attention deficit hyperactivity disorder in adults. *World J Biol Psychiatry*. 2010 Aug;11(5):684-98. doi: 10.3109/15622975.2010.483249. PMID: 20521876.
192. Rösler M, Retz W, Stieglitz RD. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations - benchmarking instruments for international multicentre trials. *Pharmacopsychiatry*. 2010 May;43(3):92-8. doi: 10.1055/s-0029-1242819. PMID: 20127615.
193. Rosso G, Portaluppi C, Teobaldi E, et al. Assessing Adult ADHD Through Objective Neuropsychological Measures: A Critical Overview. *J Atten Disord*. 2023 May;27(7):786-94. doi: 10.1177/10870547231167564. PMID: 37039121.
194. Rover C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. *BMC Med Res Methodol*. 2015 Nov 14;15:99. doi: 10.1186/s12874-015-0091-1. PMID: 26573817.
195. Salehinejad MA, Nejati V, Mosayebi-Samani M, et al. Transcranial Direct Current Stimulation in ADHD: A Systematic Review of Efficacy, Safety, and Protocol-induced Electrical Field Modeling Results. *Neurosci Bull*. 2020 Oct;36(10):1191-212. doi: 10.1007/s12264-020-00501-x. PMID: 32418073.
196. Samuele C, Cinzia Del G, Samuel C, et al. Comparing pharmacological and non-pharmacological interventions for adults with Attention-Deficit/Hyperactivity Disorder (ADHD): systematic review and network meta-analysis. 2021. PMID: CRD42021265576.
197. Samuele C, Francesca L, Gabriele M. Pharmacotherapy of emotional dysregulation in adults with ADHD: protocol for a systematic review and meta-analysis. 2017. PMID: CRD42017068426.
198. Schatz NK, Fabiano GA, Cunningham CE, et al. Systematic Review of Patients' and Parents' Preferences for ADHD Treatment Options and Processes of Care. *Patient*. 2015 Dec;8(6):483-97. doi: 10.1007/s40271-015-0112-5. PMID: 25644223.
199. Schein J, Cloutier M, Gauthier-Loiselle M, et al. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release. *J Manag Care Spec Pharm*. 2024 Jun;30(6):528-40. doi: 10.18553/jmcp.2024.30.6.528. PMID: 38824626.

Background Papers

200. Schein J, Cloutier M, Gauthier-Loiselle M, et al. Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta). *Curr Med Res Opin.* 2024 Aug;40(8):1397-406. doi: 10.1080/03007995.2024.2373883. PMID: 38958732.
201. Schein J, Cloutier M, Gauthier-Loiselle M, et al. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. *J Comp Eff Res.* 2024 Aug 12:e240089. doi: 10.57264/ceer-2024-0089. PMID: 39132746.
202. Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. *Pediatrics.* 2014 Jun;133(6):1070-80. doi: 10.1542/peds.2014-0179. PMID: 24819571.
203. Scholz L, Werle J, Philipsen A, et al. Effects and feasibility of psychological interventions to reduce inattention symptoms in adults with ADHD: a systematic review. *J Ment Health.* 2023 Feb;32(1):307-20. doi: 10.1080/09638237.2020.1818189. PMID: 32954909.
204. Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people. October 2009. https://antoniofasolino.weebly.com/uploads/2/6/2/6/2626820/sign1200_-_adhd.pdf
205. Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. *J Psychopharmacol.* 2012 Jun;26(6):753-65. doi: 10.1177/0269881111412095. PMID: 21948938.
206. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Med.* 2012 Sep 4;10:99. doi: 10.1186/1741-7015-10-99. PMID: 22947230.
207. Shou S, Xiu S, Li Y, et al. Efficacy of Online Intervention for ADHD: A Meta-Analysis and Systematic Review. *Front Psychol.* 2022;13:854810. doi: 10.3389/fpsyg.2022.854810. PMID: 35837629.
208. Sibley MH, Arnold LE, Swanson JM, et al. Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. *Am J Psychiatry.* 2022 Feb;179(2):142-51. doi: 10.1176/appi.ajp.2021.21010032. PMID: 34384227.
209. Sibley MH, Arnold LE, Swanson JM, et al. The Importance of Scrutinizing Emergent ADHD Symptoms in Adults: Response to Chamberlain and Muller. *Am J Psychiatry.* 2018 May 1;175(5):480-1. doi: 10.1176/appi.ajp.2018.17121308r. PMID: 29712477.
210. Sibley MH, Mitchell JT, Becker SP. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. *Lancet Psychiatry.* 2016 Dec;3(12):1157-65. doi: 10.1016/s2215-0366(16)30190-0. PMID: 27745869.
211. Skliarova T, Pedersen H, Holsbrekken Å, et al. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures. *BMC Psychiatry.* 2024 Jun 20;24(1):463. doi: 10.1186/s12888-024-05908-8. PMID: 38902683.

Background Papers

212. Slobodin O. The Utility of the CPT in the Diagnosis of ADHD in Individuals with Substance Abuse: A Systematic Review. *Eur Addict Res.* 2020;26(4-5):283-94. doi: 10.1159/000508041. PMID: 32535592.
213. Sopko MA, Jr., Caberwal H, Chavez B. The safety and efficacy of methylphenidate and dexamethylphenidate in adults with attention deficit/hyperactivity disorder. *J Cent Nerv Syst Dis.* 2010;2:15-30. doi: 10.4137/jcnsd.s4178. PMID: 23861628.
214. Spencer TJ, Brown A, Seidman LJ, et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. *J Clin Psychiatry.* 2013 Sep;74(9):902-17. doi: 10.4088/JCP.12r08287. PMID: 24107764.
215. Staley BS, Robinson LR, Claussen AH, et al. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults - National Center for Health Statistics Rapid Surveys System, United States, October-November 2023. *MMWR Morb Mortal Wkly Rep.* 2024 Oct 10;73(40):890-5. doi: 10.15585/mmwr.mm7340a1. PMID: 39388378.
216. Stamatis CA, Heusser AC, Simon TJ, et al. Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01. *Translational Psychiatry.* 2024;14(1). doi: 10.1038/s41398-024-03045-0.
217. Stuhec M, Lukić P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. *Ann Pharmacother.* 2019 Feb;53(2):121-33. doi: 10.1177/1060028018795703. PMID: 30117329.
218. Surman CBH, Walsh DM. Do Treatments for Adult ADHD Improve Emotional Behavior? A Systematic Review and Analysis. *J Atten Disord.* 2022 Dec;26(14):1822-32. doi: 10.1177/10870547221110926. PMID: 35822610.
219. Surman CBH, Walsh DM. Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults. *CNS Drugs.* 2022 Mar;36(3):253-60. doi: 10.1007/s40263-022-00905-5. PMID: 35246824.
220. Surman CBH, Walsh DM. Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials. *J Clin Pharmacol.* 2023 Jun;63(6):640-53. doi: 10.1002/jcph.2209. PMID: 36731171.
221. Surman CBH, Walsh DM, Bond JB. Comparing Pharmacotherapies for ADHD in Adults: Evidence From Outcome-Focused Analysis of Food and Drug Administration Drug Label Registration Trials. *J Atten Disord.* 2024 Mar;28(5):800-9. doi: 10.1177/10870547231218041. PMID: 38229445.
222. Swanson JM. Symposium on Unsolved Mysteries in the Treatment of ADHD with Psychostimulants: Is There Any Clinical Evidence for the Occurrence of Long-Term Tolerance to Methylphenidate? 8th World Congress on ADHD; 2021 May 6-9.
223. Swanson JM. Comment after symposium on Unsolved Mysteries and Tolerance. 2021.

Background Papers

224. Swanson JM. Hot Topic: Special Issues on Pharmacological Treatment of ADHD-Acute and late tolerance: Are these real problems using stimulants? World Congress on ADHD; 2023 May 6-9; Amsterdam.
225. Swanson JM. Fluctuating ADHD Across the Course of the MTA. 2024 CHADD Research Symposium; 2024.
226. Swanson JM, Coghill D. Paradoxes and Fallacies that Apply to Diagnosis and Treatment of ADHD. 2025.
227. Tamminga HG, Reneman L, Huizenga HM, et al. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. *Psychol Med*. 2016 Jul;46(9):1791-807. doi: 10.1017/s0033291716000350. PMID: 27019103.
228. Taylor A, Deb S, Unwin G. Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): a systematic review. *Res Dev Disabil*. 2011 May-Jun;32(3):924-38. doi: 10.1016/j.ridd.2010.12.036. PMID: 21316190.
229. Thomson A, Maltezos S, Paliokosta E, et al. Amphetamine for attention deficit hyperactivity disorder in people with intellectual disabilities. *Cochrane Database Syst Rev*. 2009 Jan 21;2009(1):Cd007009. doi: 10.1002/14651858.CD007009.pub2. PMID: 19160313.
230. Thomson A, Maltezos S, Paliokosta E, et al. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. *Cochrane Database Syst Rev*. 2009 Apr 15;2009(2):Cd007011. doi: 10.1002/14651858.CD007011.pub2. PMID: 19370667.
231. Torres-Acosta N, O'Keefe JH, O'Keefe CL, et al. Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2020 Aug 18;76(7):858-66. doi: 10.1016/j.jacc.2020.05.081. PMID: 32792083.
232. Tourjman V, Louis-Nascan G, Ahmed G, et al. Psychosocial Interventions for Attention Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis by the CADDRA Guidelines Work GROUP. *Brain Sci*. 2022 Aug 1;12(8). doi: 10.3390/brainsci12081023. PMID: 36009086.
233. Trejo S, Vajsz K. Research Symposium II: Dimensional Assessment of ADHD in Adults/Adolescents. 2024.
234. Treuer T, Méndez L, Montgomery W, et al. Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. *Neuropsychiatr Dis Treat*. 2016;12:1061-83. doi: 10.2147/ndt.S97724. PMID: 27217754.
235. Tsujii N, Okada T, Usami M, et al. Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. *J Clin Psychiatry*. 2020 Mar 24;81(3). doi: 10.4088/JCP.19r13015. PMID: 32237294.
236. Turner D. A review of the use of modafinil for attention-deficit hyperactivity disorder. *Expert Rev Neurother*. 2006 Apr;6(4):455-68. doi: 10.1586/14737175.6.4.455. PMID: 16623645.

Background Papers

237. Varela JL, Magnante AT, Miskey HM, et al. A systematic review of the utility of continuous performance tests among adults with ADHD. *Clin Neuropsychol*. 2024 Feb 29;1-62. doi: 10.1080/13854046.2024.2315740. PMID: 38424025.
238. Veilahti AVP, Kovarskis L, Cowley BU. Neurofeedback Learning Is Skill Acquisition but Does Not Guarantee Treatment Benefit: Continuous-Time Analysis of Learning-Curves From a Clinical Trial for ADHD. *Front Hum Neurosci*. 2021;15:668780. doi: 10.3389/fnhum.2021.668780. PMID: 34276325.
239. Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2017 Oct 2;10(10):Cd009504. doi: 10.1002/14651858.CD009504.pub2. PMID: 28965364.
240. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. *Adv Ther*. 2009 Feb;26(2):170-84. doi: 10.1007/s12325-009-0008-7. PMID: 19238340.
241. Veronesi GF, Gabellone A, Tomlinson A, et al. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. *Neurosci Biobehav Rev*. 2024 Aug;163:105774. doi: 10.1016/j.neubiorev.2024.105774. PMID: 38914177.
242. Vidal-Estrada R, Bosch-Munso R, Nogueira-Morais M, et al. Psychological treatment of attention deficit hyperactivity disorder in adults: a systematic review. *Actas Esp Psiquiatr*. 2012 May-Jun;40(3):147-54. PMID: 22723133.
243. Villas-Boas CB, Chierrito D, Fernandez-Llimos F, et al. Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review. *Int Clin Psychopharmacol*. 2019 Mar;34(2):57-64. doi: 10.1097/yic.0000000000000243. PMID: 30422834.
244. Weisler RH, Adler LA, Kollins SH, et al. Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate. *Neuropsychiatr Dis Treat*. 2014;10:1-12. doi: 10.2147/ndt.S47087. PMID: 24363557.
245. Weiss MD, Surman C, Khullar A, et al. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. *CNS Drugs*. 2021 Jun;35(6):667-79. doi: 10.1007/s40263-021-00814-z. PMID: 34057707.
246. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. *J Clin Psychopharmacol*. 2004 Feb;24(1):30-5. doi: 10.1097/01.jcp.0000104907.75206.c2. PMID: 14709944.
247. Westwood SJ, Radua J, Rubia K. Noninvasive brain stimulation in children and adults with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *J Psychiatry Neurosci*. 2021 Jan 4;46(1):E14-e33. doi: 10.1503/jpn.190179. PMID: 33009906.
248. Wietecha LA, Clemow DB, Buchanan AS, et al. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled

Background Papers

- Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials. *CNS Neurosci Ther*. 2016 Jul;22(7):546-57. doi: 10.1111/cns.12533. PMID: 26922462.
249. Wietecha LA, Ruff DD, Allen AJ, et al. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. *J Clin Psychiatry*. 2013 Mar 29;74(12):1217-23. doi: 10.4088/JCP.12m07991. PMID: 24434090.
250. Wigal SB, Wigal T, Hobart M, et al. Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. *Neuropsychiatr Dis Treat*. 2020;16:1411-26. doi: 10.2147/ndt.S242084. PMID: 32606695.
251. Wilens TE. Drug therapy for adults with attention-deficit hyperactivity disorder. *Drugs*. 2003;63(22):2395-411. doi: 10.2165/00003495-200363220-00002. PMID: 14609347.
252. Wilens TE, Biederman J, Spencer TJ, et al. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. *J Clin Psychopharmacol*. 1995 Aug;15(4):270-9. doi: 10.1097/00004714-199508000-00006. PMID: 7593710.
253. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. *J Atten Disord*. 2002 Mar;5(4):189-202. doi: 10.1177/108705470100500401. PMID: 11967475.
254. Wilson AC. Cognitive Profile in Autism and ADHD: A Meta-Analysis of Performance on the WAIS-IV and WISC-V. *Arch Clin Neuropsychol*. 2024 May 21;39(4):498-515. doi: 10.1093/arclin/acad073. PMID: 37779387.
255. Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. *CNS Drugs*. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. PMID: 22712698.
256. Wynchank D, Bijlenga D, Beekman AT, et al. Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature. *Curr Psychiatry Rep*. 2017 Oct 30;19(12):98. doi: 10.1007/s11920-017-0860-0. PMID: 29086065.
257. Xue J, Zhang Y, Huang Y. A meta-analytic investigation of the impact of mindfulness-based interventions on ADHD symptoms. *Medicine (Baltimore)*. 2019 Jun;98(23):e15957. doi: 10.1097/md.00000000000015957. PMID: 31169722.
258. Young Z, Moghaddam N, Tickle A. The Efficacy of Cognitive Behavioral Therapy for Adults With ADHD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Atten Disord*. 2020 Apr;24(6):875-88. doi: 10.1177/1087054716664413. PMID: 27554190.
259. Yu S, Shen S, Tao M. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis. *J Child Adolesc Psychopharmacol*. 2023 Mar;33(2):40-50. doi: 10.1089/cap.2022.0038. PMID: 36944092.
260. Zhang J, Díaz-Román A, Cortese S. Meditation-based therapies for attention-deficit/hyperactivity disorder in children, adolescents and adults: a systematic review and meta-analysis. *Evid Based Ment Health*. 2018 Aug;21(3):87-94. doi: 10.1136/ebmental-2018-300015. PMID: 29991532.
261. Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.

Background Papers

JAMA Netw Open. 2022 Nov 1;5(11):e2243597. doi: 10.1001/jamanetworkopen.2022.43597. PMID: 36416824.

262. Zhu S, Wang T, Wang J, et al. Efficacy and Safety of PRC-063 for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis From Randomized Controlled Trials. J Atten Disord. 2023 Mar;27(5):470-87. doi: 10.1177/10870547231153941. PMID: 36794817.

Excluded Publications

List of Excluded Publications with Reasons for Exclusion

1. Diagnosis of attention deficit disorder in adult alcoholics: The case of DSM III—R. US: Haworth Press; 1990. p. 123-7. *Exclude-Comparator*
2. Predictive power of frontal lobe tests in the diagnosis of attention-deficit hyperactivity disorder. United Kingdom: Taylor & Francis; 1999. p. 12-21. *Exclude-Population*
3. Dexamethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexamethylphenidate, dexamethylphenidate hydrochloride. Drugs R D. 2002;3(4):279-82. doi: 10.2165/00126839-200203040-00010. PMID: 12455205. *Exclude-Design*
4. Neuropsychological executive functions and DSM-IV ADHD subtypes. US: Lippincott Williams & Wilkins; 2002. p. 59-66. *Exclude-Population*
5. Messy purse girls: Adult females and ADHD. United Kingdom: Blackwell Publishing; 2002. p. 69-72. *Exclude-Intervention*
6. An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder. 2002. *Possible multiple publication*
7. CBT for Residual ADHD Symptoms in Adults. In: National Institute of Mental H, editor; 2002. *Currently being assessed for management*
8. Treatment of Adult ADHD in Methadone Patients. In: National Institute on Drug A, editor; 2003. *Possible multiple publication*
9. An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder. 2005. *Possible multiple publication*
10. A Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2005. *Exclude-Comparator*
11. A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder. 2005. *Possible multiple publication*
12. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder. 2005. *Possible multiple publication*
13. A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2005. *Possible multiple publication*

Excluded Publications

14. Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder. 2005. *Exclude-Comparator*
15. A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning. 2005. *Possible multiple publication*
16. A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD. In: National Institute on Drug A, Ortho-McNeil Janssen Scientific Affairs LLC, eds.; 2005. *Possible multiple publication*
17. A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder. 2005. *Exclude-Population*
18. A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, eds.; 2005. *Possible multiple publication*
19. Treatment of Patients With Alcoholism and Attention Deficit Disorder. 2005. *Possible multiple publication*
20. A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified. In: Eli L, Company, eds.; 2005. *Exclude-Design*
21. Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD). In: National Institute on Drug A, University of Colorado D, eds.; 2005. *Exclude-Population*
22. A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder. 2005. *Possible multiple publication*
23. A Pilot Study of Concerta Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, eds.; 2005. *Possible multiple publication*
24. A Double Blind, Placebo-Controlled Crossover Study to Determine the Effects of Methylphenidate on Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder. 2005. *Exclude-Comparator*
25. Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder. 2005. *Possible multiple publication*
26. Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, eds.; 2005. *Exclude-Comparator*

Excluded Publications

27. Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial. 2005. *Possible multiple publication*
28. Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. In: National Institute on Drug A, editor; 2005. *Currently being assessed for management*
29. Measuring and Predicting Response to Atomoxetine and Methylphenidate. In: National Institute of Mental H, editor; 2005. *Exclude-Population*
30. A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2005. *Possible multiple publication*
31. Efficacy of CBT for Residual ADHD in Adults. In: National Institute of Mental H, editor; 2005. *Currently being assessed for management*
32. Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder. 2005. *Currently being assessed for management*
33. Stimulants similarly effective for ADHD. Journal of Family Practice. 2005;54(9):750. *Currently being assessed for management*
34. A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2006. *Possible multiple publication*
35. A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD). In: Shire, editor; 2006. *Exclude-Design*
36. An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder. 2006. *Exclude-Comparator*
37. A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day. 2006. *Possible multiple publication*
38. An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder. 2006. *Possible multiple publication*
39. Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, eds.; 2006. *Possible multiple publication*

Excluded Publications

40. Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, Children's National Research I, eds.; 2006. *Possible multiple publication*
41. Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study. In: Eli L, Company, eds.; 2006. *Currently being assessed for management*
42. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). 2006. *Possible multiple publication*
43. Sleep and Tolerability of Extended Release Dexamethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY). In: Novartis, editor; 2006. *Exclude-Population*
44. Treatment of Meta-Cognitive Deficits in Adults With ADHD. In: National Institute of Mental H, editor; 2006. *Currently being assessed for management*
45. A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder. 2006. *Currently being assessed for management*
46. A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With ADDERALL XR and STRATTERA Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2007. *Possible multiple publication*
47. A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes. 2007. *Possible multiple publication*
48. A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2007. *Possible multiple publication*
49. Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD. In: Shire, editor; 2007. *Currently being assessed for management*
50. A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD. In: Ministry of H, Social Affairs S, Region S, eds.; 2007. *Possible multiple publication*
51. An Open-Label Pilot Study of Namenda (Memantine Hydrochloride) in Adult Subjects With Attention Deficit Hyperactivity Disorder (ADHD) and ADHD NOS. 2007. *Exclude-Design*
52. A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall. 2007. *Possible multiple publication*

Excluded Publications

53. A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence. In: National Institute on Drug A, editor; 2007. *Possible multiple publication*
54. A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD). 2007. *Possible multiple publication*
55. Psychometric Study of the Chinese Versions of the Swanson, Nolan, and Pelham, Version IV (SNAP-IV) Scale and Strengths Difficulties Questionnaire. 2007. *Exclude-Population*
56. Brain Dopamine Function in Adults With ADHD. In: Icahn School of Medicine at Mount S, Duke U, eds.; 2007. *Currently being assessed for management*
57. A Phase Iia, Randomized, Double Blind, Placebo Controlled, Three-treatment, Two-period Crossover Study Of The Efficacy And Safety Of Two Doses Of Pf-03654746 In Adults With Attention Deficit Hyperactivity Disorder. 2007. *Currently being assessed for management*
58. Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development. In: Ortho-McNeil Janssen Scientific Affairs LLC, editor; 2008. *Exclude-Population*
59. Further Studies of Attention Deficit Disorder - Residual Type. In: National Institute of Mental H, editor; 2008. *Possible multiple publication*
60. A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA). 2008. *Exclude-Comparator*
61. The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study. In: Shire, editor; 2008. *Currently being assessed for management*
62. Quality Assurance of Administering Methylphenidate in Adults With ADHD. 2008. *Possible multiple publication*
63. An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD). In: Shire, editor; 2008. *Exclude-Comparator*
64. Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD. 2008. *Possible multiple publication*
65. Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study. 2008. *Currently being assessed for management*

Excluded Publications

66. A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2008. *Possible multiple publication*
67. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder. 2008. *Currently being assessed for management*
68. Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia. In: Takeda, editor; 2008. *Currently being assessed for management*
69. Comparison of Self and Clinician Administered Rating Scales in Patients With Attention Deficit Hyperactivity Disorder (ADHD). 2008. *Exclude-Population*
70. Dose Response Pharmacogenetic Study of ADHD. In: National Institute of Mental H, editor; 2008. *Exclude-Population*
71. An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD). In: Targacept I, editor; 2008. *Currently being assessed for management*
72. Lis-dexamphetamine (LDX/SPD489) as a Treatment for Smoking Cessation in Nicotine Dependent Individuals With ADHD. In: Shire, editor; 2008. *Currently being assessed for management*
73. An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder. 2008. *Exclude-Design*
74. A Double Blind, Placebo Controlled, Randomized, Two Period 4-Arm Trial to Investigate the Dose-Related Efficacy and Safety of Org 26576 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). 2008. *Currently being assessed for management*
75. A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate. 2009. *Possible multiple publication*
76. An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking. 2009. *Exclude-Design*
77. Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD). 2009. *Exclude-Design*
78. A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD). 2009. *Currently being assessed for management*

Excluded Publications

79. A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD). 2009. *Possible multiple publication*
80. Treatment of College Students With ADHD Using OROS Methylphenidate. In: Ortho-McNeil Janssen Scientific Affairs LLC, editor; 2009. *Possible multiple publication*
81. Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD. In: Korea Health Industry Development I, editor; 2009. *Exclude-Population*
82. Driving Ability in Adults With ADHD Before and After 10-weeks of Treatment With 40-80mg Atomoxetine vs. Untreated Adults With ADHD. In: Heidelberg U, editor; 2009. *Possible multiple publication*
83. Psychostimulant Treatment of TBI-Related Attention Deficits: fMRI Analysis of Neural Mechanisms of Response. In: Shire, editor; 2009. *Exclude-Population*
84. Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial. 2009. *Exclude-Population*
85. Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial. 2009. *Exclude-Population*
86. A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder. 2009. *Possible multiple publication*
87. A Phase I, Randomized, Double Blind, Three-Period Crossover, Estimation Study Using Lisdexamfetamine Dimesylate, Immediate Release Mixed Amphetamine Salts and Placebo to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2009. *Possible multiple publication*
88. A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,Tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 Weeks of Treatment in Adult Non-Users and Users of Nicotine Containing Products. 2009. *Currently being assessed for management*
89. Pilot Study of the Efficacy of Duloxetine in Treating Adults With Attention Deficit Hyperactivity Disorder: a Randomized, Controlled Trial. In: Centre hospitalier de l'Université de M, editor; 2009. *Possible multiple publication*
90. A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder. 2009. *Possible multiple publication*

Excluded Publications

91. Stimulant Drug Treatment of AD/HD, Inattentive Type. In: National Institute of Mental H, editor; 2009. *Exclude-Population*
92. A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of Carbidopa. 2009. *Currently being assessed for management*
93. Predictive validity of callous–unemotional traits measured in early adolescence with respect to multiple antisocial outcomes. US: American Psychological Association; 2010. p. 752-63. *Exclude-Intervention*
94. A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD. 2010. *Possible multiple publication*
95. Diagnostic Utility of ADHD by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials. In: EIMind AL, editor; 2010. *Exclude-Comparator*
96. Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? ; 2010. *Possible multiple publication*
97. Evaluation of Pharmacokinetics and Profile of Clinical Response of Subacute Lisdexamfetamine Dimesylate (Vyvanse) Treatment vs. Clinical Response to Subacute Immediate Release Mixed Amphetamine Salt Therapy in Adult ADHD. In: Shire, editor; 2010. *Exclude-Comparator*
98. A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-Regulation) Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-World Executive Function Behavior. 2010. *Possible multiple publication*
99. Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD). In: National Institutes of H, National Institute on Drug A, eds.; 2010. *Possible multiple publication*
100. A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria. 2010. *Exclude-Population*
101. In: Shire, editor; 2010. *Currently being assessed for management*
102. A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder. 2010. *Currently being assessed for management*
103. A Phase I/IIa Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Immediate-Release Viloxazine in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). 2010. *Currently being assessed for management*

Excluded Publications

104. Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder. 2010. *Possible multiple publication*
105. A Proof of Concept Randomised Controlled Trial to Examine the Potential Efficacy, Patient Acceptability and Feasibility of Cognitive-behavioural Therapy for Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2010. *Currently being assessed for management*
106. A brief DSM-IV-referenced teacher rating scale for monitoring behavioral improvement in ADHD and co-occurring symptoms. US: Sage Publications; 2011. p. 235-45. *Exclude-Population*
107. A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day. 2011. *Currently being assessed for management*
108. Genetic Modulation of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes. In: German Research F, editor; 2011. *Currently being assessed for management*
109. A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD. 2011. *Exclude-Comparator*
110. Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students With ADHD. In: Lehigh U, editor; 2011. *Possible multiple publication*
111. An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day. 2011. *Exclude-Comparator*
112. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Inattentive-Predominant Attention Deficit/Hyperactivity Disorder (ADHD). 2011. *Possible multiple publication*
113. Efficacy Of Bupropion SR For Attention Deficit Hyperactivity Disorder (ADHD) In Adults With Recent Past or Current Substance Use Disorders. 2011. *Currently being assessed for management*
114. An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD). In: NeuroSigma I, editor; 2011. *Exclude-Population*
115. Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy. In: Fonds N, editor; 2011. *Possible multiple publication*

Excluded Publications

116. A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316. 2011. *Exclude-Population*
117. Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. 2011. *Currently being assessed for management*
118. EVALUATION OF THE EFFECTS OF THE MINDFULNESS MEDITATION PRACTICES ON COGNITION OF ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER. In: Fundação de Amparo à Pesquisa do Estado de São P, editor; 2012. *Exclude-Intervention*
119. A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder. 2012. *Currently being assessed for management*
120. Effects of Methylphenidate on Resting State Connectivity in Healthy Controls and in Adults With Attention Deficit Hyperactivity Disorder. In: Netherlands Brain F, editor; 2012. *Exclude-Timing*
121. Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist. In: United States Department of D, editor; 2012. *Possible multiple publication*
122. Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach. In: National Institute of Mental H, editor; 2012. *Exclude-Population*
123. A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2012. *Possible multiple publication*
124. Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder. 2012. *Possible multiple publication*
125. Validation of a Clinical Interview for a Diagnosis of ADHD in Adults. Cross-validity of Screening Instruments ADHD in Adults. Estimation of Prevalence in France. 2012. *Exclude-Language*
126. Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder. In: The Research Council of N, The Hospital of V, Norwegian Institute of Public H, eds.; 2013. *Possible multiple publication*
127. L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. In: Pamlab I, editor; 2013. *Currently being assessed for management*
128. An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. 2013. *Exclude-Comparator*

Excluded Publications

129. Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD. In: Shire, editor; 2013. *Possible multiple publication*
130. The Relationship of Essential Fatty Acids to Cognitive, Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls. 2013. *Possible multiple publication*
131. Sequencing Treatments for Mothers With ADHD and Their At - Risk Children. In: Shire, editor; 2013. *Possible multiple publication*
132. Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study. 2013. *Currently being assessed for management*
133. Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation. 2013. *Currently being assessed for management*
134. Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity. In: Shire, editor; 2013. *Possible multiple publication*
135. Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging. 2013. *Exclude-Comparator*
136. Double Blind Randomized Controlled Trial Evaluation of a Novel Brain Plasticity-based Training Program for the Remediation of Cognitive Deficits in Adolescents With ADHD in New Delhi, India. In: Fogarty International Center of the National Institute of H, editor; 2013. *Exclude-Population*
137. The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder. In: srl DMF, editor; 2013. *Exclude-Population*
138. Efficacy of a Neurofeedback Treatment in Adults With ADHD: a Triple-blind Randomized Placebo-controlled Study. In: German Research F, editor; 2013. *Possible multiple publication*
139. An Exploratory, Single-Blind Pilot Trial of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder. 2013. *Currently being assessed for management*
140. A Placebo-Control Evaluation of Neurofeedback Efficacy in Adults With ADHD. 2013. *Exclude-Outcome*
141. Tipepidine for ADHD. 2013. *Exclude-Population*
142. A Randomized, Double-blind Study of the Time Course of Response of PRC-063 in Adults With ADHD in a Simulated Adult Workplace Environment. In: Purdue Pharma LP, editor; 2014. *Possible multiple publication*

Excluded Publications

143. Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality. In: McNeil C, Specialty Pharmaceuticals aDoM-PPCI, eds.; 2014. *Possible multiple publication*

144. Effects of Lisdexamfetamine on Cognitive Control and Reward Response in Adolescents and Young Adults With ADHD: Neural and Clinical Outcomes. In: Shire, editor; 2014. *Exclude-Population*

145. A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2014. *Exclude-Comparator*

146. A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2014. *Possible multiple publication*

147. A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD). 2014. *Currently being assessed for management*

148. Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder. 2014. *Exclude-Comparator*

149. Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study. 2014. *Possible multiple publication*

150. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients. In: Purdue Pharma C, editor; 2014. *Possible multiple publication*

151. A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD. In: Purdue Pharma LP, editor; 2014. *Exclude-Comparator*

152. A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD). 2014. *Possible multiple publication*

153. The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit/Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids). In: South L, Maudsley NHSFT, eds.; 2014. *Currently being assessed for management*

154. A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder. 2014. *Exclude-Outcome*

Excluded Publications

155. Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2014. *Currently being assessed for management*
156. Psychological Treatment Through Internet and Smartphones for Adults With Attention Deficit Hyperactive Disorder (ADHD) - a Randomized Controlled Trial. In: Region S, editor; 2014. *Currently being assessed for management*
157. A Randomized, Sequential Parallel, Double-Blind, Placebo- Controlled Medical Food Study for the Safety and Efficacy of Vayarin® in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2014. *Currently being assessed for management*
158. A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2015. *Possible multiple publication*
159. A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD). 2015. *Possible multiple publication*
160. A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD. In: Purdue Pharma LP, editor; 2015. *Exclude-Timing*
161. Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder. 2015. *Exclude-Timing*
162. Efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). In: Shire, editor; 2015. *Possible multiple publication*
163. A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). 2015. *Currently being assessed for management*
164. Mindfulness Training Versus Treatment as Usual in Adults With Attention Deficit Hyperactivity Disorder (ADHD). In: ZonMw: The Netherlands Organisation for Health R, Development, eds.; 2015. *Currently being assessed for management*
165. Motivated Behavior in Adults With and Without ADHD. 2015. *Currently being assessed for management*
166. "The impact of failing to identify suspect effort in patients undergoing adult attention-deficit/hyperactivity disorder (ADHD) assessment": Correction to Marshall et al. (2016). Psychol

Excluded Publications

Assess. 2016 Oct;28(10):1289. doi: 10.1037/pas0000340. PMID: 27158888. *Possible multiple publication*

167. Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder. In: Federal University of Rio Grande do S, Conselho Nacional de Desenvolvimento Científico e T, Coordination for the Improvement of Higher Education P, eds.; 2016. *Exclude-Comparator*

168. Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too). 2016. *Possible multiple publication*

169. Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder. 2016. *Currently being assessed for management*

170. Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder. 2016. *Currently being assessed for management*

171. Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder. In: National Institute on Drug A, editor; 2016. *Currently being assessed for management*

172. Behavioral Activation To Reduce Problem Alcohol Use In College Students With ADHD. In: University of M, editor; 2016. *Currently being assessed for management*

173. Cognitive Restructuring in ADHD: Functional Training. In: Ehave, Ontario Brain I, eds.; 2016. *Exclude-Population*

174. Comparison of the Effects of Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control on Executive Functions and Clinical Symptoms of Attention Deficit/ Hyperactivity Disorder. 2016. *Exclude-Population*

175. Effect of a Polyphenol-rich Plant Extract on Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial. 2016. *Exclude-Population*

176. Effects of Structured Skills Training Group in Treatment of ADHD in Adults: a Controlled Multicentre Study. In: Haukeland University H, Oslo University H, The Hospital of V, eds.; 2016. *Possible multiple publication*

177. Group-based Cognitive-behavioral Therapy for Adults With Attention-deficit/Hyperactivity Disorder Inattentive-type: a Pilot Study. 2016. *Exclude-Comparator*

178. A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I. 2016. *Currently being assessed for management*

179. Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With Attention-deficit/Hyperactivity Disorder. 2017. *Possible multiple publication*

Excluded Publications

180. Melatonin as Adjuvant Treatment for ADHD in Adults. In: Fundação de Amparo à Pesquisa do Estado de São P, University of Sao P, eds.; 2017. *Currently being assessed for management*
181. Effects of Polyphenolic Extract From Pine Bark on the Inattention and Hyperactivity in Patients With Attention Deficit Hyperactivity Disorder Based on the Antioxidative Status. 2017. *Exclude-Population*
182. A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder. 2017. *Currently being assessed for management*
183. Pilot Randomized-controlled Phase-IIa Trial on the Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder. In: Heidelberg U, Radboud University Medical C, Hospital Vall dH, King's College L, eds.; 2017. *Exclude-Population*
184. Randomized Clinical Trial With Adapted Skill Training Group From Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Using Medication. 2017. *Possible multiple publication*
185. A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With Attention Deficit Hyperactivity Disorder. 2017. *Exclude-Outcome*
186. A Randomized, Double-Blind, Tw0-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine® Compound, CX717, Versus Placebo in Adults With Attention-Deficit Hyperactive Disorder. 2017. *Possible multiple publication*
187. Psychoeducational Groups for Adults With Attention-Deficit Hyperactivity/Impulsivity Disorder (ADHD): a Randomized Waitlist-controlled Multicenter Pilot Trial. In: Helse Nord-Trøndelag HF, editor; 2017. *Currently being assessed for management*
188. Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans. In: Brain, Behavior Research F, National Center for C, Integrative H, eds.; 2017. *Currently being assessed for management*
189. Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)? Netherlands: Elsevier Science; 2018. p. 38-44. *Exclude-Duplicate*
190. A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder. 2018. *Currently being assessed for management*

Excluded Publications

191. An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. 2018. *Exclude-Design*
192. Adaptive Response to Intervention (RTI) for Students With ADHD. In: University at B, editor; 2018. *Exclude-Population*
193. A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD). 2018. *Possible multiple publication*
194. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD. 2018. *Possible multiple publication*
195. A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity. In: Purdue Pharma C, editor; 2018. *Possible multiple publication*
196. ; 2018. *Currently being assessed for management*
197. Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD): a Biomarker to Predict Treatment Response. In: Shire, editor; 2018. *Exclude-Design*
198. Impact of Relationship of Epilepsy and Attention Deficit Hyperactive Disorder. 2018. *Exclude-Population*
199. A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Adult ADHD. 2018. *Currently being assessed for management*
200. Randomized Placebo-controlled Treatment of Impulsivity in Adults With Probiotics. In: Goethe U, Semmelweis U, University Medical Center N, eds.; 2018. *Exclude-Population*
201. Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant (STARS-ADHD Adjunctive). 2018. *Exclude-Population*
202. Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People: A Double-blind, Randomized, Placebo-Controlled, Crossover Trial. In: Kyunghee U, editor; 2018. *Possible multiple publication*
203. The Effects of Peer Co-led Educational Group Intervention for Adults With Attention-Deficit Hyperactivity/Impulsivity Disorder. In: St. Olavs H, editor; 2018. *Currently being assessed for management*
204. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). 2019. *Possible multiple publication*
205. A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-

Excluded Publications

Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients. 2019. *Exclude-Population*

206. Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening. 2019. *Currently being assessed for management*

207. Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD. In: Premier Research Group p, editor; 2019. *Possible multiple publication*

208. 12 Month Open Extension Study of TNS for ADHD. In: National Institute of Mental H, editor; 2019. *Exclude-Population*

209. Four-week Open-trial Extension Study of Trigeminal Nerve Stimulation (TNS) for Youth Previously Randomized to Sham in a Double-Blind Trial. In: National Institute of Mental H, editor; 2019. *Exclude-Population*

210. Improving the Educational and Social-Emotional Functioning of College Students With ADHD. In: Institute of Education S, editor; 2019. *Possible multiple publication*

211. A Novel Neuromonitoring Guided Cognitive Intervention for Targeted Enhancement of Working Memory. In: National Institute of Mental H, editor; 2019. *Exclude-Population*

212. To Explore the Influence of Appetite Reduction and Medication Effect of Methylphenidate in Patients With Attention-deficit/Hyperactivity Disorder Through Pharmacogenetics. 2019. *Exclude-Population*

213. Transcranial Direct Current Stimulation for the Treatment of Inattention Symptoms in Attention-deficit/Hyperactivity Disorder: a Randomized, Double-blind, Parallel, Controlled Clinical Trial (TUNED Trial). 2019. *Possible multiple publication*

214. Transcutaneous Electrical Acupoint Stimulation for Treating Attention Deficit Hyperactivity Disorder: A Prospective, Randomized, Controlled Trial. In: Xian Children's H, Shaanxi Hospital of Traditional Chinese M, Air Force Military Medical University C, eds.; 2019. *Exclude-Population*

215. Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States. 2020. *Exclude-Population*

216. 2/2 Treating Mothers With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial. In: Children's National Research I, University of M, Seattle Children's H, National Institute of Mental H, eds.; 2020. *Exclude-Population*

217. Psychological Group Treatment in Adults With Attention Deficit Hyperactivity Disorder: Development of a Short Cognitive -Behavioral Program. 2020. *Currently being assessed for management*

Excluded Publications

218. A Self-guided Internet-delivered Intervention for Adults With ADHD: Study Protocol for a Micro-randomized Trial Investigating the Use of Reminders. In: University of B, editor; 2020. *Currently being assessed for management*
219. Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compared to Healthy Controls. 2020. *Currently being assessed for management*
220. Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study. 2021. *Currently being assessed for management*
221. Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD. In: National Institutes of H, editor; 2021. *Exclude-Population*
222. A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder. 2021. *Exclude-Outcome*
223. Could a Strength- Based Treatment Improve Self-management in Adults With Attention Deficit Hyperactivity Disorder. 2021. *Currently being assessed for management*
224. Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM-120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial. 2021. *Currently being assessed for management*
225. Ahead of the (ROC) curve: A statistical approach to utilizing ex-Gaussian parameters of reaction time in diagnosing ADHD across three developmental periods. United Kingdom: Cambridge University Press; 2022. p. 821-34. *Exclude-Duplicate*
226. Joint consideration of validity indicators embedded in Conners' Adult ADHD Rating Scales (CAARS). Germany: Springer; 2022. p. 172-88. *Exclude-Duplicate*
227. Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill. In: Maccabi Healthcare Services I, editor; 2022. *Currently being assessed for management*
228. Assessment of TDApp2 an eHealth Tool to Make Pharmacologic and Non-pharmacologic Treatment Recommendations for Patients With ADHD. In: Institut d'Assistència S, editor; 2022. *Exclude-Population*
229. A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II. In: Abvc BioPharma I, editor; 2022. *Currently being assessed for management*
230. What Are the Long-Term Effects of Cognitive-Behavioural Therapy on Quality of Life in Adult Patients With ADHD? In: Amsterdam University Medical Centers LAMC, editor; 2022. *Currently being assessed for management*

Excluded Publications

231. Evaluation of the Effectiveness of the FOCUS ADHD Mobile Health Platform in the Monitoring of Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD). In: University of Sao P, editor; 2022. *Currently being assessed for management*
232. A Pilot Study of a Blended Intervention Targeting Emotion Dysregulation in Adults With ADHD. In: Haukeland University H, editor; 2022. *Currently being assessed for management*
233. Retrospective diagnosis of childhood ADHD using the Wender Utah Rating Scale. France: Elsevier Masson SAS; 2023. p. 481-8. *Exclude-Population*
234. A Phase IV, Open-Label, Decentralized Clinical Trial to Evaluate the Efficacy and Safety of Qelbree® in Adults With Attention-Deficit/Hyperactivity Disorder and Mood Symptoms. 2023. *Currently being assessed for management*
235. An Open-Label Treatment, Investigator-Initiated Study, on the Duration and Efficacy of Azstarys (Serdexmethylphenidate and Dexmethylphenidate) on Adult ADHD Symptoms and Executive Function in Early Evening. In: Corium I, editor; 2023. *Exclude-Design*
236. Randomized Placebo-Controlled Trial of Methylphenidate for the Treatment of Post-Traumatic Stress Disorder With Associated Neurocognitive Complaints. 2023. *Exclude-Outcome*
237. A Single Center, Flexible-Dose, 10-Week, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial To Study The Efficacy Of Dyanavel XR In Treating Co-Occurring Fatigue In Adults With Attention Deficit/Hyperactivity Disorder (ADHD). 2024. *Exclude-Outcome*
238. An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening. 2024. *Exclude-Outcome*
239. Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder. In: Medical University of South C, editor; 2024. *Currently being assessed for management*
240. Aarts E, van Holstein M, Hoogman M, et al. Reward modulation of cognitive function in adult attention-deficit/hyperactivity disorder: a pilot study on the role of striatal dopamine. Behav Pharmacol. 2015 Feb;26(1-2):227-40. doi: 10.1097/fbp.000000000000116. PMID: 25485641. *Exclude-Intervention*
241. Abbas R, Childress AC, Nagraj P, et al. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Clin Ther. 2018 May;40(5):733-40. doi: 10.1016/j.clinthera.2018.03.016. PMID: 29703430. *Exclude-Population*
242. Abbas R, Palumbo D, Walters F, et al. Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Clin Ther. 2016 May;38(5):1151-7. doi: 10.1016/j.clinthera.2016.02.026. PMID: 27021606. *Exclude-Population*

Excluded Publications

243. Abbass K, Corbisiero S, Stieglitz RD. Development and psychometric properties of the ADHD-SCL-90-R screening scale for adult ADHD. *J Clin Psychol*. 2021 Jun;77(6):1428-42. doi: 10.1002/jclp.23088. PMID: 33188720. *Exclude-Language*
244. Abdullah WNW, Yaacob MJ, Wei WK, et al. Validity and reliability of the translated malay version of the attention deficit hyperactivity disorder rating scale-IV (ADHD RS-IV). *International Medical Journal*. 2011;18(4):310-1. *Exclude-Intervention*
245. Abikoff H, Courtney M, Pelham WE, Jr., et al. Teachers' ratings of disruptive behaviors: the influence of halo effects. *J Abnorm Child Psychol*. 1993 Oct;21(5):519-33. doi: 10.1007/bf00916317. PMID: 8294651. *Exclude-Population*
246. Abramovitch A, Dar R, Mittelman A, et al. Comorbidity Between Attention Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder Across the Lifespan: A Systematic and Critical Review. *Harv Rev Psychiatry*. 2015 Jul-Aug;23(4):245-62. doi: 10.1097/hrp.000000000000050. PMID: 26052877. *Exclude-Intervention*
247. Adachi Y, Yoshikawa H, Yokoyama S, et al. Characteristics of university students supported by counseling services: Analysis of psychological tests and pulse rate variability. *PLoS One*. 2020;15(8):e0218357. doi: 10.1371/journal.pone.0218357. PMID: 32822354. *Exclude-Intervention*
248. Adam C, Döpfner M, Lehmkuhl G. [Drug therapy of hyperkinetic diseases in adults]. *Fortschr Neurol Psychiatr*. 1999 Aug;67(8):359-66. doi: 10.1055/s-2007-994986. PMID: 10478300. *Exclude-Language*
249. Adamaszek M, Khaw AV, Buck U, et al. Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users. *PLoS One*. 2010 Nov 23;5(11):e14097. doi: 10.1371/journal.pone.0014097. PMID: 21124854. *Exclude-Intervention*
250. Adams Z, Adams T, Stauffacher K, et al. The Effects of Inattentiveness and Hyperactivity on Posttraumatic Stress Symptoms: Does a Diagnosis of Posttraumatic Stress Disorder Matter? *J Atten Disord*. 2020 Jul;24(9):1246-54. doi: 10.1177/1087054715580846. PMID: 25882836. *Exclude-Population*
251. Addicott MA, Pearson JM, Schechter JC, et al. Attention-deficit/hyperactivity disorder and the explore/exploit trade-off. *Neuropsychopharmacology*. 2021 Feb;46(3):614-21. doi: 10.1038/s41386-020-00881-8. PMID: 33040092. *Exclude-Intervention*
252. Addicott MA, Schechter JC, Sapyta JJ, et al. Methylphenidate increases willingness to perform effort in adults with ADHD. *Pharmacol Biochem Behav*. 2019 Aug;183:14-21. doi: 10.1016/j.pbb.2019.06.008. PMID: 31226260. *Exclude-Intervention*
253. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. *Ann Clin Psychiatry*. 2006 Apr-Jun;18(2):107-13. doi: 10.1080/10401230600614603. PMID: 16754416. *Currently being assessed for management*

Excluded Publications

254. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. *Annals of Clinical Psychiatry*. 2006;18(2):107-13. doi: 10.1080/10401230600614603. *Currently being assessed for management*
255. Adler L, Shaw D, Sitt D, et al. Issues in the diagnosis and treatment of adult ADHD by primary care physicians. *Primary Psychiatry*. 2009;16(5):57-63. *Exclude-Intervention*
256. Adler L, Tanaka Y, Williams D, et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. *J Clin Psychopharmacol*. 2014 Aug;34(4):461-6. doi: 10.1097/jcp.000000000000138. PMID: 24977716. *Possible multiple publication*
257. Adler L, Wilens T, Zhang S, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. *Am J Addict*. 2009 Sep-Oct;18(5):393-401. doi: 10.3109/10550490903077663. PMID: 19874159. *Exclude-Intervention*
258. Adler L, Wu J, Madhoo M, et al. Post hoc analyses of the efficacy of lisdexamfetamine dimesylate in adults previously treated with attention deficit/hyperactivity disorder medication. *European Psychiatry*. 2015;30:566. *Currently being assessed for management*
259. Adler LA. Diagnosing and treating adult ADHD and comorbid conditions. *J Clin Psychiatry*. 2008 Nov 15;69(11):e31. doi: 10.4088/jcp.1108e31. PMID: 19200423. *Exclude-Design*
260. Adler LA, Alperin S, Leon T, et al. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial. *Postgrad Med*. 2014 Sep;126(5):17-24. doi: 10.3810/pgm.2014.09.2796. PMID: 25295646. *Exclude-Design*
261. Adler LA, Alperin S, Leon T, et al. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2017 Mar;27(2):196-9. doi: 10.1089/cap.2016.0121. PMID: 27935735. *Exclude-Intervention*
262. Adler LA, Anbarasan D, Leon T, et al. Pilot Study of Prism EFP NeuroFeedback in Adult ADHD. *J Atten Disord*. 2024 Mar;28(5):905-12. doi: 10.1177/10870547231215283. PMID: 38152997. *Exclude-Intervention*
263. Adler LA, Anbarasan D, Sardoff T, et al. A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day. *J Atten Disord*. 2024 Mar;28(5):810-9. doi: 10.1177/10870547231222260. PMID: 38214178. *Exclude-Intervention*
264. Adler LA, Chua HC. Management of ADHD in adults. *J Clin Psychiatry*. 2002;63 Suppl 12:29-35. PMID: 12562059. *Exclude-Intervention*

Excluded Publications

265. Adler LA, Clemow DB, Williams DW, et al. Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study. PLoS One. 2014;9(8):e104175. doi: 10.1371/journal.pone.0104175. PMID: 25148243. *Currently being assessed for management*
266. Adler LA, Clemow DB, Williams DW, et al. Atomoxetine effects on executive function as measured by the BRIEF-A in young adults with ADHD: A randomized, double-blind, placebo-controlled study. PLoS ONE. 2014;9(8). doi: 10.1371/journal.pone.0104175. *Currently being assessed for management*
267. Adler LA, Dirks B, Deas P, et al. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry. 2013 Oct 9;13:253. doi: 10.1186/1471-244x-13-253. PMID: 24106804. *Possible multiple publication*
268. Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 Jul;74(7):694-702. doi: 10.4088/JCP.12m08144. PMID: 23945447. *Currently being assessed for management*
269. Adler LA, Frick G, Yan B. A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD. J Atten Disord. 2020 Feb;24(3):434-46. doi: 10.1177/1087054717696770. PMID: 28412886. *Exclude-Design*
270. Adler LA, Goldman R, Hopkins SC, et al. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. Int Clin Psychopharmacol. 2021 May 1;36(3):117-25. doi: 10.1097/yic.0000000000000333. PMID: 33724251. *Currently being assessed for management*
271. Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009 Aug 3;5:34. doi: 10.1186/1744-9081-5-34. PMID: 19650932. *Currently being assessed for management*
272. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Sep;69(9):1364-73. doi: 10.4088/jcp.v69n0903. PMID: 19012818. *Currently being assessed for management*
273. Adler LA, Gorny SW. Pilot Study of Droxidopa With Carbidopa in Adults With ADHD. J Atten Disord. 2019 Jan;23(2):189-98. doi: 10.1177/1087054715580393. PMID: 25907673. *Currently being assessed for management*
274. Adler LA, Guida F, Irons S, et al. Screening and imputed prevalence of ADHD in adult patients with comorbid substance use disorder at a residential treatment facility. Postgrad Med. 2009 Sep;121(5):7-10. doi: 10.3810/pgm.2009.09.2047. PMID: 19820269. *Exclude-Comparator*

Excluded Publications

275. Adler LA, Kroon RA, Stein M, et al. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2012 Dec 1;72(11):971-7. doi: 10.1016/j.biopsych.2012.05.012. PMID: 22771238. *Currently being assessed for management*
276. Adler LA, Leon TL, Sardoff TM, et al. A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD. *J Clin Psychiatry*. 2021 Jun 29;82(4). doi: 10.4088/JCP.20m13687. PMID: 34232582. *Currently being assessed for management*
277. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. *Depress Anxiety*. 2009;26(3):212-21. doi: 10.1002/da.20549. PMID: 19194995. *Currently being assessed for management*
278. Adler LA, Lynch LR, Shaw DM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. *Postgrad Med*. 2011 Sep;123(5):71-9. doi: 10.3810/pgm.2011.09.2461. PMID: 21904088. *Currently being assessed for management*
279. Adler LA, Lynch LR, Shaw DM, et al. Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD. *J Atten Disord*. 2017 Jan;21(2):149-57. doi: 10.1177/1087054713485421. PMID: 23657761. *Exclude-Design*
280. Adler LA, Orman C, Starr HL, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. *J Clin Psychopharmacol*. 2011 Feb;31(1):108-14. doi: 10.1097/JCP.0b013e318203ea0a. PMID: 21192153. *Currently being assessed for management*
281. Adler LA, Shaw DM, Spencer TJ, et al. Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults. *Compr Psychiatry*. 2011 Nov-Dec;52(6):769-73. doi: 10.1016/j.comppsy.2010.12.002. PMID: 21306705. *Exclude-Intervention*
282. Adler LA, Solanto M, Escobar R, et al. Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment. *J Atten Disord*. 2020 Feb;24(3):363-72. doi: 10.1177/1087054716664411. PMID: 27521574. *Currently being assessed for management*
283. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. *J Clin Psychopharmacol*. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0. PMID: 19142107. *Currently being assessed for management*
284. Adler LA, Spencer T, Faraone SV, et al. Validity of pilot Adult ADHD Self-Report Scale (ASRS) to Rate Adult ADHD symptoms. *Ann Clin Psychiatry*. 2006 Jul-Sep;18(3):145-8. doi: 10.1080/10401230600801077. PMID: 16923651. *Exclude-Intervention*

Excluded Publications

285. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. *J Atten Disord.* 2005 Feb;8(3):121-6. doi: 10.1177/1087054705277168. PMID: 16009660. *Exclude-Intervention*
286. Adler LA, Spencer T, McGough JJ, et al. Long-term effectiveness and safety of dexamethylphenidate extended-release capsules in adult ADHD. *J Atten Disord.* 2009 Mar;12(5):449-59. doi: 10.1177/1087054708320397. PMID: 19218542. *Possible multiple publication*
287. Adler LA, Spencer TJ, Levine LR, et al. Functional outcomes in the treatment of adults with ADHD. *J Atten Disord.* 2008 May;11(6):720-7. doi: 10.1177/1087054707308490. PMID: 17968028. *Currently being assessed for management*
288. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. *J Clin Psychiatry.* 2005 Mar;66(3):294-9. doi: 10.4088/jcp.v66n0304. PMID: 15766294. *Exclude-Design*
289. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. *J Atten Disord.* 2008 Nov;12(3):248-53. doi: 10.1177/1087054708316250. PMID: 18448861. *Exclude-Comparator*
290. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. *J Clin Psychopharmacol.* 2006 Dec;26(6):648-52. doi: 10.1097/01.jcp.0000239797.21826.70. PMID: 17110824. *Exclude-Design*
291. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry.* 2009 Dec;70(12):1652-61. doi: 10.4088/JCP.09m05335pur. PMID: 20141706. *Currently being assessed for management*
292. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. *J Clin Psychopharmacol.* 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce. PMID: 19440077. *Currently being assessed for management*
293. Advokat CD, Guidry D, Martino L. Licit and illicit use of medications for Attention-Deficit Hyperactivity Disorder in undergraduate college students. *J Am Coll Health.* 2008 May-Jun;56(6):601-6. doi: 10.3200/jach.56.6.601-606. PMID: 18477513. *Exclude-Intervention*
294. Agarwal R, Goldenberg M, Perry R, et al. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. *Innov Clin Neurosci.* 2012 May;9(5-6):10-21. PMID: 22808445. *Exclude-Intervention*

Excluded Publications

295. Agay N, Yechiam E, Carmel Z, et al. Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. *Psychopharmacology (Berl)*. 2010 Jul;210(4):511-9. doi: 10.1007/s00213-010-1853-4. PMID: 20424828. *Exclude-Design*
296. Agay N, Yechiam E, Carmel Z, et al. Methylphenidate enhances cognitive performance in adults with poor baseline capacities regardless of attention-deficit/hyperactivity disorder diagnosis. *J Clin Psychopharmacol*. 2014 Apr;34(2):261-5. doi: 10.1097/jcp.0000000000000076. PMID: 24525641. *Exclude-Intervention*
297. Agoalikum E, Klugah-Brown B, Wu H, et al. Gender Differences in Dynamic Functional Network Connectivity in Pediatric and Adult Patients with Attention-Deficit/Hyperactivity Disorder. *Brain Connect*. 2023 May;13(4):226-36. doi: 10.1089/brain.2022.0069. PMID: 36719777. *Exclude-Population*
298. Agoalikum E, Klugah-Brown B, Yang H, et al. Differences in Disrupted Dynamic Functional Network Connectivity Among Children, Adolescents, and Adults With Attention Deficit/Hyperactivity Disorder: A Resting-State fMRI Study. *Front Hum Neurosci*. 2021;15:697696. doi: 10.3389/fnhum.2021.697696. PMID: 34675790. *Exclude-Population*
299. Aguglia E, Fusar-Poli L. Pharmacological treatment strategies for emotional lability in adults with attention deficit/hyperactivity disorder: Focus on the Conners' Adult ADHD Rating Scales. *Journal of Psychopathology*. 2024;30(1):38-43. *Exclude-Design*
300. Aharonovich E, Garawi F, Bisaga A, et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. *Am J Drug Alcohol Abuse*. 2006;32(4):629-35. doi: 10.1080/00952990600919005. PMID: 17127551. *Exclude-Intervention*
301. Ahlers J, Baumgartner C, Augsburg M, et al. Cannabis Use in Adults Who Screen Positive for Attention Deficit/Hyperactivity Disorder: CANreduce 2.0 Randomized Controlled Trial Subgroup Analysis. *J Med Internet Res*. 2022 Apr 20;24(4):e30138. doi: 10.2196/30138. PMID: 35442196. *Currently being assessed for management*
302. Al-Wardat M, Etoom M, Almhdawi KA, et al. Prevalence of attention-deficit hyperactivity disorder in children, adolescents and adults in the Middle East and North Africa region: a systematic review and meta-analysis. *BMJ Open*. 2024 Jan 18;14(1):e078849. doi: 10.1136/bmjopen-2023-078849. PMID: 38238059. *Exclude-Intervention*
303. Alam N, Najam R. Buspirone attenuates methylphenidate-induced growth inhibition. *Pak J Pharm Sci*. 2017 Mar;30(2):369-74. PMID: 28649058. *Exclude-Population*
304. Alejandro P-S, Dr Inmaculada P-C, Dr Rocío N-J, et al. Video games for the treatment of attention-deficit/hyperactivity disorder: a systematic review. 2020. PMID: CRD42020156360. *Currently being assessed for management*
305. Alexander L, Liljequist L. Determining the Accuracy of Self-Report Versus Informant-Report Using the Conners' Adult ADHD Rating Scale. *J Atten Disord*. 2016 Apr;20(4):346-52. doi: 10.1177/1087054713478652. PMID: 23503811. *Exclude-Outcome*

Excluded Publications

306. Alexander SJ, Harrison AG. Cognitive responses to stress, depression, and anxiety and their relationship to ADHD symptoms in first year psychology students. *J Atten Disord.* 2013 Jan;17(1):29-37. doi: 10.1177/1087054711413071. PMID: 21825110. *Exclude-Intervention*
307. Alice L, Luis F, Cinzia Del G, et al. Comparative cardiovascular side effects of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. 2021. PMID: CRD42021295352. *Currently being assessed for management*
308. Allenby C, Falcone M, Bernardo L, et al. Transcranial direct current brain stimulation decreases impulsivity in ADHD. *Brain Stimul.* 2018 Sep-Oct;11(5):974-81. doi: 10.1016/j.brs.2018.04.016. PMID: 29885858. *Exclude-Intervention*
309. Almeida Montes LG, Friederichsen Alonso A, Olivia Hernández A, et al. [Construction, validity and reliability, of the screening scale "FASCT" for attention deficit hyperactivity disorder in adults (self-reported and observer versions)]. *Actas Esp Psiquiatr.* 2006 Jul-Aug;34(4):231-8. PMID: 16823683. *Exclude-Language*
310. Alotaibi MM, Motl RW, Stavrinou D, et al. Moderate-to-Vigorous Physical Activity and Response Inhibition Predict Balance in Adults with Attention Deficit/Hyperactivity Disorder. *J Clin Med.* 2024 Feb 8;13(4). doi: 10.3390/jcm13040968. PMID: 38398282. *Exclude-Intervention*
311. Altin M, Alev L, Durell TM, et al. Atomoxetine for the treatment of ADHD in young adults with an assessment of associated functional outcomes. *Klinik Psikofarmakoloji Bulteni.* 2011;21:S135-S6. *Currently being assessed for management*
312. Amador-Campos JA, Gómez-Benito J, Ramos-Quiroga JA. The Conners' Adult ADHD Rating Scales—short self-report and observer forms: Psychometric properties of the Catalan version. *Journal of Attention Disorders.* 2014;18(8):671-9. doi: 10.1177/1087054712446831. *Exclude-Intervention*
313. Amani Jabalkandi S, Raisi F, Shahrivar Z, et al. A study on sexual functioning in adults with attention-deficit/hyperactivity disorder. *Perspect Psychiatr Care.* 2020 Jul;56(3):642-8. doi: 10.1111/ppc.12480. PMID: 32043624. *Exclude-Intervention*
314. Amiri S, Farhang S, Ghoreishizadeh MA, et al. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. *Hum Psychopharmacol.* 2012 Jan;27(1):76-81. doi: 10.1002/hup.1274. PMID: 22252909. *Currently being assessed for management*
315. Amiri S, Ghoreishizadeh MA, Sadeghi-Bazargani H, et al. Prevalence of Adult Attention Deficit Hyperactivity Disorder (Adult ADHD): Tabriz. *Iran J Psychiatry.* 2014 Apr;9(2):83-8. PMID: 25632285. *Exclude-Intervention*
316. Anastopoulos AD, Langberg JM, Eddy LD, et al. A randomized controlled trial examining CBT for college students with ADHD. *J Consult Clin Psychol.* 2021 Jan;89(1):21-33. doi: 10.1037/ccp0000553. PMID: 33507774. *Currently being assessed for management*

Excluded Publications

317. Anderson CM, Lowen SB, Renshaw PF. Emotional task-dependent low-frequency fluctuations and methylphenidate: Wavelet scaling analysis of 1/f-type fluctuations in fMRI of the cerebellar vermis. *J Neurosci Methods*. 2006 Feb 15;151(1):52-61. doi: 10.1016/j.jneumeth.2005.09.020. PMID: 16427128. *Exclude-Comparator*
318. Andersson HW, Lauvsnes ADF, Nordfjærn T. Emerging Adults in Inpatient Substance Use Treatment: A Prospective Cohort Study of Patient Characteristics and Treatment Outcomes. *Eur Addict Res*. 2021;27(3):206-15. doi: 10.1159/000512156. PMID: 33279896. *Exclude-Intervention*
319. Andolsek K, Rosenberg MT, Abdolrasulnia M, et al. Complex cases in primary care: report of a CME-certified series addressing patients with multiple comorbidities. *Int J Clin Pract*. 2013 Sep;67(9):911-7. doi: 10.1111/ijcp.12175. PMID: 23952468. *Exclude-Intervention*
320. Ang A, Hillhouse M, Jenkins J, et al. Methylphenidate for methamphetamine use disorders in participants with and without ADHD. *Drug and Alcohol Dependence*. 2015;156:e7. doi: 10.1016/j.drugalcdep.2015.07.938. *Currently being assessed for management*
321. Anker E, Ogrim G, Heir T. Verbal working memory and processing speed: Correlations with the severity of attention deficit and emotional dysregulation in adult ADHD. *J Neuropsychol*. 2022 Mar;16(1):211-35. doi: 10.1111/jnp.12260. PMID: 34218514. *Exclude-Intervention*
322. Antel J, Albayrak Ö, Heusch G, et al. Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)? *Eur Arch Psychiatry Clin Neurosci*. 2015 Apr;265(3):233-47. doi: 10.1007/s00406-014-0522-8. PMID: 25149468. *Exclude-Design*
323. Antshel KM, Biederman J, Spencer TJ, et al. The Neuropsychological Profile of Comorbid Post-Traumatic Stress Disorder in Adult ADHD. *J Atten Disord*. 2016 Dec;20(12):1047-55. doi: 10.1177/1087054714522512. PMID: 24567364. *Exclude-Intervention*
324. Antshel KM, Park A, Maisto S, et al. Primary prevention of prescription stimulant misuse in first-year college students. *J Am Coll Health*. 2024 Jan 16:1-9. doi: 10.1080/07448481.2023.2299409. PMID: 38227922. *Exclude-Intervention*
325. Aoki Y, Tsuboi T, Takaesu Y, et al. Development and field testing of a decision aid to facilitate shared decision making for adults newly diagnosed with attention-deficit hyperactivity disorder. *Health Expect*. 2022 Feb;25(1):366-73. doi: 10.1111/hex.13393. PMID: 34856044. *Exclude-Intervention*
326. Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel $\alpha_4\beta_2$ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. *Psychopharmacology (Berl)*. 2012 Feb;219(3):715-25. doi: 10.1007/s00213-011-2393-2. PMID: 21748252. *Currently being assessed for management*

Excluded Publications

327. Aragonès E, Cañisá A, Caballero A, et al. [Screening for attention deficit hyperactivity disorder in adult patients in primary care]. *Rev Neurol*. 2013 May 1;56(9):449-55. PMID: 23629746. *Exclude-Language*
328. Aragonès E, Lluís Piñol J, Ramos-Quiroga JA, et al. [Prevalence in adults of attention deficit hyperactivity disorder using the medical records of primary care]. *Rev Esp Salud Publica*. 2010 Jul-Aug;84(4):417-22. PMID: 21141268. *Exclude-Language*
329. Arentsen TJ, Burley CT, Winiarski HR, et al. Clinical Validation of an ADHD Dissimulation Scale (Ds-ADHD) on the MMPI-2-RF. *Journal of Psychopathology and Behavioral Assessment*. 2024;46(1):158-69. doi: 10.1007/s10862-023-10110-3. *Exclude-Comparator*
330. Arican I, Bass N, Neelam K, et al. Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia. *Acta Psychiatr Scand*. 2019 Jan;139(1):89-96. doi: 10.1111/acps.12948. PMID: 30105761. *Exclude-Population*
331. Armstrong IT, Munoz DP. Inhibitory control of eye movements during oculomotor countermanding in adults with attention-deficit hyperactivity disorder. *Exp Brain Res*. 2003 Oct;152(4):444-52. doi: 10.1007/s00221-003-1569-3. PMID: 12879174. *Exclude-Intervention*
332. Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). *Ann N Y Acad Sci*. 2001 Jun;931:310-41. doi: 10.1111/j.1749-6632.2001.tb05788.x. PMID: 11462750. *Exclude-Intervention*
333. Arnold LE, Arns M, Conners K, et al. A Proposed Multisite Double-Blind Randomized Clinical Trial of Neurofeedback for ADHD: Need, Rationale, and Strategy. *Journal of Attention Disorders*. 2013;17(5):420-36. doi: 10.1177/1087054713482580. *Currently being assessed for management*
334. Arnold LE, Roy A, Taylor E, et al. Predictive utility of childhood diagnosis of ICD-10 hyperkinetic disorder: adult outcomes in the MTA and effect of comorbidity. *Eur Child Adolesc Psychiatry*. 2019 Apr;28(4):557-70. doi: 10.1007/s00787-018-1222-0. PMID: 30232561. *Exclude-Population*
335. Arnold VK, Feifel D, Earl CQ, et al. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. *J Atten Disord*. 2014 Feb;18(2):133-44. doi: 10.1177/1087054712441969. PMID: 22617860. *Currently being assessed for management*
336. Arns M, Drinkenburg W, Leon Kenemans J. The effects of QEEG-informed neurofeedback in ADHD: an open-label pilot study. *Appl Psychophysiol Biofeedback*. 2012 Sep;37(3):171-80. doi: 10.1007/s10484-012-9191-4. PMID: 22446998. *Exclude-Design*
337. Aron AR, Dowson JH, Sahakian BJ, et al. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2003 Dec 15;54(12):1465-8. doi: 10.1016/s0006-3223(03)00609-7. PMID: 14675812. *Exclude-Timing*

Excluded Publications

338. Arshiani H, Artounian V, Motamed M, et al. Psychometric Properties of the Persian Version of Brown Attention Deficit Disorder Scale (BADDs). *Iranian Journal of Psychiatry and Behavioral Sciences*. 2022;16(3). doi: 10.5812/ijpbs-118912. *Exclude-Language*
339. Arteaga-Henríquez G, Ramos-Sayalero C, Ibañez-Jimenez P, et al. Efficacy of a synbiotic in the management of adults with Attention-Deficit and Hyperactivity Disorder and/or Borderline Personality Disorder and high levels of irritability: Results from a multicenter, randomized, placebo-controlled, "basket" trial. *Brain Behav Immun*. 2024 Aug;120:360-71. doi: 10.1016/j.bbi.2024.06.012. PMID: 38885746. *Currently being assessed for management*
340. Arteaga-Henríquez G, Rosales-Ortiz SK, Arias-Vásquez A, et al. Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. *Trials*. 2020 Feb 11;21(1):161. doi: 10.1186/s13063-019-4040-x. PMID: 32046750. *Possible multiple publication*
341. Asbjørnsen AE, Jones L, Munkvold LH, et al. An examination of shared variance in self-report and objective measures of attention in the incarcerated adult population. *J Atten Disord*. 2010 Sep;14(2):182-93. doi: 10.1177/1087054709356395. PMID: 20065071. *Exclude-Population*
342. Ashdown-Franks G, Firth J, Carney R, et al. Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes. *Sports Med*. 2020 Jan;50(1):151-70. doi: 10.1007/s40279-019-01187-6. PMID: 31541410. *Exclude-Population*
343. Asherson P, Akehurst R, Kooij JJ, et al. Under diagnosis of adult ADHD: cultural influences and societal burden. *J Atten Disord*. 2012 Jul;16(5 Suppl):20s-38s. doi: 10.1177/1087054711435360. PMID: 22377849. *Exclude-Comparator*
344. Asherson P, Buitelaar J, Faraone SV, et al. ADHD Management in Adolescents Transitioning to Adulthood: Challenges and Opportunities. *Postgraduate Medicine*. 2016;128(8):774-83. *Currently being assessed for management*
345. Asherson P, Cooper R. Treatment of ADHD with cannabinoids. *European Psychiatry*. 2017;41:S55. doi: 10.1016/j.eurpsy.2017.01.031. *Currently being assessed for management*
346. Asherson P, Johansson L, Holland R, et al. Efficacy and Mechanism Evaluation. OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT. Southampton (UK): National Institute for Health and Care Research

Copyright © 2022 Asherson et al. This work was produced by Asherson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the

Excluded Publications

publication source – NIHR Journals Library, and the DOI of the publication must be cited.; 2022.
Currently being assessed for management

347. Asherson P, Johansson L, Holland R, et al. Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II). *Trials*. 2019 Dec 2;20(1):663. doi: 10.1186/s13063-019-3705-9. PMID: 31791384. *Currently being assessed for management*

348. Asherson PJ, Johansson L, Holland R, et al. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. *Br J Psychiatry*. 2023 Jan;222(1):7-17. doi: 10.1192/bjp.2022.77. PMID: 35657651. *Currently being assessed for management*

349. Asken BM, DeKosky ST, Clugston JR, et al. Diffusion tensor imaging (DTI) findings in adult civilian, military, and sport-related mild traumatic brain injury (mTBI): a systematic critical review. *Brain Imaging Behav*. 2018 Apr;12(2):585-612. doi: 10.1007/s11682-017-9708-9. PMID: 28337734. *Exclude-Population*

350. Aubele T, Kritzer MF. Gonadectomy and hormone replacement affects in vivo basal extracellular dopamine levels in the prefrontal cortex but not motor cortex of adult male rats. *Cereb Cortex*. 2011 Jan;21(1):222-32. doi: 10.1093/cercor/bhq083. PMID: 20466748. *Exclude-Population*

351. Auclair V, Harvey PO, Lepage M. [Cognitive Behavioral Therapy and the Treatment of ADHD in Adults]. *Sante Ment Que*. 2016 Spring;41(1):291-311. PMID: 27570962. *Exclude-Language*

352. Auiler JF, Liu K, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. *Curr Med Res Opin*. 2002;18(5):311-6. doi: 10.1185/030079902125000840. PMID: 12240794. *Exclude-Intervention*

353. Ausloos-Lozano JE, Bing-Canar H, Khan H, et al. Assessing performance validity during attention-deficit/hyperactivity disorder evaluations: Cross-validation of non-memory embedded validity indicators. *Developmental neuropsychology*. 2022;47(5):247-57. doi: 10.1080/87565641.2022.2096889. *Exclude-Intervention*

354. Awada M, Becerik-Gerber B, Lucas G, et al. Cognitive performance, creativity and stress levels of neurotypical young adults under different white noise levels. *Sci Rep*. 2022 Aug 26;12(1):14566. doi: 10.1038/s41598-022-18862-w. PMID: 36028546. *Exclude-Comparator*

355. Ayan D, Andy L, Michael M, et al. Pharmacological and Non-Pharmacological Interventions for Insomnia in ADHD: An Umbrella Review of Management Strategies Across the Lifespan. 2024. PMID: CRD42024585807. *Currently being assessed for management*

Excluded Publications

356. Aycicegi A, Dinn WM, Harris CL. Assessing adult attention-deficit/hyperactivity disorder: a Turkish version of the current symptoms scale. *Psychopathology*. 2003 May-Jun;36(3):160-7. doi: 10.1159/000071261. PMID: 12845287. *Exclude-Outcome*
357. Ayesha J, Jumana A, Nicolaas P, et al. EEG Proxy markers of sensory sensitivities in ASD. 2021. PMID: CRD42021192625. *Currently being assessed for management*
358. Aymamí N, Jiménez-Murcia S, Granero R, et al. Clinical, Psychopathological, and Personality Characteristics Associated with ADHD among Individuals Seeking Treatment for Gambling Disorder. *Biomed Res Int*. 2015;2015:965303. doi: 10.1155/2015/965303. PMID: 26229967. *Exclude-Intervention*
359. Ayme-Dietrich E, Kaguelidou F, Bertschy G, et al. Use of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults. *Pharmacoepidemiol Drug Saf*. 2024 Jun;33(6):e5814. doi: 10.1002/pds.5814. PMID: 38837561. *Exclude-Design*
360. Baader A, Kiani B, Brunkhorst-Kanaan N, et al. A Within-Sample Comparison of Two Innovative Neuropsychological Tests for Assessing ADHD. *Brain Sci*. 2020 Dec 31;11(1). doi: 10.3390/brainsci11010036. PMID: 33396421. *Exclude-Intervention*
361. Babajanyan D, Freame L, Steele R, et al. Understanding Attentional Functioning in Adult Attention Deficit Hyperactivity Disorder-Could This Improve Diagnostic Specificity? *Int J Environ Res Public Health*. 2023 Mar 14;20(6). doi: 10.3390/ijerph20065077. PMID: 36981985. *Exclude-Intervention*
362. Babajanyan D, Freame L, Steele R, et al. Understanding Attentional Functioning in Adult Attention Deficit Hyperactivity Disorder—Could This Improve Diagnostic Specificity? *International Journal of Environmental Research and Public Health*. 2023;20(6). doi: 10.3390/ijerph20065077. *Exclude-Intervention*
363. Babcock T, Dirks B, Adeyi B, et al. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. *BMC Pharmacol Toxicol*. 2012 Dec 19;13:18. doi: 10.1186/2050-6511-13-18. PMID: 23254273. *Possible multiple publication*
364. Babcock T, Ornstein CS. Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective. *Postgrad Med*. 2009 May;121(3):73-82. doi: 10.3810/pgm.2009.05.2005. PMID: 19491543. *Exclude-Comparator*
365. Babinski DE, Waxmonsky JG, Pelham WE, Jr. Treating parents with attention-deficit/hyperactivity disorder: the effects of behavioral parent training and acute stimulant medication treatment on parent-child interactions. *J Abnorm Child Psychol*. 2014 Oct;42(7):1129-40. doi: 10.1007/s10802-014-9864-y. PMID: 24687848. *Exclude-Population*
366. Babinski DE, Waxmonsky JG, Waschbusch DA, et al. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of

Excluded Publications

- Parental Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2017 Apr;27(3):250-7. doi: 10.1089/cap.2016.0129. PMID: 27991835. *Currently being assessed for management*
367. Babinski DE, Waxmonsky JG, Waschbusch DA, et al. A pilot study of stimulant medication for adults with attention-deficit/hyperactivity disorder (ADHD) who are parents of adolescents with ADHD: the acute effects of stimulant medication on observed parent-adolescent interactions. *J Child Adolesc Psychopharmacol*. 2014 Dec;24(10):582-5. doi: 10.1089/cap.2014.0092. PMID: 25386742. *Exclude-Design*
368. Bachmann CS, Risnes K, Bjørngaard JH, et al. Association of Preterm Birth With Prescription of Psychotropic Drugs in Adolescence and Young Adulthood. *JAMA Netw Open*. 2021 Mar 1;4(3):e211420. doi: 10.1001/jamanetworkopen.2021.1420. PMID: 33710290. *Exclude-Intervention*
369. Bachmann K, Lam AP, Sörös P, et al. Effects of mindfulness and psychoeducation on working memory in adult ADHD: A randomised, controlled fMRI study. *Behav Res Ther*. 2018 Jul;106:47-56. doi: 10.1016/j.brat.2018.05.002. PMID: 29758392. *Currently being assessed for management*
370. Baeyens D, Moniquet A, Danckaerts M, et al. [A comparative study of the structural stigmatisation of ADHD and autism spectrum disorder in Flemish newspapers]. *Tijdschr Psychiatr*. 2017;59(5):269-77. PMID: 28593620. *Exclude-Language*
371. Baggio S, Baudat S, Daepfen J-B, et al. Screening for alcohol use disorder among individuals with comorbid psychiatric disorders: Diagnostic accuracy in a sample of young Swiss men. *Addictive Behaviors*. 2020;106. doi: 10.1016/j.addbeh.2020.106354. *Exclude-Population*
372. Baggio S, Bayard S, Cabelguen C, et al. Diagnostic Accuracy of the French Version of the Adult Attention Deficit / Hyperactivity Disorder Self-Report Screening Scale for DSM-5 (ASRS-5). *Journal of Psychopathology and Behavioral Assessment*. 2021;43(2):367-75. doi: 10.1007/s10862-020-09822-7. *Exclude-Language*
373. Baggio S, Fructuoso A, Guimaraes M, et al. Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis. *Front Psychiatry*. 2018;9:331. doi: 10.3389/fpsy.2018.00331. PMID: 30116206. *Exclude-Intervention*
374. Baggio S, Hasler R, Deiber MP, et al. Associations of executive and functional outcomes with full-score intellectual quotient among ADHD adults. *Psychiatry Res*. 2020 Dec;294:113521. doi: 10.1016/j.psychres.2020.113521. PMID: 33161177. *Exclude-Intervention*
375. Bahcelioglu M, Gozil R, Take G, et al. Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat. *World J Biol Psychiatry*. 2009;10(4 Pt 2):531-43. doi: 10.1080/15622970903176683. PMID: 19707959. *Exclude-Population*
376. Bahn GH, Lee SM, Hong M, et al. Preliminary Study of ADHD Biomarkers in Adults with Focus on Serum Iron and Transcranial Sonography of the Substantia Nigra. *Int J Environ Res*

Excluded Publications

Public Health. 2021 May 3;18(9). doi: 10.3390/ijerph18094875. PMID: 34063655. *Exclude-Outcome*

377. Bahn GH, Lee YS, Yoo HK, et al. Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder. Soa Chongsonyon Chongsin Uihak. 2020 Jan 1;31(1):5-25. doi: 10.5765/jkacap.190030. PMID: 32612409. *Exclude-Intervention*

378. Bahn GH, Seo K. Combined Medication with Stimulants and Non-stimulants for Attention-deficit/hyperactivity Disorder. Clin Psychopharmacol Neurosci. 2021 Nov 30;19(4):705-11. doi: 10.9758/cpn.2021.19.4.705. PMID: 34690125. *Exclude-Design*

379. Bain E, Robieson W, Garimella T, et al. A randomized, double-blind, placebo-controlled Phase 2 study of $\alpha 4\beta 2$ agonist ABT-894 in adults with ADHD. Biochemical Pharmacology. 2011;82(8):1043. doi: 10.1016/j.bcp.2011.07.053. *Currently being assessed for management*

380. Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel $\alpha 4\beta 2$ neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012 Jun;73(6):783-9. doi: 10.4088/JCP.10m06719. PMID: 22795204. *Currently being assessed for management*

381. Bain EE, Robieson W, Pritchett Y, et al. A randomized, double-blind, placebo-controlled phase 2 study of $\alpha 4\beta 2$ agonist ABT-894 in adults with ADHD. Neuropsychopharmacology. 2013 Feb;38(3):405-13. doi: 10.1038/npp.2012.194. PMID: 23032073. *Currently being assessed for management*

382. Ballmann C, Kölle MA, Bekavac-Günther I, et al. Evaluation of the German Version of the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5 as a Screening Tool for Adult Attention-Deficit/Hyperactivity Disorder in Primary Care. Front Psychol. 2022;13:858147. doi: 10.3389/fpsyg.2022.858147. PMID: 35529560. *Exclude-Language*

383. Bang Madsen K, Bliddal M, Skoglund CB, et al. Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period. CNS Drugs. 2024 Apr;38(4):303-14. doi: 10.1007/s40263-024-01076-1. PMID: 38489019. *Exclude-Intervention*

384. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008;31(4):345-54. doi: 10.2165/00002018-200831040-00008. PMID: 18366245. *Exclude-Design*

385. Bangs ME, Wietecha LA, Wang S, et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014 Oct;24(8):426-34. doi: 10.1089/cap.2014.0005. PMID: 25019647. *Exclude-Design*

386. Barden EP, Polizzi CP, Vizgaitis AL, et al. Hyperactivity or mania: Examining the overlap of scales measuring attention-deficit/hyperactivity disorder and bipolar spectrum disorders in an assessment context. Practice Innovations. 2023;8(2):102-15. doi: 10.1037/pri0000202. *Exclude-Intervention*

Excluded Publications

387. Barham H, Büyükgök D, Aksu S, et al. Evidence for modulation of planning and working memory capacities by transcranial direct current stimulation in a sample of adults with attention deficit hyperactivity disorder. *Neurosci Lett*. 2022 Nov 1;790:136883. doi: 10.1016/j.neulet.2022.136883. PMID: 36152744. *Currently being assessed for management*
388. Barker-Collo SL, Feigin VL, Lawes CM, et al. Reducing attention deficits after stroke using attention process training: a randomized controlled trial. *Stroke*. 2009 Oct;40(10):3293-8. doi: 10.1161/strokeaha.109.558239. PMID: 19628801. *Exclude-Population*
389. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. *CNS Spectr*. 2008 Nov;13(11):977-84. doi: 10.1017/s1092852900014036. PMID: 19037178. *Exclude-Intervention*
390. Barkley RA, Murphy KR, O'Connell T, et al. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. *J Safety Res*. 2005;36(2):121-31. doi: 10.1016/j.jsr.2005.01.001. PMID: 15896352. *Exclude-Intervention*
391. Barnhart WR, Buelow MT. Assessing impulsivity: Relationships between behavioral and self-report measures in individuals with and without self-reported ADHD. *Personality and Individual Differences*. 2017;106:41-5. doi: 10.1016/j.paid.2016.10.034. *Exclude-Intervention*
392. Barrilleaux K, Advokat C. Attribution and self-evaluation of continuous performance test task performance in medicated and unmedicated adults with ADHD. *Journal of Attention Disorders*. 2009;12(4):291-8. doi: 10.1177/1087054708314604. *Exclude-Intervention*
393. Barry RJ, Clarke AR, McCarthy R, et al. Event-related potentials in adults with Attention-Deficit/Hyperactivity Disorder: an investigation using an inter-modal auditory/visual oddball task. *Int J Psychophysiol*. 2009 Feb;71(2):124-31. doi: 10.1016/j.ijpsycho.2008.09.009. PMID: 19022305. *Exclude-Intervention*
394. Barth B, Mayer-Carius K, Strehl U, et al. A randomized-controlled neurofeedback trial in adult attention-deficit/hyperactivity disorder. *Sci Rep*. 2021 Aug 19;11(1):16873. doi: 10.1038/s41598-021-95928-1. PMID: 34413344. *Currently being assessed for management*
395. Basiri N, Hadianfard H. Adult ADHD Treatment Based on Combination of Dialectical Behavior Therapy (DBT) and Transcranial Direct Current Stimulation (tDCS) as Measured by Subjective and Objective Scales. *J Atten Disord*. 2023 Jan;27(1):57-66. doi: 10.1177/10870547221118527. PMID: 36047471. *Currently being assessed for management*
396. Bean JL. Attentional contributions to social cognition and social behaviors: Implications for autism spectrum disorder and attention-deficit/hyperactivity disorder. US: ProQuest Information & Learning; 2024. *Exclude-Population*
397. Becke M, Fuermaier ABM, Buehren J, et al. Utility of the Structured Interview of Reported Symptoms (SIRS-2) in detecting feigned adult attention-deficit/hyperactivity disorder. *J Clin Exp Neuropsychol*. 2019 Oct;41(8):786-802. doi: 10.1080/13803395.2019.1621268. PMID: 31156034. *Exclude-Language*

Excluded Publications

398. Becke M, Tucha L, Weisbrod M, et al. Non-credible symptom report in the clinical evaluation of adult ADHD: development and initial validation of a new validity index embedded in the Conners' adult ADHD rating scales. *J Neural Transm (Vienna)*. 2021 Jul;128(7):1045-63. doi: 10.1007/s00702-021-02318-y. PMID: 33651237. *Exclude-Language*
399. Becke M, Tucha L, Weisbrod M, et al. Correction to: Non-credible symptom report in the clinical evaluation of adult ADHD: development and initial validation of a new validity index embedded in the Conners' adult ADHD rating scales. *J Neural Transm (Vienna)*. 2022 Oct;129(10):1315-9. doi: 10.1007/s00702-022-02533-1. PMID: 35974247. *Possible multiple publication*
400. Becke M, Tucha L, Weisbrod M, et al. Joint consideration of validity indicators embedded in Conners' Adult ADHD Rating Scales (CAARS). *Psychological Injury and Law*. 2022;15(2):172-88. doi: 10.1007/s12207-022-09445-1. *Exclude-Language*
401. Becke M, Tucha L, Weisbrod M, et al. "Non-credible symptom report in the clinical evaluation of adult ADHD: Development and initial validation of a new validity index embedded in the Conners' adult ADHD rating scales": Correction. *Journal of Neural Transmission*. 2022;129(10):1315-9. doi: 10.1007/s00702-022-02533-1. *Possible multiple publication*
402. Becker SP, Langberg JM, Luebbe AM, et al. Sluggish cognitive tempo is associated with academic functioning and internalizing symptoms in college students with and without attention-deficit/hyperactivity disorder. *J Clin Psychol*. 2014 Apr;70(4):388-403. doi: 10.1002/jclp.22046. PMID: 24114716. *Exclude-Intervention*
403. Bédard AC, Trampush JW, Newcorn JH, et al. Perceptual and motor inhibition in adolescents/young adults with childhood-diagnosed ADHD. *Neuropsychology*. 2010 Jul;24(4):424-34. doi: 10.1037/a0018752. PMID: 20604617. *Exclude-Population*
404. Bellak L, Black RB. Attention-deficit hyperactivity disorder in adults. *Clin Ther*. 1992 Mar-Apr;14(2):138-47. PMID: 1351794. *Exclude-Design*
405. Bellino S, Mirra M, Brignolo E, et al. Pharmacological treatment of attention deficit hyperactivity disorder (ADHD): A systematic review of recent data. *Current Psychopharmacology*. 2014;3(2):93-107. *Currently being assessed for management*
406. Bemmouna D, Weibel S, Kosel M, et al. The utility of the autism-spectrum quotient to screen for autism spectrum disorder in adults with attention deficit/hyperactivity disorder. *Psychiatry Res*. 2022 Jun;312:114580. doi: 10.1016/j.psychres.2022.114580. PMID: 35523029. *Exclude-Intervention*
407. Ben-Ami IS, Ankory R, Kadar A, et al. The Effect of Previous Methylphenidate Use on Incidence of Stress Fractures in Military Recruits: A Retrospective Cohort. *J Bone Joint Surg Am*. 2018 Jun 6;100(11):930-5. doi: 10.2106/jbjs.17.01267. PMID: 29870443. *Exclude-Design*
408. Ben-Sheetrit J, Peskin M, Newcorn JH, et al. Characterizing the Placebo Response in Adults With ADHD. *J Atten Disord*. 2020 Feb;24(3):425-33. doi: 10.1177/1087054718780328. PMID: 29926752. *Exclude-Intervention*

Excluded Publications

409. Ben-Sheetrit J, Tasker H, Avnat L, et al. Possible Age-Related Progression of Attentional Impairment in ADHD and Its Attenuation by Past Diagnosis and Treatment. *J Atten Disord*. 2021 Jan;25(1):14-21. doi: 10.1177/1087054717743328. PMID: 29233062. *Exclude-Intervention*
410. Benkert D, Krause KH, Wasem J, et al. Effectiveness of pharmaceutical therapy of ADHD (attention-deficit/hyperactivity disorder) in adults-A health technology assessment. *Value in Health*. 2010;13(7):A458. *Currently being assessed for management*
411. Benkert D, Krause KH, Wasem J, et al. The economic aspects of medical treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults - A systematic review. *Journal of Mental Health Policy and Economics*. 2011;14:S3-S4. *Currently being assessed for management*
412. Berberat J, Huggenberger R, Montali M, et al. Brain activation patterns in medicated versus medication-naïve adults with attention-deficit hyperactivity disorder during fMRI tasks of motor inhibition and cognitive switching. *BMC Med Imaging*. 2021 Mar 19;21(1):53. doi: 10.1186/s12880-021-00579-3. PMID: 33740903. *Exclude-Outcome*
413. Bergey M. "Pills Don't Teach Skills": ADHD Coaching, Identity Work, and the Push toward the Liminal Medicalization of ADHD. *J Health Soc Behav*. 2024 Jun;65(2):256-72. doi: 10.1177/00221465231220385. PMID: 38279814. *Exclude-Design*
414. Berry S, Belden H, Childress A. Single dose pharmacokinetics of NWP06, a novel extended release methylphenidate oral suspension for the treatment of ADHD. *Annals of Neurology*. 2011;70:S147-S8. doi: 10.1002/ana.22558. *Currently being assessed for management*
415. Bhavya G, Justin Y, Haneen H. Systematic Review of Psychological Treatment of ADHD and Comorbid Substance Use Disorders. 2023. PMID: CRD42023439593. *Currently being assessed for management*
416. Bidwell LC, Balestrieri SG, Colby SM, et al. Abstinence-induced withdrawal severity among adolescent smokers with and without ADHD: disentangling effects of nicotine and smoking reinstatement. *Psychopharmacology (Berl)*. 2018 Jan;235(1):169-78. doi: 10.1007/s00213-017-4753-z. PMID: 29018894. *Exclude-Population*
417. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. *J Clin Psychiatry*. 2003;64 Suppl 11:3-8. PMID: 14529323. *Exclude-Population*
418. Biederman J, DiSalvo M, Woodworth KY, et al. Toward operationalizing deficient emotional self-regulation in newly referred adults with ADHD: A receiver operator characteristic curve analysis. *Eur Psychiatry*. 2020 Feb 24;63(1):e21. doi: 10.1192/j.eurpsy.2019.11. PMID: 32093797. *Exclude-Intervention*
419. Biederman J, DiSalvo ML, Hutt Vater CR, et al. Toward Operationalizing Executive Function Deficits in Adults With ADHD Using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A). *J Clin Psychiatry*. 2022 Nov 21;84(1). doi: 10.4088/JCP.22m14530. PMID: 36416743. *Exclude-Comparator*

Excluded Publications

420. Biederman J, Fitzgerald M, Uchida M, et al. Towards operationalising internal distractibility (Mind Wandering) in adults with ADHD. *Acta Neuropsychiatr*. 2017 Dec;29(6):330-6. doi: 10.1017/neu.2016.70. PMID: 29151406. *Exclude-Intervention*
421. Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. *J Psychiatr Res*. 2012 Apr;46(4):484-91. doi: 10.1016/j.jpsychires.2012.01.007. PMID: 22277301. *Currently being assessed for management*
422. Biederman J, Fried R, Petty CR, et al. Examining the association between stimulant treatment and cognitive outcomes across the life cycle of adults with attention-deficit/hyperactivity disorder: a controlled cross-sectional study. *J Nerv Ment Dis*. 2012 Jan;200(1):69-75. doi: 10.1097/NMD.0b013e31823e55ef. PMID: 22210365. *Exclude-Design*
423. Biederman J, Fried R, Tarko L, et al. Memantine in the Treatment of Executive Function Deficits in Adults With ADHD. *J Atten Disord*. 2017 Feb;21(4):343-52. doi: 10.1177/1087054714538656. PMID: 24970718. *Currently being assessed for management*
424. Biederman J, Lanier J, DiSalvo M, et al. Clinical correlates of mind wandering in adults with ADHD. *J Psychiatr Res*. 2019 Oct;117:15-23. doi: 10.1016/j.jpsychires.2019.06.012. PMID: 31272014. *Exclude-Intervention*
425. Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. *J Psychopharmacol*. 2019 Apr;33(4):511-21. doi: 10.1177/0269881119832538. PMID: 30843450. *Currently being assessed for management*
426. Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. *Journal of Psychopharmacology*. 2019;33(4):511-21. doi: 10.1177/0269881119832538. *Currently being assessed for management*
427. Biederman J, Mick E. A randomized, three phase 34 week double-blind long-term efficacy study of extended-release methylphenidate in adults with ADHD. *European Neuropsychopharmacology*. 2010;20:S329-S30. doi: 10.1016/S0924-977X(10)70450-8. *Currently being assessed for management*
428. Biederman J, Mick E, Faraone S, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. *J Clin Psychopharmacol*. 2006 Apr;26(2):163-6. doi: 10.1097/01.jcp.0000204139.20417.8a. PMID: 16633145. *Currently being assessed for management*
429. Biederman J, Mick E, Fried R, et al. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in

Excluded Publications

- adults with ADHD. *Eur Neuropsychopharmacol.* 2011 Jul;21(7):508-15. doi: 10.1016/j.euroneuro.2010.11.005. PMID: 21303732. *Currently being assessed for management*
430. Biederman J, Mick E, Spencer T, et al. Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD. *CNS Neurosci Ther.* 2012 Feb;18(2):126-32. doi: 10.1111/j.1755-5949.2010.00233.x. PMID: 22070421. *Exclude-Intervention*
431. Biederman J, Mick E, Spencer T, et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. *CNS Spectr.* 2006 May;11(5):390-6. doi: 10.1017/s1092852900014528. PMID: 16641844. *Exclude-Design*
432. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry.* 2006 May 1;59(9):829-35. doi: 10.1016/j.biopsych.2005.09.011. PMID: 16373066. *Currently being assessed for management*
433. Biederman J, Mick E, Surman C, et al. "A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder": Erratum. *Biological Psychiatry.* 2007;61(12):1402-. doi: 10.1016/j.biopsych.2007.05.009. *Currently being assessed for management*
434. Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol.* 2010 Oct;30(5):549-53. doi: 10.1097/JCP.0b013e3181ee84a7. PMID: 20814332. *Currently being assessed for management*
435. Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. *Pediatrics.* 2009 Jul;124(1):71-8. doi: 10.1542/peds.2008-3347. PMID: 19564285. *Exclude-Population*
436. Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: an 11-year follow-up study. *J Psychiatr Res.* 2011 Feb;45(2):150-5. doi: 10.1016/j.jpsychires.2010.06.009. PMID: 20656298. *Exclude-Intervention*
437. Biederman J, Petty CR, Fried R, et al. Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. *Acta Psychiatr Scand.* 2007 Aug;116(2):129-36. doi: 10.1111/j.1600-0447.2007.01008.x. PMID: 17650275. *Exclude-Population*
438. Biederman J, Seidman LJ, Petty CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry.* 2008 Jul;69(7):1150-6. doi: 10.4088/jcp.v69n0715. PMID: 18517288. *Exclude-Population*

Excluded Publications

439. Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. *CNS Spectr*. 2005 Dec;10(12 Suppl 20):16-25. doi: 10.1017/s1092852900002406. PMID: 16344837. *Possible multiple publication*
440. Biehl SC, Merz CJ, Dresler T, et al. Increase or Decrease of fMRI Activity in Adult Attention Deficit/ Hyperactivity Disorder: Does It Depend on Task Difficulty? *Int J Neuropsychopharmacol*. 2016 May 6;19(10). doi: 10.1093/ijnp/pyw049. PMID: 27207920. *Currently being assessed for management*
441. Bihlar Muld B, Jokinen J, Bölte S, et al. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study. *J Subst Abuse Treat*. 2015 Apr;51:82-90. doi: 10.1016/j.jsat.2014.11.005. PMID: 25491733. *Exclude-Design*
442. Bihlar Muld B, Jokinen J, Bölte S, et al. Skills training groups for men with ADHD in compulsory care due to substance use disorder: a feasibility study. *Atten Defic Hyperact Disord*. 2016 Sep;8(3):159-72. doi: 10.1007/s12402-016-0195-4. PMID: 27059489. *Exclude-Design*
443. Bijlenga D, Jasperse M, Gehlhaar SK, et al. Objective QbTest and subjective evaluation of stimulant treatment in adult attention deficit-hyperactivity disorder. *Eur Psychiatry*. 2015 Jan;30(1):179-85. doi: 10.1016/j.eurpsy.2014.06.003. PMID: 25172155. *Exclude-Design*
444. Bijlenga D, Tjon-Ka-Jie JYM, Schuijers F, et al. Atypical sensory profiles as core features of adult ADHD, irrespective of autistic symptoms. *Eur Psychiatry*. 2017 Jun;43:51-7. doi: 10.1016/j.eurpsy.2017.02.481. PMID: 28371743. *Exclude-Intervention*
445. Bilgiç A, Bilgiç Ö, Hergüner S, et al. Autistic Trait, Empathy, and Attention-Deficit/Hyperactivity Symptoms in Women with Idiopathic Hirsutism. *Int J Trichology*. 2015 Jul-Sep;7(3):113-8. doi: 10.4103/0974-7753.167458. PMID: 26622154. *Exclude-Intervention*
446. Bilodeau M, Simon T, Beauchamp MH, et al. Duloxetine in adults with ADHD: A randomized, placebo-controlled pilot study. *Journal of Attention Disorders*. 2014;18(2):169-75. doi: 10.1177/1087054712443157. *Currently being assessed for management*
447. Bilodeau M, Simon T, Beauchamp MH, et al. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study. *J Atten Disord*. 2014 Feb;18(2):169-75. doi: 10.1177/1087054712443157. PMID: 22582349. *Currently being assessed for management*
448. Bitter I, Angyalosi A, Czobor P. Pharmacological treatment of adult ADHD. *Curr Opin Psychiatry*. 2012 Nov;25(6):529-34. doi: 10.1097/YCO.0b013e328356f87f. PMID: 22801362. *Exclude-Design*
449. Bitter I, Mohr P, Balogh L, et al. ADHD: a hidden comorbidity in adult psychiatric patients. *Atten Defic Hyperact Disord*. 2019 Mar;11(1):83-9. doi: 10.1007/s12402-019-00285-9. PMID: 30927233. *Exclude-Intervention*
450. Bitter I, Simon V, Bálint S, et al. How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological

Excluded Publications

- study in a Hungarian community sample. *Eur Arch Psychiatry Clin Neurosci*. 2010 Jun;260(4):287-96. doi: 10.1007/s00406-009-0076-3. PMID: 19806424. *Exclude-Intervention*
451. Black DW, Shaw M, McCormick B, et al. Neuropsychological performance, impulsivity, ADHD symptoms, and novelty seeking in compulsive buying disorder. *Psychiatry Res*. 2012 Dec 30;200(2-3):581-7. doi: 10.1016/j.psychres.2012.06.003. PMID: 22766012. *Exclude-Population*
452. Bleich-Cohen M, Gurevitch G, Carmi N, et al. A functional magnetic resonance imaging investigation of prefrontal cortex deep transcranial magnetic stimulation efficacy in adults with attention deficit/hyperactive disorder: A double blind, randomized clinical trial. *Neuroimage Clin*. 2021;30:102670. doi: 10.1016/j.nicl.2021.102670. PMID: 34215144. *Currently being assessed for management*
453. Bloch Y, Dor-Ziderman Y. Spectral analysis of magnetoencephalographic (MEG) correlates of, anxiety, and the effect of methylphenidate, a possible distinction between patients suffering from ADHD and controls. *European Psychiatry*. 2019;56:S564. doi: 10.1016/j.eurpsy.2019.01.001. *Currently being assessed for management*
454. Bloch Y, Harel EV, Aviram S, et al. Positive effects of repetitive transcranial magnetic stimulation on attention in ADHD Subjects: a randomized controlled pilot study. *World J Biol Psychiatry*. 2010 Aug;11(5):755-8. doi: 10.3109/15622975.2010.484466. PMID: 20521875. *Exclude-Timing*
455. Bloemers S, Mummert A, Gibson TB. PMH27 ADHD TREATMENT AND DIAGNOSIS AMONG TEENAGE AND COLLEGE-AGED WOMEN. *Value in Health*. 2020;23:S205. doi: 10.1016/j.jval.2020.04.647. *Currently being assessed for management*
456. Blomberg R, Signoret C, Danielsson H, et al. Aberrant resting-state connectivity of auditory, ventral attention/salience and default-mode networks in adults with attention deficit hyperactivity disorder. *Front Neurosci*. 2022;16. doi: 10.3389/fnins.2022.972730. PMID: 36148149. *Exclude-Intervention*
457. Blume F, Buhr L, Kühnhausen J, et al. Validation of the Self-Report Version of the German Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Scale (SWAN-DE-SB). *Assessment*. 2024 Mar 24:10731911241236699. doi: 10.1177/10731911241236699. PMID: 38523357. *Exclude-Language*
458. Boatwright BS. The Adult-ADHD Rating Scale: A report of its development and initial validation. US: ProQuest Information & Learning; 1995. *Currently being assessed for management*
459. Bodenbunrg S, Wendiggensen J, Kasten E. Scores in self-report questionnaires assessing adult ADHD can be influenced by negative response bias but are unrelated to performance on executive function and attention tests. *Psychological Injury and Law*. 2022;15(2):189-99. doi: 10.1007/s12207-022-09448-y. *Exclude-Intervention*

Excluded Publications

460. Boesen K, Paludan-Müller AS, Gøtzsche PC, et al. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews. 2022(2). doi: 10.1002/14651858.CD012857.pub2. PMID: CD012857. *Currently being assessed for management*
461. Bolea-Alamanac BM, Green A, Verma G, et al. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol. 2014 Jan;77(1):96-101. doi: 10.1111/bcp.12138. PMID: 23593966. *Exclude-Population*
462. Bonvicini C, Cortese S, Maj C, et al. DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder. Translational Psychiatry. 2020;10(1). doi: 10.1038/s41398-020-0755-4. *Exclude-Population*
463. Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016 Jul;21(7):872-84. doi: 10.1038/mp.2016.74. PMID: 27217152. *Exclude-Intervention*
464. Boonstra AM, Kooij JJ, Oosterlaan J, et al. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? J Clin Exp Neuropsychol. 2005 Apr;27(3):278-98. doi: 10.1080/13803390490515757. PMID: 15969353. *Currently being assessed for management*
465. Boonstra AM, Kooij JJS, Oosterlaan J, et al. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? Journal of Clinical and Experimental Neuropsychology. 2005;27(3):278-98. doi: 10.1080/13803390490515757. *Currently being assessed for management*
466. Boonstra AM, Kooij JJS, Oosterlaan J, et al. Hyperactive night and day? Actigraphy studies in adult ADHD: A baseline comparison and the effect of methylphenidate. Sleep. 2007;30(4):433-42. doi: 10.1093/sleep/30.4.433. *Currently being assessed for management*
467. Boonstra AM, Oosterlaan J, Sergeant JA, et al. Executive functioning in adult ADHD: a meta-analytic review. Psychol Med. 2005 Aug;35(8):1097-108. doi: 10.1017/s003329170500499x. PMID: 16116936. *Exclude-Intervention*
468. Bottelier MA, Schranter A, Ferguson B, et al. Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naïve patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Res Neuroimaging. 2017 Nov 30;269:36-42. doi: 10.1016/j.psychres.2017.09.009. PMID: 28938219. *Currently being assessed for management*
469. Bouffard R, Hechtman L, Minde K, et al. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2003 Sep;48(8):546-54. doi: 10.1177/070674370304800806. PMID: 14574830. *Currently being assessed for management*
470. Bouziane C, Filatova OG, Schranter A, et al. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-

Excluded Publications

- Deficit/Hyperactivity Disorder. Radiology. 2019 Oct;293(1):186-92. doi: 10.1148/radiol.2019182528. PMID: 31407970. *Currently being assessed for management*
471. Bowden SC, Gregg N, Bandalos D, et al. Latent mean and covariance differences with measurement equivalence in college students with developmental difficulties versus the Wechsler Adult Intelligence Scale-III/Wechsler Memory Scale-III normative sample. Educational and Psychological Measurement. 2008;68(4):621-42. doi: 10.1177/0013164407310126. *Exclude-Intervention*
472. Bramham J, Susan Y, Bickerdike A, et al. Evaluation of group cognitive behavioral therapy for adults with ADHD. Journal of Attention Disorders. 2009;12(5):434-41. doi: 10.1177/1087054708314596. *Currently being assessed for management*
473. Bramham J, Young S, Bickerdike A, et al. Evaluation of group cognitive behavioral therapy for adults with ADHD. J Atten Disord. 2009 Mar;12(5):434-41. doi: 10.1177/1087054708314596. PMID: 18310557. *Currently being assessed for management*
474. Brams M, Giblin J, Gasior M, et al. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Postgrad Med. 2011 May;123(3):99-108. doi: 10.3810/pgm.2011.05.2288. PMID: 21566420. *Possible multiple publication*
475. Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. PMID: 22780921. *Currently being assessed for management*
476. Brancati GE, De Dominicis F, Petrucci A, et al. Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and response. World J Biol Psychiatry. 2023 Jun-Jul;24(6):523-38. doi: 10.1080/15622975.2023.2168750. PMID: 36637001. *Exclude-Design*
477. Brancati GE, De Rosa U, Acierno D, et al. Development of a self-report screening instrument for emotional dysregulation: the Reactivity, Intensity, Polarity and Stability questionnaire, screening version (RIPoSt-SV). J Affect Disord. 2024 Jun 15;355:406-14. doi: 10.1016/j.jad.2024.03.167. PMID: 38570039. *Exclude-Intervention*
478. Brandejsky L, Micoulaud Franchi JA, Lopez R, et al. [Noninvasive cerebral stimulation for treatment of ADHD: A review of the literature]. Encephale. 2017 Oct;43(5):457-63. doi: 10.1016/j.encep.2016.08.011. PMID: 27745724. *Exclude-Language*
479. Brandley ET, Holton KF. Breakfast Positively Impacts Cognitive Function in College Students With and Without ADHD. Am J Health Promot. 2020 Jul;34(6):668-71. doi: 10.1177/0890117120903235. PMID: 32013526. *Exclude-Intervention*
480. Braulio MG-S, Alejandro P-S, Inmaculada P-C, et al. Video games for the treatment and assessment of attention-deficit/hyperactivity disorder: a systematic review. 2020. PMID: CRD42020166313. *Currently being assessed for management*

Excluded Publications

481. Braun CM, Delisle J, Suffren S, et al. Atypical left-right balance of visuomotor awareness in adult ADHD (combined type) on a test of executive function. *Laterality*. 2013;18(4):385-406. doi: 10.1080/1357650x.2012.695796. PMID: 22757589. *Exclude-Intervention*
482. Braun DL, Dulit RA, Adler DA, et al. Attention-deficit/hyperactivity disorder in adults: Clinical information for primary care physicians. *Primary Psychiatry*. 2004;11(9):56-65. *Exclude-Intervention*
483. Braverman ER, Chen AL, Chen TJ, et al. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. *Neuropsychiatr Dis Treat*. 2010 Oct 15;6:681-90. doi: 10.2147/ndt.S12243. PMID: 21127685. *Exclude-Intervention*
484. Braverman ER, Chen AL-C, Chen TJH, et al. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. *Neuropsychiatric Disease and Treatment*. 2010;6. *Exclude-Intervention*
485. Braverman ER, Chen TJH, Prihoda TJ, et al. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. *Age*. 2007;29(2-3):55-67. doi: 10.1007/s11357-007-9030-3. *Exclude-Intervention*
486. Braverman ER, Chen TJH, Schoolfield J, et al. Delayed P300 latency correlates with abnormal test of variables of attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. *Advances in Therapy*. 2006;23(4):582-600. doi: 10.1007/BF02850047. *Exclude-Population*
487. Bray CL, Cahill KS, Oshier JT, et al. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. *J Investig Med*. 2004 Apr;52(3):192-201. doi: 10.1136/jim-52-03-34. PMID: 15222409. *Misuse only*
488. Breda V, Rohde LA, Menezes AMB, et al. Revisiting ADHD age-of-onset in adults: to what extent should we rely on the recall of childhood symptoms? *Psychol Med*. 2020 Apr;50(5):857-66. doi: 10.1017/s003329171900076x. PMID: 30968792. *Exclude-Intervention*
489. Breda V, Rovaris DL, Vitola ES, et al. Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample. *Aust N Z J Psychiatry*. 2016 Jun;50(6):557-65. doi: 10.1177/0004867415609421. PMID: 26460329. *Exclude-Intervention*
490. Breslau J, Miller E, Joanie Chung WJ, et al. Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time. *J Psychiatr Res*. 2011 Mar;45(3):295-301. doi: 10.1016/j.jpsychires.2010.06.014. PMID: 20638079. *Exclude-Outcome*
491. Brevik EJ, Lundervold AJ, Haavik J, et al. Validity and accuracy of the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) and the Wender Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and without ADHD.

Excluded Publications

Brain Behav. 2020 Jun;10(6):e01605. doi: 10.1002/brb3.1605. PMID: 32285644. *Exclude-Language*

492. Bridgett DJ, Walker ME. Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD. Psychol Assess. 2006 Mar;18(1):1-14. doi: 10.1037/1040-3590.18.1.1. PMID: 16594807. *Exclude-Intervention*

493. Brikell I, Kuja-Halkola R, Larsson JO, et al. Relative Immaturity in Childhood and Attention-Deficit/Hyperactivity Disorder Symptoms From Childhood to Early Adulthood: Exploring Genetic and Environmental Overlap Across Development. J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):886-95. doi: 10.1016/j.jaac.2016.06.014. PMID: 27663944. *Exclude-Population*

494. Brod M, Adler LA, Lipsius S, et al. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA. Atten Defic Hyperact Disord. 2015 Jun;7(2):141-50. doi: 10.1007/s12402-014-0160-z. PMID: 25563210. *Exclude-Outcome*

495. Brod M, Johnston J, Able S, et al. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006 Feb;15(1):117-29. doi: 10.1007/s11136-005-8325-z. PMID: 16411036. *Exclude-Intervention*

496. Bron TI, Bijlenga D, Boonstra AM, et al. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2014 Apr;24(4):519-28. doi: 10.1016/j.euroneuro.2014.01.007. PMID: 24508533. *Currently being assessed for management*

497. Bron TI, Bijlenga D, Kasander MV, et al. Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study. Eur Neuropsychopharmacol. 2013 Jun;23(6):542-54. doi: 10.1016/j.euroneuro.2012.06.004. PMID: 22809706. *Exclude-Intervention*

498. Bron TI, Bijlenga D, Verduijn J, et al. Prevalence of ADHD symptoms across clinical stages of major depressive disorder. J Affect Disord. 2016 Jun;197:29-35. doi: 10.1016/j.jad.2016.02.053. PMID: 26970265. *Exclude-Intervention*

499. Brown TE, Brams M, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010 Sep;122(5):7-17. doi: 10.3810/pgm.2010.09.2196. PMID: 20861583. *Exclude-Design*

500. Brown TE, Brams M, Gasior M, et al. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin. 2011;27 Suppl 2:23-33. doi: 10.1185/03007995.2011.605441. PMID: 21973229. *Possible multiple publication*

Excluded Publications

501. Brown TE, Chen J, Robertson B. Relationships Between Executive Function Improvement and ADHD Symptom Improvement With Lisdexamfetamine Dimesylate in Adults With ADHD and Executive Function Deficits: A Post Hoc Analysis. *Prim Care Companion CNS Disord.* 2020 May 28;22(3). doi: 10.4088/PCC.19m02559. PMID: 32470230. *Possible multiple publication*
502. Brown TE, Chen J, Robertson B. Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies. *J Atten Disord.* 2022 Jan;26(2):256-66. doi: 10.1177/1087054720961819. PMID: 33150816. *Possible multiple publication*
503. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. *J Atten Disord.* 2011 Feb;15(2):130-8. doi: 10.1177/1087054709356165. PMID: 20026871. *Currently being assessed for management*
504. Brownlie EB, Lazare K, Beitchman J. Validating a self-report screen for ADHD in early adulthood using childhood parent and teacher ratings. *J Atten Disord.* 2012 Aug;16(6):467-77. doi: 10.1177/1087054711398902. PMID: 21903889. *Exclude-Comparator*
505. Bruce CR, Unsworth CA, Dillon MP, et al. Hazard perception skills of young drivers with Attention Deficit Hyperactivity Disorder (ADHD) can be improved with computer based driver training: An exploratory randomised controlled trial. *Accid Anal Prev.* 2017 Dec;109:70-7. doi: 10.1016/j.aap.2017.10.002. PMID: 29040873. *Exclude-Population*
506. Brus MJ, Solanto MV, Goldberg JF. Adult ADHD vs. bipolar disorder in the DSM-5 era: a challenging differentiation for clinicians. *J Psychiatr Pract.* 2014 Nov;20(6):428-37. doi: 10.1097/01.pra.0000456591.20622.9e. PMID: 25406047. *Exclude-Design*
507. Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, et al. ADHD pharmacogenetics across the life cycle: New findings and perspectives. *Am J Med Genet B Neuropsychiatr Genet.* 2014 Jun;165b(4):263-82. doi: 10.1002/ajmg.b.32240. PMID: 24804845. *Exclude-Intervention*
508. Bucherbeam TR, Lovett BJ, Harrison AG. ADHD and Anxiety Symptoms: Does Construct or Assessment Type Matter More? *J Atten Disord.* 2024 May;28(7):1152-7. doi: 10.1177/10870547231220905. PMID: 38323532. *Exclude-Intervention*
509. Buchsbaum MS, Haier RJ, Sostek AJ, et al. Attention dysfunction and psychopathology in college men. *Arch Gen Psychiatry.* 1985 Apr;42(4):354-60. doi: 10.1001/archpsyc.1985.01790270044004. PMID: 3977552. *Exclude-Intervention*
510. Buitelaar JK, Casas M, Philipsen A, et al. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. *Psychol Med.* 2012 Jan;42(1):195-204. doi: 10.1017/s0033291711000845. PMID: 21733214. *Exclude-Design*

Excluded Publications

511. Buitelaar JK, Kooij JJ. [Attention deficit hyperactivity disorder (ADHD): etiology, diagnosis and treatment]. Ned Tijdschr Geneesk. 2000 Sep 2;144(36):1716-23. PMID: 10992893. *Exclude-Language*
512. Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, et al. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):554-60. doi: 10.1016/j.pnpbp.2010.12.016. PMID: 21185347. *Possible multiple publication*
513. Buitelaar JK, Sobanski E, Stieglitz RD, et al. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry. 2012 Aug;73(8):1097-102. doi: 10.4088/JCP.11m07528. PMID: 22780962. *Exclude-Intervention*
514. Buitelaar JK, Trott GE, Hofecker M, et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol. 2012 Feb;15(1):1-13. doi: 10.1017/s1461145711001131. PMID: 21798108. *Exclude-Design*
515. Bumb JM, Mier D, Noelte I, et al. Associations of pineal volume, chronotype and symptom severity in adults with attention deficit hyperactivity disorder and healthy controls. Eur Neuropsychopharmacol. 2016 Jul;26(7):1119-26. doi: 10.1016/j.euroneuro.2016.03.016. PMID: 27150337. *Exclude-Intervention*
516. Burgess GC, Depue BE, Ruzic L, et al. Attentional control activation relates to working memory in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2010 Apr 1;67(7):632-40. doi: 10.1016/j.biopsych.2009.10.036. PMID: 20060961. *Exclude-Intervention*
517. Burton B, Grant M, Feigenbaum A, et al. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab. 2015 Mar;114(3):415-24. doi: 10.1016/j.ymgme.2014.11.011. PMID: 25533024. *Exclude-Population*
518. Bush G, Spencer TJ, Holmes J, et al. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry. 2008 Jan;65(1):102-14. doi: 10.1001/archgenpsychiatry.2007.16. PMID: 18180434. *Currently being assessed for management*
519. Bushe C, Day K, Reed V, et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. J Psychopharmacol. 2016 May;30(5):444-58. doi: 10.1177/0269881116636105. PMID: 27005307. *Exclude-Duplicate*
520. Bushe C, Sobanski E, Coghill D, et al. Predictors of response to atomoxetine for the treatment of adult patients with Attention-Deficit/Hyperactivity Disorder. ADHD Attention Deficit and Hyperactivity Disorders. 2015;7:S49. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*

Excluded Publications

521. Bushe C, Sobanski E, Coghill D, et al. Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database. *CNS Drugs*. 2016 Apr;30(4):317-34. doi: 10.1007/s40263-016-0323-x. PMID: 27055440. *Exclude-Intervention*
522. Bussing R, Mason D, Garvan CW, et al. Willingness to use ADHD Self-Management: Mixed Methods Study of Perceptions by Adolescents and Parents. *J Child Fam Stud*. 2016 Feb 1;25(2):562-73. doi: 10.1007/s10826-015-0241-4. PMID: 26834448. *Exclude-Population*
523. Butnik SM. Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. *J Clin Psychol*. 2005 May;61(5):621-5. doi: 10.1002/jclp.20124. PMID: 15723361. *Exclude-Design*
524. Butterfield ME, Saal J, Young B, et al. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. *Psychiatry Res*. 2016 Feb 28;236:136-41. doi: 10.1016/j.psychres.2015.12.017. PMID: 26730446. *Currently being assessed for management*
525. Butzbach M, Fuermaier ABM, Aschenbrenner S, et al. Metacognition in adult ADHD: subjective and objective perspectives on self-awareness of cognitive functioning. *J Neural Transm (Vienna)*. 2021 Jul;128(7):939-55. doi: 10.1007/s00702-020-02293-w. PMID: 33464422. *Exclude-Intervention*
526. Cachoeira CT, Leffa DT, Mittelstadt SD, et al. Positive effects of transcranial direct current stimulation in adult patients with attention-deficit/hyperactivity disorder - A pilot randomized controlled study. *Psychiatry Res*. 2017 Jan;247:28-32. doi: 10.1016/j.psychres.2016.11.009. PMID: 27863315. *Exclude-Timing*
527. Caci H, Asherson P, Donfrancesco R, et al. Daily life impairments associated with childhood/adolescent attention-deficit/hyperactivity disorder as recalled by adults: results from the European Lifetime Impairment Survey. *CNS Spectr*. 2015 Apr;20(2):112-21. doi: 10.1017/s1092852914000078. PMID: 24571924. *Exclude-Intervention*
528. Caci H, Didier C, Wynchank D. Validation and bifactor structure of the French Adult ADHD Symptoms Rating Scale v1.1 (ASRS). *Encephale*. 2024 Feb;50(1):68-74. doi: 10.1016/j.encep.2022.11.007. PMID: 36641267. *Exclude-Language*
529. Caci HM, Morin AJ, Tran A. Prevalence and correlates of attention deficit hyperactivity disorder in adults from a French community sample. *J Nerv Ment Dis*. 2014 Apr;202(4):324-32. doi: 10.1097/nmd.0000000000000126. PMID: 24647218. *Exclude-Intervention*
530. Caci HM, Morin AJ, Tran A. Teacher Ratings of the ADHD-RS IV in a Community Sample: Results From the ChiP-ARD Study. *J Atten Disord*. 2016 May;20(5):434-44. doi: 10.1177/1087054712473834. PMID: 23422236. *Exclude-Population*
531. Cairncross M, Milosevic A, Struble CA, et al. Clinical and Personality Characteristics of Problem and Pathological Gamblers With and Without Symptoms of Adult ADHD. *J Nerv Ment*

Excluded Publications

Dis. 2019 Apr;207(4):246-54. doi: 10.1097/nmd.0000000000000959. PMID: 30882557.

Exclude-Population

532. Callahan BL, Plamondon A. Examining the validity of the ADHD concept in adults and older adults. *CNS Spectr.* 2019 Oct;24(5):518-25. doi: 10.1017/s1092852918001190. PMID: 30295232. *Exclude-Intervention*

533. Callahan BL, Plamondon A, Gill S, et al. Contribution of vascular risk factors to the relationship between ADHD symptoms and cognition in adults and seniors. *Sci Rep.* 2021 Dec 20;11(1):24276. doi: 10.1038/s41598-021-03782-y. PMID: 34930996. *Exclude-Intervention*

534. Cambron-Mellott MJ, Mikl J, Matos JE, et al. Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment. *Patient Prefer Adherence.* 2021;15:1061-73. doi: 10.2147/ppa.S311836. PMID: 34054292. *Exclude-Intervention*

535. Camporeale A, Upadhyaya H, Ramos-Quiroga JA, et al. Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and Non-European adults with attention-deficit/ hyperactivity disorder. *European Journal of Psychiatry.* 2013;27(3):206-24. doi: 10.4321/S0213-61632013000300005. *Currently being assessed for management*

536. Cantilena L, Kahn R, Duncan CC, et al. Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants. *J Addict Med.* 2012 Dec;6(4):265-73. doi: 10.1097/ADM.0b013e31826b767f. PMID: 22987022. *Exclude-Population*

537. Canu WH, Carlson CL. Differences in heterosocial behavior and outcomes of ADHD-symptomatic subtypes in a college sample. *J Atten Disord.* 2003 Apr;6(3):123-33. doi: 10.1177/108705470300600304. PMID: 12821877. *Exclude-Intervention*

538. Capuzzi E, Caldiroli A, Auxilia AM, et al. Biological Predictors of Treatment Response in Adult Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review. *J Pers Med.* 2022 Oct 20;12(10). doi: 10.3390/jpm12101742. PMID: 36294881. *Exclude-Intervention*

539. Cardo E, Servera M, Bernad M, et al. Pharmacological treatment versus neurofeedback in typical symptomatology of attention deficit hyperactivity disorder. *European Neuropsychopharmacology.* 2013;23:S584. doi: 10.1016/S0924-977X(13)70930-1. *Currently being assessed for management*

540. Cardo Jalon E. Influence of different rating scale ADHD RS and SNAP IV based on DSM IV criteria in the prevalence of subtype of ADHD. *European Journal of Paediatric Neurology.* 2011;15:S127. doi: 10.1016/S1090-3798(11)70444-5. *Exclude-Design*

541. Cardullo S, Gómez Pérez LJ, Cuppone D, et al. A Retrospective Comparative Study in Patients With Cocaine Use Disorder Comorbid With Attention Deficit Hyperactivity Disorder Undergoing an rTMS Protocol Treatment. *Front Psychiatry.* 2021;12:659527. doi: 10.3389/fpsy.2021.659527. PMID: 33841218. *Exclude-Design*

Excluded Publications

542. Caresia L, Pugnetti L, Besana R, et al. EEG and clinical findings during pemoline treatment in children and adults with attention deficit disorder. An 8-week open trial. *Neuropsychobiology*. 1984;11(3):158-67. doi: 10.1159/000118070. PMID: 6472603. *Exclude-Outcome*
543. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. *Addiction*. 2005 Dec;100(12):1868-74. doi: 10.1111/j.1360-0443.2005.01272.x. PMID: 16367988. *Currently being assessed for management*
544. Carroll P, Hirvikoski T, Lindholm C, et al. Group-based emotion regulation skills training for adults with ADHD: A feasibility study in an outpatient psychiatric setting. *Appl Neuropsychol Adult*. 2023 Jan-Feb;30(1):71-82. doi: 10.1080/23279095.2021.1910512. PMID: 33905287. *Exclude-Design*
545. Carter SL. College students' acceptance of potential treatments for ADHD. *Psychol Rep*. 2005 Aug;97(1):258-64. doi: 10.2466/pr0.97.1.258-264. PMID: 16279332. *Exclude-Intervention*
546. Carvalho LR, Haas LM, Zeni G, et al. Evaluation of the effectiveness of the FOCUS ADHD App in monitoring adults with attention-deficit/hyperactivity disorder. *Eur Psychiatry*. 2023 Jun 21;66(1):e53. doi: 10.1192/j.eurpsy.2023.2422. PMID: 37341028. *Exclude-Intervention*
547. Casas M, Rösler M, Sandra Kooij JJ, et al. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. *World J Biol Psychiatry*. 2013 May;14(4):268-81. doi: 10.3109/15622975.2011.600333. PMID: 22106853. *Currently being assessed for management*
548. Casaseca-de-la-Higuera P, Martín-Martínez D, Alberola-López S, et al. Automatic diagnosis of ADHD based on multichannel nonlinear analysis of actimetry registries. *Annu Int Conf IEEE Eng Med Biol Soc*. 2012;2012:4204-7. doi: 10.1109/embc.2012.6346894. PMID: 23366855. *Exclude-Comparator*
549. Castaneda R, Sussman N, Levy R, et al. A Treatment Algorithm for Attention Deficit Hyperactivity Disorder in Cocaine-Dependent Adults: A One-Year Private Practice Study with Long-Acting Stimulants, Fluoxetine, and Bupropion. *Subst Abus*. 1999 Mar;20(1):59-71. doi: 10.1080/0897079909511394. PMID: 12511821. *Exclude-Design*
550. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database of Systematic Reviews*. 2018(8). doi: 10.1002/14651858.CD007813.pub3. PMID: CD007813. *Currently being assessed for management*
551. Castells X, Cunill R. Pharmacological treatment of ADHD: An evidence map using minerva database, a new tool for clinical psychopharmacology research. *European*

Excluded Publications

Neuropsychopharmacology. 2019;29:S141-S2. doi: 10.1016/j.euroneuro.2018.11.256. *Currently being assessed for management*

552. Castells X, Cunill R, Riera M, et al. Treatment discontinuation in clinical trials of methylphenidate and atomoxetine for adults with attention deficit/hyperactivity disorder: A systematic review and meta-analysis of clinical trials. Basic and Clinical Pharmacology and Toxicology. 2012;111:22. doi: 10.1111/bcpt.12014. *Currently being assessed for management*

553. Cataldo M, Donnelly G, Cutler AJ, et al. Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHD. J Atten Disord. 2022 Dec;26(14):1870-81. doi: 10.1177/10870547221106238. PMID: 35786058. *Possible multiple publication*

554. Cavanagh R, Clifford JS, Gregory WL. The use of bromocriptine for the treatment of attention deficit disorder in two chemically dependent patients. J Psychoactive Drugs. 1989 Apr-Jun;21(2):217-20. doi: 10.1080/02791072.1989.10472161. PMID: 2668485. *Exclude-Design*

555. Caye A, Spadini AV, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016 Nov;25(11):1151-9. doi: 10.1007/s00787-016-0831-8. PMID: 27021056. *Exclude-Intervention*

556. Cazorla P, Kroon R, Shahid M, et al. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Neuropsychopharmacology. 2011;36:S230. doi: 10.1038/npp.2011.292. *Currently being assessed for management*

557. Çelik HEA, Küçükgöncü S, Erdoğan A, et al. Response Inhibition and Interference Control in Adult Attention Deficit Hyperactivity Disorder. Noro Psikiyatr Ars. 2023;60(1):3-8. doi: 10.29399/npa.28192. PMID: 36911564. *Exclude-Intervention*

558. Chae PK. Correlation study between WISC-III scores and TOVA performance. Psychology in the Schools. 1999;36(3):179-85. doi: 10.1002/(SICI)1520-6807(199905)36:3<179::AID-PITS1>3.0.CO;2-W. *Exclude-Population*

559. Chamberlain SR, Cortese S, Grant JE. Screening for adult ADHD using brief rating tools: What can we conclude from a positive screen? Some caveats. Compr Psychiatry. 2021 Apr;106:152224. doi: 10.1016/j.comppsy.2021.152224. PMID: 33581449. *Exclude-Comparator*

560. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007 Nov 1;62(9):977-84. doi: 10.1016/j.biopsych.2007.03.003. PMID: 17644072. *Currently being assessed for management*

561. Chamberlain SR, Hampshire A, Müller U, et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry. 2009 Apr 1;65(7):550-5. doi: 10.1016/j.biopsych.2008.10.014. PMID: 19026407. *Exclude-Population*

Excluded Publications

562. Chao TC, Chou MC, Yang P, et al. Effects of interpolation methods in spatial normalization of diffusion tensor imaging data on group comparison of fractional anisotropy. *Magn Reson Imaging*. 2009 Jun;27(5):681-90. doi: 10.1016/j.mri.2008.09.004. PMID: 19027254. *Exclude-Intervention*
563. Chaplin S. Lisdexamfetamine for the management of ADHD in adults. *Prescriber*. 2015;26(21):12-4. doi: 10.1002/psb.1406. *Currently being assessed for management*
564. Charernboon L, Kosulwit W. Pharmacological Treatments for Attention-Deficit Hyperactivity Disorder (ADHD) in Adults: A Systematic Review and Meta-analysis. *Revista de Psiquiatria Clinica*. 2023;50(1):150-6. doi: 10.15761/0101-60830000000536. *Currently being assessed for management*
565. Chen J, Niemeier M. Altered perceptual pseudoneglect in ADHD: Evidence for a functional disconnection from early visual activation. *Neuropsychologia*. 2017 May;99:12-23. doi: 10.1016/j.neuropsychologia.2017.02.022. PMID: 28254649. *Exclude-Intervention*
566. Chen Y-L, Chen VC-H, Gossop M. Reliability and validity of the Chen ADHD Scale (C-ADHDS). *Neuropsychiatric Disease and Treatment*. 2021;17. doi: 10.2147/NDT.S292696. *Exclude-Population*
567. Cheng YS, Shyu YC, Lee SY, et al. Trend, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit/hyperactivity disorder: a nationwide survey in Taiwan. *Neuropsychiatr Dis Treat*. 2017;13:643-51. doi: 10.2147/ndt.S126438. PMID: 28280346. *Exclude-Intervention*
568. Cherkasova MV, Faridi N, Casey KF, et al. Differential Associations between Cortical Thickness and Striatal Dopamine in Treatment-Naïve Adults with ADHD vs. Healthy Controls. *Front Hum Neurosci*. 2017;11:421. doi: 10.3389/fnhum.2017.00421. PMID: 28878639. *Exclude-Intervention*
569. Cherkasova MV, Faridi N, Casey KF, et al. Amphetamine-induced dopamine release and neurocognitive function in treatment-naïve adults with ADHD. *Neuropsychopharmacology*. 2014 May;39(6):1498-507. doi: 10.1038/npp.2013.349. PMID: 24378745. *Exclude-Intervention*
570. Cherkasova MV, French LR, Syer CA, et al. Efficacy of Cognitive Behavioral Therapy With and Without Medication for Adults With ADHD: A Randomized Clinical Trial. *J Atten Disord*. 2020 Apr;24(6):889-903. doi: 10.1177/1087054716671197. PMID: 28413900. *Currently being assessed for management*
571. Chermá MD, Josefsson M, Rydberg I, et al. Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage. *Eur J Drug Metab Pharmacokinet*. 2017 Apr;42(2):295-307. doi: 10.1007/s13318-016-0346-1. PMID: 27220743. *Exclude-Outcome*
572. Cheung T, Chau B, Fong KH, et al. Evaluating the efficacy and safety of transcranial pulse stimulation on adolescents with attention deficit hyperactivity disorder: Study protocol of a pilot

Excluded Publications

- randomized, double-blind, sham-controlled trial. *Front Neurol.* 2023;14:1076086. doi: 10.3389/fneur.2023.1076086. PMID: 37056363. *Exclude-Population*
573. Chhibber A, Watanabe AH, Chaisai C, et al. Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. *Pharmacoeconomics.* 2021 Apr;39(4):399-420. doi: 10.1007/s40273-020-00998-0. PMID: 33554324. *Exclude-Intervention*
574. Childress A, Cutler AJ, Marraffino AH, et al. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD. *J Atten Disord.* 2022 Apr;26(6):857-69. doi: 10.1177/10870547211025610. PMID: 34189995. *Currently being assessed for management*
575. Childress A, Mehrotra S, Gobburu J, et al. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol.* 2018 Feb;28(1):10-8. doi: 10.1089/cap.2017.0044. PMID: 29039979. *Exclude-Timing*
576. Childress A, Sottile R, Khanbijian S. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients. *Expert Rev Neurother.* 2023 Jul-Dec;23(11):945-53. doi: 10.1080/14737175.2023.2265068. PMID: 37846759. *Exclude-Design*
577. Childress AC. 12.1 What's New With Medication Treatment for ADHD? *Journal of the American Academy of Child and Adolescent Psychiatry.* 2023;62(10):S19. doi: 10.1016/j.jaac.2023.07.188. *Currently being assessed for management*
578. Childress AC, Uchida CL, Po MD, et al. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial. *Clinical Therapeutics.* 2020;42(12):2332-40. doi: 10.1016/j.clinthera.2020.10.004. *Currently being assessed for management*
579. Chiu S, Campbell K. CADTH Rapid Response Reports. Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health
- Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.; 2018. *Exclude-Intervention*
580. Christensen L, Sasane R, Hodgkins P, et al. Treatment patterns by race/ethnicity and income levels among attention-deficit hyperactivity disorder (ADHD) subjects treated with short-, intermediate-and long-acting stimulants. *Value in Health.* 2009;12(3):A189. doi: 10.1111/j.1524-4733.2009.00537-2.x. *Currently being assessed for management*
581. Christiansen H, Hirsch O, Philipsen A, et al. German validation of the conners adult ADHD rating scale-self-report: confirmation of factor structure in a large sample of participants

Excluded Publications

with ADHD. *J Atten Disord.* 2013 Nov;17(8):690-8. doi: 10.1177/1087054711435680. PMID: 22441889. *Exclude-Outcome*

582. Christiansen H, Kis B, Hirsch O, et al. German validation of the Conners Adult ADHD Rating Scales (CAARS) II: reliability, validity, diagnostic sensitivity and specificity. *Eur Psychiatry.* 2012 Jul;27(5):321-8. doi: 10.1016/j.eurpsy.2010.12.010. PMID: 21392946. *Exclude-Language*

583. Christiansen H, Kis B, Hirsch O, et al. German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: factor structure and normative data. *Eur Psychiatry.* 2011 Mar;26(2):100-7. doi: 10.1016/j.eurpsy.2009.12.024. PMID: 20619613. *Exclude-Population*

584. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. *Pharmacotherapy.* 2004 Aug;24(8):1020-36. doi: 10.1592/phco.24.11.1020.36146. PMID: 15338851. *Exclude-Design*

585. Chronis-Tuscano A. Sequencing treatments for mothers with attention-deficit/hyperactivity disorder and their young children: A SMART pilot. *Journal of the American Academy of Child and Adolescent Psychiatry.* 2016;55(10):S264. doi: 10.1016/j.jaac.2016.07.141. *Currently being assessed for management*

586. Chronis-Tuscano A, Seymour KE, Stein MA, et al. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. *J Clin Psychiatry.* 2008 Dec;69(12):1938-47. doi: 10.4088/jcp.v69n1213. PMID: 19192455. *Currently being assessed for management*

587. Chronis-Tuscano A, Wang CH, Strickland J, et al. Personalized Treatment of Mothers With ADHD and Their Young At-Risk Children: A SMART Pilot. *J Clin Child Adolesc Psychol.* 2016 Jul-Aug;45(4):510-21. doi: 10.1080/15374416.2015.1102069. PMID: 26799502. *Exclude-Design*

588. Chu KC, Huang YS, Tseng CF, et al. Reliability and validity of DS-ADHD: A decision support system on attention deficit hyperactivity disorders. *Comput Methods Programs Biomed.* 2017 Mar;140:241-8. doi: 10.1016/j.cmpb.2016.12.003. PMID: 28254080. *Exclude-Population*

589. Chung W, Jiang SF, Paksarian D, et al. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. *JAMA Netw Open.* 2019 Nov 1;2(11):e1914344. doi: 10.1001/jamanetworkopen.2019.14344. PMID: 31675080. *Exclude-Intervention*

590. Churchill SS, Leo MC, Brennan EM, et al. Longitudinal Impact of a Randomized Clinical Trial to Improve Family Function, Reduce Maternal Stress and Improve Child Outcomes in Families of Children with ADHD. *Matern Child Health J.* 2018 Aug;22(8):1172-82. doi: 10.1007/s10995-018-2502-5. PMID: 29476416. *Exclude-Population*

Excluded Publications

591. Chutko LS, Surushkina S, Iakovenko EA, et al. [Attention deficit syndrome in adults: clinical, psychophysiological features and treatment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(8):38-41. PMID: 24077549. *Exclude-Language*
592. Clark C, Prior M, Kinsella GJ. Do executive function deficits differentiate between adolescents with ADHD and oppositional defiant/conduct disorder? A neuropsychological study using the Six Elements Test and Hayling Sentence Completion Test. Journal of Abnormal Child Psychology. 2000;28(5):403-14. doi: 10.1023/A:1005176320912. *Exclude-Population*
593. Clarke AR, Barry RJ, Dupuy FE, et al. Childhood EEG as a predictor of adult attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2011 Jan;122(1):73-80. doi: 10.1016/j.clinph.2010.05.032. PMID: 20598939. *Exclude-Population*
594. Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005 Dec;10(12 Suppl 20):6-15. PMID: 16344836. *Exclude-Population*
595. Cleland C, Magura S, Foote J, et al. Factor structure of the Conners Adult ADHD Rating Scale (CAARS) for substance users. Addict Behav. 2006 Jul;31(7):1277-82. doi: 10.1016/j.addbeh.2005.08.014. PMID: 16169157. *Exclude-Intervention*
596. Clemow DB, Mason OW, Sarkis EH, et al. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. Expert Rev Neurother. 2015;15(11):1353-66. doi: 10.1586/14737175.2015.1102060. PMID: 26488905. *Exclude-Population*
597. Cody JT, Valtier S, Nelson SL. Amphetamine excretion profile following multidose administration of mixed salt amphetamine preparation. J Anal Toxicol. 2004 Oct;28(7):563-74. doi: 10.1093/jat/28.7.563. PMID: 15516315. *Exclude-Intervention*
598. Coghill D. Why is phillip such a fidget and johnny an air head? recognising and managing ADHD in a mental health setting. Australian and New Zealand Journal of Psychiatry. 2021;55(SUPPL 1):8. doi: 10.1177/00048674211004750. *Currently being assessed for management*
599. Coghill D, Sorooshian S, Caballero B. Safety outcomes from the clinical development programme for lisdexamfetamine dimesylate: A prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder. European Child and Adolescent Psychiatry. 2013;22(2):S224. doi: 10.1007/s00787-013-0423-9. *Currently being assessed for management*
600. Coghill DR, Banaschewski T, Lecendreux M, et al. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/ hyperactivity disorder in a randomized, Controlled trial. Neuropsychiatric Disease and Treatment. 2014;10:2039-47. doi: 10.2147/NDT.S68273. *Currently being assessed for management*

Excluded Publications

601. Cohen E, Kalanthroff E. Visuospatial processing bias in ADHD: A potential artifact in the Wechsler Adult Intelligence Scale and the Rorschach Inkblots Test. *Psychol Assess*. 2019 May;31(5):699-706. doi: 10.1037/pas0000687. PMID: 30556717. *Exclude-Intervention*
602. Cohen-Yavin I, Yoran-Hegesh R, Strous RD, et al. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. *Clin Neuropharmacol*. 2009 Jul-Aug;32(4):179-82. doi: 10.1097/WNF.0b013e318183796d. PMID: 19644227. *Exclude-Population*
603. Cole P, Weibel S, Nicastro R, et al. CBT/DBT skills training for adults with attention deficit hyperactivity disorder (ADHD). *Psychiatr Danub*. 2016 Sep;28(Suppl-1):103-7. PMID: 27663817. *Currently being assessed for management*
604. Conners CK, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). *Psychopharmacol Bull*. 1996;32(1):67-73. PMID: 8927677. *Exclude-Intervention*
605. Constantino JN, Zhang Y, Holzhauer K, et al. Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. *J Pediatr*. 2015 Sep;167(3):621-6.e1. doi: 10.1016/j.jpeds.2015.04.075. PMID: 26051969. *Exclude-Intervention*
606. Converse AK, Ahlers EO, Travers BG, et al. Tai chi training reduces self-report of inattention in healthy young adults. *Front Hum Neurosci*. 2014;8:13. doi: 10.3389/fnhum.2014.00013. PMID: 24478679. *Exclude-Population*
607. Converse AK, Barrett BP, Chewning BA, et al. Tai Chi training for attention deficit hyperactivity disorder: A feasibility trial in college students. *Complement Ther Med*. 2020 Sep;53:102538. doi: 10.1016/j.ctim.2020.102538. PMID: 33066865. *Currently being assessed for management*
608. Conzelmann A, Woidich E, Mucha RF, et al. Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder. *J Neural Transm (Vienna)*. 2016 Aug;123(8):971-9. doi: 10.1007/s00702-016-1512-y. PMID: 26852138. *Exclude-Intervention*
609. Coogan AN, Schenk M, Palm D, et al. Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. *Neuropsychopharmacology*. 2019 Jun;44(7):1198-206. doi: 10.1038/s41386-019-0327-6. PMID: 30758328. *Exclude-Design*
610. Cook C, Buelow MT, Lee E, et al. Malingered attention deficit/hyperactivity disorder on the Conners' Adult ADHD Rating Scales: Do reasons for malingering matter? *Journal of Psychoeducational Assessment*. 2018;36(6):552-61. doi: 10.1177/0734282917696934. *Exclude-Intervention*
611. Cook J, Knight E, Hume I, et al. The self-esteem of adults diagnosed with attention-deficit/hyperactivity disorder (ADHD): a systematic review of the literature. *Atten Defic Hyperact Disord*. 2014 Dec;6(4):249-68. doi: 10.1007/s12402-014-0133-2. PMID: 24668198. *Exclude-Intervention*

Excluded Publications

612. Cook J, Lloyd-Jones M, Arunogiri S, et al. Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review. *Aust N Z J Psychiatry*. 2017 Sep;51(9):876-85. doi: 10.1177/0004867417714878. PMID: 28639480. *Misuse only*
613. Cooper M, Hammerton G, Collishaw S, et al. Investigating late-onset ADHD: a population cohort investigation. *J Child Psychol Psychiatry*. 2018 Oct;59(10):1105-13. doi: 10.1111/jcpp.12911. PMID: 29683192. *Exclude-Intervention*
614. Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. *European Neuropsychopharmacology*. 2016;26:S130. *Currently being assessed for management*
615. Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. *Eur Neuropsychopharmacol*. 2017 Aug;27(8):795-808. doi: 10.1016/j.euroneuro.2017.05.005. PMID: 28576350. *Currently being assessed for management*
616. Corbisiero S, Bitto H, Newark P, et al. A comparison of cognitive-behavioral therapy and pharmacotherapy vs. pharmacotherapy alone in adults with attention-deficit/hyperactivity disorder (ADHD)—A randomized controlled trial. *Frontiers in Psychiatry*. 2018;9. doi: 10.3389/fpsy.2018.00571. *Currently being assessed for management*
617. Corbisiero S, Bitto H, Newark P, et al. A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial. *Front Psychiatry*. 2018;9:571. doi: 10.3389/fpsy.2018.00571. PMID: 30505283. *Currently being assessed for management*
618. Corbisiero S, Bitto H, Newark P, et al. A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)—A Randomized Controlled Trial. *Frontiers in Psychiatry*. 2018;9. doi: 10.3389/fpsy.2018.00571. *Currently being assessed for management*
619. Corbisiero S, Riecher-Rössler A, Buchli-Kammermann J, et al. Symptom overlap and screening for symptoms of attention-deficit/hyperactivity disorder and psychosis risk in help-seeking psychiatric patients. *Frontiers in Psychiatry*. 2017;8. doi: 10.3389/fpsy.2017.00206. *Exclude-Duplicate*
620. Corbisiero S, Riecher-Rössler A, Buchli-Kammermann J, et al. Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. *Front Psychiatry*. 2017;8:206. doi: 10.3389/fpsy.2017.00206. PMID: 29163233. *Exclude-Comparator*
621. Corkum P, Elik N, Blotnicky-Gallant PAC, et al. Web-Based Intervention for Teachers of Elementary Students With ADHD: Randomized Controlled Trial. *J Atten Disord*. 2019 Feb;23(3):257-69. doi: 10.1177/1087054715603198. PMID: 26362259. *Exclude-Population*

Excluded Publications

622. Corrales M, García-González S, Richarte V, et al. Long-term efficacy of a new 6-session cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder: A randomized, controlled clinical trial. *Psychiatry Res.* 2024 Jan;331:115642. doi: 10.1016/j.psychres.2023.115642. PMID: 38103281. *Currently being assessed for management*
623. Correll CU, Starling BR, Huss M. Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: Implications for use in adult patients. *CNS Spectrums.* 2022;27(4):437-49. doi: 10.1017/S1092852921000341. *Currently being assessed for management*
624. Cortese S. 5.2 2024 Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder: Systematic Review and Meta-analysis: Clinical Utility of Continuous Performance Tests for Identification of Attention-Deficit/Hyperactivity Disorder. 2024. p. S139. *Exclude-Design*
625. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. *The Lancet Psychiatry.* 2018;5(9):727-38. doi: 10.1016/S2215-0366(18)30269-4. *Currently being assessed for management*
626. Cortese S, Adamo N, Mohr-Jensen C, et al. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. *BMJ Open.* 2017 Jan 10;7(1):e013967. doi: 10.1136/bmjopen-2016-013967. PMID: 28073796. *Exclude-Design*
627. Cortese S, Kelly C, Chabernaud C, et al. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. *Am J Psychiatry.* 2012 Oct;169(10):1038-55. doi: 10.1176/appi.ajp.2012.11101521. PMID: 22983386. *Exclude-Population*
628. Cortese S, Kelly C, Chabernaud C, et al. Toward systems neuroscience of ADHD: A meta-analysis of 55 fMRI studies. *American Journal of Psychiatry.* 2012;169(10):1038-55. doi: 10.1176/appi.ajp.2012.11101521. *Currently being assessed for management*
629. Cortese S, Tessari L. Attention-Deficit/Hyperactivity Disorder (ADHD) and Obesity: Update 2016. *Curr Psychiatry Rep.* 2017 Jan;19(1):4. doi: 10.1007/s11920-017-0754-1. PMID: 28102515. *Exclude-Intervention*
630. Cosmo C, Baptista A, De Araújo AN, et al. Transcranial direct current stimulation effects in inhibitory control in individuals with attention deficit/hyperactivity disorder. *Neurology.* 2017;88(16). *Currently being assessed for management*
631. Cosmo C, Baptista AF, de Araújo AN, et al. A Randomized, Double-Blind, Sham-Controlled Trial of Transcranial Direct Current Stimulation in Attention-Deficit/Hyperactivity Disorder. *PLoS One.* 2015;10(8):e0135371. doi: 10.1371/journal.pone.0135371. PMID: 26267861. *Exclude-Timing*
632. Cosmo C, Baptista AF, de Sena EP. Contribution of transcranial direct current stimulation on inhibitory control to assess the neurobiological aspects of attention deficit hyperactivity

Excluded Publications

- disorder: randomized controlled trial. JMIR Res Protoc. 2015 May 18;4(2):e56. doi: 10.2196/resprot.4138. PMID: 25986784. *Exclude-Outcome*
633. Coutlee CG, Politzer CS, Hoyle RH, et al. An Abbreviated Impulsiveness Scale constructed through confirmatory factor analysis of the Barratt Impulsiveness Scale Version 11. Archives of Scientific Psychology. 2014;2(1):1-12. doi: 10.1037/arc0000005. *Exclude-Intervention*
634. Covey LS, Hu MC, Winhusen T, et al. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug Alcohol Depend. 2010 Jul 1;110(1-2):156-9. doi: 10.1016/j.drugalcdep.2010.02.002. PMID: 20219292. *Currently being assessed for management*
635. Cowart MD, Esbenshade TA, Browman KE, et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3-receptor antagonist. Inflammation Research. 2010;59:S334. doi: 10.1007/s00011-010-0263-8. *Currently being assessed for management*
636. Cowles BJ. Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009 Apr;43(4):669-76. doi: 10.1345/aph.1L521. PMID: 19318601. *Exclude-Design*
637. Cowley B, Holmström É, Juurmaa K, et al. Computer Enabled Neuroplasticity Treatment: A Clinical Trial of a Novel Design for Neurofeedback Therapy in Adult ADHD. Front Hum Neurosci. 2016;10:205. doi: 10.3389/fnhum.2016.00205. PMID: 27242472. *Currently being assessed for management*
638. Cowley BU, Juurmaa K, Palomäki J. Reduced Power in Fronto-Parietal Theta EEG Linked to Impaired Attention-Sampling in Adult ADHD. eNeuro. 2022 Jan-Feb;9(1). doi: 10.1523/eneuro.0028-21.2021. PMID: 34893505. *Exclude-Intervention*
639. Cox DJ, Davis M, Mikami AY, et al. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2012 Apr;32(2):225-30. doi: 10.1097/JCP.0b013e3182496dc5. PMID: 22367664. *Currently being assessed for management*
640. Cox DJ, Merkel RL, Kovatchev B, et al. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis. 2000 Apr;188(4):230-4. doi: 10.1097/00005053-200004000-00006. PMID: 10790000. *Exclude-Timing*
641. Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006 Sep;118(3):e704-10. doi: 10.1542/peds.2005-2947. PMID: 16950962. *Exclude-Population*
642. Cox DJ, Merkel RL, Penberthy JK, et al. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J

Excluded Publications

- Am Acad Child Adolesc Psychiatry. 2004 Mar;43(3):269-75. doi: 10.1097/00004583-200403000-00007. PMID: 15076259. *Exclude-Population*
643. Culpepper L, Mattingly G. A practical guide to recognition and diagnosis of ADHD in adults in the primary care setting. Postgrad Med. 2008 Sep;120(3):16-26. doi: 10.3810/pgm.2008.09.1904. PMID: 18824822. *Exclude-Comparator*
644. Cutler AJ, Childress AC, Pardo A, et al. Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2022 Jul 20;83(5). doi: 10.4088/JCP.22m14438. PMID: 35857716. *Currently being assessed for management*
645. Cutler AJ, Childress AC, Pardo A, et al. Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of the Amphetamine Extended-Release Tablet in Adults with Attention-Deficit/ Hyperactivity Disorder. CNS Spectrums. 2022;27(2):242-3. doi: 10.1017/s1092852922000487. *Currently being assessed for management*
646. D'Agostino AR, Wesley MJ, Brown J, et al. Effects of multisensory stop signals on alcohol-induced disinhibition in adults with ADHD. Exp Clin Psychopharmacol. 2019 Jun;27(3):247-56. doi: 10.1037/pha0000251. PMID: 30628812. *Exclude-Intervention*
647. Daigre Blanco C, Ramos-Quiroga JA, Valero S, et al. Adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist in patients with substance use disorders. Actas Esp Psiquiatr. 2009 Nov-Dec;37(6):299-305. PMID: 20066581. *Exclude-Language*
648. Daigre C, Roncero C, Rodríguez-Cintas L, et al. Adult ADHD screening in alcohol-dependent patients using the Wender-Utah Rating Scale and the adult ADHD Self-Report Scale. J Atten Disord. 2015 Apr;19(4):328-34. doi: 10.1177/1087054714529819. PMID: 24743975. *Exclude-Language*
649. Dakwar-Kawar O, Mairon N, Hochman S, et al. Transcranial random noise stimulation combined with cognitive training for treating ADHD: a randomized, sham-controlled clinical trial. Transl Psychiatry. 2023 Aug 2;13(1):271. doi: 10.1038/s41398-023-02547-7. PMID: 37528107. *Exclude-Population*
650. Daley D, Sonuga-Barke EJ, Thompson M. Assessing expressed emotion in mothers of preschool AD/HD children: psychometric properties of a modified speech sample. Br J Clin Psychol. 2003 Mar;42(Pt 1):53-67. doi: 10.1348/014466503762842011. PMID: 12675979. *Exclude-Population*
651. Dalla Bella S, Foster NEV, Laflamme H, et al. Mobile version of the Battery for the Assessment of Auditory Sensorimotor and Timing Abilities (BAASTA): Implementation and adult norms. Behav Res Methods. 2024 Mar 8. doi: 10.3758/s13428-024-02363-x. PMID: 38459221. *Exclude-Intervention*
652. Dang LC, Samanez-Larkin GR, Young JS, et al. Caudate asymmetry is related to attentional impulsivity and an objective measure of ADHD-like attentional problems in healthy

Excluded Publications

- adults. *Brain Struct Funct*. 2016 Jan;221(1):277-86. doi: 10.1007/s00429-014-0906-6. PMID: 25269835. *Exclude-Intervention*
653. Danielson ML, Bohm MK, Newsome K, et al. Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults - United States, 2016-2021. *MMWR Morb Mortal Wkly Rep*. 2023 Mar 31;72(13):327-32. doi: 10.15585/mmwr.mm7213a1. PMID: 36995976. *Exclude-Population*
654. Das D, Vélez JI, Acosta MT, et al. Retrospective assessment of childhood ADHD symptoms for diagnosis in adults: validity of a short 8-item version of the Wender-Utah Rating Scale. *Atten Defic Hyperact Disord*. 2016 Dec;8(4):215-23. doi: 10.1007/s12402-016-0202-9. PMID: 27510231. *Exclude-Intervention*
655. Davids E, Gastpar M. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder]. *Fortschr Neurol Psychiatr*. 2004 Oct;72(10):586-91. doi: 10.1055/s-2004-830049. PMID: 15472782. *Exclude-Language*
656. Davids E, Kis B, Specka M, et al. A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006 Aug 30;30(6):1033-8. doi: 10.1016/j.pnpbp.2006.03.035. PMID: 16698160. *Exclude-Design*
657. Davids E, Krause DA, Specka M, et al. [Analysis of a special consultation for attention deficit/hyperactivity disorder in adults]. *Gesundheitswesen*. 2004 Jul;66(7):416-22. doi: 10.1055/s-2004-813327. PMID: 15314733. *Exclude-Language*
658. Davtian M, Reid RC, Fong TW. Investigating facets of personality in adult pathological gamblers with ADHD. *Neuropsychiatry (London)*. 2012 Apr;2(2):163-74. doi: 10.2217/npv.12.11. PMID: 22815658. *Exclude-Outcome*
659. Dawson EL, Shear PK, Howe SR, et al. Impulsivity predicts time to reach euthymia in adults with bipolar disorder. *Bipolar Disord*. 2014 Dec;16(8):846-56. doi: 10.1111/bdi.12232. PMID: 25039396. *Exclude-Outcome*
660. De Bruyckere K, Bushe C, Bartel C, et al. Effects of atomoxetine on functional outcomes, and correlation with the core symptoms of Attention-Deficit/Hyperactivity Disorder in adult patients. *ADHD Attention Deficit and Hyperactivity Disorders*. 2015;7:S49. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
661. de Graaf R, ten Have M, Tuithof M, et al. First-incidence of DSM-IV mood, anxiety and substance use disorders and its determinants: results from the Netherlands Mental Health Survey and Incidence Study-2. *J Affect Disord*. 2013 Jul;149(1-3):100-7. doi: 10.1016/j.jad.2013.01.009. PMID: 23399481. *Exclude-Intervention*
662. de Jong S, Newhouse SJ, Patel H, et al. Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis. *Br J Psychiatry*. 2016 Sep;209(3):202-8. doi: 10.1192/bjp.bp.115.175471. PMID: 27151072. *Exclude-Intervention*

Excluded Publications

663. de Lacy N, Ramshaw MJ. Selectively predicting the onset of ADHD, oppositional defiant disorder, and conduct disorder in early adolescence with high accuracy. *Front Psychiatry*. 2023;14:1280326. doi: 10.3389/fpsyt.2023.1280326. PMID: 38144472. *Exclude-Population*
664. de Oliveira DC, de Sousa PG, dos Reis CB, et al. Safety of treatments for ADHD in adults: Pairwise and network meta-analyses. *Journal of Attention Disorders*. 2019;23(2):111-20. doi: 10.1177/1087054717696773. *Currently being assessed for management*
665. de Zeeuw P, Weusten J, van Dijk S, et al. Deficits in cognitive control, timing and reward sensitivity appear to be dissociable in ADHD. *PLoS One*. 2012;7(12):e51416. doi: 10.1371/journal.pone.0051416. PMID: 23236497. *Exclude-Intervention*
666. Deal LS, Sleeper-Triplett J, DiBenedetti DB, et al. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). *J Atten Disord*. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118. PMID: 25477019. *Exclude-Intervention*
667. Dehili VM, Prevatt F, Coffman TP. An Analysis of the Barkley Deficits in Executive Functioning Scale in a College Population: Does It Predict Symptoms of ADHD Better Than a Visual-Search Task? *J Atten Disord*. 2017 May;21(7):567-74. doi: 10.1177/1087054713498932. PMID: 24026813. *Exclude-Intervention*
668. Deiber MP, Ammann C, Hasler R, et al. Electrophysiological correlates of improved executive function following EEG neurofeedback in adult attention deficit hyperactivity disorder. *Clin Neurophysiol*. 2021 Aug;132(8):1937-46. doi: 10.1016/j.clinph.2021.05.017. PMID: 34153722. *Exclude-Comparator*
669. del Campo N, Fryer TD, Hong YT, et al. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. *Brain*. 2013 Nov;136(Pt 11):3252-70. doi: 10.1093/brain/awt263. PMID: 24163364. *Exclude-Timing*
670. DeLong DM. The utility of the Personality Assessment Inventory as a screening tool for adult Attention Deficit/Hyperactivity Disorder. US: ProQuest Information & Learning; 2009. *Exclude-Design*
671. Dennison CA, Legge SE, Bracher-Smith M, et al. Association of genetic liability for psychiatric disorders with accelerometer-assessed physical activity in the UK Biobank. *PLoS One*. 2021;16(3):e0249189. doi: 10.1371/journal.pone.0249189. PMID: 33770123. *Exclude-Intervention*
672. Dentz A, Guay M-C, Parent V, et al. Working memory training for adults with ADHD. *Journal of Attention Disorders*. 2020;24(6):918-27. doi: 10.1177/1087054717723987. *Currently being assessed for management*
673. Dentz A, Guay MC, Parent V, et al. Working Memory Training for Adults With ADHD. *J Atten Disord*. 2020 Apr;24(6):918-27. doi: 10.1177/1087054717723987. PMID: 28856932. *Currently being assessed for management*

Excluded Publications

674. Depue BE, Burgess GC, Bidwell LC, et al. Behavioral performance predicts grey matter reductions in the right inferior frontal gyrus in young adults with combined type ADHD. *Psychiatry Res.* 2010 Jun 30;182(3):231-7. doi: 10.1016/j.psychresns.2010.01.012. PMID: 20493669. *Exclude-Outcome*
675. Depue BE, Burgess GC, Willcutt EG, et al. Symptom-correlated brain regions in young adults with combined-type ADHD: their organization, variability, and relation to behavioral performance. *Psychiatry Res.* 2010 May 30;182(2):96-102. doi: 10.1016/j.psychresns.2009.11.011. PMID: 20399622. *Exclude-Intervention*
676. Dey S, Rao AR, Shah M. Attributed graph distance measure for automatic detection of attention deficit hyperactive disordered subjects. *Front Neural Circuits.* 2014;8:64. doi: 10.3389/fncir.2014.00064. PMID: 24982615. *Exclude-Population*
677. Di Nuovo SF, Buono S. Psychiatric syndromes comorbid with mental retardation: differences in cognitive and adaptive skills. *J Psychiatr Res.* 2007 Nov;41(9):795-800. doi: 10.1016/j.jpsychires.2006.02.011. PMID: 16697412. *Exclude-Population*
678. Dias G, Mattos P, Coutinho G, et al. Agreement rates between parent and self-report on past ADHD symptoms in an adult clinical sample. *J Atten Disord.* 2008 Jul;12(1):70-5. doi: 10.1177/1087054707311221. PMID: 18192619. *Exclude-Intervention*
679. Dickinson K, Parmar P, Reyes AB, et al. Bariatric Surgery Is Highly Effective and Underutilized in Patients with ADHD: A 5-Year Retrospective Cohort Study. *Obes Surg.* 2024 Jun;34(6):2066-72. doi: 10.1007/s11695-024-07211-7. PMID: 38619772. *Exclude-Intervention*
680. Dinu LM, Phattharakulnij N, Dommett EJ. Tryptophan modulation in individuals with attention deficit hyperactivity disorder: a systematic review. *J Neural Transm (Vienna).* 2022 Apr;129(4):361-77. doi: 10.1007/s00702-022-02478-5. PMID: 35286460. *Exclude-Intervention*
681. Dinu LM, Singh SN, Baker NS, et al. The effects of tryptophan loading on Attention Deficit Hyperactivity in adults: A remote double blind randomised controlled trial. *PLoS One.* 2023;18(11):e0294911. doi: 10.1371/journal.pone.0294911. PMID: 38033150. *Currently being assessed for management*
682. Dinu LM, Singh SN, Baker NS, et al. The Effects of Different Exercise Approaches on Attention Deficit Hyperactivity Disorder in Adults: A Randomised Controlled Trial. *Behav Sci (Basel).* 2023 Feb 2;13(2). doi: 10.3390/bs13020129. PMID: 36829357. *Currently being assessed for management*
683. Dittner AJ, Hodsoll J, Rimes KA, et al. Cognitive-behavioural therapy for adult attention-deficit hyperactivity disorder: a proof of concept randomised controlled trial. *Acta Psychiatr Scand.* 2018 Feb;137(2):125-37. doi: 10.1111/acps.12836. PMID: 29282731. *Currently being assessed for management*
684. Dittner AJ, Rimes KA, Russell AJ, et al. Protocol for a proof of concept randomized controlled trial of cognitive-behavioural therapy for adult ADHD as a supplement to treatment as

Excluded Publications

usual, compared with treatment as usual alone. *BMC Psychiatry*. 2014 Sep 3;14:248. doi: 10.1186/s12888-014-0248-1. PMID: 25207986. *Exclude-Design*

685. Dobrosavljevic M, Solares C, Cortese S, et al. Prevalence of attention-deficit/hyperactivity disorder in older adults: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2020 Nov;118:282-9. doi: 10.1016/j.neubiorev.2020.07.042. PMID: 32798966. *Exclude-Intervention*

686. Dodson WW. Pharmacotherapy of adult ADHD. *J Clin Psychol*. 2005 May;61(5):589-606. doi: 10.1002/jclp.20122. PMID: 15723384. *Exclude-Design*

687. Doehnert M, Brandeis D, Schneider G, et al. A neurophysiological marker of impaired preparation in an 11-year follow-up study of attention-deficit/hyperactivity disorder (ADHD). *J Child Psychol Psychiatry*. 2013 Mar;54(3):260-70. doi: 10.1111/j.1469-7610.2012.02572.x. PMID: 22788246. *Exclude-Population*

688. Doering S, Lichtenstein P, Gillberg C, et al. Anxiety at age 15 predicts psychiatric diagnoses and suicidal ideation in late adolescence and young adulthood: results from two longitudinal studies. *BMC Psychiatry*. 2019 Nov 14;19(1):363. doi: 10.1186/s12888-019-2349-3. PMID: 31727035. *Exclude-Population*

689. Dogan-Sander E, Strauß M. Case Report: Treatment of a Comorbid Attention Deficit Hyperactivity Disorder and Obsessive-Compulsive Disorder With Psychostimulants. *Front Psychiatry*. 2021;12:649833. doi: 10.3389/fpsy.2021.649833. PMID: 34054609. *Exclude-Design*

690. Doi H, Kanai C, Ohta H. Transdiagnostic and sex differences in cognitive profiles of autism spectrum disorder and attention-deficit/hyperactivity disorder. *Autism Res*. 2022 Jun;15(6):1130-41. doi: 10.1002/aur.2712. PMID: 35347878. *Exclude-Intervention*

691. Dong H, Koerts J, Pijnenborg GHM, et al. Cognitive Underperformance in a Mixed Neuropsychiatric Sample at Diagnostic Evaluation of Adult ADHD. *Journal of Clinical Medicine*. 2023;12(21). doi: 10.3390/jcm12216926. *Exclude-Duplicate*

692. Dong H, Koerts J, Pijnenborg GHM, et al. Cognitive Underperformance in a Mixed Neuropsychiatric Sample at Diagnostic Evaluation of Adult ADHD. *J Clin Med*. 2023 Nov 4;12(21). doi: 10.3390/jcm12216926. PMID: 37959391. *Exclude-Comparator*

693. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. *Pharmacotherapy*. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. PMID: 19476419. *Exclude-Design*

694. Dor-Ziderman Y, Zeev-Wolf M, Hirsch Klein E, et al. High-gamma oscillations as neurocorrelates of ADHD: A MEG crossover placebo-controlled study. *J Psychiatr Res*. 2021 May;137:186-93. doi: 10.1016/j.jpsychires.2021.02.050. PMID: 33684643. *Exclude-Intervention*

695. Dorrego MF, Canevaro L, Kuzis G, et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary

Excluded Publications

- findings. *J Neuropsychiatry Clin Neurosci*. 2002 Summer;14(3):289-95. doi: 10.1176/jnp.14.3.289. PMID: 12154153. *Currently being assessed for management*
696. Dosis S, Van der Oord S, Huizenga HM, et al. Prevalence and diagnostic validity of motivational impairments and deficits in visuospatial short-term memory and working memory in ADHD subtypes. *European Child & Adolescent Psychiatry*. 2015;24(5):575-90. doi: 10.1007/s00787-014-0612-1. *Exclude-Duplicate*
697. Downey KK, Stelson FW, Pomerleau OF, et al. Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. *J Nerv Ment Dis*. 1997 Jan;185(1):32-8. doi: 10.1097/00005053-199701000-00006. PMID: 9040531. *Exclude-Intervention*
698. Doyle AE, Wilens TE, Kwon A, et al. Neuropsychological functioning in youth with bipolar disorder. *Biol Psychiatry*. 2005 Oct 1;58(7):540-8. doi: 10.1016/j.biopsych.2005.07.019. PMID: 16199011. *Exclude-Population*
699. Du Rietz E, James S-N, Banaschewski T, et al. Autonomic arousal profiles in adolescents and young adults with ADHD as a function of recording context. *Psychiatry Research*. 2019;275:212-20. doi: 10.1016/j.psychres.2019.03.039. *Exclude-Population*
700. Dubreuil-Vall L, Gomez-Bernal F, Villegas AC, et al. Transcranial Direct Current Stimulation to the Left Dorsolateral Prefrontal Cortex Improves Cognitive Control in Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Behavioral and Neurophysiological Study. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021 Apr;6(4):439-48. doi: 10.1016/j.bpsc.2020.11.006. PMID: 33549516. *Exclude-Timing*
701. Dupaul GJ, Weyandt LL, Rossi JS, et al. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. *J Atten Disord*. 2012 Apr;16(3):202-20. doi: 10.1177/1087054711427299. PMID: 22166471. *Exclude-Design*
702. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. *J Atten Disord*. 2010 Jan;13(4):401-6. doi: 10.1177/1087054709342203. PMID: 19706876. *Possible multiple publication*
703. Durell TM, Adler LA, Williams DW, et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. *J Clin Psychopharmacol*. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. PMID: 23277268. *Currently being assessed for management*
704. Durell TM, Adler LA, Williams DW, et al. "Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes. A randomized, double-blind, placebo-controlled clinical trial": Erratum. *Journal of Clinical Psychopharmacology*. 2014;34(4):542-. doi: 10.1097/JCP.0000000000000186. *Currently being assessed for management*

Excluded Publications

705. Dyresen A, Stubberud J, Fjermestad KW, et al. Executive control training for adolescents with ADHD: Study protocol for a randomised controlled trial. *Contemp Clin Trials*. 2024 Jan;136:107404. doi: 10.1016/j.cct.2023.107404. PMID: 38070766. *Exclude-Population*
706. Eberhard D, Gillberg C, Billstedt E. Cognitive functioning in adult psychiatric patients with and without attention-deficit/hyperactivity disorder. *Brain Behav*. 2024 Jul;14(7):e3626. doi: 10.1002/brb3.3626. PMID: 39054265. *Exclude-Intervention*
707. Eddy LD, Anastopoulos AD, Dvorsky MR, et al. An RCT of a CBT Intervention for Emerging Adults with ADHD Attending College: Functional Outcomes. *J Clin Child Adolesc Psychol*. 2021 Nov-Dec;50(6):844-57. doi: 10.1080/15374416.2020.1867989. PMID: 33617367. *Currently being assessed for management*
708. Edel MA, Hölter T, Wassink K, et al. A Comparison of Mindfulness-Based Group Training and Skills Group Training in Adults With ADHD. *J Atten Disord*. 2017 Apr;21(6):533-9. doi: 10.1177/1087054714551635. PMID: 25300813. *Currently being assessed for management*
709. Edel MA, Pfütze EM, Lieder A, et al. Self concept, action control and ADHD symptoms under methylphenidate treatment in adults with ADHD. *Pharmacopsychiatry*. 2009 May;42(3):109-13. doi: 10.1055/s-0028-1112130. PMID: 19452379. *Exclude-Design*
710. Egeland J, Kovalik-Gran I. Validity of the factor structure of Conners' CPT. *J Atten Disord*. 2010 Jan;13(4):347-57. doi: 10.1177/1087054709332477. PMID: 19448149. *Exclude-Intervention*
711. Egeland J, Kovalik-Gran I. Measuring several aspects of attention in one test: the factor structure of conners's continuous performance test. *J Atten Disord*. 2010 Jan;13(4):339-46. doi: 10.1177/1087054708323019. PMID: 18728238. *Exclude-Intervention*
712. Eiland LS, Guest AL. Atomoxetine treatment of attention-deficit/hyperactivity disorder. *Ann Pharmacother*. 2004 Jan;38(1):86-90. doi: 10.1345/aph.1D144. PMID: 14742801. *Exclude-Design*
713. Ekinci O, Arman AR, Işık U, et al. EEG abnormalities and epilepsy in autistic spectrum disorders: clinical and familial correlates. *Epilepsy Behav*. 2010 Feb;17(2):178-82. doi: 10.1016/j.yebeh.2009.11.014. PMID: 20042370. *Exclude-Intervention*
714. El Archi S, Barrault S, Garcia M, et al. Adult ADHD Diagnosis, Symptoms of Impulsivity, and Emotional Dysregulation in a Clinical Sample of Outpatients Consulting for a Behavioral Addiction. *J Atten Disord*. 2023 May;27(7):731-42. doi: 10.1177/10870547231161336. PMID: 36945199. *Exclude-Design*
715. Eleanor D, Clara K, Burcu Goz T. A systematic review of the use of meditation to manage Attention Deficit Hyperactivity Disorder. 2021. PMID: CRD42021292110. *Currently being assessed for management*

Excluded Publications

716. Elliott GR, Diner A, Sitbon E. An Objective Assessment of Effect of Stimulants on Attention in Individuals With ADHD. *J Atten Disord*. 2024 Feb;28(4):451-7. doi: 10.1177/10870547231215285. PMID: 38197370. *Exclude-Design*
717. Elliott H. Attention deficit hyperactivity disorder in adults: a guide for the primary care physician. *South Med J*. 2002 Jul;95(7):736-42. PMID: 12144080. *Exclude-Design*
718. Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. *BMC Psychiatry*. 2011 Jul 25;11:116. doi: 10.1186/1471-244x-11-116. PMID: 21787431. *Currently being assessed for management*
719. Endres D, Perlov E, Maier S, et al. Normal Neurochemistry in the Prefrontal and Cerebellar Brain of Adults with Attention-Deficit Hyperactivity Disorder. *Front Behav Neurosci*. 2015;9:242. doi: 10.3389/fnbeh.2015.00242. PMID: 26441572. *Exclude-Outcome*
720. Endres D, Perlov E, Maier S, et al. Normal neurochemistry in the prefrontal and cerebellar brain of adults with attention-deficit hyperactivity disorder. *Frontiers in Behavioral Neuroscience*. 2015;9(September). doi: 10.3389/fnbeh.2015.00242. *Exclude-Intervention*
721. Eng AG, Bansal PS, Goh PK, et al. Evidence-Based Assessment for Attention-Deficit/Hyperactivity Disorder. *Assessment*. 2024 Jan;31(1):42-52. doi: 10.1177/10731911221149957. PMID: 36633097. *Exclude-Design*
722. Engel-Yeger B. The development and validation of the "SENSE" - Sensory and Behavioral Modulation Questionnaire for adults. *Res Dev Disabil*. 2024 Apr;147:104715. doi: 10.1016/j.ridd.2024.104715. PMID: 38471295. *Exclude-Comparator*
723. Engelhardt PE, Veld SN, Nigg JT, et al. Are language production problems apparent in adults who no longer meet diagnostic criteria for attention-deficit/hyperactivity disorder? *Cogn Neuropsychol*. 2012;29(3):275-99. doi: 10.1080/02643294.2012.712957. PMID: 23005917. *Exclude-Population*
724. Enrico C, Alice C, Anna Maria A, et al. Clinical and biological predictors of treatment response in adult attention deficit hyperactivity disorder: a systematic review. 2022. PMID: CRD42022298758. *Exclude-Intervention*
725. Epperson CN, Pittman B, Czarkowski KA, et al. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. *Menopause*. 2011 May;18(5):542-8. doi: 10.1097/gme.0b013e3181fc6fd6. PMID: 21293309. *Exclude-Population*
726. Epstein JN, Casey BJ, Tonev ST, et al. ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD. *J Child Psychol Psychiatry*. 2007 Sep;48(9):899-913. doi: 10.1111/j.1469-7610.2007.01761.x. PMID: 17714375. *Exclude-Outcome*

Excluded Publications

727. Epstein JN, Kollins SH. Psychometric properties of an adult ADHD diagnostic interview. *J Atten Disord.* 2006 Feb;9(3):504-14. doi: 10.1177/1087054705283575. PMID: 16481667.

Exclude-Intervention

728. Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. *Prim Care Companion CNS Disord.* 2012;14(6). doi: 10.4088/PCC.11r01336. PMID: 23585986. *Exclude-Design*

729. Epstein T, Patsopoulos NA, Weiser M. Methylphenidate for adults with attention deficit-hyperactivity disorder, a systematic review. *European Neuropsychopharmacology.* 2009;19:S341. doi: 10.1016/S0924-977X(09)70515-2. *Currently being assessed for management*

730. Epstein T, Patsopoulos NA, Weiser M. WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev.* 2016 May 26(5):Cd005041. doi: 10.1002/14651858.CD005041.pub3. PMID: 27228176. *Exclude-Design*

731. Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database of Systematic Reviews.* 2016;2016(5). doi: 10.1002/14651858.CD005041.pub3. *Currently being assessed for management*

732. Erdodi LA. Aggregating validity indicators embedded in Conners' CPT-II outperforms individual cutoffs at separating valid from invalid performance in adults with traumatic brain injury. *Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.* 2014;29(5):456-66. doi: 10.1093/arclin/acu026. *Exclude-Intervention*

733. Erdodi LA, Lajiness-O'Neill R, Saules KK. Order of Conners' CPT-II administration within a cognitive test battery influences ADHD indices. *J Atten Disord.* 2010 Jul;14(1):43-51. doi: 10.1177/1087054709347199. PMID: 19833866. *Exclude-Design*

734. Erdoğan E, Hakan Delibas D, Kartı Ö. Assessment of Optical Coherence Tomography Findings in Adults with Attention Deficit Hyperactivity Disorder: A Case-Control Study. *Psychiatry Clin Psychopharmacol.* 2021 Dec;31(4):370-8. doi: 10.5152/pcp.2021.21183. PMID: 38765643. *Exclude-Intervention*

735. Eriksson JM, Andersen LM, Bejerot S. RAADS-14 Screen: validity of a screening tool for autism spectrum disorder in an adult psychiatric population. *Mol Autism.* 2013 Dec 9;4(1):49. doi: 10.1186/2040-2392-4-49. PMID: 24321513. *Exclude-Intervention*

736. Ermer J, Roesch B, Buckwalter M, et al. Pharmacokinetics of coadministration of guanfacine extended release and lisdexamfetamine dimesylate. *Journal of Pharmacy Practice.* 2011;24(2):256. doi: 10.1177/0897190011403437. *Currently being assessed for management*

737. Ernst M, Liebenauer LL, Jons PH, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. *Psychopharmacol Bull.* 1996;32(3):327-34. PMID: 8961775. *Currently being assessed for management*

Excluded Publications

738. Ernst M, Liebenauer LL, Tebeka D, et al. Selegiline in ADHD adults: plasma monoamines and monoamine metabolites. *Neuropsychopharmacology*. 1997 Apr;16(4):276-84. doi: 10.1016/s0893-133x(96)00243-6. PMID: 9094145. *Currently being assessed for management*
739. Ernst M, Zametkin AJ, Matochik JA, et al. Effects of intravenous dextroamphetamine on brain metabolism in adults with attention-deficit hyperactivity disorder (ADHD). Preliminary findings. *Psychopharmacol Bull*. 1994;30(2):219-25. PMID: 7831459. *Exclude-Design*
740. Estrada RV, Bosch R, Nogueira M, et al. Psychoeducation for adults with attention deficit hyperactivity disorder vs. cognitive behavioral group therapy: A randomized controlled pilot study. *Journal of Nervous and Mental Disease*. 2013;201(10):894-900. doi: 10.1097/NMD.0b013e3182a5c2c5. *Currently being assessed for management*
741. Etter NM, Cadely FA, Peters MG, et al. Speech motor control and orofacial point pressure sensation in adults with ADHD. *Neurosci Lett*. 2021 Jan 23;744:135592. doi: 10.1016/j.neulet.2020.135592. PMID: 33359925. *Exclude-Design*
742. Ezard N, Dunlop A, Clifford B, et al. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. *BMC Psychiatry*. 2016 Dec 1;16(1):428. doi: 10.1186/s12888-016-1141-x. PMID: 27905916. *Exclude-Design*
743. Faber A, Keizer RJ, van den Berg PB, et al. Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. *Eur J Clin Pharmacol*. 2007 Jan;63(1):57-63. doi: 10.1007/s00228-006-0219-7. PMID: 17115147. *Exclude-Population*
744. Fadeuilhe Grau C, Palma-Álvarez RF, Nasillo V, et al. Criteria and concurrent validity of DIVA 2.0: A semi-structured diagnostic interview for adult ADHD. *European Psychiatry*. 2016;33:S630. doi: 10.1016/j.eurpsy.2016.01.2368. *Exclude-Design*
745. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. *J Clin Psychopharmacol*. 2021 Mar-Apr 01;41(2):155-62. doi: 10.1097/jcp.0000000000001361. PMID: 33587403. *Exclude-Population*
746. Fallu A, Dabouz F, Furtado M, et al. A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic). *Ther Adv Psychopharmacol*. 2016 Aug;6(4):237-51. doi: 10.1177/2045125316643674. PMID: 27536342. *Currently being assessed for management*
747. Fallu A, Richard C, Prinzo R, et al. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. *Curr Med Res Opin*. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906x154132. PMID: 17166338. *Exclude-Design*
748. Fan LY, Chou TL, Gau SS. Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder. *Hum*

Excluded Publications

Brain Mapp. 2017 Oct;38(10):4850-64. doi: 10.1002/hbm.23683. PMID: 28657141. *Currently being assessed for management*

749. Farahbakhshian S, Ayyagari R, Barczak DS, et al. Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA. CNS Drugs. 2021 May;35(5):575-89. doi: 10.1007/s40263-021-00808-x. PMID: 33856656. *Exclude-Population*

750. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008 Jun;9(9):1565-74. doi: 10.1517/14656566.9.9.1565. PMID: 18518785. *Exclude-Design*

751. Faraone SV, Biederman J, Spencer TJ, et al. The drug-placebo response curve: a new method for assessing drug effects in clinical trials. J Clin Psychopharmacol. 2000 Dec;20(6):673-9. doi: 10.1097/00004714-200012000-00014. PMID: 11106140. *Exclude-Intervention*

752. Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med. 2007 Dec;37(12):1743-52. doi: 10.1017/s0033291707000335. PMID: 17349106. *Exclude-Design*

753. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353-64. doi: 10.1007/s00787-009-0054-3. PMID: 19763664. *Exclude-Population*

754. Faraone SV, Childress A, Caras S, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2021 Aug 24;82(5). doi: 10.4088/JCP.21m13927. PMID: 34428356. *Currently being assessed for management*

755. Faraone SV, Doyle AE, Mick E, et al. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry. 2001 Jul;158(7):1052-7. doi: 10.1176/appi.ajp.158.7.1052. PMID: 11431226. *Exclude-Intervention*

756. Faraone SV, Gomeni R, Hull JT, et al. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial. Psychiatry Res. 2022 Dec;318:114922. doi: 10.1016/j.psychres.2022.114922. PMID: 36375329. *Possible multiple publication*

757. Faraone SV, Newcorn JH, Cipriani A, et al. Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis. Mol Psychiatry. 2022 Jan;27(1):212-9. doi: 10.1038/s41380-021-01134-w. PMID: 33972692. *Exclude-Population*

758. Faraone SV, Rostain AL, Blader J, et al. Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention. J

Excluded Publications

Child Psychol Psychiatry. 2019 Feb;60(2):133-50. doi: 10.1111/jcpp.12899. PMID: 29624671.

Exclude-Intervention

759. Faraone SV, Short EJ, Biederman J, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. *Int J Neuropsychopharmacol*. 2002 Jun;5(2):121-9. doi:

10.1017/s1461145702002845. PMID: 12135536. *Exclude-Design*

760. Faraone SV, Silverstein MJ, Antshel K, et al. The Adult ADHD Quality Measures Initiative. *J Atten Disord*. 2019 Aug;23(10):1063-78. doi: 10.1177/1087054718804354. PMID: 30511593. *Exclude-Intervention*

761. Faraone SV, Spencer TJ, Kollins SH, et al. Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study. *J Atten Disord*. 2012 Feb;16(2):118-27. doi: 10.1177/1087054711403716. PMID: 21527575. *Currently being assessed for management*

762. Farber GT. The diagnosis of attention deficit hyperactivity disorder in college-aged deaf individuals: An examination of the Barkley Adult ADHD Rating Scale-IV (BAARS-IV). US: ProQuest Information & Learning; 2022. *Exclude-Intervention*

763. Fargason RE, Fobian AD, Hablitz LM, et al. Correcting delayed circadian phase with bright light therapy predicts improvement in ADHD symptoms: A pilot study. *J Psychiatr Res*. 2017 Aug;91:105-10. doi: 10.1016/j.jpsychires.2017.03.004. PMID: 28327443. *Exclude-Design*

764. Fargason RE, Gamble K, Avis KT, et al. Ramelteon for Insomnia Related to Attention-Deficit/Hyperactivity Disorder (ADHD). *Psychopharmacol Bull*. 2011 May 15;44(2):32-53. PMID: 27738354. *Currently being assessed for management*

765. Faries DE, Houston JP, Sulcs EM, et al. A cross-validation of the provisional diagnostic instrument (PDI-4). *BMC Fam Pract*. 2012 Oct 15;13:104. doi: 10.1186/1471-2296-13-104. PMID: 23067304. *Exclude-Comparator*

766. Farokhzadi F, Mohammadi MR, Salmanian M. Discriminant of validity the Wender Utah rating scale in Iranian adults. *Acta Med Iran*. 2014;52(5):360-9. PMID: 24902016. *Exclude-Outcome*

767. Fatseas M, Debrabant R, Auriacombe M. The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders. *Curr Opin Psychiatry*. 2012 May;25(3):219-25. doi: 10.1097/YCO.0b013e3283523d7c. PMID: 22449768. *Exclude-Intervention*

768. Fay TB, Alpert MA. Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring. *Cardiol Rev*. 2019 Jul/Aug;27(4):173-8. doi: 10.1097/crd.0000000000000234. PMID: 30531411. *Exclude-Design*

Excluded Publications

769. Feifel D, Minassian A, Perry W. Prepulse inhibition of startle in adults with ADHD. *J Psychiatr Res.* 2009 Jan;43(4):484-9. doi: 10.1016/j.jpsychires.2008.06.004. PMID: 18674783. *Exclude-Intervention*
770. Ferguson B, Schrantz AGM, De Ruiter MB, et al. Opposite effects of acute methylphenidate administration in children versus adult ADHD patients during emotional processing. *European Neuropsychopharmacology.* 2014;24:S728-S9. *Currently being assessed for management*
771. Fergusson DM, Boden JM, Horwood LJ. Classification of behavior disorders in adolescence: scaling methods, predictive validity, and gender differences. *J Abnorm Psychol.* 2010 Nov;119(4):699-712. doi: 10.1037/a0018610. PMID: 20853914. *Exclude-Intervention*
772. Fernández-Jaén A, Fernández-Mayoralas DM, Calleja Pérez B, et al. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. *Pediatr Neurol.* 2010 Nov;43(5):341-7. doi: 10.1016/j.pediatrneurol.2010.06.003. PMID: 20933178. *Exclude-Population*
773. Fernández-Jaén A, Martín Fernández-Mayoralas D, Calleja-Pérez B, et al. [The effects of methylphenidate on cognitive-attentional processes. The use of continuous performance tests]. *Rev Neurol.* 2008;46 Suppl 1:S47-9. PMID: 18302122. *Exclude-Language*
774. Fife D, Cepeda MS, Baseman A, et al. Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study. *PLoS One.* 2018;13(2):e0193453. doi: 10.1371/journal.pone.0193453. PMID: 29489906. *Exclude-Design*
775. Fijal BA, Guo Y, Li SG, et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. *J Clin Pharmacol.* 2015 Oct;55(10):1167-74. doi: 10.1002/jcph.530. PMID: 25919121. *Exclude-Intervention*
776. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. *J Clin Psychiatry.* 1996 May;57(5):184-9. PMID: 8626348. *Exclude-Design*
777. Finke K, Schwarzkopf W, Müller U, et al. Disentangling the adult attention-deficit hyperactivity disorder endophenotype: parametric measurement of attention. *J Abnorm Psychol.* 2011 Nov;120(4):890-901. doi: 10.1037/a0024944. PMID: 21859167. *Exclude-Design*
778. Finley JA, Rodriguez VJ, Cerny BM, et al. Comparing embedded performance validity indicators within the WAIS-IV Letter-Number sequencing subtest to Reliable Digit Span among adults referred for evaluation of attention-deficit/hyperactivity disorder. *Clin Neuropsychol.* 2024 Feb 13:1-20. doi: 10.1080/13854046.2024.2315738. PMID: 38351710. *Exclude-Intervention*
779. Flannery JE, Hinshaw SP, Kollins SH, et al. Secondary analyses of sex differences in attention improvements across three clinical trials of a digital therapeutic in children,

Excluded Publications

- adolescents, and adults with ADHD. BMC Public Health. 2024 Apr 29;24(1):1195. doi: 10.1186/s12889-024-18597-5. PMID: 38685016. *Exclude-Outcome*
780. Fleming AP, McMahon RJ, Moran LR, et al. Pilot randomized controlled trial of dialectical behavior therapy group skills training for ADHD among college students. J Atten Disord. 2015 Mar;19(3):260-71. doi: 10.1177/1087054714535951. PMID: 24874347. *Currently being assessed for management*
781. Flobak E, Nordby ES, Guribye F, et al. Designing Videos With and for Adults With ADHD for an Online Intervention: Participatory Design Study and Thematic Analysis of Evaluation. JMIR Ment Health. 2021 Sep 14;8(9):e30292. doi: 10.2196/30292. PMID: 34519666. *Exclude-Design*
782. Forbes GB. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. J Clin Psychol. 1998 Jun;54(4):461-76. doi: 10.1002/(sici)1097-4679(199806)54:4<461::aid-jclp8>3.0.co;2-q. PMID: 9623751. *Exclude-Population*
783. Foreman D, Morton S, Ford T. Exploring the clinical utility of the Development and Well-Being Assessment (DAWBA) in the detection of hyperkinetic disorders and associated diagnoses in clinical practice. Journal of Child Psychology and Psychiatry. 2009;50(4):460-70. doi: 10.1111/j.1469-7610.2008.02017.x. *Exclude-Population*
784. Forsström D, Oscarsson M, Buhrman M, et al. A study protocol of a randomized controlled study of internet-based cognitive behavioral therapy for adult attention deficit hyperactivity disorder. Internet Interv. 2023 Sep;33:100652. doi: 10.1016/j.invent.2023.100652. PMID: 37529408. *Exclude-Design*
785. Fossati A, Novella L, Donati D, et al. History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Compr Psychiatry. 2002 Sep-Oct;43(5):369-77. doi: 10.1053/comp.2002.34634. PMID: 12216012. *Exclude-Outcome*
786. Frampton JE. Lisdexamfetamine: A Review in ADHD in Adults. CNS Drugs. 2016 Apr;30(4):343-54. doi: 10.1007/s40263-016-0327-6. PMID: 27048350. *Exclude-Design*
787. Francisco AP, Lethbridge G, Patterson B, et al. Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review. J Psychiatr Res. 2023 Jan;157:239-56. doi: 10.1016/j.jpsychires.2022.11.029. PMID: 36508935. *Exclude-Intervention*
788. Frank MJ, Santamaria A, O'Reilly RC, et al. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2007 Jul;32(7):1583-99. doi: 10.1038/sj.npp.1301278. PMID: 17164816. *Exclude-Outcome*
789. Fredericks EM, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl). 2004 Oct;175(4):391-8. doi: 10.1007/s00213-004-1838-2. PMID: 15258716. *Exclude-Intervention*

Excluded Publications

790. Fredriksen M. How to evaluate the treatment of ADHD in adults. *Acta Neuropsychiatrica*. 2017;29:9-10. doi: 10.1017/neu.2017.17. *Currently being assessed for management*
791. Fredriksen M, Dahl AA, Martinsen EW, et al. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity. *Eur Neuropsychopharmacol*. 2014 Dec;24(12):1873-84. doi: 10.1016/j.euroneuro.2014.09.013. PMID: 25453480. *Exclude-Intervention*
792. Freichel R, Zink N, Chang FY, et al. Alpha event-related decreases during encoding in adults with ADHD - An investigation of sustained attention and working memory processes. *Behav Brain Res*. 2024 Apr 19;469:115003. doi: 10.1016/j.bbr.2024.115003. PMID: 38642862. *Exclude-Intervention*
793. French B, Hall C, Perez Vallejos E, et al. Evaluation of a Web-Based ADHD Awareness Training in Primary Care: Pilot Randomized Controlled Trial With Nested Interviews. *JMIR Med Educ*. 2020 Dec 11;6(2):e19871. doi: 10.2196/19871. PMID: 33306027. *Currently being assessed for management*
794. French B, Sayal K, Daley D. Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. *Eur Child Adolesc Psychiatry*. 2019 Aug;28(8):1037-64. doi: 10.1007/s00787-018-1256-3. PMID: 30552584. *Exclude-Intervention*
795. Frick G, Yan B, Adler LA. Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial. *J Atten Disord*. 2020 Feb;24(3):402-13. doi: 10.1177/1087054717696771. PMID: 28413925. *Currently being assessed for management*
796. Fried M, Tsitsiashvili E, Bonneh YS, et al. ADHD subjects fail to suppress eye blinks and microsaccades while anticipating visual stimuli but recover with medication. *Vision Res*. 2014 Aug;101:62-72. doi: 10.1016/j.visres.2014.05.004. PMID: 24863585. *Exclude-Intervention*
797. Fritz K, O'Connor PJ. Effects of a 6 Week Yoga Intervention on Executive Functioning in Women Screening Positive for Adult ADHD: A Pilot Study. *Front Sports Act Living*. 2022;4:746409. doi: 10.3389/fspor.2022.746409. PMID: 35280225. *Currently being assessed for management*
798. Frölich J, Banaschewski T, Spanagel R, et al. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents]. *Z Kinder Jugendpsychiatr Psychother*. 2012 Sep;40(5):287-99; quiz 99-300. doi: 10.1024/1422-4917/a000185. PMID: 22869222. *Currently being assessed for management*
799. Frölich J, Lehmkuhl G. [Pharmacological treatment in adults with attention deficit hyperactivity disorder]. *Nervenarzt*. 2004 Nov;75(11):1074-82. doi: 10.1007/s00115-004-1756-x. PMID: 15549216. *Exclude-Language*

Excluded Publications

800. Frost-Karlsson M, Capusan AJ, Olausson H, et al. Altered somatosensory processing in adult attention deficit hyperactivity disorder. *BMC Psychiatry*. 2024 Aug 13;24(1):558. doi: 10.1186/s12888-024-06002-9. PMID: 39138461. *Exclude-Intervention*
801. Fuermaier AB, Tucha L, Koerts J, et al. Measurement of stigmatization towards adults with attention deficit hyperactivity disorder. *PLoS One*. 2012;7(12):e51755. doi: 10.1371/journal.pone.0051755. PMID: 23284760. *Exclude-Outcome*
802. Fuermaier AB, Tucha L, Koerts J, et al. Good vibrations--effects of whole body vibration on attention in healthy individuals and individuals with ADHD. *PLoS One*. 2014;9(2):e90747. doi: 10.1371/journal.pone.0090747. PMID: 24587412. *Exclude-Comparator*
803. Fuermaier AB, Tucha L, Koerts J, et al. Effects of methylphenidate on memory functions of adults with ADHD. *Appl Neuropsychol Adult*. 2017 May-Jun;24(3):199-211. doi: 10.1080/23279095.2015.1124108. PMID: 27088304. *Exclude-Design*
804. Fuermaier AB, Tucha L, Mueller AK, et al. Stigmatization in teachers towards adults with attention deficit hyperactivity disorder. *Springerplus*. 2014 Jan 14;3:26. doi: 10.1186/2193-1801-3-26. PMID: 24455470. *Exclude-Outcome*
805. Fuermaier ABM, Hüpen P, De Vries SM, et al. Perception in attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord*. 2018 Mar;10(1):21-47. doi: 10.1007/s12402-017-0230-0. PMID: 28401487. *Exclude-Intervention*
806. Fuermaier ABM, Tucha L, Guo N, et al. It Takes Time: Vigilance and Sustained Attention Assessment in Adults with ADHD. *Int J Environ Res Public Health*. 2022 Apr 25;19(9). doi: 10.3390/ijerph19095216. PMID: 35564612. *Exclude-Intervention*
807. Fujibayashi H, Kitayama S, Matsuo M. Score of inattention subscale of ADHD rating scale-IV is significantly higher for AD/HD than PDD. *Kobe J Med Sci*. 2010 Aug 19;56(1):E12-7. PMID: 21063141. *Exclude-Population*
808. Furster C, Hallerback MU. The use of melatonin in Swedish children and adolescents--a register-based study according to age, gender, and medication of ADHD. *Eur J Clin Pharmacol*. 2015 Jul;71(7):877-81. doi: 10.1007/s00228-015-1866-3. PMID: 25995170. *Exclude-Population*
809. Furukawa E, da Costa RQM, Bado P, et al. Methylphenidate modifies reward cue responses in adults with ADHD: An fMRI study. *Neuropharmacology*. 2020 Jan 1;162:107833. doi: 10.1016/j.neuropharm.2019.107833. PMID: 31689423. *Exclude-Timing*
810. Fusar-Poli P, Rubia K, Rossi G, et al. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. *Am J Psychiatry*. 2012 Mar;169(3):264-72. doi: 10.1176/appi.ajp.2011.11060940. PMID: 22294258. *Exclude-Intervention*
811. Gabriel A. The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially

Excluded Publications

- responsive generalized anxiety: an open-label study. *Atten Defic Hyperact Disord*. 2010 Jun;2(2):87-92. doi: 10.1007/s12402-010-0025-z. PMID: 21432593. *Exclude-Design*
812. Gabriel A, Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. *Atten Defic Hyperact Disord*. 2011 Dec;3(4):319-26. doi: 10.1007/s12402-011-0063-1. PMID: 21833565. *Exclude-Design*
813. Gabriely R, Tarrasch R, Velicki M, et al. The influence of mindfulness meditation on inattention and physiological markers of stress on students with learning disabilities and/or attention deficit hyperactivity disorder. *Res Dev Disabil*. 2020 May;100:103630. doi: 10.1016/j.ridd.2020.103630. PMID: 32163834. *Exclude-Population*
814. Galler JR, Bryce CP, Zichlin ML, et al. Infant malnutrition is associated with persisting attention deficits in middle adulthood. *J Nutr*. 2012 Apr;142(4):788-94. doi: 10.3945/jn.111.145441. PMID: 22378333. *Exclude-Intervention*
815. Galloway-Long H, Huang-Pollock C, Neely K. Ahead of the (ROC) Curve: A Statistical Approach to Utilizing Ex-Gaussian Parameters of Reaction Time in Diagnosing ADHD Across Three Developmental Periods. *J Int Neuropsychol Soc*. 2022 Sep;28(8):821-34. doi: 10.1017/s1355617721000990. PMID: 34488917. *Exclude-Intervention*
816. Gamble KL, May RS, Besing RC, et al. Delayed sleep timing and symptoms in adults with attention-deficit/hyperactivity disorder: a controlled actigraphy study. *Chronobiol Int*. 2013 May;30(4):598-606. doi: 10.3109/07420528.2012.754454. PMID: 23445512. *Exclude-Intervention*
817. Gao L, Man KKC, Fan M, et al. Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self-controlled case series study. *British Journal of Clinical Pharmacology*. 2023;89(8):2519-28. doi: 10.1111/bcp.15714. *Currently being assessed for management*
818. Gao Q, Liu L, Chen Y, et al. Synaptosome-related (SNARE) genes and their interactions contribute to the susceptibility and working memory of attention-deficit/hyperactivity disorder in males. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015 Mar 3;57:132-9. doi: 10.1016/j.pnpbp.2014.11.001. PMID: 25445064. *Exclude-Intervention*
819. Garces K. Atomoxetine for attention deficit/hyperactivity disorder. *Issues Emerg Health Technol*. 2003 May(46):1-4. PMID: 12751480. *Currently being assessed for management*
820. Garcia Pimenta M, Gruhnert RK, Fuermaier ABM, et al. The role of executive functions in mediating the relationship between adult ADHD symptoms and hyperfocus in university students. *Res Dev Disabil*. 2024 Jan;144:104639. doi: 10.1016/j.ridd.2023.104639. PMID: 38039699. *Exclude-Intervention*
821. Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus

Excluded Publications

- erythematosus. *Arthritis Rheum*. 2013 May;65(5):1313-8. doi: 10.1002/art.37893. PMID: 23400548. *Exclude-Population*
822. Garnier-Dykstra LM, Pinchevsky GM, Caldeira KM, et al. Self-reported adult attention-deficit/hyperactivity disorder symptoms among college students. *J Am Coll Health*. 2010;59(2):133-6. doi: 10.1080/07448481.2010.483718. PMID: 20864440. *Exclude-Intervention*
823. Gauillard J, Castelnau C, Vacheron-Trystram MN, et al. [Use of methylphenidate in adults with attention deficit disorder with hyperactivity]. *Encephale*. 1997 Jul-Aug;23(4):251-6. PMID: 9417389. *Exclude-Language*
824. Gauthier M. Stimulant medications in adults with attention deficit disorder. *Can J Psychiatry*. 1984 Aug;29(5):435-40. doi: 10.1177/070674378402900515. PMID: 6148139. *Exclude-Design*
825. Gehricke JG, Gevorkian J, Stehli A, et al. Discrepancies in the Validity of Self-Reported Cigarette Smoking in Adults With and Without ADHD. *J Dual Diagn*. 2019 Jul-Sep;15(3):177-83. doi: 10.1080/15504263.2019.1620399. PMID: 31156069. *Exclude-Intervention*
826. Gehricke JG, Hong N, Wigal TL, et al. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. *Pharmacol Biochem Behav*. 2011 May;98(3):485-91. doi: 10.1016/j.pbb.2011.02.021. PMID: 21356232. *Exclude-Intervention*
827. Gehricke JG, Kruggel F, Thampipop T, et al. The brain anatomy of attention-deficit/hyperactivity disorder in young adults - a magnetic resonance imaging study. *PLoS One*. 2017;12(4):e0175433. doi: 10.1371/journal.pone.0175433. PMID: 28406942. *Exclude-Intervention*
828. Gehricke JG, Whalen CK, Jamner LD, et al. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination. *Nicotine Tob Res*. 2006 Feb;8(1):37-47. doi: 10.1080/14622200500431619. PMID: 16497598. *Exclude-Timing*
829. Geiss L, Stemmler M, Beck B, et al. Dysregulation of the autonomic nervous system in adult attention deficit hyperactivity disorder. A systematic review. *Cogn Neuropsychiatry*. 2023 Jul;28(4):285-306. doi: 10.1080/13546805.2023.2255336. PMID: 37702351. *Exclude-Intervention*
830. Gellan A, Maria Teresa L-P, Hossam k, et al. Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review. 2018. PMID: CRD42018073651. *Currently being assessed for management*
831. Genç HA, Yorguner N, Bulut S, et al. Validity and reliability of the Turkish version of the adult ADHD Self-Report Screening Scale for DSM-5. *Balkan Med J*. 2021 Mar;38(2):111-5. doi: 10.4274/balkanmedj.galenos.2020.2020.5.119. PMID: 32996464. *Exclude-Language*

Excluded Publications

832. Gerard A. Adult ADHD: Tips for an accurate diagnosis. *Current Psychiatry*. 2023;22(12):25 and 57. doi: 10.12788/cp.0418. *Exclude-Intervention*
833. Geurts DEM, den Ouden HEM, Janssen L, et al. Aversive Pavlovian inhibition in adult attention-deficit/hyperactivity disorder and its restoration by mindfulness-based cognitive therapy. *Front Behav Neurosci*. 2022;16:938082. doi: 10.3389/fnbeh.2022.938082. PMID: 35957921. *Currently being assessed for management*
834. Geurts DEM, Schellekens MPJ, Janssen L, et al. Mechanisms of Change in Mindfulness-Based Cognitive Therapy in Adults With ADHD. *J Atten Disord*. 2021 Jul;25(9):1331-42. doi: 10.1177/1087054719896865. PMID: 31904295. *Possible multiple publication*
835. Ghawami H, Homaei Shoa J, Moazenzadeh M, et al. Ecological validity of executive function tests in predicting driving performance. *Appl Neuropsychol Adult*. 2022 Sep 24:1-13. doi: 10.1080/23279095.2022.2126940. PMID: 36152341. *Exclude-Intervention*
836. Giblin J, Brams M, Gao J, et al. Effect of treatment with lisdexamfetamine dimesylate on self-reported quality of life in adults with attention-deficit/hyperactivity disorder. *European Psychiatry*. 2010;25. doi: 10.1016/S0924-9338(10)70938-X. *Currently being assessed for management*
837. Gift TE, Reimherr FW, Marchant BK, et al. Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment. *J Nerv Ment Dis*. 2016 May;204(5):355-63. doi: 10.1097/nmd.0000000000000470. PMID: 27082828. *Exclude-Intervention*
838. Gilbert DL, Ridel KR, Sallee FR, et al. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. *Neuropsychopharmacology*. 2006 Feb;31(2):442-9. doi: 10.1038/sj.npp.1300806. PMID: 16034446. *Exclude-Population*
839. Ginapp CM, Greenberg NR, MacDonald-Gagnon G, et al. "Dysregulated not deficit": A qualitative study on symptomatology of ADHD in young adults. *PLoS One*. 2023;18(10):e0292721. doi: 10.1371/journal.pone.0292721. PMID: 37824501. *Exclude-Outcome*
840. Ging-Jehli NR, Kraemer HC, Arnold LE, et al. Cognitive markers for efficacy of neurofeedback for attention-deficit hyperactivity disorder – Personalized medicine using computational psychiatry in a randomized clinical trial. *Journal of Clinical and Experimental Neuropsychology*. 2023;45(2):118-31. doi: 10.1080/13803395.2023.2206637. *Exclude-Population*
841. Ginsberg L, Katic A, Adeyi B, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. *Curr Med Res Opin*. 2011 Jun;27(6):1097-107. doi: 10.1185/03007995.2011.567256. PMID: 21438796. *Exclude-Design*

Excluded Publications

842. Ginsberg Y. Pharmacological treatment of offenders with ADHD. ADHD Attention Deficit and Hyperactivity Disorders. 2015;7:S4. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
843. Ginsberg Y, Arngrim T, Philipsen A, et al. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. CNS Drugs. 2014 Oct;28(10):951-62. doi: 10.1007/s40263-014-0180-4. PMID: 25183661. *Exclude-Design*
844. Ginsberg Y, Hirvikoski T, Grann M, et al. Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. Eur Arch Psychiatry Clin Neurosci. 2012 Dec;262(8):705-24. doi: 10.1007/s00406-012-0317-8. PMID: 22526730. *Exclude-Intervention*
845. Ginsberg Y, Hirvikoski T, Grann M, et al. Osmotic-release oral system methylphenidate (OROS-MPH) treatment of adult prison inmates with ADHD: A randomised controlled trial with open-label extension. European Psychiatry. 2013;28. *Currently being assessed for management*
846. Ginsberg Y, Långström N, Larsson H, et al. Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial. J Clin Psychopharmacol. 2015 Oct;35(5):535-43. doi: 10.1097/jcp.0000000000000395. PMID: 26284932. *Exclude-Design*
847. Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry. 2012 Jan;200(1):68-73. doi: 10.1192/bjp.bp.111.092940. PMID: 22075648. *Currently being assessed for management*
848. Girard-Joyal O, Gauthier B. Creativity in the Predominantly Inattentive and Combined Presentations of ADHD in Adults. J Atten Disord. 2022 Jul;26(9):1187-98. doi: 10.1177/10870547211060547. PMID: 34894845. *Exclude-Intervention*
849. Gisbert L, Richarte V, Corrales M, et al. The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. J Atten Disord. 2019 Oct;23(12):1514-25. doi: 10.1177/1087054718780323. PMID: 29890879. *Exclude-Intervention*
850. Gito M, Ihara H, Ogata H, et al. Gender Differences in the Behavioral Symptom Severity of Prader-Willi Syndrome. Behav Neurol. 2015;2015:294127. doi: 10.1155/2015/294127. PMID: 26633919. *Exclude-Intervention*
851. Glaser PEA, Riggs P. STIMULANT USE DISORDER IN TEENS AND COLLEGE STUDENTS: PROBLEMS AND TREATMENT. Journal of the American Academy of Child and Adolescent Psychiatry. 2021;60(10):S58. doi: 10.1016/j.jaac.2021.07.250. *Currently being assessed for management*

Excluded Publications

852. Gloger EM, Suhr JA. Correlates of Poor Sleep and Subsequent Risk of Misdiagnosis in College Students Presenting with Cognitive Complaints. *Arch Clin Neuropsychol*. 2020 Aug 28;35(6):692-70. doi: 10.1093/arclin/aaa023. PMID: 32380521. *Exclude-Intervention*
853. Godfrey E, Fuermaier ABM, Tucha L, et al. Public perceptions of adult ADHD: Indications of stigma? *J Neural Transm (Vienna)*. 2021 Jul;128(7):993-1008. doi: 10.1007/s00702-020-02279-8. PMID: 33241459. *Exclude-Intervention*
854. Goh Kah K, Chun-Yi L. The efficacy of cognitive behavioral-based therapy in adults with attention-deficit/hyperactivity disorder beyond core symptoms: A meta-analysis and meta-regression of randomized controlled trials. 2021. PMID: CRD42021273633. *Currently being assessed for management*
855. Goksøyr PK, Nøttestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. *Addict Behav*. 2008 Feb;33(2):342-6. doi: 10.1016/j.addbeh.2007.09.008. PMID: 17920777. *Exclude-Population*
856. Goldberg E, Bougakov D. Neuropsychologic assessment of frontal lobe dysfunction. *Psychiatr Clin North Am*. 2005 Sep;28(3):567-80, 78-9. doi: 10.1016/j.psc.2005.05.005. PMID: 16122567. *Exclude-Intervention*
857. Golubchik P, Sever J, Weizman A. Influence of methylphenidate treatment on smoking behavior in adolescent girls with attention-deficit/hyperactivity and borderline personality disorders. *Clin Neuropharmacol*. 2009 Sep-Oct;32(5):239-42. doi: 10.1097/wnf.0b013e3181a5d075. PMID: 19834989. *Exclude-Population*
858. Golubchik P, Sever J, Weizman A. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. *Harefuah*. 2011 Oct;150(10):788-90, 814. PMID: 22111124. *Currently being assessed for management*
859. Golubchik P, Sever J, Zalsman G, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. *Int Clin Psychopharmacol*. 2008 Jul;23(4):228-31. doi: 10.1097/YIC.0b013e3282f94ac2. PMID: 18446088. *Exclude-Population*
860. Gomez R, Vance A, Watson S, et al. ROC analyses of relevant Conners 3–Short Forms, CBCL, and TRF scales for screening ADHD and ODD. *Assessment*. 2021;28(1):73-85. doi: 10.1177/1073191119876023. *Exclude-Population*
861. Gonzalez-Garrido AA, Barrios FA, de la Serna-Tuya JM, et al. [Methylphenidate and short-term memory in young females with attention deficit hyperactivity disorder. A study using functional magnetic resonance imaging]. *Rev Neurol*. 2009 May 16-31;48(10):509-14. PMID: 19434584. *Exclude-Language*
862. Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. *J Psychiatr Pract*. 2007 Sep;13(5):318-27. doi: 10.1097/01.pra.0000290670.87236.18. PMID: 17890980. *Exclude-Outcome*

Excluded Publications

863. Goodman DW. ADHD in adults: Update for clinicians on diagnosis and assessment. *Primary Psychiatry*. 2009;16(11):38-47. *Exclude-Design*
864. Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. *CNS Spectr*. 2005 Dec;10(12 Suppl 20):26-34. doi: 10.1017/s1092852900002418. PMID: 16344838. *Exclude-Intervention*
865. Goodman DW, Starr HL, Ma YW, et al. Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. *J Clin Psychiatry*. 2017 Jan;78(1):105-14. doi: 10.4088/JCP.15m10348. PMID: 27487193. *Currently being assessed for management*
866. Goossensen MA, van de Glind G, Carpentier PJ, et al. An intervention program for ADHD in patients with substance use disorders: preliminary results of a field trial. *J Subst Abuse Treat*. 2006 Apr;30(3):253-9. doi: 10.1016/j.jsat.2005.12.004. PMID: 16616170. *Exclude-Design*
867. Gordon CT, Fabiano GA, Hulme KF, et al. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder. *Exp Clin Psychopharmacol*. 2021 Aug;29(4):308-18. doi: 10.1037/pha0000365. PMID: 32297783. *Currently being assessed for management*
868. Gorlin EI, Dalrymple K, Chelminski I, et al. Reliability and validity of a semi-structured DSM-based diagnostic interview module for the assessment of Attention Deficit Hyperactivity Disorder in adult psychiatric outpatients. *Psychiatry Res*. 2016 Aug 30;242:46-53. doi: 10.1016/j.psychres.2016.05.020. PMID: 27259136. *Exclude-Outcome*
869. Gorlin EI, Dalrymple K, Chelminski I, et al. Diagnostic profiles of adult psychiatric outpatients with and without attention deficit hyperactivity disorder. *Compr Psychiatry*. 2016 Oct;70:90-7. doi: 10.1016/j.comppsy.2016.06.015. PMID: 27624427. *Exclude-Intervention*
870. Goto T, Adler L, Upadhyaya H, et al. Executive function in adult patients with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled withdrawal study. *International Journal of Neuropsychopharmacology*. 2012;15:220. doi: 10.1017/S1461145712000508. *Currently being assessed for management*
871. Goto T, Hirata Y, Takita Y, et al. Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD. *J Atten Disord*. 2017 Jan;21(2):100-9. doi: 10.1177/1087054713510352. PMID: 24203774. *Currently being assessed for management*
872. Grabemann M, Mette C, Zimmermann M, et al. No clear effects of acute tryptophan depletion on processing affective prosody in male adults with ADHD. *Acta Psychiatr Scand*. 2013 Aug;128(2):142-8. doi: 10.1111/acps.12130. PMID: 23581825. *Exclude-Design*
873. Grabemann M, Zimmermann M, Strunz L, et al. [New Ways of Diagnosing ADHD in Adults]. *Psychiatr Prax*. 2017 May;44(4):221-7. doi: 10.1055/s-0043-100714. PMID: 28335040. *Exclude-Design*

Excluded Publications

874. Grabemann M, Zimmermann M, Strunz L, et al. New Ways of Diagnosing ADHD in Adults: The Essen-Interview-for-School-Days-Related-Biography (EIS-B). *Psychiatrische Praxis*. 2017;44(4):221-7. doi: 10.1055/s-0043-100714. *Exclude-Duplicate*
875. Grane VA, Brunner JF, Endestad T, et al. ERP Correlates of Proactive and Reactive Cognitive Control in Treatment-Naïve Adult ADHD. *PLoS One*. 2016;11(7):e0159833. doi: 10.1371/journal.pone.0159833. PMID: 27448275. *Exclude-Intervention*
876. Grann M, Ginsberg Y, Hirvikoski T, et al. Methylphenidate treatment of adult prison inmates with ADHD: A randomised double-blind placebo-controlled trial with open-label extension. *Acta Neuropsychiatrica*. 2013;25(1):13. doi: 10.1017/neu.2013.10. *Currently being assessed for management*
877. Green R, Baker NL, Ferguson PL, et al. ADHD symptoms and smoking outcomes in a randomized controlled trial of varenicline for adolescent and young adult tobacco cessation. *Drug Alcohol Depend*. 2023 Mar 1;244:109798. doi: 10.1016/j.drugalcdep.2023.109798. PMID: 36774808. *Exclude-Population*
878. Greer SM, Trujillo AJ, Glover GH, et al. Control of nucleus accumbens activity with neurofeedback. *Neuroimage*. 2014 Aug 1;96:237-44. doi: 10.1016/j.neuroimage.2014.03.073. PMID: 24705203. *Exclude-Intervention*
879. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. *Dis Mon*. 2007 Feb;53(2):70-131. doi: 10.1016/j.disamonth.2007.01.001. PMID: 17386306. *Exclude-Population*
880. Griffin JM. Assessment of Attention-Deficit/Hyperactivity Disorder in adults using the Wechsler Adult Intelligence Scale-III and brief neuropsychological techniques. US: ProQuest Information & Learning; 1999. *Exclude-Intervention*
881. Grimm O, Kopfer V, Küpper-Tetzel L, et al. Amisulpride and l-DOPA modulate subcortical brain nuclei connectivity in resting-state pharmacologic magnetic resonance imaging. *Hum Brain Mapp*. 2020 May;41(7):1806-18. doi: 10.1002/hbm.24913. PMID: 31880365. *Exclude-Population*
882. Grimm O, van Rooij D, Tshagharyan A, et al. Effects of comorbid disorders on reward processing and connectivity in adults with ADHD. *Transl Psychiatry*. 2021 Dec 16;11(1):636. doi: 10.1038/s41398-021-01758-0. PMID: 34911950. *Exclude-Outcome*
883. Grimmsmann T, Himmel W. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. *Eur J Clin Pharmacol*. 2021 Jan;77(1):107-15. doi: 10.1007/s00228-020-02948-3. PMID: 32803292. *Exclude-Design*
884. Grinblat N, Rosenblum S. Work participation, sensory processing and sleep quality in adults with attention-deficit hyperactive disorder. *Work*. 2022;73(4):1235-44. doi: 10.3233/wor-211129. PMID: 35694942. *Exclude-Intervention*

Excluded Publications

885. Grinblat N, Rosenblum S. Work-MAP Telehealth Metacognitive Work-Performance Intervention for Adults With ADHD: Randomized Controlled Trial. OTJR (Thorofare N J). 2023 Jul;43(3):435-45. doi: 10.1177/15394492231159902. PMID: 36971429. *Currently being assessed for management*
886. Grinblat N, Rosenblum S. Randomized controlled trial of work-map: telehealth metacognitive intervention for work performance enhancement of adults with attention-deficit/hyperactivity disorder. European Psychiatry. 2024;67:S550. doi: 10.1192/j.eurpsy.2024.1142. *Currently being assessed for management*
887. Grizenko N, Bhat M, Schwartz G, et al. Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. J Psychiatry Neurosci. 2006 Jan;31(1):46-51. PMID: 16496035. *Exclude-Population*
888. Groen RN, Wichers M, Wigman JTW, et al. Specificity of psychopathology across levels of severity: a transdiagnostic network analysis. Sci Rep. 2019 Dec 4;9(1):18298. doi: 10.1038/s41598-019-54801-y. PMID: 31797974. *Exclude-Outcome*
889. Groen Y, Fuermaier ABM, Tucha L, et al. A situation-specific approach to measure attention in adults with ADHD: The everyday life attention scale (ELAS). Appl Neuropsychol Adult. 2019 Sep-Oct;26(5):411-40. doi: 10.1080/23279095.2018.1437730. PMID: 29537898. *Exclude-Outcome*
890. Grogan K, Bramham J. Current Mood Symptoms Do Not Affect the Accuracy of Retrospective Self-Ratings of Childhood ADHD Symptoms. J Atten Disord. 2016 Dec;20(12):1039-46. doi: 10.1177/1087054714528536. PMID: 24691528. *Exclude-Intervention*
891. Gropper RJ, Gotlieb H, Kronitz R, et al. Working memory training in college students with ADHD or LD. J Atten Disord. 2014 May;18(4):331-45. doi: 10.1177/1087054713516490. PMID: 24420765. *Exclude-Population*
892. Groß S, Figge C, Matthies S, et al. [ADHD in adulthood: Diagnostics and therapy]. Nervenarzt. 2015 Sep;86(9):1171-8; quiz 9-80. doi: 10.1007/s00115-015-4328-3. PMID: 26341837. *Exclude-Language*
893. Gu Y, Xu G, Zhu Y. A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for College Students With ADHD. J Atten Disord. 2018 Feb;22(4):388-99. doi: 10.1177/1087054716686183. PMID: 28038496. *Currently being assessed for management*
894. Guevara JP, Greenbaum PE, Shera D, et al. Development and psychometric assessment of the collaborative care for attention-deficit disorders scale. Ambul Pediatr. 2008 Jan-Feb;8(1):18-24. doi: 10.1016/j.ambp.2007.10.002. PMID: 18191777. *Exclude-Population*
895. Guineau MG, Ikani N, Rinck M, et al. Anhedonia as a transdiagnostic symptom across psychological disorders: a network approach. Psychol Med. 2023 Jul;53(9):3908-19. doi: 10.1017/s0033291722000575. PMID: 35348051. *Exclude-Intervention*

Excluded Publications

896. Gumenyuk V, Korzyukov O, Tapaskar N, et al. Deficiency in Re-Orienting of Attention in Adults with Attention-Deficit Hyperactivity Disorder. *Clin EEG Neurosci*. 2023 Mar;54(2):141-50. doi: 10.1177/15500594221115737. PMID: 35861774. *Exclude-Outcome*
897. Gumustas F, Yilmaz I, Sirin DY, et al. Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder. *Hum Exp Toxicol*. 2017 Sep;36(9):981-92. doi: 10.1177/0960327116678294. PMID: 27837176. *Exclude-Intervention*
898. Guo X, Yao D, Cao Q, et al. Shared and distinct resting functional connectivity in children and adults with attention-deficit/hyperactivity disorder. *Transl Psychiatry*. 2020 Feb 12;10(1):65. doi: 10.1038/s41398-020-0740-y. PMID: 32066697. *Exclude-Intervention*
899. Gupta R, Kar BR, Srinivasan N. Cognitive-motivational deficits in ADHD: Development of a classification system. *Child Neuropsychology*. 2011;17(1):67-81. doi: 10.1080/09297049.2010.524152. *Exclude-Population*
900. Gürbüz N, Zengil S, Laloğlu E, et al. The Potential Impact of Agouti Related Peptide and Asprosin on Metabolic Parameters and Eating Behavior in Attention Deficit Hyperactivity Disorder. *Noro Psikiyatrs Ars*. 2024;61(1):30-8. doi: 10.29399/npa.28458. PMID: 38496220. *Exclude-Intervention*
901. Gutman SA, Balasubramanian S, Herzog M, et al. Effectiveness of a Tailored Intervention for Women With Attention Deficit Hyperactivity Disorder (ADHD) and ADHD Symptoms: A Randomized Controlled Study. *Am J Occup Ther*. 2020 Jan/Feb;74(1):7401205010p1-p11. doi: 10.5014/ajot.2020.033316. PMID: 32078512. *Currently being assessed for management*
902. Haberstick BC, Timberlake D, Hopfer CJ, et al. Genetic and environmental contributions to retrospectively reported DSM-IV childhood attention deficit hyperactivity disorder. *Psychol Med*. 2008 Jul;38(7):1057-66. doi: 10.1017/s0033291707001584. PMID: 17892623. *Exclude-Intervention*
903. Hackett A, Joseph R, Robinson K, et al. Adult attention deficit/hyperactivity disorder in the ambulatory care setting. *Jaapa*. 2020 Aug;33(8):12-6. doi: 10.1097/01.Jaa.0000684108.89007.52. PMID: 32740107. *Exclude-Comparator*
904. Hale TS, Smalley SL, Walshaw PD, et al. Atypical EEG beta asymmetry in adults with ADHD. *Neuropsychologia*. 2010 Oct;48(12):3532-9. doi: 10.1016/j.neuropsychologia.2010.08.002. PMID: 20705076. *Exclude-Comparator*
905. Hale TS, Zaidel E, McGough JJ, et al. Atypical brain laterality in adults with ADHD during dichotic listening for emotional intonation and words. *Neuropsychologia*. 2006;44(6):896-904. doi: 10.1016/j.neuropsychologia.2005.08.014. PMID: 16216289. *Exclude-Intervention*
906. Halevy-Yosef R, Bachar E, Shalev L, et al. The complexity of the interaction between binge-eating and attention. *PLoS One*. 2019;14(4):e0215506. doi: 10.1371/journal.pone.0215506. PMID: 31017971. *Exclude-Intervention*

Excluded Publications

907. Hallelund HB, Haavik J, Lundervold AJ. Set-shifting in adults with ADHD. *J Int Neuropsychol Soc.* 2012 Jul;18(4):728-37. doi: 10.1017/s1355617712000355. PMID: 22613368. *Exclude-Intervention*
908. Halmøy A, Ring AE, Gjestad R, et al. Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial. *BMC Psychiatry.* 2022 Nov 28;22(1):738. doi: 10.1186/s12888-022-04356-6. PMID: 36443712. *Currently being assessed for management*
909. Halmøy A, Ring AE, Gjestad R, et al. Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: A multicenter randomized controlled trial. *BMC Psychiatry.* 2022;22. doi: 10.1186/s12888-022-04356-6. *Currently being assessed for management*
910. Halperin JM, Matier K, Bedi G, et al. Specificity of inattention, impulsivity, and hyperactivity to the diagnosis of attention-deficit hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry.* 1992;31(2):190-6. doi: 10.1097/00004583-199203000-00002. *Exclude-Population*
911. Halperin JM, Trampush JW, Miller CJ, et al. Neuropsychological outcome in adolescents/young adults with childhood ADHD: profiles of persisters, remitters and controls. *J Child Psychol Psychiatry.* 2008 Sep;49(9):958-66. doi: 10.1111/j.1469-7610.2008.01926.x. PMID: 18573145. *Exclude-Intervention*
912. Hamed M, Mohammdi M, Ghaleiha A, et al. Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. *Acta Med Iran.* 2014;52(9):675-80. PMID: 25325205. *Currently being assessed for management*
913. Hamidovic A, Dlugos A, Palmer AA, et al. Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. *Behav Genet.* 2010 Mar;40(2):255-61. doi: 10.1007/s10519-009-9331-7. PMID: 20091113. *Exclude-Population*
914. Hammerness PG, Surman CBH, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. *Current Psychiatry Reports.* 2011;13(5):357-63. doi: 10.1007/s11920-011-0213-3. *Currently being assessed for management*
915. Handal N, LePage J, Dayley P, et al. Validation, reliability, and specificity of CliniCom™ Psychiatric Assessment Software. *Psychiatry Res.* 2018 Jul;265:334-40. doi: 10.1016/j.psychres.2018.05.029. PMID: 29778712. *Exclude-Comparator*
916. Hannah W, Blandine F, Nicholas H, et al. The Efficacy of Cognitive Behavioral Therapy for Adults With Attention Deficit and Hyperactivity Disorder (ADHD): An umbrella review. 2024. PMID: CRD42024516558. *Exclude-Design*
917. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. *Biol*

Excluded Publications

- Psychiatry. 2010 Nov 1;68(9):854-60. doi: 10.1016/j.biopsych.2010.06.017. PMID: 20691429. *Exclude-Population*
918. Hanssen KT, Brevik EJ, Småstuen MC, et al. Improvement of anxiety in ADHD following goal-focused cognitive remediation: a randomized controlled trial. *Front Psychol*. 2023;14:1212502. doi: 10.3389/fpsyg.2023.1212502. PMID: 38046113. *Currently being assessed for management*
919. Harada Y, Satoh Y, Sakuma A, et al. Behavioral and developmental disorders among conduct disorder. *Psychiatry Clin Neurosci*. 2002 Dec;56(6):621-5. doi: 10.1046/j.1440-1819.2002.01065.x. PMID: 12485304. *Exclude-Population*
920. Hariprasad VR, Arasappa R, Varambally S, et al. Feasibility and efficacy of yoga as an add-on intervention in attention deficit-hyperactivity disorder: An exploratory study. *Indian J Psychiatry*. 2013 Jul;55(Suppl 3):S379-84. doi: 10.4103/0019-5545.116317. PMID: 24049203. *Exclude-Population*
921. Harrison AG, Alexander SJ, Armstrong IT. Higher reported levels of depression, stress, and anxiety are associated with increased endorsement of ADHD symptoms by postsecondary students. US: Sage Publications; 2013. p. 243-60. *Exclude-Intervention*
922. Harrison AG, Armstrong IT, Harrison LE, et al. Comparing Canadian and American normative scores on the Wechsler Adult Intelligence Scale-Fourth Edition. *Arch Clin Neuropsychol*. 2014 Dec;29(8):737-46. doi: 10.1093/arclin/acu048. PMID: 25313225. *Exclude-Population*
923. Harrison AG, Rosenblum Y, Currie S. Examining unusual digit span performance in a population of postsecondary students assessed for academic difficulties. *Assessment*. 2010 Sep;17(3):283-93. doi: 10.1177/1073191109348590. PMID: 19915200. *Exclude-Population*
924. Hartman C, Hox J, Mellenbergh GJ, et al. DSM-IV internal construct validity: When a taxonomy meets data. United Kingdom: Cambridge University Press; 2001. p. 817-36. *Exclude-Intervention*
925. Hashemian F, Mohammadian S, Riahi F, et al. A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD). *Daru*. 2011;19(3):231-5. PMID: 22615662. *Currently being assessed for management*
926. Hauser PC, Lukomski J, Samar V. Reliability and validity of the BRIEF-A for assessing deaf college students' executive function. *Journal of Psychoeducational Assessment*. 2013;31(4):363-74. doi: 10.1177/0734282912464466. *Exclude-Comparator*
927. Hautmann C, Döpfner M, Katzmann J, et al. Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial. *BMC Psychiatry*. 2018 Dec 13;18(1):388. doi: 10.1186/s12888-018-1963-9. PMID: 30545333. *Currently being assessed for management*

Excluded Publications

928. Hawton K, Saunders K, Topiwala A, et al. Psychiatric disorders in patients presenting to hospital following self-harm: a systematic review. *J Affect Disord.* 2013 Dec;151(3):821-30. doi: 10.1016/j.jad.2013.08.020. PMID: 24091302. *Exclude-Population*
929. Hayashi W, Hanawa Y, Saga N, et al. ASD symptoms in adults with ADHD: a comparative study using ADOS-2. *Eur Arch Psychiatry Clin Neurosci.* 2022 Dec;272(8):1481-94. doi: 10.1007/s00406-021-01362-9. PMID: 34993599. *Exclude-Intervention*
930. Hayashi W, Hanawa Y, Yuriko I, et al. ASD symptoms in adults with ADHD: a preliminary study using the ADOS-2. *Eur Arch Psychiatry Clin Neurosci.* 2022 Mar;272(2):217-32. doi: 10.1007/s00406-021-01250-2. PMID: 33751200. *Exclude-Intervention*
931. Hayatbakhsh MR, Najman JM, Jamrozik K, et al. Adolescent problem behaviours predicting DSM-IV diagnoses of multiple substance use disorder. Findings of a prospective birth cohort study. *Soc Psychiatry Psychiatr Epidemiol.* 2008 May;43(5):356-63. doi: 10.1007/s00127-008-0325-1. PMID: 18301851. *Exclude-Outcome*
932. Hazell P. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. *Australas Psychiatry.* 2004 Dec;12(4):369-75. doi: 10.1080/j.1440-1665.2004.02129.x. PMID: 15715810. *Exclude-Design*
933. Hazell PL, Carr V, Lewin TJ, et al. Manic symptoms in young males with ADHD predict functioning but not diagnosis after 6 years. *J Am Acad Child Adolesc Psychiatry.* 2003 May;42(5):552-60. doi: 10.1097/01.Chi.0000046830.95464.33. PMID: 12707559. *Exclude-Population*
934. He Q, Jantac Mam-Lam-Fook C, Chaignaud J, et al. Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis. *Transl Psychiatry.* 2021 Oct 9;11(1):518. doi: 10.1038/s41398-021-01624-z. PMID: 34628483. *Exclude-Intervention*
935. Heather-Catherine M, Adam J, Heather C. A systematic review of the efficacy of dietary interventions in the management of attention-deficit hyperactivity disorder in adults. 2020. PMID: CRD42020167335. *Currently being assessed for management*
936. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. *J Am Acad Child Psychiatry.* 1984 May;23(3):261-9. doi: 10.1016/s0002-7138(09)60501-x. PMID: 6736490. *Exclude-Population*
937. Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. *Psychopharmacol Bull.* 1995;31(4):779-83. PMID: 8851653. *Exclude-Design*
938. Heffner JL, Lewis DF, Winhusen TM. Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD. *Nicotine Tob Res.* 2013 Feb;15(2):583-7. doi: 10.1093/ntr/nts152. PMID: 22955246. *Possible multiple publication*

Excluded Publications

939. Heffner JL, Lewis DF, Winhusen TM. Preliminary evidence that adherence to counseling mediates the effects of pretreatment self-efficacy and motivation on outcome of a cessation attempt in smokers with ADHD. *Nicotine Tob Res.* 2013 Feb;15(2):393-400. doi: 10.1093/ntr/nts135. PMID: 22949577. *Exclude-Intervention*
940. Hei Ting W. Systematic review of interventions to improve self-care in adults with severe mental illness. 2019. PMID: CRD42019144615. *Exclude-Design*
941. Heinrichs-Graham E, Franzen JD, Knott NL, et al. Pharmac-MEG evidence for attention related hyper-connectivity between auditory and prefrontal cortices in ADHD. *Psychiatry Res.* 2014 Mar 30;221(3):240-5. doi: 10.1016/j.psychres.2014.01.002. PMID: 24495532. *Exclude-Intervention*
942. Heinzel S, Dresler T, Baehne CG, et al. COMT x DRD4 epistasis impacts prefrontal cortex function underlying response control. *Cereb Cortex.* 2013 Jun;23(6):1453-62. doi: 10.1093/cercor/bhs132. PMID: 22617852. *Exclude-Intervention*
943. Heo S, Kim JH, Joung YS, et al. Clinical Utility of the Korean Version of the WHO Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale Screener. *Psychiatry Investig.* 2018 Mar;15(3):325-9. doi: 10.30773/pi.2017.07.10. PMID: 29486543. *Exclude-Language*
944. Hepark S, Janssen L, de Vries A, et al. The Efficacy of Adapted MBCT on Core Symptoms and Executive Functioning in Adults With ADHD: A Preliminary Randomized Controlled Trial. *J Atten Disord.* 2019 Feb;23(4):351-62. doi: 10.1177/1087054715613587. PMID: 26588940. *Currently being assessed for management*
945. Herring WJ, Wilens TE, Adler LA, et al. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. *J Clin Psychiatry.* 2012 Jul;73(7):e891-8. doi: 10.4088/JCP.11m07178. PMID: 22901359. *Currently being assessed for management*
946. Hesdorffer DC, Baldin E, Caplan R, et al. How do we measure psychiatric diagnoses? Implications of the choice of instruments in epilepsy. *Epilepsy Behav.* 2014 Feb;31:351-5. doi: 10.1016/j.yebeh.2013.10.001. PMID: 24230987. *Exclude-Design*
947. Hesse M. Course of self-reported symptoms of attention deficit and hyperactivity in substance abusers during early treatment. *Addict Behav.* 2010 May;35(5):504-6. doi: 10.1016/j.addbeh.2009.12.007. PMID: 20071099. *Exclude-Intervention*
948. Hesse M, Thiesen H. The use of the ADHD self-rating scale (ASRS-6) in the homeless: psychometric properties, alcohol use, and self-nurse agreement. *J Addict Nurs.* 2013 Apr-Jun;24(2):108-15. doi: 10.1097/JAN.0b013e3182929447. PMID: 24621489. *Exclude-Design*
949. Hesslinger B, Tebartz van Elst L, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults--a pilot study using a structured skills training program. *Eur Arch Psychiatry Clin Neurosci.* 2002 Aug;252(4):177-84. doi: 10.1007/s00406-002-0379-0. PMID: 12242579. *Currently being assessed for management*

Excluded Publications

950. Hester R, Nandam LS, O'Connell RG, et al. Neurochemical enhancement of conscious error awareness. *J Neurosci*. 2012 Feb 22;32(8):2619-27. doi: 10.1523/jneurosci.4052-11.2012. PMID: 22357846. *Exclude-Population*
951. Hida M, Hayashi W, Okajima Y, et al. Neuropsychological characteristics of adults with attention-deficit/hyperactivity disorder without intellectual disability. *Neuropsychopharmacol Rep*. 2020 Dec;40(4):407-11. doi: 10.1002/npr2.12134. PMID: 32862563. *Exclude-Intervention*
952. Hill BD, Pella RD, Singh AN, et al. The Wender Utah Rating Scale: Adult ADHD diagnostic tool or personality index? *J Atten Disord*. 2009 Jul;13(1):87-94. doi: 10.1177/1087054708320384. PMID: 18596301. *Exclude-Intervention*
953. Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. *Am J Psychiatry*. 1996 Sep;153(9):1143-6. doi: 10.1176/ajp.153.9.1143. PMID: 8780416. *Exclude-Intervention*
954. Hiltunen S, Virta M, Salakari A, et al. Better long-term outcome for hypnotherapy than for CBT in adults with ADHD: Results of a six-month follow-up. *Contemporary Hypnosis & Integrative Therapy*. 2014;30(3):118-34. *Currently being assessed for management*
955. Hines JL, King TS, Curry WJ. The adult ADHD self-report scale for screening for adult attention deficit-hyperactivity disorder (ADHD). *J Am Board Fam Med*. 2012 Nov-Dec;25(6):847-53. doi: 10.3122/jabfm.2012.06.120065. PMID: 23136325. *Exclude-Comparator*
956. Hinshaw SP, Nguyen PT, O'Grady SM, et al. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. *J Child Psychol Psychiatry*. 2022 Apr;63(4):484-96. doi: 10.1111/jcpp.13480. PMID: 34231220. *Exclude-Design*
957. Hirata Y, Goto T, Takita Y, et al. Efficacy and safety of atomoxetine in Asian adults with ADHD: A multinational 10-week randomized, double-blind placebo-controlled Asian study. *International Journal of Neuropsychopharmacology*. 2012;15:221-2. doi: 10.1017/S1461145712000508. *Currently being assessed for management*
958. Hirata Y, Goto T, Takita Y, et al. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. *Asia Pac Psychiatry*. 2014 Sep;6(3):292-301. doi: 10.1111/appy.12119. PMID: 24376099. *Possible multiple publication*
959. Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. *J Hum Nutr Diet*. 2014 Apr;27 Suppl 2:284-91. doi: 10.1111/jhn.12090. PMID: 23495677. *Exclude-Population*
960. Hirsch O, Chavanon M, Riechmann E, et al. Emotional dysregulation is a primary symptom in adult Attention-Deficit/Hyperactivity Disorder (ADHD). *J Affect Disord*. 2018 May;232:41-7. doi: 10.1016/j.jad.2018.02.007. PMID: 29477097. *Exclude-Intervention*

Excluded Publications

961. Hirsch O, Christiansen H. Faking ADHD? Symptom Validity Testing and Its Relation to Self-Reported, Observer-Reported Symptoms, and Neuropsychological Measures of Attention in Adults With ADHD. *J Atten Disord*. 2018 Feb;22(3):269-80. doi: 10.1177/1087054715596577. PMID: 26246589. *Exclude-Population*
962. Hirvikoski T, Alfredsson J, Morgensterns E. Structured skills training for adults with ADHD in an outpatient psychiatric context: An open feasibility trial. *ADHD Attention Deficit and Hyperactivity Disorders*. 2015;7:S95. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
963. Hirvikoski T, Lajic S, Jokinen J, et al. Using the five to fifteen-collateral informant questionnaire for retrospective assessment of childhood symptoms in adults with and without autism or ADHD. *Eur Child Adolesc Psychiatry*. 2021 Sep;30(9):1367-81. doi: 10.1007/s00787-020-01600-w. PMID: 32710229. *Exclude-Design*
964. Hirvikoski T, Lindström T, Carlsson J, et al. Psychoeducational groups for adults with ADHD and their significant others (PEGASUS): A pragmatic multicenter and randomized controlled trial. *Eur Psychiatry*. 2017 Jul;44:141-52. doi: 10.1016/j.eurpsy.2017.04.005. PMID: 28641216. *Currently being assessed for management*
965. Hirvikoski T, Lindström T, Carlsson J, et al. PEGASUS psychoeducational groups for adults with ADHD and their significant others/family members. *ADHD Attention Deficit and Hyperactivity Disorders*. 2019;11(1):S47. doi: 10.1007/s12402-019-00295-7. *Currently being assessed for management*
966. Hirvikoski T, Olsson EM, Nordenstrom A, et al. Deficient cardiovascular stress reactivity predicts poor executive functions in adults with attention-deficit/hyperactivity disorder. *J Clin Exp Neuropsychol*. 2011 Jan;33(1):63-73. doi: 10.1080/13803395.2010.493145. PMID: 20603741. *Exclude-Design*
967. Hirvikoski T, Waaler E, Alfredsson J, et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial. *Behav Res Ther*. 2011 Mar;49(3):175-85. doi: 10.1016/j.brat.2011.01.001. PMID: 21295767. *Currently being assessed for management*
968. Hirvikoski T, Waaler E, Lindström T, et al. Cognitive behavior therapy-based psychoeducational groups for adults with ADHD and their significant others (PEGASUS): an open clinical feasibility trial. *Atten Defic Hyperact Disord*. 2015 Mar;7(1):89-99. doi: 10.1007/s12402-014-0141-2. PMID: 24863143. *Exclude-Design*
969. Høberg A, Solberg BS, Hegvik TA, et al. Using polygenic scores in combination with symptom rating scales to identify attention-deficit/hyperactivity disorder. *BMC Psychiatry*. 2024;24(1). doi: 10.1186/s12888-024-05925-7. *Exclude-Outcome*
970. Hodges K, Horwitz E, Kline J, et al. Comparison of various WISC-R summary scores for a psychiatric sample. *J Clin Psychol*. 1982 Oct;38(4):830-7. doi: 10.1002/1097-4679(198210)38:4<830::aid-jclp2270380424>3.0.co;2-d. PMID: 7174817. *Exclude-Intervention*

Excluded Publications

971. Hoelzle JB, Ritchie KA, Marshall PS, et al. Erroneous conclusions: The impact of failing to identify invalid symptom presentation when conducting adult attention-deficit/hyperactivity disorder (ADHD) research. *Psychol Assess*. 2019 Sep;31(9):1174-9. doi: 10.1037/pas0000752. PMID: 31343208. *Exclude-Intervention*
972. Holst Y, Thorell LB. Neuropsychological Functioning in Adults With ADHD and Adults With Other Psychiatric Disorders. *J Atten Disord*. 2017 Jan;21(2):137-48. doi: 10.1177/1087054713506264. PMID: 24134875. *Exclude-Comparator*
973. Holst Y, Thorell LB. Adult executive functioning inventory (ADEXI): Validity, reliability, and relations to ADHD. *Int J Methods Psychiatr Res*. 2018 Mar;27(1). doi: 10.1002/mpr.1567. PMID: 28497641. *Exclude-Language*
974. Homack SR. Measuring the validity of two continuous performance tests: Different parameters and scoring indices. US: ProQuest Information & Learning; 2007. *Exclude-Population*
975. Hong JS, Bae S, Starcervic V, et al. Correlation Between Attention Deficit Hyperactivity Disorder, Internet Gaming Disorder or Gaming Disorder. *J Atten Disord*. 2023 Sep;27(11):1252-62. doi: 10.1177/10870547231176861. PMID: 37254501. *Exclude-Design*
976. Hong M, Kooij JJS, Kim B, et al. Validity of the Korean version of DIVA-5: A semi-structured diagnostic interview for adult ADHD. *Neuropsychiatric Disease and Treatment*. 2020;16. doi: 10.2147/NDT.S262995. *Exclude-Language*
977. Hong M, Kooij JJS, Kim B, et al. Validity of the Korean Version of DIVA-5: A Semi-Structured Diagnostic Interview for Adult ADHD. *Neuropsychiatr Dis Treat*. 2020;16:2371-6. doi: 10.2147/ndt.S262995. PMID: 33116536. *Exclude-Setting*
978. Hong M, Lee WH, Moon DS, et al. A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2014 Aug;24(6):341-6. doi: 10.1089/cap.2013.0090. PMID: 24955936. *Exclude-Population*
979. Hong M, Lee YS, Kim B, et al. Clinical Utility and Cut-Off Scores of the Korean Adult Attention-Deficit/Hyperactivity Disorder Rating Scale. *Soa Chongsongyon Chongsin Uihak*. 2019 Jul 1;30(3):116-20. doi: 10.5765/jkacap.190022. PMID: 32595329. *Exclude-Setting*
980. Hoogman M, Rijpkema M, Janss L, et al. Current self-reported symptoms of attention deficit/hyperactivity disorder are associated with total brain volume in healthy adults. *PLoS One*. 2012;7(2):e31273. doi: 10.1371/journal.pone.0031273. PMID: 22348063. *Exclude-Design*
981. Hopkins S, Sunkaraneni S, Skende E, et al. Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. *Journal of Pharmacokinetics and Pharmacodynamics*. 2015;42(1):S16. doi: 10.1007/s10928-015-9432-2. *Currently being assessed for management*
982. Hornig M. Addressing comorbidity in adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 1998;59 Suppl 7:69-75. PMID: 9680055. *Exclude-Design*

Excluded Publications

983. Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2000 Jun;61(6):414-7. doi: 10.4088/jcp.v61n0604. PMID: 10901338. *Exclude-Design*
984. Horton AM, Jr. Neuropsychological findings in adult attention deficit disorder: a pilot study. *Appl Neuropsychol*. 1996 Aug-Nov;3(3-4):181-3. doi: 10.1080/09084282.1996.9645384. PMID: 16318511. *Exclude-Design*
985. Houck Z, Asken B, Bauer R, et al. Predictors of post-concussion symptom severity in a university-based concussion clinic. *Brain Inj*. 2019;33(4):480-9. doi: 10.1080/02699052.2019.1565897. PMID: 30626213. *Exclude-Intervention*
986. Howard AL, Molina BS, Swanson JM, et al. Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. *Addiction*. 2015 May;110(5):784-95. doi: 10.1111/add.12880. PMID: 25664657. *Exclude-Population*
987. Howard AL, Strickland NJ, Murray DW, et al. Progression of impairment in adolescents with attention-deficit/hyperactivity disorder through the transition out of high school: Contributions of parent involvement and college attendance. *J Abnorm Psychol*. 2016 Feb;125(2):233-47. doi: 10.1037/abn0000100. PMID: 26854508. *Exclude-Population*
988. Howe AE, Arnell KM, Klein RM, et al. The ABCs of computerized naming: equivalency, reliability, and predictive validity of a computerized rapid automatized naming (RAN) task. *J Neurosci Methods*. 2006 Feb 15;151(1):30-7. doi: 10.1016/j.jneumeth.2005.07.014. PMID: 16412518. *Exclude-Design*
989. Howland RH. Lisdexamfetamine: a prodrug stimulant for ADHD. *J Psychosoc Nurs Ment Health Serv*. 2008 Aug;46(8):19-22. doi: 10.3928/02793695-20080801-05. PMID: 18777964. *Exclude-Design*
990. Howlett JR, Campbell-Sills L, Jain S, et al. Attention Deficit Hyperactivity Disorder and Risk of Posttraumatic Stress and Related Disorders: A Prospective Longitudinal Evaluation in U.S. Army Soldiers. *J Trauma Stress*. 2018 Dec;31(6):909-18. doi: 10.1002/jts.22347. PMID: 30461069. *Exclude-Intervention*
991. Hoxhaj E, Sadohara C, Borel P, et al. Mindfulness vs psychoeducation in adult ADHD: a randomized controlled trial. *Eur Arch Psychiatry Clin Neurosci*. 2018 Jun;268(4):321-35. doi: 10.1007/s00406-018-0868-4. PMID: 29356899. *Currently being assessed for management*
992. Hsu T, Cutler A, Childress A, et al. A pilot study of a novel monoamine triple reuptake inhibitor centanafadine SR (EB-1020 SR) in the treatment of ADHD in adults. *Neuropsychopharmacology*. 2014;39:S352. doi: 10.1038/npp.2014.281. *Currently being assessed for management*
993. Hu C, El Fakhri G, Li Q. Evaluating structural symmetry of weighted brain networks via graph matching. *Med Image Comput Comput Assist Interv*. 2014;17(Pt 2):733-40. doi: 10.1007/978-3-319-10470-6_91. PMID: 25485445. *Exclude-Intervention*

Excluded Publications

994. Huang C, Hu W, Tan G, et al. Clinical and electroencephalographic features of benign childhood epilepsy with centrottemporal spikes comorbidity with attention-deficit hyperactivity disorder in Southwest China. *Epilepsy Behav.* 2020 Oct;111:107240. doi: 10.1016/j.yebeh.2020.107240. PMID: 32603807. *Exclude-Intervention*
995. Huang F, Qian Q, Wang Y. Cognitive behavioral therapy for adults with attention-deficit hyperactivity disorder: study protocol for a randomized controlled trial. *Trials.* 2015 Apr 14;16:161. doi: 10.1186/s13063-015-0686-1. PMID: 25873090. *Exclude-Design*
996. Huang F, Tang YL, Zhao M, et al. Cognitive-Behavioral Therapy for Adult ADHD: A Randomized Clinical Trial in China. *J Atten Disord.* 2019 Jul;23(9):1035-46. doi: 10.1177/1087054717725874. PMID: 28866911. *Currently being assessed for management*
997. Huang J, Ahlers E, Bogatsch H, et al. The role of comorbid depressive symptoms on long-range temporal correlations in resting EEG in adults with ADHD. *Eur Arch Psychiatry Clin Neurosci.* 2022 Dec;272(8):1421-35. doi: 10.1007/s00406-022-01452-2. PMID: 35781841. *Exclude-Intervention*
998. Huang J, Mauche N, Ahlers E, et al. The impact of emotional dysregulation and comorbid depressive symptoms on clinical features, brain arousal, and treatment response in adults with ADHD. *Front Psychiatry.* 2023;14:1294314. doi: 10.3389/fpsy.2023.1294314. PMID: 38250266. *Exclude-Intervention*
999. Hudak J, Blume F, Dresler T, et al. Near-Infrared Spectroscopy-Based Frontal Lobe Neurofeedback Integrated in Virtual Reality Modulates Brain and Behavior in Highly Impulsive Adults. *Front Hum Neurosci.* 2017;11:425. doi: 10.3389/fnhum.2017.00425. PMID: 28928644. *Exclude-Population*
1000. Hughes EC, Weinstein RC, Gott PS. Food sensitivity in attention deficit disorder with hyperactivity (ADD/HA): A procedure for differential diagnosis. *Annals of Allergy.* 1982;49(5):276-80. *Exclude-Population*
1001. Humfleet GL, Prochaska JJ, Mengis M, et al. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. *Nicotine Tob Res.* 2005 Jun;7(3):453-60. doi: 10.1080/14622200500125310. PMID: 16085513. *Exclude-Population*
1002. Hunt MG, Bienstock SW, Qiang JK. Effects of diurnal variation on the Test of Variables of Attention performance in young adults with attention-deficit/hyperactivity disorder. *Psychol Assess.* 2012 Mar;24(1):166-72. doi: 10.1037/a0025233. PMID: 21910547. *Exclude-Comparator*
1003. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry.* 1995 Jan;34(1):50-4. doi: 10.1097/00004583-199501000-00013. PMID: 7860456. *Exclude-Population*
1004. Hupfeld KE, Osborne JB, Tran QT, et al. Validation of the dispositional adult hyperfocus questionnaire (AHQ-D). *Sci Rep.* 2024 Aug 22;14(1):19460. doi: 10.1038/s41598-024-70028-y. PMID: 39169147. *Exclude-Intervention*

Excluded Publications

1005. Hupli AMM. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. *Med Cannabis Cannabinoids*. 2019 Jan;1(2):112-8. doi: 10.1159/000495307. PMID: 34676327. *Exclude-Design*
1006. Huss M, Ginsberg Y, Arngrim T, et al. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial. *Clin Drug Investig*. 2014 Sep;34(9):639-49. doi: 10.1007/s40261-014-0213-2. PMID: 25015027. *Exclude-Design*
1007. Huss M, Ginsberg Y, Philipsen A, et al. 40-Week, randomized, double-blind, placebo-controlled, multicenter, efficacy and safety study of methylphenidate hydrochloride modified release (MPH-LA) in adults with attention deficit hyperactivity disorder (ADHD). *European Psychiatry*. 2013;28. *Currently being assessed for management*
1008. Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified release improved inattention and hyperactivity/impulsivity scores in adult ADHD patients. *European Neuropsychopharmacology*. 2013;23:S604-S5. doi: 10.1016/S0924-977X(13)70961-1. *Currently being assessed for management*
1009. Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. *Adv Ther*. 2014 Jan;31(1):44-65. doi: 10.1007/s12325-013-0085-5. PMID: 24371021. *Currently being assessed for management*
1010. Hutt Vater C, DiSalvo M, Ehrlich A, et al. ADHD in Adults: Does Age at Diagnosis Matter? *J Atten Disord*. 2024 Mar;28(5):614-24. doi: 10.1177/10870547231218450. PMID: 38166536. *Exclude-Intervention*
1011. Huybrechts KF, Bröms G, Christensen LB, et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. *JAMA Psychiatry*. 2018 Feb 1;75(2):167-75. doi: 10.1001/jamapsychiatry.2017.3644. PMID: 29238795. *Exclude-Intervention*
1012. Ibáñez A, Aguado J, Baez S, et al. From neural signatures of emotional modulation to social cognition: Individual differences in healthy volunteers and psychiatric participants. *Social Cognitive and Affective Neuroscience*. 2014;9(7):939-50. doi: 10.1093/scan/nst067. *Exclude-Intervention*
1013. Ibáñez A, Petroni A, Urquina H, et al. Cortical deficits of emotional face processing in adults with ADHD: Its relation to social cognition and executive function. *Social Neuroscience*. 2011;6(5-6):464-81. doi: 10.1080/17470919.2011.620769. *Exclude-Intervention*
1014. Inoue K, Nadaoka T, Oiji A, et al. Clinical evaluation of attention-deficit hyperactivity disorder by objective quantitative measures. *Child Psychiatry and Human Development*. 1998;28(3):179-88. doi: 10.1023/A:1022885827086. *Exclude-Population*
1015. Insa Pineda I, Huguet Miguel A, Chamorro Fernández M, et al. ADHD Symptoms, Academic and Social Difficulties in Parents of Children with ADHD. *Psychiatry*. 2020

Excluded Publications

- Fall;83(3):231-43. doi: 10.1080/00332747.2020.1762395. PMID: 32729785. *Exclude-Intervention*
1016. IRCT2016053028182N1. Use of memantin in treatment of adult with attention deficit hyperactivity disorder. 2017. *Currently being assessed for management*
1017. Isaacs D, Key AP, Cascio CJ, et al. Sensory Hypersensitivity Severity and Association with Obsessive-Compulsive Symptoms in Adults with Tic Disorder. *Neuropsychiatr Dis Treat*. 2020;16:2591-601. doi: 10.2147/ndt.S274165. PMID: 33173296. *Exclude-Intervention*
1018. Ishii-Takahashi A, Takizawa R, Nishimura Y, et al. Prefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults. *Neuroimage Clin*. 2014;4:53-63. doi: 10.1016/j.nicl.2013.10.002. PMID: 24298446. *Exclude-Intervention*
1019. ISRCTN16827947. A Study of Concerta XL on reducing ADHD symptoms and behavioural problems in adult offenders with ADHD. 2016. *Currently being assessed for management*
1020. Itahashi T, Fujino J, Hashimoto RI, et al. Transdiagnostic subtyping of males with developmental disorders using cortical characteristics. *Neuroimage Clin*. 2020;27:102288. doi: 10.1016/j.nicl.2020.102288. PMID: 32526684. *Exclude-Design*
1021. Itahashi T, Fujino J, Sato T, et al. Neural correlates of shared sensory symptoms in autism and attention-deficit/hyperactivity disorder. *Brain Commun*. 2020;2(2):fcaa186. doi: 10.1093/braincomms/fcaa186. PMID: 33381756. *Exclude-Design*
1022. Iwanami A, Saito K, Fujiwara M, et al. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study. *BMC Psychiatry*. 2020 Oct 2;20(1):485. doi: 10.1186/s12888-020-02867-8. PMID: 33008345. *Exclude-Design*
1023. Iwanami A, Saito K, Fujiwara M, et al. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study. *J Clin Psychiatry*. 2020 Apr 14;81(3). doi: 10.4088/JCP.19m12979. PMID: 32297719. *Currently being assessed for management*
1024. Jacob CP, Philipsen A, Ebert D, et al. [Multimodal treatment of adult attention-deficit hyperactivity disorder]. *Nervenarzt*. 2008 Jul;79(7):801-8. doi: 10.1007/s00115-008-2510-6. PMID: 18542905. *Exclude-Language*
1025. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. *Evid Rep Technol Assess (Summ)*. 1999 Nov(11):i-viii, 1-341. PMID: 10790990. *Currently being assessed for management*
1026. Jadidian A, Hurley RA, Taber KH. Neurobiology of adult ADHD: Emerging evidence for network dysfunctions. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2015;27(3):172-8. doi: 10.1176/appi.neuropsych.15060142. *Exclude-Intervention*

Excluded Publications

1027. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. *J Clin Psychiatry*. 2007 Feb;68(2):268-77. doi: 10.4088/jcp.v68n0213. PMID: 17335326. *Currently being assessed for management*
1028. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. *Journal of Clinical Psychiatry*. 2007;68(2):268-77. doi: 10.4088/JCP.v68n0213. *Currently being assessed for management*
1029. Jakobsen KD, Callesen K, Larsen EB, et al. Validity of the Systemizer Profile Questionnaire: A New Tool to Identify Cognitive, Mentalizing, Sensory, Social, and Systemizing Abilities in Adults with Autism-Spectrum-Disorders With and Without Comorbid ADHD. *Journal of Autism and Developmental Disorders*. 2024. doi: 10.1007/s10803-024-06511-2. *Exclude-Intervention*
1030. Jang S, Kim JJ, Kim SJ, et al. Mobile app-based chatbot to deliver cognitive behavioral therapy and psychoeducation for adults with attention deficit: A development and feasibility/usability study. *Int J Med Inform*. 2021 Jun;150:104440. doi: 10.1016/j.ijmedinf.2021.104440. PMID: 33799055. *Currently being assessed for management*
1031. Jans T, Graf E, Jacob C, et al. A randomized controlled multicentre trial on the treatment for ADHD in mothers and children: enrolment and basic characteristics of the study sample. *Atten Defic Hyperact Disord*. 2013 Mar;5(1):29-40. doi: 10.1007/s12402-012-0092-4. PMID: 23070786. *Possible multiple publication*
1032. Jans T, Jacob C, Warnke A, et al. Does intensive multimodal treatment for maternal ADHD improve the efficacy of parent training for children with ADHD? A randomized controlled multicenter trial. *J Child Psychol Psychiatry*. 2015 Dec;56(12):1298-313. doi: 10.1111/jcpp.12443. PMID: 26123832. *Exclude-Population*
1033. Jans T, Philipsen A, Graf E, et al. Does the treatment of maternal attention deficit and hyperactivity disorder (ADHD) enhance the efficacy of a behavioural parent training for the treatment of their children's ADHD? Study protocol of a randomized controlled multicentre trial. *Atten Defic Hyperact Disord*. 2009 May;1(1):33-45. doi: 10.1007/s12402-009-0004-4. PMID: 21432578. *Exclude-Population*
1034. Janssen L, de Vries AM, Hepark S, et al. The Feasibility, Effectiveness, and Process of Change of Mindfulness-Based Cognitive Therapy for Adults With ADHD: A Mixed-Method Pilot Study. *J Atten Disord*. 2020 Apr;24(6):928-42. doi: 10.1177/1087054717727350. PMID: 28853328. *Exclude-Design*
1035. Janssen L, Grutters JPC, Schellekens MPJ, et al. Mindfulness-based cognitive therapy versus treatment as usual in adults with ADHD: A trial-based economic evaluation. *Mindfulness*. 2019;10(9):1803-14. doi: 10.1007/s12671-019-01133-7. *Currently being assessed for management*

Excluded Publications

1036. Janssen L, Kan CC, Carpentier PJ, et al. Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD). *BMC Psychiatry*. 2015 Sep 15;15:216. doi: 10.1186/s12888-015-0591-x. PMID: 26373634. *Exclude-Design*
1037. Janssen L, Kan CC, Carpentier PJ, et al. Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD). *BMC Psychiatry*. 2015;15(1). doi: 10.1186/s12888-015-0591-x. *Currently being assessed for management*
1038. Janssen L, Kan CC, Carpentier PJ, et al. Mindfulness-Based Cognitive Therapy v. treatment as usual in adults with ADHD: a multicentre, single-blind, randomised controlled trial - ERRATUM. *Psychol Med*. 2018 Aug;48(11):1920. doi: 10.1017/s0033291718000776. PMID: 29655378. *Possible multiple publication*
1039. Janssen L, Kan CC, Carpentier PJ, et al. Mindfulness-based cognitive therapy v. treatment as usual in adults with ADHD: a multicentre, single-blind, randomised controlled trial. *Psychol Med*. 2019 Jan;49(1):55-65. doi: 10.1017/s0033291718000429. PMID: 29486807. *Currently being assessed for management*
1040. Jansson L, Löhman M, Östlund M, et al. Effects of one single-dose methylphenidate compared to one single-dose placebo on QbTest performance in adults with untreated ADHD: a randomized controlled trial. *BMC Psychiatry*. 2023 Oct 17;23(1):762. doi: 10.1186/s12888-023-05231-8. PMID: 37848887. *Exclude-Timing*
1041. Jasinski LJ, Harp JP, Berry DT, et al. Using symptom validity tests to detect malingered ADHD in college students. *Clin Neuropsychol*. 2011 Nov;25(8):1415-28. doi: 10.1080/13854046.2011.630024. PMID: 22084858. *Exclude-Intervention*
1042. Jastrowski KE, Berlin KS, Sato AF, et al. Disclosure of attention-deficit/hyperactivity disorder may minimize risk of social rejection. *Psychiatry*. 2007 Fall;70(3):274-82. doi: 10.1521/psyc.2007.70.3.274. PMID: 17937532. *Exclude-Intervention*
1043. Javorsky DJ. A validation study of the Boston qualitative scoring system (bqss) for the Rey-Osterrieth Complex Figure test. US: ProQuest Information & Learning; 2000. *Exclude-Intervention*
1044. Jelenchick LA, Eickhoff J, Zhang C, et al. Screening for Adolescent Problematic Internet Use: Validation of the Problematic and Risky Internet Use Screening Scale (PRIUSS). *Acad Pediatr*. 2015 Nov-Dec;15(6):658-65. doi: 10.1016/j.acap.2015.07.001. PMID: 26547545. *Exclude-Intervention*
1045. Jenkins M, Cohen R, Malloy P, et al. Neuropsychological measures which discriminate among adults with residual symptoms of attention deficit disorder and other attentional complaints. *Clinical Neuropsychologist*. 1998;12(1):74-83. *Exclude-Intervention*
1046. Jensen DA, Halmøy A, Stubberud J, et al. An Exploratory Investigation of Goal Management Training in Adults With ADHD: Improvements in Inhibition and Everyday

Excluded Publications

Functioning. *Front Psychol.* 2021;12:659480. doi: 10.3389/fpsyg.2021.659480. PMID: 34566748. *Exclude-Design*

1047. Jensen DA, Lundervold AJ, Stubberud J, et al. Goal management training improves executive control in adults with ADHD: an open trial employing attention network theory to examine effects on attention. *BMC Psychol.* 2022 Aug 26;10(1):207. doi: 10.1186/s40359-022-00902-9. PMID: 36028907. *Exclude-Design*

1048. Jensen PS. Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting. *Am J Manag Care.* 2009 May;15(5 Suppl):S129-40. PMID: 19601688. *Exclude-Design*

1049. Jernelöv S, Larsson Y, Llenas M, et al. Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation. *BMC Psychiatry.* 2019 Jul 24;19(1):226. doi: 10.1186/s12888-019-2216-2. PMID: 31340804. *Exclude-Intervention*

1050. Jesse E, George W, Shannon K, et al. Pharmacologic treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. 2015. PMID: CRD42015026049. *Currently being assessed for management*

1051. Jiang X, Zai CC, Dimick MK, et al. Psychiatric Polygenic Risk Scores Across Youth With Bipolar Disorder, Youth at High Risk for Bipolar Disorder, and Controls. *J Am Acad Child Adolesc Psychiatry.* 2024 Feb 8. doi: 10.1016/j.jaac.2023.12.009. PMID: 38340895. *Exclude-Population*

1052. Jie B, Wee CY, Shen D, et al. Hyper-connectivity of functional networks for brain disease diagnosis. *Med Image Anal.* 2016 Aug;32:84-100. doi: 10.1016/j.media.2016.03.003. PMID: 27060621. *Exclude-Population*

1053. Joao Braga S. Efficacy of methylphenidate in adults with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. 2018. PMID: CRD42018101959. *Exclude-Design*

1054. Joao Carlos Peixoto F, Silvia Cristina M. Systematic Review of Educational Accommodations and Interventions for College Students with ADHD. 2024. PMID: CRD42024504644. *Currently being assessed for management*

1055. Johanna Louise G, Cora B, Regina Wehrstedt von N-L, et al. ADHD in adults - A review on screening-tools for adult ADHD patients in primary care. 2022. PMID: CRD42022374597. *Currently being assessed for management*

1056. Johnson CL, Gross MA, Jorm AF, et al. Mental Health Literacy for Supporting Children: A Systematic Review of Teacher and Parent/Carer Knowledge and Recognition of Mental Health Problems in Childhood. *Clin Child Fam Psychol Rev.* 2023 Jun;26(2):569-91. doi: 10.1007/s10567-023-00426-7. PMID: 36763174. *Exclude-Population*

Excluded Publications

1057. Johnson M, Cederlund M, Råstam M, et al. Open-label trial of atomoxetine hydrochloride in adults with ADHD. *J Atten Disord*. 2010 Mar;13(5):539-45. doi: 10.1177/1087054709332372. PMID: 19458384. *Exclude-Design*
1058. Johnston BA, Mwangi B, Matthews K, et al. Brainstem abnormalities in attention deficit hyperactivity disorder support high accuracy individual diagnostic classification. *Hum Brain Mapp*. 2014 Oct;35(10):5179-89. doi: 10.1002/hbm.22542. PMID: 24819333. *Exclude-Design*
1059. Johnston K, Dittner A, Bramham J, et al. Attention deficit hyperactivity disorder symptoms in adults with autism spectrum disorders. *Autism Res*. 2013 Aug;6(4):225-36. doi: 10.1002/aur.1283. PMID: 23788522. *Exclude-Design*
1060. Jones NP, Versace A, Lindstrom R, et al. Reduced Activation in the Pallidal-Thalamic-Motor Pathway Is Associated With Deficits in Reward-Modulated Inhibitory Control in Adults With a History of Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2020 Dec;5(12):1123-33. doi: 10.1016/j.bpsc.2020.06.011. PMID: 32830098. *Exclude-Intervention*
1061. Joseph A, Kosmas CE, Patel C, et al. Health-Related Quality of Life and Work Productivity of Adults With ADHD: A U.K. Web-Based Cross-Sectional Survey. *J Atten Disord*. 2019 Nov 1;23(13):1610-23. doi: 10.1177/1087054718799367. PMID: 30215265. *Exclude-Intervention*
1062. Joshi G, DiSalvo M, Wozniak J, et al. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. *World J Biol Psychiatry*. 2020 Apr;21(4):274-90. doi: 10.1080/15622975.2019.1679392. PMID: 31607204. *Possible multiple publication*
1063. Joshi G, Wilens T, Firmin ES, et al. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. *J Psychopharmacol*. 2021 Mar;35(3):203-10. doi: 10.1177/0269881120972336. PMID: 33349107. *Exclude-Population*
1064. Jou R, Handen B, Hardan A. Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder. *Australas Psychiatry*. 2004 Dec;12(4):376-9. doi: 10.1080/j.1440-1665.2004.02130.x. PMID: 15715811. *Exclude-Design*
1065. Jucaite A, Öhd J, Potter AS, et al. A randomized, double-blind, placebo-controlled crossover study of $\alpha\beta$ 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl)*. 2014 Mar;231(6):1251-65. doi: 10.1007/s00213-013-3116-7. PMID: 23640072. *Currently being assessed for management*
1066. Jusyte A, Zaretskaya N, Höhnle NM, et al. Binocular rivalry transitions predict inattention symptom severity in adult ADHD. *Eur Arch Psychiatry Clin Neurosci*. 2018 Jun;268(4):373-82. doi: 10.1007/s00406-017-0790-1. PMID: 28409230. *Exclude-Design*

Excluded Publications

1067. Kahveci Öncü B, İnözü Mermerkaya M. Psychological and Psychosocial Interventions in Attention Deficit Hyperactivity Disorder: A Systematic Review. *Turk Psikiyatri Derg.* 2024 Sep 19. doi: 10.5080/u27201. PMID: 39297262. *Currently being assessed for management*
1068. Kaisari P, Dourish CT, Rotshtein P, et al. Associations Between Core Symptoms of Attention Deficit Hyperactivity Disorder and Both Binge and Restrictive Eating. *Front Psychiatry.* 2018;9:103. doi: 10.3389/fpsy.2018.00103. PMID: 29651258. *Exclude-Intervention*
1069. Kaiser A, Bottelier MA, de Ruiter MB, et al. Effects of prolonged methylphenidate treatment on amygdala reactivity and connectivity: a randomized controlled trial in stimulant treatment-naïve, male participants with ADHD. *Psychoradiology.* 2021 Sep;1(3):152-63. doi: 10.1093/psyrad/kkab013. PMID: 38665807. *Currently being assessed for management*
1070. Kakubo SM, Mendez M, Silveira JD, et al. Translation and validation of the brown attention-deficit disorder scale for use in Brazil: Identifying cases of attention-deficit/hyperactivity disorder among samples of substance users and non-users. cross-cultural validation study. *Sao Paulo Medical Journal.* 2018;136(2):157-64. doi: 10.1590/1516-3180.2017.0227121217. *Exclude-Duplicate*
1071. Kakubo SM, Mendez M, Silveira JD, et al. Translation and validation of the Brown attention-deficit disorder scale for use in Brazil: identifying cases of attention-deficit/hyperactivity disorder among samples of substance users and non-users. Cross-cultural validation study. *Sao Paulo Med J.* 2018 Mar-Apr;136(2):157-64. doi: 10.1590/1516-3180.2017.0227121217. PMID: 29694493. *Exclude-Intervention*
1072. Kakuszi B, Bitter I, Czobor P. Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. *Compr Psychiatry.* 2018 Aug;85:23-9. doi: 10.1016/j.comppsy.2018.06.003. PMID: 29957374. *Exclude-Intervention*
1073. Kalil KL, Bau CH, Grevet EH, et al. Smoking is associated with lower performance in WAIS-R Block Design scores in adults with ADHD. *Nicotine Tob Res.* 2008 Apr;10(4):683-8. doi: 10.1080/14622200801979019. PMID: 18418790. *Exclude-Intervention*
1074. Kamath MS, Dahm CR, Tucker JR, et al. Sensory profiles in adults with and without ADHD. *Res Dev Disabil.* 2020 Sep;104:103696. doi: 10.1016/j.ridd.2020.103696. PMID: 32526674. *Exclude-Intervention*
1075. Karatekin C. Improving antisaccade performance in adolescents with attention-deficit/hyperactivity disorder (ADHD). *Exp Brain Res.* 2006 Sep;174(2):324-41. doi: 10.1007/s00221-006-0467-x. PMID: 16639499. *Exclude-Population*
1076. Karen K, Pernille K, Niels B, et al. Systematic review on the psychometric properties of the Attention Deficit/Hyperactivity Disorder-Rating Scale (ADHD-RS). 2023. PMID: CRD42023466144. *Currently being assessed for management*
1077. Karlstad Ø, Zoëga H, Furu K, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. *Eur J Clin Pharmacol.* 2016 Dec;72(12):1507-14. doi: 10.1007/s00228-016-2125-y. PMID: 27586399. *Exclude-Intervention*

Excluded Publications

1078. Kasahara S, Niwa SI, Matsudaira K, et al. High Attention-Deficit/Hyperactivity Disorder Scale Scores Among Patients with Persistent Chronic Nonspecific Low Back Pain. *Pain Physician*. 2021 May;24(3):E299-e307. PMID: 33988951. *Exclude-Population*
1079. Kasper S. Editorial. *The World Journal of Biological Psychiatry*. 2013;14(4):247-. doi: 10.3109/15622975.2013.788864. *Exclude-Intervention*
1080. Katragadda S, Schubiner H. ADHD in children, adolescents, and adults. *Prim Care*. 2007 Jun;34(2):317-41; abstract viii. doi: 10.1016/j.pop.2007.04.012. PMID: 17666230. *Exclude-Design*
1081. Katz LJ, Wood DS, Goldstein G, et al. The utility of neuropsychological tests in evaluation of Attention-Deficit/ Hyperactivity Disorder (ADHD) versus depression in adults. *Assessment*. 1998 Mar;5(1):45-52. doi: 10.1177/107319119800500107. PMID: 9458341. *Currently being assessed for management*
1082. Katzman MA, Mattingly G, Klassen LJ, et al. Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults. *J Clin Psychopharmacol*. 2020 Nov/Dec;40(6):579-87. doi: 10.1097/jcp.0000000000001277. PMID: 33009228. *Exclude-Population*
1083. Kaur A, Kahlon KS. Accurate Identification of ADHD among Adults Using Real-Time Activity Data. *Brain Sci*. 2022 Jun 26;12(7). doi: 10.3390/brainsci12070831. PMID: 35884638. *Exclude-Intervention*
1084. Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. *J Atten Disord*. 2009 Jan;12(4):316-29. doi: 10.1177/1087054708322986. PMID: 18815438. *Currently being assessed for management*
1085. Keck School of Medicine of USC. Sweeping review reveals latest evidence on the diagnosis, treatment, and monitoring of ADHD. *Medical press*. 2024. *Exclude-Design*
1086. Kelarde SM, Mikaeili N, Narimani M, et al. Effectiveness of mindfulness-based cognitive therapy on inhibitory control and selective attention in adults with attention-deficient/hyperactivity disorder. *Advances in Cognitive Science*. 2022;24(2):1-12. *Exclude-Design*
1087. Kemner JE, Lage MJ. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. *Am J Health Syst Pharm*. 2006 Feb 15;63(4):317-22. doi: 10.2146/ajhp050129. PMID: 16452517. *Exclude-Intervention*
1088. Kendler KS, Ohlsson H, Sundquist J, et al. Selecting cases of major psychiatric and substance use disorders in Swedish national registries on the basis of clinical features to maximize the strength or specificity of the genetic risk. *Mol Psychiatry*. 2023 Dec;28(12):5195-205. doi: 10.1038/s41380-023-02156-2. PMID: 37414926. *Exclude-Intervention*

Excluded Publications

1089. Kennedy TM, Pedersen SL, Molina BSG. 2.14 Symptom Tracking for ADHD in Real Time Using Smartphones (START Smart): A Promising Mobile-Health Intervention for Reducing Impairment in Transitional-Aged Youth With ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2023;62(10):S185. doi: 10.1016/j.jaac.2023.09.101. *Currently being assessed for management*
1090. Kennel S, Taylor AG, Lyon D, et al. Pilot feasibility study of binaural auditory beats for reducing symptoms of inattention in children and adolescents with attention-deficit/hyperactivity disorder. *J Pediatr Nurs*. 2010 Feb;25(1):3-11. doi: 10.1016/j.pedn.2008.06.010. PMID: 20117669. *Exclude-Population*
1091. Kenter RMF, Gjestad R, Lundervold AJ, et al. A self-guided internet-delivered intervention for adults with ADHD: Results from a randomized controlled trial. *Internet Interv*. 2023 Apr;32:100614. doi: 10.1016/j.invent.2023.100614. PMID: 36969389. *Currently being assessed for management*
1092. Kenter RMF, Lundervold AJ, Nordgreen T. A self-guided Internet-delivered intervention for adults with ADHD: a protocol for a randomized controlled trial. *Internet Interv*. 2021 Dec;26:100485. doi: 10.1016/j.invent.2021.100485. PMID: 34877262. *Exclude-Design*
1093. Kernbach JM, Satterthwaite TD, Bassett DS, et al. Shared endo-phenotypes of default mode dysfunction in attention deficit/hyperactivity disorder and autism spectrum disorder. *Transl Psychiatry*. 2018 Jul 17;8(1):133. doi: 10.1038/s41398-018-0179-6. PMID: 30018328. *Exclude-Population*
1094. Kerson C. A proposed multisite double-blind randomized clinical trial of neurofeedback for ADHD: Need, rationale, and strategy. *Journal of Attention Disorders*. 2013;17(5):420-36. doi: 10.1177/1087054713482580. *Currently being assessed for management*
1095. Kessler D, Angstadt M, Sripada C. Growth Charting of Brain Connectivity Networks and the Identification of Attention Impairment in Youth. *JAMA Psychiatry*. 2016 May 1;73(5):481-9. doi: 10.1001/jamapsychiatry.2016.0088. PMID: 27076193. *Exclude-Population*
1096. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. *Psychol Med*. 2005 Feb;35(2):245-56. doi: 10.1017/s0033291704002892. PMID: 15841682. *Exclude-Intervention*
1097. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. *Biol Psychiatry*. 2005 Jun 1;57(11):1442-51. doi: 10.1016/j.biopsych.2005.04.001. PMID: 15950019. *Exclude-Intervention*
1098. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. *Int J Methods Psychiatr Res*. 2007;16(2):52-65. doi: 10.1002/mpr.208. PMID: 17623385. *Exclude-Intervention*

Excluded Publications

1099. Kessler RC, Santiago PN, Colpe LJ, et al. Clinical reappraisal of the Composite International Diagnostic Interview Screening Scales (CIDI-SC) in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). *Int J Methods Psychiatr Res.* 2013 Dec;22(4):303-21. doi: 10.1002/mpr.1398. PMID: 24318219. *Exclude-Population*
1100. Keune PM, Wiedemann E, Schneidt A, et al. Frontal brain asymmetry in adult attention-deficit/hyperactivity disorder (ADHD): extending the motivational dysfunction hypothesis. *Clin Neurophysiol.* 2015 Apr;126(4):711-20. doi: 10.1016/j.clinph.2014.07.008. PMID: 25097090. *Exclude-Intervention*
1101. Khan A, Fahl Mar K, Brown WA. Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000-2009. *J Psychiatr Res.* 2017 Nov;94:202-7. doi: 10.1016/j.jpsychires.2017.07.018. PMID: 28755620. *Exclude-Design*
1102. Khan MU, Aslani P. A Review of Factors Influencing the Three Phases of Medication Adherence in People with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol.* 2019 Aug;29(6):398-418. doi: 10.1089/cap.2018.0153. PMID: 31120328. *Exclude-Intervention*
1103. Khan MU, Aslani P. Exploring factors influencing initiation, implementation and discontinuation of medications in adults with ADHD. *Health Expect.* 2021 May;24 Suppl 1(Suppl 1):82-94. doi: 10.1111/hex.13031. PMID: 32032467. *Exclude-Intervention*
1104. Kiblawi ZN, Smith LM, LaGasse LL, et al. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: results from the Infant Development, Environment, and Lifestyle study. *J Dev Behav Pediatr.* 2013 Jan;34(1):31-7. doi: 10.1097/DBP.0b013e318277a1c5. PMID: 23275056. *Exclude-Population*
1105. Kiger NC. An evaluation of parent and teacher rating scales as predictors of the T.O.V.A. measures of Inattention, Impulsivity, Response Time and Variability. US: ProQuest Information & Learning; 1998. *Exclude-Population*
1106. Kiliç Ö. Diagnosis and Treatment of ADHD in College Students. *Psychiatry and Clinical Psychopharmacology.* 2017;27:278-80. doi: 10.1080/24750573.2017.1314599. *Currently being assessed for management*
1107. Kim DH, Lim HJ, Byeon JY, et al. Pharmacokinetics of atomoxetine after administration of paroxetine in relation to CYP2D6 genotype status. *Pharmacotherapy.* 2015;35(11):e316-e7. doi: 10.1002/phar.1659. *Currently being assessed for management*
1108. Kim Jae H, Choi S, Kim Jong Y. Comparison of executive function between ASD and ASD+ADHD: a systematic review and meta-analysis. 2021. PMID: CRD42021244058. *Exclude-Intervention*
1109. Kim JS, Kim DW, Kwon YJ, et al. The relationship between auditory evoked potentials and symptoms of attention-deficit/hyperactivity disorder in adult patients with major depressive

Excluded Publications

disorder. *Int J Psychophysiol.* 2019 Aug;142:50-6. doi: 10.1016/j.ijpsycho.2019.06.008. PMID: 31207261. *Exclude-Intervention*

1110. Kim S, Al-Haj M, Chen S, et al. Colour vision in ADHD: part 1--testing the retinal dopaminergic hypothesis. *Behav Brain Funct.* 2014 Oct 24;10:38. doi: 10.1186/1744-9081-10-38. PMID: 25344625. *Exclude-Comparator*

1111. Kim S, Al-Haj M, Fuller S, et al. Color vision in ADHD: part 2--does attention influence color perception? *Behav Brain Funct.* 2014 Oct 24;10:39. doi: 10.1186/1744-9081-10-39. PMID: 25344205. *Exclude-Comparator*

1112. Kim S, Lee H, Lee K. Can the mmpi predict adult adhd? An approach using machine learning methods. *Diagnostics.* 2021;11(6). doi: 10.3390/diagnostics11060976. *Exclude-Comparator*

1113. Kim S, Lee HK, Lee K. Can the MMPI Predict Adult ADHD? An Approach Using Machine Learning Methods. *Diagnostics (Basel).* 2021 May 28;11(6). doi: 10.3390/diagnostics11060976. PMID: 34071385. *Exclude-Comparator*

1114. Kim S, Liu Z, Glizer D, et al. Adult ADHD and working memory: neural evidence of impaired encoding. *Clin Neurophysiol.* 2014 Aug;125(8):1596-603. doi: 10.1016/j.clinph.2013.12.094. PMID: 24411642. *Exclude-Intervention*

1115. Kim SH, Byeon JY, Kim YH, et al. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. *Sci Rep.* 2018 Aug 17;8(1):12405. doi: 10.1038/s41598-018-30841-8. PMID: 30120390. *Exclude-Intervention*

1116. Kimberley L. Systematic Review: Technological Applications for the Diagnosis and Treatment of ADHD. 2020. PMID: CRD42020171385. *Currently being assessed for management*

1117. King JA, Colla M, Brass M, et al. Inefficient cognitive control in adult ADHD: evidence from trial-by-trial Stroop test and cued task switching performance. *Behav Brain Funct.* 2007 Aug 20;3:42. doi: 10.1186/1744-9081-3-42. PMID: 17708762. *Exclude-Intervention*

1118. King JA, Colla M, Brass M, et al. Inefficient cognitive control in adult ADHD: Evidence from trial-by-trial Stroop test and cued task switching performance. *Behavioral and Brain Functions.* 2007;3. doi: 10.1186/1744-9081-3-42. *Exclude-Intervention*

1119. Kinsbourne M, De Quiros GB, Tocci Rufo D. Adult ADHD. Controlled medication assessment. *Ann N Y Acad Sci.* 2001 Jun;931:287-96. PMID: 11462747. *Exclude-Design*

1120. Kirkland AE, Langan MT, Holton KF. Artificial food coloring affects EEG power and ADHD symptoms in college students with ADHD: a pilot study. *Nutr Neurosci.* 2022 Jan;25(1):159-68. doi: 10.1080/1028415x.2020.1730614. PMID: 32116139. *Currently being assessed for management*

Excluded Publications

1121. Kirsch RD. A multi-component model of attention deficits: Dysfunction of attention-working memory-executive functions as assessed by the CVLT-C. US: ProQuest Information & Learning; 1999. *Exclude-Intervention*
1122. Kirsty L, Almuth M, Harriet T. A systematic review of the existing interventions, documented in the literature, that aim to support adults with ADHD: contexts, mechanisms, outcomes, and effectiveness. 2018. PMID: CRD42018092237. *Currently being assessed for management*
1123. Kis B, Lücke C, Abdel-Hamid M, et al. Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. Pharmacopsychiatry. 2020 Nov;53(6):263-71. doi: 10.1055/a-1207-9851. PMID: 33017854. *Currently being assessed for management*
1124. Kisicki JC, Fiske K, Lyne A. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther. 2007 Sep;29(9):1967-79. doi: 10.1016/j.clinthera.2007.09.020. PMID: 18035196. *Exclude-Population*
1125. Kittel-Schneider S, Quednow BB, Leutritz AL, et al. Parental ADHD in pregnancy and the postpartum period - A systematic review. Neurosci Biobehav Rev. 2021 May;124:63-77. doi: 10.1016/j.neubiorev.2021.01.002. PMID: 33516734. *Exclude-Intervention*
1126. Kivisaari S, Laasonen M, Leppämäki S, et al. Retrospective assessment of ADHD symptoms in childhood: discriminatory validity of Finnish translation of the Wender Utah Rating Scale. J Atten Disord. 2012 Aug;16(6):449-59. doi: 10.1177/1087054710397801. PMID: 22286113. *Exclude-Comparator*
1127. Kjernisted K. The Potential Role of LDX (lisdexamfetamine) in the Treatment of ADHD Across the Life-span. Acta Neuropsychiatrica. 2013;25(1):14. doi: 10.1017/neu.2013.10. *Currently being assessed for management*
1128. Klassen LJ, Bilkey TS, Katzman MA, et al. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev. 2012 Sep;5(3):190-8. doi: 10.2174/1874473711205030190. PMID: 22571450. *Currently being assessed for management*
1129. Klil-Drori S, Hechtman L. Potential Social and Neurocognitive Benefits of Aerobic Exercise as Adjunct Treatment for Patients With ADHD. J Atten Disord. 2020 Mar;24(5):795-809. doi: 10.1177/1087054716652617. PMID: 27288905. *Exclude-Population*
1130. Klusek J, O'Connor SL, Hickey A, et al. Attention/Deficit Hyperactivity Disorder in Adolescent and Young Adult Males With Fragile X Syndrome. Am J Intellect Dev Disabil. 2022 May 1;127(3):213-30. doi: 10.1352/1944-7558-127.3.213. PMID: 35443049. *Exclude-Population*

Excluded Publications

1131. Knop J, Penick EC, Nickel EJ, et al. Childhood ADHD and conduct disorder as independent predictors of male alcohol dependence at age 40. *J Stud Alcohol Drugs*. 2009 Mar;70(2):169-77. doi: 10.15288/jsad.2009.70.169. PMID: 19261228. *Exclude-Intervention*
1132. Knouse LE, Hu X, Sachs G, et al. Usability and feasibility of a cognitive-behavioral mobile app for ADHD in adults. *PLOS Digit Health*. 2022 Aug;1(8):e0000083. doi: 10.1371/journal.pdig.0000083. PMID: 36812621. *Exclude-Design*
1133. Knouse LE, Mitchell JT, Brown LH, et al. The expression of adult ADHD symptoms in daily life: an application of experience sampling methodology. *J Atten Disord*. 2008 May;11(6):652-63. doi: 10.1177/1087054707299411. PMID: 17495239. *Exclude-Intervention*
1134. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. *Psychiatr Clin North Am*. 2010 Sep;33(3):497-509. doi: 10.1016/j.psc.2010.04.001. PMID: 20599129. *Exclude-Intervention*
1135. Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. *Neuropsychopharmacology*. 2015 Nov;40(12):2745-52. doi: 10.1038/npp.2015.124. PMID: 25948101. *Currently being assessed for management*
1136. Koehm M, Kauert GF, Toennes SW. Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate. *Arzneimittelforschung*. 2010;60(5):238-44. doi: 10.1055/s-0031-1296279. PMID: 20533759. *Exclude-Intervention*
1137. Kohn MR, Tsang TW, Clarke SD. Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder. *Clin Med Insights Pediatr*. 2012;6:95-162. doi: 10.4137/CMPed.S7868. PMID: 23641171. *Exclude-Population*
1138. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. *J Clin Psychiatry*. 2003;64 Suppl 11:14-8. PMID: 14529325. *Exclude-Intervention*
1139. Kollins SH, English J, Robinson R, et al. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). *Psychopharmacology (Berl)*. 2009 May;204(1):73-83. doi: 10.1007/s00213-008-1439-6. PMID: 19104775. *Exclude-Design*
1140. Kollins SH, English JS, Itchon-Ramos N, et al. A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. *J Atten Disord*. 2014 Feb;18(2):158-68. doi: 10.1177/1087054712440320. PMID: 22508760. *Currently being assessed for management*
1141. Kollins SH, Schoenfelder E, English JS, et al. Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD). *Exp Clin Psychopharmacol*. 2013 Oct;21(5):375-84. doi: 10.1037/a0033851. PMID: 24099358. *Exclude-Intervention*

Excluded Publications

1142. Kollins SH, Schoenfelder EN, English JS, et al. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. *J Subst Abuse Treat.* 2015 Jan;48(1):96-103. doi: 10.1016/j.jsat.2014.07.014. PMID: 25175495. *Exclude-Population*
1143. Kollins SH, Youcha S, Lasser R, et al. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. *Innov Clin Neurosci.* 2011 Feb;8(2):28-32. PMID: 21468295. *Possible multiple publication*
1144. Komaroff M, Cutler AJ, Czobor P, et al. 5.9 Clinically Meaningful Score Difference (MSD) and Meaningful Score Regions (MSR) in ADHD Rating Scale IV (ADHD-RS-IV) Total Score From Post Hoc Analyses of the Dextroamphetamine Transdermal System (d-ATS) Pivotal Clinical Trial. 2024. p. S257-S8. *Exclude-Design*
1145. Konold TR, Glutting JJ. ADHD and method variance: a latent variable approach applied to a nationally representative sample of college freshmen. *J Learn Disabil.* 2008 Sep-Oct;41(5):405-16. doi: 10.1177/0022219408321111. PMID: 18768773. *Exclude-Comparator*
1146. Konstenius M, Jayaram-Lindström N, Beck O, et al. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. *Drug Alcohol Depend.* 2010 Apr 1;108(1-2):130-3. doi: 10.1016/j.drugalcdep.2009.11.006. PMID: 20015599. *Currently being assessed for management*
1147. Konstenius M, Jayaram-Lindström N, Guterstam J, et al. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. *Addiction.* 2014 Mar;109(3):440-9. doi: 10.1111/add.12369. PMID: 24118269. *Currently being assessed for management*
1148. Konstenius M, Jayaram-Lindström N, Guterstam J, et al. Methylphenidate for adhd in adults with substance dependence: A 24-week randomized placebo-controlled trial. *European Psychiatry.* 2013;28. *Currently being assessed for management*
1149. Konstenius M, Larsson H, Lundholm L, et al. An epidemiological study of ADHD, substance use, and comorbid problems in incarcerated women in Sweden. *J Atten Disord.* 2015 Jan;19(1):44-52. doi: 10.1177/1087054712451126. PMID: 22797213. *Exclude-Intervention*
1150. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. *Psychol Med.* 2004 Aug;34(6):973-82. doi: 10.1017/s0033291703001776. PMID: 15554568. *Currently being assessed for management*
1151. Kooij JJ, Michielsen M, Kruithof H, et al. ADHD in old age: a review of the literature and proposal for assessment and treatment. *Expert Rev Neurother.* 2016 Dec;16(12):1371-81. doi: 10.1080/14737175.2016.1204914. PMID: 27334252. *Exclude-Design*

Excluded Publications

1152. Kooij JJ, Middelkoop HA, van Gils K, et al. The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. *J Clin Psychiatry*. 2001 Dec;62(12):952-6. doi: 10.4088/jcp.v62n1206. PMID: 11780875. *Exclude-Comparator*
1153. Kooij JJ, Rösler M, Philipsen A, et al. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. *BMC Psychiatry*. 2013 Jan 24;13:36. doi: 10.1186/1471-244x-13-36. PMID: 23347693. *Possible multiple publication*
1154. Kooij JJ, Rösler M, Philipsen A, et al. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: Results from a randomized, placebo-controlled trial. *BMC Psychiatry*. 2013;13. doi: 10.1186/1471-244X-13-36. *Currently being assessed for management*
1155. Kooij JS, Boonstra AM, Vermeulen SH, et al. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). *Am J Med Genet B Neuropsychiatr Genet*. 2008 Mar 5;147b(2):201-8. doi: 10.1002/ajmg.b.30586. PMID: 17955457. *Exclude-Intervention*
1156. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC Psychiatry*. 2010 Sep 3;10:67. doi: 10.1186/1471-244X-10-67. PMID: 20815868. *Exclude-Design*
1157. Korkeila J, Tani P. [Attention deficit hyperactivity disorder in adults]. *Duodecim*. 2005;121(2):153-60. PMID: 15745352. *Exclude-Language*
1158. Korzyukov O, Tapaskar N, Pflieger ME, et al. Event related potentials study of aberrations in voice control mechanisms in adults with attention deficit hyperactivity disorder. *Clin Neurophysiol*. 2015 Jun;126(6):1159-70. doi: 10.1016/j.clinph.2014.09.016. PMID: 25308310. *Exclude-Intervention*
1159. Kosky KM, Lace JW, Austin TA, et al. The utility of the Wisconsin card sorting test, 64-card version to detect noncredible attention-deficit/hyperactivity disorder. *Appl Neuropsychol Adult*. 2022 Sep-Oct;29(5):1231-41. doi: 10.1080/23279095.2020.1864633. PMID: 33372539. *Exclude-Intervention*
1160. Kouros I, Hörberg N, Ekselius L, et al. Wender Utah Rating Scale-25 (WURS-25): psychometric properties and diagnostic accuracy of the Swedish translation. *Ups J Med Sci*. 2018 Dec;123(4):230-6. doi: 10.1080/03009734.2018.1515797. PMID: 30373435. *Exclude-Language*
1161. Kovshoff H, Banaschewski T, Buitelaar JK, et al. Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. *J Child Adolesc Psychopharmacol*. 2016 Aug;26(6):537-47. doi: 10.1089/cap.2015.0218. PMID: 27007169. *Exclude-Design*

Excluded Publications

1162. Kratochvil CJ, Vaughan BS, Daughton JM, et al. Atomoxetine in the treatment of attention deficit hyperactivity disorder. *Expert Rev Neurother*. 2004 Jul;4(4):601-11. doi: 10.1586/14737175.4.4.601. PMID: 15853579. *Exclude-Design*
1163. Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. *Expert Opin Pharmacother*. 2003 Jul;4(7):1165-74. doi: 10.1517/14656566.4.7.1165. PMID: 12831341. *Exclude-Design*
1164. Krause J, la Fougere C, Krause KH, et al. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. *Eur Arch Psychiatry Clin Neurosci*. 2005 Dec;255(6):428-31. doi: 10.1007/s00406-005-0602-x. PMID: 16091862. *Exclude-Design*
1165. Krause KH, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. *Neurosci Lett*. 2000 May 12;285(2):107-10. doi: 10.1016/s0304-3940(00)01040-5. PMID: 10793238. *Exclude-Design*
1166. Krepel N, Egtberts T, Sack AT, et al. A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. *Neuroimage Clin*. 2020;28:102399. doi: 10.1016/j.nicl.2020.102399. PMID: 32891892. *Exclude-Intervention*
1167. Kristiansen CB, Shanmuganathan JW, Gustafsson LN, et al. Increasing incidence and diagnostic instability in adult attention-deficit hyperactivity disorder nationwide between 1995 and 2012. *Atten Defic Hyperact Disord*. 2015 Jun;7(2):151-6. doi: 10.1007/s12402-014-0155-9. PMID: 25304687. *Exclude-Intervention*
1168. Kronenberg G, Ende G, Alm B, et al. Increased NAA and reduced choline levels in the anterior cingulum following chronic methylphenidate. A spectroscopic test-retest study in adult ADHD. *Eur Arch Psychiatry Clin Neurosci*. 2008 Oct;258(7):446-50. doi: 10.1007/s00406-008-0810-2. PMID: 18330668. *Exclude-Design*
1169. Kubo Y, Kanazawa T, Kawabata Y, et al. Comparative Analysis of the WISC between Two ADHD Subgroups. *Psychiatry Investig*. 2018 Feb;15(2):172-7. doi: 10.30773/pi.2017.07.12. PMID: 29475226. *Exclude-Population*
1170. Kucyi A, Esterman M, Capella J, et al. Prediction of stimulus-independent and task-unrelated thought from functional brain networks. *Nat Commun*. 2021 Mar 19;12(1):1793. doi: 10.1038/s41467-021-22027-0. PMID: 33741956. *Exclude-Intervention*
1171. Kumano H, Nobukawa S, Shirama A, et al. Asymmetric Complexity in a Pupil Control Model With Laterally Imbalanced Neural Activity in the Locus Coeruleus: A Potential Biomarker for Attention-Deficit/Hyperactivity Disorder. *Neural Comput*. 2022 Nov 8;34(12):2388-407. doi: 10.1162/neco_a_01545. PMID: 36283044. *Exclude-Intervention*

Excluded Publications

1172. Kumar R. Approved and investigational uses of modafinil : an evidence-based review. *Drugs*. 2008;68(13):1803-39. doi: 10.2165/00003495-200868130-00003. PMID: 18729534. *Exclude-Intervention*
1173. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. *Ann Clin Psychiatry*. 2001 Sep;13(3):129-34. doi: 10.1023/a:1012239823148. PMID: 11791949. *Currently being assessed for management*
1174. Kurscheidt JC, Peiler P, Behnken A, et al. Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy. *J Neural Transm (Vienna)*. 2008;115(2):357-62. doi: 10.1007/s00702-008-0871-4. PMID: 18264813. *Exclude-Design*
1175. La Malfa G, Lassi S, Bertelli M, et al. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability The use of Conners' Adult ADHD Rating Scales (CAARS). *Res Dev Disabil*. 2008 Mar-Apr;29(2):158-64. doi: 10.1016/j.ridd.2007.02.002. PMID: 17416484. *Exclude-Intervention*
1176. Laatsch J, Stein F, Maier S, et al. Neural correlates of inattention in adults with ADHD. *European Archives of Psychiatry and Clinical Neuroscience*. 2024. doi: 10.1007/s00406-024-01872-2. *Exclude-Intervention*
1177. Lakhan SE, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. *Brain Behav*. 2012 Sep;2(5):661-77. doi: 10.1002/brb3.78. PMID: 23139911. *Misuse only*
1178. Lam AP, Matthies S, Graf E, et al. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial. *JAMA Netw Open*. 2019 May 3;2(5):e194980. doi: 10.1001/jamanetworkopen.2019.4980. PMID: 31150084. *Exclude-Design*
1179. Lam AP, Matthies S, Graf E, et al. Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms follow-up analysis of the compas Trial. *JAMA Network Open*. 2019;2(5). doi: 10.1001/jamanetworkopen.2019.4980. *Currently being assessed for management*
1180. Lampert A, Tesarz J, Volkert AK, et al. An N-of-1 trial as an individualized withdrawal treatment approach to psychological methylphenidate dependence. *Psychother Psychosom*. 2014;83(6):379-81. doi: 10.1159/000365094. PMID: 25323763. *Exclude-Design*
1181. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. *J Atten Disord*. 2007 Nov;11(3):351-62. doi: 10.1177/1087054707299400. PMID: 17494834. *Exclude-Intervention*
1182. Langberg JM, Epstein JN, Graham AJ. Organizational-skills interventions in the treatment of ADHD. *Expert Rev Neurother*. 2008 Oct;8(10):1549-61. doi: 10.1586/14737175.8.10.1549. PMID: 18928347. *Exclude-Design*

Excluded Publications

1183. Lannes A, Farhat LC, Del Giovane C, et al. Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. *BMJ Open*. 2022 Sep 26;12(9):e062748. doi: 10.1136/bmjopen-2022-062748. PMID: 36167386. *Exclude-Intervention*
1184. Lansbergen MM, Kenemans JL, van Engeland H. Stroop interference and attention-deficit/hyperactivity disorder: a review and meta-analysis. *Neuropsychology*. 2007 Mar;21(2):251-62. doi: 10.1037/0894-4105.21.2.251. PMID: 17402825. *Exclude-Population*
1185. Larisch R, Sitte W, Antke C, et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. *Nucl Med Commun*. 2006 Mar;27(3):267-70. doi: 10.1097/00006231-200603000-00010. PMID: 16479247. *Exclude-Population*
1186. Latronica JR, Clegg TJ, Tuan WJ, et al. Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals? *J Am Board Fam Med*. 2021 Nov-Dec;34(6):1074-81. doi: 10.3122/jabfm.2021.06.210228. PMID: 34772763. *Exclude-Design*
1187. Laura R, Anna T. What is the experience of adults with ADHD of engaging in stimulant medication treatment? A systematic review and meta-ethnography. 2024. PMID: CRD42024560054. *Currently being assessed for management*
1188. Laura Steen Ga, Rosa Franco J, Joaquín Alejandro Ibañez A. Use of Transcranial Direct Current Stimulation (tDCS) in Adult Patients with ADHD for the Improvement of Executive Functions and Emotional Regulation. 2023. PMID: CRD42023322346. *Currently being assessed for management*
1189. Lauvsnes ADF, Langaas M, Olsen A, et al. Adhd and mental health symptoms in the identification of young adults with increased risk of alcohol dependency in the general population—the hunt4 population study. *International Journal of Environmental Research and Public Health*. 2021;18(21). doi: 10.3390/ijerph18211601. *Exclude-Intervention*
1190. Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. *Neuropsychiatr Dis Treat*. 2006 Dec;2(4):455-66. doi: 10.2147/ndt.2006.2.4.455. PMID: 19412494. *Exclude-Population*
1191. Lee CY, Goh JOS, Gau SS. Differential neural processing of value during decision-making in adults with attention-deficit/hyperactivity disorder and healthy controls. *J Psychiatry Neurosci*. 2023 Mar-Apr;48(2):E115-e24. doi: 10.1503/jpn.220123. PMID: 36990469. *Exclude-Intervention*
1192. Lee GJ, Do C, Suhr J. Noncredible Presentations of Symptoms and Functional Impairment in the Assessment of Adult Attention-Deficit/Hyperactivity Disorder. *Psychology and Neuroscience*. 2023;16(3):284-301. doi: 10.1037/pne0000319. *Exclude-Intervention*
1193. Lee GJ, Suhr JA. Expectancy Effects on Self-Reported Attention-Deficit/Hyperactivity Disorder Symptoms in Simulated Neurofeedback: A Pilot Study. *Arch Clin Neuropsychol*. 2019 Mar 1;34(2):200-5. doi: 10.1093/arclin/acy026. PMID: 29617704. *Exclude-Intervention*

Excluded Publications

1194. Lee GJ, Suhr JA. Expectancy effects of placebo neurofeedback in ADHD treatment seekers: A neuropsychological investigation. *Neuropsychology*. 2020 Oct;34(7):774-82. doi: 10.1037/neu0000689. PMID: 32730049. *Exclude-Intervention*
1195. Lee J, Lee D, Ihm H, et al. Network structure of symptomatology of adult attention-deficit hyperactivity disorder in patients with mood disorders. *Eur Arch Psychiatry Clin Neurosci*. 2023 Dec 6. doi: 10.1007/s00406-023-01719-2. PMID: 38055014. *Exclude-Intervention*
1196. Lee L, Kepple J, Wang Y, et al. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. *Biopharm Drug Dispos*. 2003 Sep;24(6):233-43. doi: 10.1002/bdd.358. PMID: 12973820. *Exclude-Population*
1197. Lee SI, Song DH, Shin DW, et al. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder. *Asia Pac Psychiatry*. 2014 Dec;6(4):386-96. doi: 10.1111/appy.12160. PMID: 25345739. *Possible multiple publication*
1198. Lee TY. Clinical observation on treatment of adult-attention deficit hyperactivity disorder by acupuncture refreshing brain method. *Global Advances in Health and Medicine*. 2018;7:108-9. doi: 10.1177/2164956118773837. *Currently being assessed for management*
1199. Lee YC, Ward McIntosh C, Winston F, et al. Design of an experimental protocol to examine medication non-adherence among young drivers diagnosed with ADHD: A driving simulator study. *Contemp Clin Trials Commun*. 2018 Sep;11:149-55. doi: 10.1016/j.conctc.2018.07.007. PMID: 30101205. *Exclude-Design*
1200. Leffa D, Schneider M, Ferraza C, et al. P73. Transcranial Direct Current Stimulation for the Treatment of Inattention in Adult Patients With ADHD: Results From the TUNED Trial. *Biological Psychiatry*. 2022;91(9):S116-S7. doi: 10.1016/j.biopsych.2022.02.307. *Currently being assessed for management*
1201. Leffa DT, Grevet EH, Bau CHD, et al. Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial. *JAMA Psychiatry*. 2022 Sep 1;79(9):847-56. doi: 10.1001/jamapsychiatry.2022.2055. PMID: 35921102. *Currently being assessed for management*
1202. Lefler EK, Flory K, Canu WH, et al. Unique considerations in the assessment of ADHD in college students. *J Clin Exp Neuropsychol*. 2021 May;43(4):352-69. doi: 10.1080/13803395.2021.1936462. PMID: 34078248. *Exclude-Comparator*
1203. Leib SI, Keezer RD, Cerny BM, et al. Distinct Latent Profiles of Working Memory and Processing Speed in Adults with ADHD. *Dev Neuropsychol*. 2021 Nov;46(8):574-87. doi: 10.1080/87565641.2021.1999454. PMID: 34743616. *Exclude-Intervention*
1204. Lensing MB, Zeiner P, Sandvik L, et al. Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey. *J Clin Psychiatry*. 2013 Jan;74(1):e87-93. doi: 10.4088/JCP.12m07714. PMID: 23419235. *Exclude-Design*

Excluded Publications

1205. Lensing MB, Zeiner P, Sandvik L, et al. Psychopharmacological treatment of ADHD in adults aged 50+: an empirical study. *J Atten Disord.* 2015 May;19(5):380-9. doi: 10.1177/1087054714527342. PMID: 24681898. *Exclude-Design*
1206. Leontyev A, Yamauchi T. Mouse movement measures enhance the stop-signal task in adult ADHD assessment. *PLoS One.* 2019;14(11):e0225437. doi: 10.1371/journal.pone.0225437. PMID: 31770416. *Exclude-Intervention*
1207. Leopold DR, Bryan AD, Pennington BF, et al. Evaluating the construct validity of adult ADHD and SCT among college students: a multitrait-multimethod analysis of convergent and discriminant validity. *J Atten Disord.* 2015 Mar;19(3):200-10. doi: 10.1177/1087054714553051. PMID: 25304149. *Exclude-Intervention*
1208. Leuchter AF, McGough JJ, Korb AS, et al. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. *J Psychiatr Res.* 2014 Jul;54:11-8. doi: 10.1016/j.jpsychires.2014.03.009. PMID: 24726639. *Exclude-Intervention*
1209. Leuchter AF, McGough JJ, Korb AS, et al. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: A pilot project. *Journal of Psychiatric Research.* 2014;54(1):11-8. doi: 10.1016/j.jpsychires.2014.03.009. *Currently being assessed for management*
1210. Leung VM, Chan LF. A Cross-sectional Cohort Study of Prevalence, Co-Morbidities, and Correlates of Attention-deficit Hyperactivity Disorder among Adult Patients Admitted to the Li Ka Shing Psychiatric Outpatient Clinic, Hong Kong. *East Asian Arch Psychiatry.* 2017 Jun;27(2):63-70. PMID: 28652499. *Exclude-Intervention*
1211. Levin ED, Conners CK, Silva D, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. *Exp Clin Psychopharmacol.* 2001 Feb;9(1):83-90. doi: 10.1037/1064-1297.9.1.83. PMID: 11519638. *Currently being assessed for management*
1212. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl).* 1996 Jan;123(1):55-63. doi: 10.1007/bf02246281. PMID: 8741955. *Currently being assessed for management*
1213. Levin F, Mariani J, Pavlicova M, et al. Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial. *Drug and Alcohol Dependence.* 2024;260. doi: 10.1016/j.drugalcdep.2023.110349. *Currently being assessed for management*
1214. Levin FR, Bisaga A, Raby W, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. *J Subst Abuse Treat.* 2008 Jan;34(1):80-9. doi: 10.1016/j.jsat.2006.11.012. PMID: 17574796. *Exclude-Intervention*

Excluded Publications

1215. Levin FR, Choi CJ, Pavlicova M, et al. How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. *Drug Alcohol Depend.* 2018 Jul 1;188:135-40. doi: 10.1016/j.drugalcdep.2018.03.043. PMID: 29775957. *Exclude-Intervention*
1216. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. *Drug Alcohol Depend.* 2007 Feb 23;87(1):20-9. doi: 10.1016/j.drugalcdep.2006.07.004. PMID: 16930863. *Currently being assessed for management*
1217. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. *Drug Alcohol Depend.* 2006 Feb 1;81(2):137-48. doi: 10.1016/j.drugalcdep.2005.06.012. PMID: 16102908. *Currently being assessed for management*
1218. Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. *J Addict Dis.* 2002;21(2):1-16. doi: 10.1300/J069v21n02_01. PMID: 11916368. *Exclude-Design*
1219. Levin FR, Evans SM, McDowell DM, et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. *J Clin Psychiatry.* 1998 Jun;59(6):300-5. doi: 10.4088/jcp.v59n0605. PMID: 9671342. *Exclude-Design*
1220. Levin FR, Mariani JJ, Mahony A, et al. Mixed amphetamine salts-extended release for ADHD adults with cocaine use disorder. *Drug and Alcohol Dependence.* 2015;146:e175. doi: 10.1016/j.drugalcdep.2014.09.393. *Currently being assessed for management*
1221. Levin FR, Mariani JJ, Pavlicova M, et al. Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial. *J Atten Disord.* 2024 Jul 25;10870547241264675. doi: 10.1177/10870547241264675. PMID: 39051597. *Currently being assessed for management*
1222. Levin FR, Mariani JJ, Pavlicova M, et al. Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial. *J Atten Disord.* 2024 Sep;28(11):1467-81. doi: 10.1177/10870547241264675. PMID: 39051597. *Exclude-Duplicate*
1223. Levin FR, Mariani JJ, Secora A, et al. Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. *J Dual Diagn.* 2009 Jan 1;5(1):41-56. doi: 10.1080/15504260802628767. PMID: 19430599. *Exclude-Intervention*
1224. Levin FR, Mariani JJ, Specker S, et al. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry.* 2015 Jun;72(6):593-602. doi: 10.1001/jamapsychiatry.2015.41. PMID: 25887096. *Currently being assessed for management*

Excluded Publications

1225. Levine SZ, Rotstein A, Kodesh A, et al. Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia. *JAMA Netw Open*. 2023 Oct 2;6(10):e2338088. doi: 10.1001/jamanetworkopen.2023.38088. PMID: 37847497. *Exclude-Intervention*
1226. Levy JD, Kronenberger WG, Dunn DW. Development of a Very Brief Measure of ADHD: The CHAOS Scale. *J Atten Disord*. 2017 May;21(7):575-86. doi: 10.1177/1087054713497792. PMID: 23995051. *Exclude-Population*
1227. Levy O, Hackmon SL, Zvilichovsky Y, et al. Neurophysiological Patterns of Attention and Distraction during Realistic Virtual-Reality Classroom Learning in Adults with and without ADHD. *bioRxiv*. 2024 Apr 20. doi: 10.1101/2024.04.17.590012. PMID: 38659916. *Exclude-Intervention*
1228. Lewczuk K, Marcowski P, Wizła M, et al. Cross-Cultural Adult ADHD Assessment in 42 Countries Using the Adult ADHD Self-Report Scale Screener. *J Atten Disord*. 2024 Feb;28(4):512-30. doi: 10.1177/10870547231215518. PMID: 38180045. *Exclude-Intervention*
1229. Li L, Zhu N, Zhang L, et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. *Jama*. 2024 Mar 12;331(10):850-60. doi: 10.1001/jama.2024.0851. PMID: 38470385. *Exclude-Design*
1230. Li Y, Liu W, Zhu Y, et al. Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder. *J Clin Psychopharmacol*. 2017 Oct;37(5):546-54. doi: 10.1097/jcp.0000000000000759. PMID: 28787373. *Exclude-Intervention*
1231. Libutzki B, Ludwig S, May M, et al. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. *Eur Psychiatry*. 2019 May;58:38-44. doi: 10.1016/j.eurpsy.2019.01.019. PMID: 30802682. *Exclude-Intervention*
1232. Libutzki B, Neukirch B, Kittel-Schneider S, et al. Risk of accidents and unintentional injuries in men and women with attention deficit hyperactivity disorder across the adult lifespan. *Acta Psychiatr Scand*. 2023 Feb;147(2):145-54. doi: 10.1111/acps.13524. PMID: 36464800. *Exclude-Intervention*
1233. Libutzki B, Neukirch B, Kittel-Schneider S, et al. Risk of accidents and unintentional injuries in men and women with attention deficit hyperactivity disorder across the adult lifespan. *Acta Psychiatrica Scandinavica*. 2023;147(2):145-54. doi: 10.1111/acps.13524. *Exclude-Duplicate*
1234. Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. *N Engl J Med*. 2012 Nov 22;367(21):2006-14. doi: 10.1056/NEJMoa1203241. PMID: 23171097. *Exclude-Design*
1235. Lie N. [Central stimulants in adults with AD/HD. Do they help?]. *Tidsskr Nor Laegeforen*. 1998 Nov 10;118(27):4223-7. PMID: 9857806. *Currently being assessed for management*

Excluded Publications

1236. Liechti MD, Valko L, Müller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. *Brain Topography*. 2013;26(1):135-51. doi: 10.1007/s10548-012-0258-6. *Exclude-Intervention*

1237. Liechti MD, Valko L, Müller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. *Brain Topogr*. 2013 Jan;26(1):135-51. doi: 10.1007/s10548-012-0258-6. PMID: 23053601. *Exclude-Population*

1238. Lile JA, Babalonis S, Emurian C, et al. Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. *J Clin Pharmacol*. 2011 Jun;51(6):888-98. doi: 10.1177/0091270010375956. PMID: 20671295. *Exclude-Population*

1239. Lin H-Y, Gau SS-F. Atomoxetine treatment strengthens an anti-correlated relationship between functional brain networks in medication-naïve adults with attention-deficit hyperactivity disorder: A randomized double-blind placebo-controlled clinical trial. *International Journal of Neuropsychopharmacology*. 2016;19(3):1-15. doi: 10.1093/ijnp/pyv094. *Currently being assessed for management*

1240. Lin HY, Gau SS. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial. *Int J Neuropsychopharmacol*. 2015 Sep 16;19(3):pyv094. doi: 10.1093/ijnp/pyv094. PMID: 26377368. *Exclude-Outcome*

1241. Lindström T, Buddgård S, Westholm L, et al. Parent Training Tailored to Parents With ADHD: Development of the Improving Parenting Skills Adult ADHD (IPSA) Program. *J Atten Disord*. 2024 Feb;28(4):531-41. doi: 10.1177/10870547231217090. PMID: 38152999. *Exclude-Design*

1242. Lindvall MA, Holmqvist KL, Svedell LA, et al. START - physical exercise and person-centred cognitive skills training as treatment for adult ADHD: protocol for a randomized controlled trial. *BMC Psychiatry*. 2023 Sep 25;23(1):697. doi: 10.1186/s12888-023-05181-1. PMID: 37749523. *Exclude-Design*

1243. Lindvall MA, Holmqvist KL, Svedell LA, et al. START – physical exercise and person-centred cognitive skills training as treatment for adult ADHD: protocol for a randomized controlled trial. *BMC Psychiatry*. 2023;23(1). doi: 10.1186/s12888-023-05181-1. *Currently being assessed for management*

1244. Liu YH, Stein MT. Attention-deficit/hyperactivity disorder: evidence-based diagnosis and management for primary care clinicians. *Minerva Pediatr*. 2004 Dec;56(6):567-83. PMID: 15765020. *Exclude-Design*

1245. Liu ZX, Lishak V, Tannock R, et al. Effects of working memory training on neural correlates of Go/Nogo response control in adults with ADHD: A randomized controlled trial. *Neuropsychologia*. 2017 Jan 27;95:54-72. doi: 10.1016/j.neuropsychologia.2016.11.023. PMID: 27939188. *Currently being assessed for management*

Excluded Publications

1246. Lloyd TQ. Delis-Kaplan Executive Function System performance as measure of executive dysfunction in adult ADHD. US: ProQuest Information & Learning; 2011. *Exclude-Intervention*
1247. Lofthouse N, Arnold LE, Arns M, et al. Planning for a collaborative multisite, double-blind, sham-controlled randomized clinical trial of neurofeedback for ADHD. *Journal of Neurotherapy*. 2011;15(4):416-7. doi: 10.1080/10874208.2011.623098. *Currently being assessed for management*
1248. Logan J, Wang GJ, Telang F, et al. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. *Nucl Med Biol*. 2007 Aug;34(6):667-79. doi: 10.1016/j.nucmedbio.2007.03.013. PMID: 17707807. *Exclude-Population*
1249. Löhman M, Domingo B, Östlund M, et al. Contrasting expectancy effects with objective measures in adults with untreated ADHD during QbTest. *Scand J Psychol*. 2023 Aug;64(4):461-9. doi: 10.1111/sjop.12906. PMID: 36786078. *Exclude-Intervention*
1250. López-Pinar C, Rosen H, Selaskowski B, et al. Exploring the Relationship between Adherence to Therapy, Treatment Acceptability, and Clinical Outcomes in Adults with Attention-Deficit/Hyperactivity Disorder: Results from the COMPAS Multicenter Randomized Controlled Trial. *Psychother Psychosom*. 2024;93(1):46-64. doi: 10.1159/000532043. PMID: 38142690. *Currently being assessed for management*
1251. López-Pinar C, Selaskowski B, Braun N, et al. Exploring the efficacy of dialectical behaviour therapy and methylphenidate on emotional comorbid symptoms in adults with attention Deficit/Hyperactivity disorder: Results of the COMPAS multicentre randomised controlled trial. *Psychiatry Res*. 2023 Dec;330:115610. doi: 10.1016/j.psychres.2023.115610. PMID: 37992514. *Possible multiple publication*
1252. Lovett BJ, Davis KM. Adult ADHD assessment: An integrated clinical-forensic perspective. *Professional Psychology: Research and Practice*. 2017;48(6):438-44. doi: 10.1037/pro0000159. *Exclude-Intervention*
1253. Low AM, le Sommer J, Vangkilde S, et al. Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. *Int J Neuropsychopharmacol*. 2018 Nov 1;21(11):997-1006. doi: 10.1093/ijnp/pyy070. PMID: 30124878. *Exclude-Design*
1254. Low AM, Vangkilde S, le Sommer J, et al. Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. *Psychol Med*. 2019 Nov;49(15):2617-25. doi: 10.1017/s0033291718003628. PMID: 30560740. *Currently being assessed for management*
1255. Low AM, Vangkilde S, le Sommer J, et al. Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. *Nord J Psychiatry*. 2023 Jan;77(1):102-7. doi: 10.1080/08039488.2022.2080253. PMID: 35635014. *Exclude-Design*

Excluded Publications

1256. Lu T-F, Shuai L, Zhang J-S, et al. Validity and reliability of the Behavior Rating Scale of Executive Function-Preschool Version parent form in China. *Chinese Mental Health Journal*. 2017;31(2):138-43. *Exclude-Population*

1257. Lu T-H, Lin S-H, Chi MH, et al. Harm avoidance is correlated with the reward system in adult patients with attention deficit hyperactivity disorder: A functional magnetic resonance imaging study. *Clinical Psychopharmacology and Neuroscience*. 2023;21(1):99-107. doi: 10.9758/cpn.2023.21.1.99. *Exclude-Duplicate*

1258. Lu TH, Lin SH, Chi MH, et al. Harm Avoidance is Correlated with the Reward System in Adult Patients with Attention Deficit Hyperactivity Disorder: A Functional Magnetic Resonance Imaging Study. *Clin Psychopharmacol Neurosci*. 2023 Feb 28;21(1):99-107. doi: 10.9758/cpn.2023.21.1.99. PMID: 36700316. *Exclude-Intervention*

1259. Lu Y, Sjölander A, Cederlöf M, et al. Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder. *JAMA Psychiatry*. 2017 Aug 1;74(8):815-22. doi: 10.1001/jamapsychiatry.2017.1472. PMID: 28658471. *Exclude-Intervention*

1260. Luderer M, Kaplan-Wickel N, Sick C, et al. [ADHD screening in alcohol dependent subjects : Psychometric characteristics of ADHD self-report scale and Wender Utah Rating Scale short form]. *Nervenarzt*. 2019 Nov;90(11):1156-61. doi: 10.1007/s00115-019-0706-6. PMID: 30976828. *Exclude-Language*

1261. Luderer M, Seidt J, Gerhardt S, et al. Drinking alcohol to cope with hyperactive ADHD? Self-reports vs. continuous performance test in patients with ADHD and/or alcohol use disorder. *Front Psychiatry*. 2023;14:1112843. doi: 10.3389/fpsy.2023.1112843. PMID: 36950259. *Exclude-Intervention*

1262. Lundervold AJ, Adolfsdottir S, Halleland H, et al. Attention Network Test in adults with ADHD--the impact of affective fluctuations. *Behav Brain Funct*. 2011 Jul 27;7:27. doi: 10.1186/1744-9081-7-27. PMID: 21794128. *Exclude-Intervention*

1263. Lundervold AJ, Halleland HB, Brevik EJ, et al. Verbal Memory Function in Intellectually Well-Functioning Adults With ADHD: Relations to Working Memory and Response Inhibition. *J Atten Disord*. 2019 Aug;23(10):1188-98. doi: 10.1177/1087054715580842. PMID: 25903587. *Exclude-Intervention*

1264. Lundin A, Kosidou K, Dalman C. Testing the Discriminant and Convergent Validity of the World Health Organization Six-Item Adult ADHD Self-Report Scale Screener Using the Stockholm Public Health Cohort. *J Atten Disord*. 2019 Aug;23(10):1170-7. doi: 10.1177/1087054717735381. PMID: 29073818. *Exclude-Intervention*

1265. Luo SX, Covey L, Hu MC, et al. Predictive modeling and nonlinear treatment effects in a multicenter, randomized controlled trial of methylphenidate in smoke cessation intervention. *American Journal on Addictions*. 2013;22(3):305. doi: 10.1111/j.1521-0391.2013.12069.x. *Currently being assessed for management*

Excluded Publications

1266. Luo SX, Covey LS, Hu MC, et al. Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers. *Am J Addict*. 2015 Jun;24(4):348-56. doi: 10.1111/ajad.12193. PMID: 25659348. *Exclude-Intervention*
1267. Luo SX, Wall M, Covey L, et al. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. *Am J Drug Alcohol Abuse*. 2018;44(6):653-9. doi: 10.1080/00952990.2017.1416474. PMID: 29370538. *Possible multiple publication*
1268. Luo Y, Alvarez TL, Halperin JM, et al. Multimodal neuroimaging-based prediction of adult outcomes in childhood-onset ADHD using ensemble learning techniques. *Neuroimage Clin*. 2020;26:102238. doi: 10.1016/j.nicl.2020.102238. PMID: 32182578. *Exclude-Intervention*
1269. Lynch R. The psychometric properties of the Barkley Adult ADHD Rating Scale: IV (BAARS-IV) in a college sample. US: ProQuest Information & Learning; 2018. *Exclude-Intervention*
1270. Lystad GO, Johannessen B. Acupuncture and Methylphenidate Drugs in Adults with Attention Deficit Hyperactivity Disorder: A Pilot Study of Self-Reported Symptoms. *Complement Med Res*. 2018;25(3):198-200. doi: 10.1159/000476064. PMID: 29169166. *Currently being assessed for management*
1271. MacDonald L, Sadek J. Management Strategies for Borderline Personality Disorder and Bipolar Disorder Comorbidities in Adults with ADHD: A Narrative Review. *Brain Sci*. 2023 Oct 26;13(11). doi: 10.3390/brainsci13111517. PMID: 38002478. *Exclude-Design*
1272. Mackin RS, Horner MD. Relationship of the Wender Utah Rating Scale to objective measures of attention. *Compr Psychiatry*. 2005 Nov-Dec;46(6):468-71. doi: 10.1016/j.comppsy.2005.03.004. PMID: 16275215. *Exclude-Intervention*
1273. Macphee FL, Brewer SK, Sibley MH, et al. Study protocol of a randomized trial of STRIPES: a schoolyear, peer-delivered high school intervention for students with ADHD. *BMC Psychol*. 2023 Sep 5;11(1):268. doi: 10.1186/s40359-023-01291-3. PMID: 37670368. *Exclude-Population*
1274. Madaan V, Bhaskar S, Donnelly GAE, et al. A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD. *J Atten Disord*. 2024 Apr;28(6):947-56. doi: 10.1177/10870547241226634. PMID: 38404033. *Currently being assessed for management*
1275. Madaan V, Daughton J, Lubberstedt B, et al. Assessing the efficacy of treatments for ADHD : overview of methodological issues. *CNS Drugs*. 2008;22(4):275-90. doi: 10.2165/00023210-200822040-00002. PMID: 18336058. *Exclude-Design*

Excluded Publications

1276. Madaan V, Kolli V, Bestha DP, et al. Update on optimal use of lisdexamfetamine in the treatment of ADHD. *Neuropsychiatr Dis Treat*. 2013;9:977-83. doi: 10.2147/ndt.S34092. PMID: 23901276. *Exclude-Design*
1277. Madiouni C, Lopez R, Gély-Nargeot MC, et al. Mind-wandering and sleepiness in adults with attention-deficit/hyperactivity disorder. *Psychiatry Res*. 2020 May;287:112901. doi: 10.1016/j.psychres.2020.112901. PMID: 32155443. *Exclude-Intervention*
1278. Maffly-Kipp J, Morey LC. Detecting Attention Deficit Hyperactivity Disorder and its feigning using the Personality Assessment Inventory. *Appl Neuropsychol Adult*. 2023 May 8:1-10. doi: 10.1080/23279095.2023.2207215. PMID: 37155738. *Exclude-Comparator*
1279. Magnante AT, Ord AS, Kuschel S, et al. An Evaluation of the Relationship Between Objective and Subjective Measures of Attention. *Psychology and Neuroscience*. 2024;17(2):104-21. doi: 10.1037/pne0000333. *Exclude-Intervention*
1280. Magnin E, Maurs C. Attention-deficit/hyperactivity disorder during adulthood. *Rev Neurol (Paris)*. 2017 Jul-Aug;173(7-8):506-15. doi: 10.1016/j.neurol.2017.07.008. PMID: 28844700. *Exclude-Outcome*
1281. Magnotti S, Beatty A, Bickford E, et al. Prescription Stimulant Misuse Among Nursing Students: A Systematic Review. *J Addict Nurs*. 2023 Jul-Sep 01;34(3):216-23. doi: 10.1097/jan.0000000000000539. PMID: 37669341. *Misuse only*
1282. Magnússon P, Smári J, Sigurdardóttir D, et al. Validity of self-report and informant rating scales of adult ADHD symptoms in comparison with a semistructured diagnostic interview. *J Atten Disord*. 2006 Feb;9(3):494-503. doi: 10.1177/1087054705283650. PMID: 16481666. *Exclude-Language*
1283. Maia CR, Matte BC, Ludwig HT, et al. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry*. 2008 Apr;17(3):133-42. doi: 10.1007/s00787-007-0647-7. PMID: 17846812. *Exclude-Comparator*
1284. Maia CRM, Matte BC, Ludwig HT, et al. Switching from methylphenidate immediate release to MPH-SODAS™ in attention-deficit/hyperactivity disorder. *European Child and Adolescent Psychiatry*. 2008;17(3):133-42. doi: 10.1007/s00787-007-0647-7. *Currently being assessed for management*
1285. Maier LJ, Ferris JA, Winstock AR. Pharmacological cognitive enhancement among non-ADHD individuals-A cross-sectional study in 15 countries. *Int J Drug Policy*. 2018 Aug;58:104-12. doi: 10.1016/j.drugpo.2018.05.009. PMID: 29902691. *Exclude-Population*
1286. Maier S, Tebartz van Elst L, Philipsen A, et al. Effects of 12-Week Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The First Double-Blind Placebo-Controlled MR Spectroscopy Study. *J Clin Med*. 2020 Aug 11;9(8). doi: 10.3390/jcm9082601. PMID: 32796630. *Exclude-Outcome*

Excluded Publications

1287. Mama Y, Icht M. Production Effect in Adults With ADHD With and Without Methylphenidate (MPH): Vocalization Improves Verbal Learning. *J Int Neuropsychol Soc.* 2019 Feb;25(2):230-5. doi: 10.1017/s1355617718001017. PMID: 30458897. *Exclude-Design*
1288. Maneeton B, Maneeton N, Intaprasert S, et al. A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of ADHD. *European Neuropsychopharmacology.* 2014;24:S202-S3. *Currently being assessed for management*
1289. Maneeton N, Maneeton B, Suttajit S, et al. A systematic review of randomised controlled trials of lisdexamfetamine versus placebo in the treatment of adults with ADHD. *European Neuropsychopharmacology.* 2014;24:S208. *Currently being assessed for management*
1290. Mannuzza S, Klein RG, Klein DF, et al. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. *Am J Psychiatry.* 2002 Nov;159(11):1882-8. doi: 10.1176/appi.ajp.159.11.1882. PMID: 12411223. *Exclude-Population*
1291. Manor I, Ben-Hayun R, Aharon J, et al. Metadoxine: A novel non-stimulant extended-release drug for treating ADHD. *European Neuropsychopharmacology.* 2012;22:S144. *Currently being assessed for management*
1292. Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry.* 2012 Dec;73(12):1517-23. doi: 10.4088/JCP.12m07767. PMID: 23290324. *Currently being assessed for management*
1293. Manor I, Corbex M, Eisenberg J, et al. Association of the dopamine D5 receptor with attention deficit hyperactivity disorder (ADHD) and scores on a continuous performance test (TOVA). *Am J Med Genet B Neuropsychiatr Genet.* 2004 May 15;127b(1):73-7. doi: 10.1002/ajmg.b.30020. PMID: 15108184. *Exclude-Intervention*
1294. Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. *Postgrad Med.* 2013 Jul;125(4):181-90. doi: 10.3810/pgm.2013.07.2689. PMID: 23933905. *Currently being assessed for management*
1295. Manor I, Rubin J, Daniely Y, et al. Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD. *Postgrad Med.* 2014 Sep;126(5):7-16. doi: 10.3810/pgm.2014.09.2795. PMID: 25295645. *Exclude-Timing*
1296. Manor I, Vurembandt N, Rozen S, et al. Low self-awareness of ADHD in adults using a self-report screening questionnaire. *Eur Psychiatry.* 2012 Jul;27(5):314-20. doi: 10.1016/j.eurpsy.2010.08.013. PMID: 22112307. *Exclude-Language*
1297. Manos MJ. Pharmacologic treatment of ADHD: Road conditions in driving patients to successful outcomes. *MedGenMed Medscape General Medicine.* 2008;10(1). *Currently being assessed for management*

Excluded Publications

1298. Mansell H, Quinn D, Kelly LE, et al. Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases. *Med Cannabis Cannabinoids*. 2022;5(1):1-6. doi: 10.1159/000521370. PMID: 35224434. *Exclude-Design*
1299. Maoz H, Aviram S, Nitzan U, et al. Association Between Continuous Performance and Response Inhibition Tests in Adults With ADHD. *J Atten Disord*. 2018 Feb;22(3):293-9. doi: 10.1177/1087054715584056. PMID: 25922185. *Exclude-Intervention*
1300. Marchant BK, Reimherr FW, Halls C, et al. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. *Ann Clin Psychiatry*. 2010 Aug;22(3):196-204. PMID: 20680193. *Exclude-Design*
1301. Marchant BK, Reimherr FW, Halls C, et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. *Atten Defic Hyperact Disord*. 2011 Sep;3(3):237-44. doi: 10.1007/s12402-011-0054-2. PMID: 21442440. *Exclude-Intervention*
1302. Marchant BK, Reimherr FW, Robison D, et al. Psychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale. *Psychol Assess*. 2013 Sep;25(3):942-50. doi: 10.1037/a0032797. PMID: 23647041. *Exclude-Intervention*
1303. Marchant BK, Reimherr FW, Robison RJ, et al. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. *J Atten Disord*. 2011 May;15(4):295-304. doi: 10.1177/1087054710365986. PMID: 20410322. *Currently being assessed for management*
1304. Marchetta ND, Hurks PP, De Sonneville LM, et al. Sustained and focused attention deficits in adult ADHD. *J Atten Disord*. 2008 May;11(6):664-76. doi: 10.1177/1087054707305108. PMID: 17712171. *Exclude-Intervention*
1305. Marfatia S, Shroff K, Munshi S, et al. Quality of life assessments in adults with attention deficit/hyperactivity disorder - A systematic review. *Value in Health*. 2011;14(7):A327-A8. doi: 10.1016/j.jval.2011.08.522. *Currently being assessed for management*
1306. Markham PT, Porter BE, Ball JD. Effectiveness of a program using a vehicle tracking system, incentives, and disincentives to reduce the speeding behavior of drivers with ADHD. *J Atten Disord*. 2013 Apr;17(3):233-48. doi: 10.1177/1087054711423630. PMID: 22210797. *Exclude-Intervention*
1307. Markovska-Simoska S, Pop-Jordanova N. Quantitative EEG in Children and Adults With Attention Deficit Hyperactivity Disorder: Comparison of Absolute and Relative Power Spectra and Theta/Beta Ratio. *Clin EEG Neurosci*. 2017 Jan;48(1):20-32. doi: 10.1177/1550059416643824. PMID: 27170672. *Exclude-Intervention*
1308. Markovska-Simoska S, Pop-Jordanova N, Pop-Jordanov J. Analysis of independent components of cognitive event related potentials in a group of ADHD adults. *Pril (Makedon Akad Nauk Umet Odd Med Nauki)*. 2016;37(1):37-49. doi: 10.1515/prilozi-2016-0004. PMID: 27442415. *Exclude-Intervention*

Excluded Publications

1309. Marrero RJ, Fumero A, de Miguel A, et al. Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. *Patient Educ Couns*. 2020 Oct;103(10):2116-31. doi: 10.1016/j.pec.2020.04.030. PMID: 32402489. *Exclude-Population*
1310. Marshall PS, Hoelzle JB, Heyerdahl D, et al. The impact of failing to identify suspect effort in patients undergoing adult attention-deficit/hyperactivity disorder (ADHD) assessment. *Psychol Assess*. 2016 Oct;28(10):1290-302. doi: 10.1037/pas0000247. PMID: 26751085. *Exclude-Intervention*
1311. Martel MM, Schimmack U, Nigg JT. Future directions for work on refinement of ADHD assessment in young adults: Response to Sibley, Coxe, and Molina. *Assessment*. 2017;24(3):297-9. doi: 10.1177/1073191116687392. *Exclude-Intervention*
1312. Marten F, Keuppens L, Baeyens D, et al. Sleep architecture and sleep problems in adolescents and young adults with and without ADHD: A systematic review and meta-analysis. *Sleep*. 2021;44(SUPPL 2):A298-A9. doi: 10.1093/sleep/zsab072.764. *Currently being assessed for management*
1313. Martin CA, Guenther G, Bingcan C, et al. Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2007 Feb;17(1):63-73. doi: 10.1089/cap.2006.0020. PMID: 17343554. *Exclude-Population*
1314. Martin PT, Corcoran M, Zhang P, et al. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder. *Clin Drug Investig*. 2014 Feb;34(2):147-57. doi: 10.1007/s40261-013-0156-z. PMID: 24297663. *Currently being assessed for management*
1315. Martinez B, Peplow PV. MicroRNAs as potential biomarkers for diagnosis of attention deficit hyperactivity disorder. *Neural Regen Res*. 2024 Mar;19(3):557-62. doi: 10.4103/1673-5374.380880. PMID: 37721284. *Exclude-Intervention*
1316. Martins-Silva T, Vaz JDS, Hutz MH, et al. Assessing causality in the association between attention-deficit/hyperactivity disorder and obesity: a Mendelian randomization study. *Int J Obes (Lond)*. 2019 Dec;43(12):2500-8. doi: 10.1038/s41366-019-0346-8. PMID: 31000774. *Exclude-Intervention*
1317. Martiny K, Nielsen NP, Wiig EH. Differentiating depression and ADHD without depression in adults with processing-speed measures. *Acta Neuropsychiatr*. 2020 Oct;32(5):237-46. doi: 10.1017/neu.2020.17. PMID: 32338233. *Exclude-Intervention*
1318. Massa J, O'Desky IH. Impaired visual habituation in adults with ADHD. *J Atten Disord*. 2012 Oct;16(7):553-61. doi: 10.1177/1087054711423621. PMID: 22166470. *Exclude-Intervention*

Excluded Publications

1319. Máté O, Somogyi K, Miklósi M. [Cognitive conceptualization of adult attention deficit hyperactivity disorder: a systematic review]. *Psychiatr Hung*. 2015;30(1):68-77. PMID: 25867890. *Exclude-Language*
1320. Matheson L, Asherson P, Wong IC, et al. Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study. *BMC Health Serv Res*. 2013 May 21;13:184. doi: 10.1186/1472-6963-13-184. PMID: 23692803. *Exclude-Design*
1321. Matier-Sharma K, Perachio N, Newcorn JH, et al. Differential diagnosis of ADHD: Are objective measures of attention, impulsivity, and activity level helpful? *Child Neuropsychology*. 1995;1(2):118-27. doi: 10.1080/09297049508402243. *Exclude-Population*
1322. Matsuo Y, Okita M, Ermer J, et al. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults. *Clin Drug Investig*. 2017 Aug;37(8):745-53. doi: 10.1007/s40261-017-0527-y. PMID: 28421383. *Exclude-Population*
1323. Matte B, Anselmi L, Salum GA, et al. ADHD in DSM-5: a field trial in a large, representative sample of 18- to 19-year-old adults. *Psychol Med*. 2015 Jan;45(2):361-73. doi: 10.1017/s0033291714001470. PMID: 25066615. *Exclude-Language*
1324. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. *Arch Gen Psychiatry*. 1984 Nov;41(11):1059-63. doi: 10.1001/archpsyc.1983.01790220049008. PMID: 6388523. *Exclude-Intervention*
1325. Matthys F, Soye V, van den Brink W, et al. Barriers to implementation of treatment guidelines for ADHD in adults with substance use disorder. *J Dual Diagn*. 2014;10(3):130-8. doi: 10.1080/15504263.2014.926691. PMID: 25392286. *Exclude-Design*
1326. Mattia M, Edoardo De M, Federico R, et al. Pharmacological treatments for ADHD comorbid with substance use disorder: a systematic review and network meta-analysis. 2024. PMID: CRD42024577835. *Currently being assessed for management*
1327. Mattingly G, Weisler R, Dirks B, et al. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. *Innov Clin Neurosci*. 2012 May;9(5-6):22-30. PMID: 22808446. *Exclude-Design*
1328. Mattingly GW, Weisler RH, Young J, et al. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. *BMC Psychiatry*. 2013 Jan 29;13:39. doi: 10.1186/1471-244x-13-39. PMID: 23356790. *Possible multiple publication*
1329. Mattos P, Louzã MR, Palmini AL, et al. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study. *J Atten Disord*. 2013 Jul;17(5):444-8. doi: 10.1177/1087054711434772. PMID: 22334621. *Exclude-Design*

Excluded Publications

1330. Matza LS, Johnston JA, Faries DE, et al. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). *Qual Life Res.* 2007 Nov;16(9):1511-20. doi: 10.1007/s11136-007-9254-9. PMID: 17874207. *Exclude-Intervention*
1331. Mauche N, Ulke C, Huang J, et al. Treatment of adult attention-deficit hyperactivity disorder (ADHD) with transcranial direct current stimulation (tDCS): study protocol for a parallel, randomized, double-blinded, sham-controlled, multicenter trial (Stim-ADHD). *Eur Arch Psychiatry Clin Neurosci.* 2024 Feb;274(1):71-82. doi: 10.1007/s00406-023-01652-4. PMID: 37479914. *Exclude-Design*
1332. Maul J, Advokat C. Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) improve memory of emotional stimuli in ADHD-diagnosed college students. *Pharmacol Biochem Behav.* 2013 Apr;105:58-62. doi: 10.1016/j.pbb.2013.01.021. PMID: 23395972. *Exclude-Design*
1333. Mawjee K, Woltering S, Tannock R. Working Memory Training in Post-Secondary Students with ADHD: A Randomized Controlled Study. *PLoS One.* 2015;10(9):e0137173. doi: 10.1371/journal.pone.0137173. PMID: 26397109. *Currently being assessed for management*
1334. May N, Bennett A. The Impact of Acupuncture on Self-Perceived Stress and ADHD Core Symptomatology in an Adult, Atomoxetine-taking ADHD Participant. Insights from an In-depth Single Case Study. *Integr Med (Encinitas).* 2023 Jul;22(3):28-36. PMID: 37534023. *Exclude-Population*
1335. May T, Birch E, Chaves K, et al. The Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder. *Aust N Z J Psychiatry.* 2023 Aug;57(8):1101-16. doi: 10.1177/00048674231166329. PMID: 37254562. *Exclude-Design*
1336. Maya-Piedrahita MC, Herrera-Gomez PM, Berrío-Mesa L, et al. Supported Diagnosis of Attention Deficit and Hyperactivity Disorder from EEG Based on Interpretable Kernels for Hidden Markov Models. *Int J Neural Syst.* 2022 Mar;32(3):2250008. doi: 10.1142/s0129065722500083. PMID: 34996341. *Exclude-Population*
1337. Mayer JS, Hees K, Medda J, et al. Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in adolescents and young adults with attention-deficit / hyperactivity disorder: study protocol for a randomized controlled trial. *Trials.* 2018 Feb 26;19(1):140. doi: 10.1186/s13063-017-2426-1. PMID: 29482662. *Exclude-Design*
1338. Mayer JS, Kohlhas L, Stermann J, et al. Bright light therapy versus physical exercise to prevent co-occurring depression in adolescents and young adults with attention-deficit/hyperactivity disorder: a multicentre, three-arm, randomised controlled, pilot phase-IIa trial. *Eur Arch Psychiatry Clin Neurosci.* 2024 Apr 16. doi: 10.1007/s00406-024-01784-1. PMID: 38627266. *Exclude-Population*
1339. Mayer K, Blume F, Wyckoff SN, et al. Neurofeedback of slow cortical potentials as a treatment for adults with Attention Deficit/Hyperactivity Disorder. *Clin Neurophysiol.* 2016 Feb;127(2):1374-86. doi: 10.1016/j.clinph.2015.11.013. PMID: 26684900. *Exclude-Intervention*

Excluded Publications

1340. Mayer K, Wyckoff SN, Fallgatter AJ, et al. Neurofeedback as a nonpharmacological treatment for adults with attention-deficit/hyperactivity disorder (ADHD): study protocol for a randomized controlled trial. *Trials*. 2015 Apr 18;16:174. doi: 10.1186/s13063-015-0683-4. PMID: 25928870. *Exclude-Intervention*
1341. Mayer K, Wyckoff SN, Strehl U. Underarousal in Adult ADHD: How Are Peripheral and Cortical Arousal Related? *Clin EEG Neurosci*. 2016 Jul;47(3):171-9. doi: 10.1177/1550059415577544. PMID: 25802473. *Exclude-Intervention*
1342. McBurnett K, Starr HL. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. *Expert Opin Pharmacother*. 2011 Feb;12(2):315-24. doi: 10.1517/14656566.2011.546058. PMID: 21226641. *Exclude-Design*
1343. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089-96. doi: 10.2165/11317630-000000000-00000. PMID: 19810780. *Exclude-Population*
1344. McClernon FJ, Kollins SH, Lutz AM, et al. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. *Psychopharmacology (Berl)*. 2008 Mar;197(1):95-105. doi: 10.1007/s00213-007-1009-3. PMID: 18038223. *Exclude-Design*
1345. McCormick-Deaton CM, Mohiuddin S. New onset ADHD symptoms in adolescents and college students: Diagnostic challenges and recommendations. *Adolescent Psychiatry*. 2018;8(2):79-92. doi: 10.2174/2210676608666180208162023. *Exclude-Population*
1346. McCredie MN, Morey LC. Evaluating new supplemental indicators for the Personality Assessment Inventory: Standardization and cross-validation. *Psychol Assess*. 2018 Oct;30(10):1292-9. doi: 10.1037/pas0000574. PMID: 29781665. *Exclude-Intervention*
1347. McElligott JT, Lemay JR, O'Brien ES, et al. Practice patterns and guideline adherence in the management of attention deficit/hyperactivity disorder. *Clin Pediatr (Phila)*. 2014 Sep;53(10):960-6. doi: 10.1177/0009922814540985. PMID: 24982441. *Exclude-Population*
1348. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. *Am J Psychiatry*. 2004 Nov;161(11):1948-56. doi: 10.1176/appi.ajp.161.11.1948. PMID: 15514392. *Exclude-Design*
1349. McGough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of adderall. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2003;42(6):684-91. doi: 10.1097/01.CHI.0000046850.56865.CB. *Currently being assessed for management*
1350. McGough JJ, Pataki CS, Suddath R. Dexamethylphenidate extended-release capsules for attention deficit hyperactivity disorder. *Expert Rev Neurother*. 2005 Jul;5(4):437-41. doi: 10.1586/14737175.5.4.437. PMID: 16026226. *Exclude-Design*

Excluded Publications

1351. McGuier EA, Kolko DJ, Joseph HM, et al. Use of Stimulant Diversion Prevention Strategies in Pediatric Primary Care and Associations With Provider Characteristics. *J Adolesc Health*. 2021 Apr;68(4):808-15. doi: 10.1016/j.jadohealth.2020.12.006. PMID: 33446402. *Exclude-Intervention*
1352. McIntyre RS, Alsuwaidan M, Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. *Hum Psychopharmacol*. 2013 Sep;28(5):421-7. doi: 10.1002/hup.2325. PMID: 24014142. *Exclude-Comparator*
1353. McNicholas F, Tatlow-Golden M, Gavin B, et al. A systematic review of service transitions in people with ADHD. *European Psychiatry*. 2016;33:S58. doi: 10.1016/j.eurpsy.2016.01.940. *Currently being assessed for management*
1354. McPherson DL, Salamat MT. Interactions among variables in the P300 response to a continuous performance task in normal and ADHD adults. *J Am Acad Audiol*. 2004 Nov-Dec;15(10):666-77. doi: 10.3766/jaaa.15.10.2. PMID: 15646665. *Exclude-Intervention*
1355. McRae-Clark AL, Brady KT, Hartwell KJ, et al. Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial. *J Atten Disord*. 2011 Oct;15(7):539-44. doi: 10.1177/1087054710371171. PMID: 20538968. *Exclude-Design*
1356. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. *Am J Addict*. 2010 Nov-Dec;19(6):481-9. doi: 10.1111/j.1521-0391.2010.00076.x. PMID: 20958842. *Currently being assessed for management*
1357. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. *The American Journal on Addictions*. 2010;19(6):481-9. doi: 10.1111/j.1521-0391.2010.00076.x. *Currently being assessed for management*
1358. Mechler K, Banaschewski T, Hohmann S, et al. Evidence-based pharmacological treatment options for ADHD in children and adolescents. *Pharmacol Ther*. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. PMID: 34174276. *Exclude-Population*
1359. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. PMID: 18206857. *Currently being assessed for management*
1360. Mehren A, Özyurt J, Lam AP, et al. Acute Effects of Aerobic Exercise on Executive Function and Attention in Adult Patients With ADHD. *Front Psychiatry*. 2019;10:132. doi: 10.3389/fpsy.2019.00132. PMID: 30971959. *Exclude-Timing*
1361. Mehren A, Philipsen A. [Is Physical Activity a Treatment Option for ADHD?]. *Z Kinder Jugendpsychiatr Psychother*. 2024;52(2):124-33. doi: 10.1024/1422-4917/a000963. PMID: 38335974. *Exclude-Language*

Excluded Publications

1362. Mehren A, Thiel CM, Bruns S, et al. Unimpaired social cognition in adult patients with ADHD: Brain volumetric and behavioral results. *Social Cognitive and Affective Neuroscience*. 2021;16(11):1160-9. doi: 10.1093/scan/nsab060. *Exclude-Intervention*
1363. Meinzer MC, Lewinsohn PM, Pettit JW, et al. Attention-deficit/hyperactivity disorder in adolescence predicts onset of major depressive disorder through early adulthood. *Depress Anxiety*. 2013 Jun;30(6):546-53. doi: 10.1002/da.22082. PMID: 23424020. *Exclude-Population*
1364. Meinzer MC, Oddo LE, Vasko JM, et al. Motivational interviewing plus behavioral activation for alcohol misuse in college students with ADHD. *Psychol Addict Behav*. 2021 Nov;35(7):803-16. doi: 10.1037/adb0000663. PMID: 33600197. *Currently being assessed for management*
1365. Melby-Lervåg M, Hulme C. Is working memory training effective? A meta-analytic review. *Dev Psychol*. 2013 Feb;49(2):270-91. doi: 10.1037/a0028228. PMID: 22612437. *Exclude-Population*
1366. Memon AM. Transcranial Magnetic Stimulation in Treatment of Adolescent Attention Deficit/Hyperactivity Disorder: A Narrative Review of Literature. *Innov Clin Neurosci*. 2021 Jan-Mar;18(1-3):43-6. PMID: 34150364. *Exclude-Population*
1367. Menna Ayman Abd E, Hazem EM, Rashad GM. The Therapeutic Effects of Probiotics on Attention Deficit Hyperactivity Disorder (ADHD) symptoms : A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2024. PMID: CRD42024509919. *Currently being assessed for management*
1368. Mészáros A, Czobor P, Bálint S, et al. [Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review]. *Psychiatr Hung*. 2007;22(4):259-70. PMID: 18167421. *Currently being assessed for management*
1369. Mette C, Grabemann M, Zimmermann M, et al. No Clear Association between Impaired Short-Term or Working Memory Storage and Time Reproduction Capacity in Adult ADHD Patients. *PLoS One*. 2015;10(7):e0133714. doi: 10.1371/journal.pone.0133714. PMID: 26221955. *Exclude-Intervention*
1370. Mette C, Zimmermann M, Grabemann M, et al. The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD. *Acta Psychiatr Scand*. 2013 Aug;128(2):124-32. doi: 10.1111/acps.12090. PMID: 23419004. *Exclude-Intervention*
1371. Meyer J, Ramklint M, Hallerbäck MU, et al. Evaluation of a structured skills training group for adolescents with attention deficit/hyperactivity disorder (ADHD) - study protocol of a randomised controlled trial. *BMC Psychiatry*. 2019 Jun 10;19(1):171. doi: 10.1186/s12888-019-2133-4. PMID: 31182047. *Exclude-Population*
1372. Michalek AM, Watson SM, Ash I, et al. Effects of noise and audiovisual cues on speech processing in adults with and without ADHD. *Int J Audiol*. 2014 Mar;53(3):145-52. doi: 10.3109/14992027.2013.866282. PMID: 24456181. *Exclude-Intervention*

Excluded Publications

1373. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. *Biol Psychiatry*. 2003 Jan 15;53(2):112-20. doi: 10.1016/s0006-3223(02)01671-2. PMID: 12547466. *Currently being assessed for management*
1374. Michielsen M, Kleef D, Bijlenga D, et al. Response and Side Effects Using Stimulant Medication in Older Adults With ADHD: An Observational Archive Study. *J Atten Disord*. 2021 Oct;25(12):1712-9. doi: 10.1177/1087054720925884. PMID: 32508213. *Exclude-Design*
1375. Mick E, Biederman J, Spencer T, et al. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. *Am J Med Genet B Neuropsychiatr Genet*. 2006 Dec 5;141b(8):890-4. doi: 10.1002/ajmg.b.30376. PMID: 16917950. *Exclude-Intervention*
1376. Micoulaud-Franchi JA, Lopez R, Michel P, et al. The development of the SGI-16: a shortened sensory gating deficit and distractibility questionnaire for adults with ADHD. *Atten Defic Hyperact Disord*. 2017 Sep;9(3):179-87. doi: 10.1007/s12402-016-0215-4. PMID: 28039669. *Exclude-Intervention*
1377. Micoulaud-Franchi JA, Lopez R, Vaillant F, et al. Perceptual abnormalities related to sensory gating deficit are core symptoms in adults with ADHD. *Psychiatry Res*. 2015 Dec 15;230(2):357-63. doi: 10.1016/j.psychres.2015.09.016. PMID: 26416589. *Exclude-Intervention*
1378. Micoulaud-Franchi JA, Vaillant F, Lopez R, et al. Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia. *Biol Psychol*. 2015 Apr;107:16-23. doi: 10.1016/j.biopsycho.2015.03.002. PMID: 25766264. *Exclude-Intervention*
1379. Mihan R, Shahriar Z, Mahmoudi-Gharaei J, et al. Attention-Deficit Hyperactivity Disorder in Adults Using Methamphetamine: Does It Affect Comorbidity, Quality of Life, and Global Functioning? *Iran J Psychiatry*. 2018 Apr;13(2):111-8. PMID: 29997656. *Exclude-Design*
1380. Miller M, Hanford RB, Fassbender C, et al. Affect recognition in adults with ADHD. *J Atten Disord*. 2011 Aug;15(6):452-60. doi: 10.1177/1087054710368636. PMID: 20555036. *Exclude-Intervention*
1381. Mira S, Sylvia L, Ronan W, et al. Treating Executive Function Deficits in Individuals with Attention Deficit Hyperactivity Disorder: A Review of Pharmacological and Non-Pharmacological Interventions. 2022. PMID: CRD42022363558. *Currently being assessed for management*
1382. Miranda A, Mercader J, Fernández MI, et al. Reading performance of young adults with ADHD diagnosed in childhood: Relations with executive functioning. *Journal of Attention Disorders*. 2017;21(4):294-304. doi: 10.1177/1087054713507977. *Exclude-Intervention*
1383. Misa JD. Factor analysis of the personality assessment inventory and connors adult ADHD Rating Scales in adults with symptoms of attention and concentration problems. US: ProQuest Information & Learning; 2014. *Exclude-Intervention*

Excluded Publications

1384. Mitchell HM, Park G, Hammond CJ. Are non-abstinent reductions in World Health Organization drinking risk level a valid treatment target for alcohol use disorders in adolescents with ADHD? *Addict Behav Rep.* 2020 Dec;12:100312. doi: 10.1016/j.abrep.2020.100312. PMID: 33364320. *Exclude-Population*
1385. Mitchell JT, McClernon FJ, Beckham JC, et al. Smoking abstinence effects on emotion dysregulation in adult cigarette smokers with and without attention-deficit/hyperactivity disorder. *Drug Alcohol Depend.* 2019 Dec 1;205:107594. doi: 10.1016/j.drugalcdep.2019.107594. PMID: 31639512. *Exclude-Population*
1386. Mitchell JT, McIntyre EM, English JS, et al. A Pilot Trial of Mindfulness Meditation Training for ADHD in Adulthood: Impact on Core Symptoms, Executive Functioning, and Emotion Dysregulation. *J Atten Disord.* 2017 Nov;21(13):1105-20. doi: 10.1177/1087054713513328. PMID: 24305060. *Currently being assessed for management*
1387. Mocanu V, Tavakoli I, MacDonald A, et al. The Impact of ADHD on Outcomes Following Bariatric Surgery: a Systematic Review and Meta-analysis. *Obes Surg.* 2019 Apr;29(4):1403-9. doi: 10.1007/s11695-019-03735-5. PMID: 30706311. *Exclude-Population*
1388. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. *J Clin Pharmacol.* 2000 Apr;40(4):379-88. doi: 10.1177/00912700022009080. PMID: 10761165. *Exclude-Design*
1389. Modi NB, Wang B, Noveck RJ, et al. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. *J Clin Pharmacol.* 2000 Oct;40(10):1141-9. PMID: 11028253. *Exclude-Population*
1390. Moffitt TE, Houts R, Asherson P, et al. Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study. *Am J Psychiatry.* 2015 Oct;172(10):967-77. doi: 10.1176/appi.ajp.2015.14101266. PMID: 25998281. *Exclude-Intervention*
1391. Mohamed SM, Börger NA, Geuze RH, et al. Brain lateralization and self-reported symptoms of ADHD in a population sample of adults: a dimensional approach. *Front Psychol.* 2015;6:1418. doi: 10.3389/fpsyg.2015.01418. PMID: 26441789. *Exclude-Intervention*
1392. Mohammad Ali S, Elham G. A systematic review of randomized controlled trials on efficacy and safety of transcranial direct current stimulation in major neurodevelopmental disorders: ADHD, autism, and dyslexia. 2022. PMID: CRD42022321430. *Currently being assessed for management*
1393. Mohammadzadeh S, Ahangari TK, Yousefi F. The effect of memantine in adult patients with attention deficit hyperactivity disorder. *Hum Psychopharmacol.* 2019 Jan;34(1):e2687. doi: 10.1002/hup.2687. PMID: 30663824. *Currently being assessed for management*

Excluded Publications

1394. Mokhtari H, Rabiei M, Salimi SH. Psychometric properties of the Persian version of Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale. *Iranian Journal of Psychiatry and Clinical Psychology*. 2015;21(3):244-53. *Exclude-Intervention*
1395. Molina BS, Marshal MP, Pelham WE, Jr., et al. Coping skills and parent support mediate the association between childhood attention-deficit/hyperactivity disorder and adolescent cigarette use. *J Pediatr Psychol*. 2005 Jun;30(4):345-57. doi: 10.1093/jpepsy/jsi029. PMID: 15863431. *Exclude-Population*
1396. Molina BS, Pelham WE, Gnagy EM, et al. Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. *Alcohol Clin Exp Res*. 2007 Apr;31(4):643-54. doi: 10.1111/j.1530-0277.2007.00349.x. PMID: 17374044. *Exclude-Intervention*
1397. Monastra VJ, Lubar JF, Linden M. The development of a quantitative electroencephalographic scanning process for attention deficit-hyperactivity disorder: reliability and validity studies. *Neuropsychology*. 2001 Jan;15(1):136-44. doi: 10.1037//0894-4105.15.1.136. PMID: 11216884. *Exclude-Population*
1398. Monastra VJ, Lubar JF, Linden M, et al. Assessing attention deficit hyperactivity disorder via quantitative electroencephalography: an initial validation study. *Neuropsychology*. 1999 Jul;13(3):424-33. doi: 10.1037/0894-4105.13.3.424. PMID: 10447303. *Exclude-Population*
1399. Monastra VJ, Monastra DM, George S. The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. *Appl Psychophysiol Biofeedback*. 2002 Dec;27(4):231-49. doi: 10.1023/a:1021018700609. PMID: 12557451. *Exclude-Population*
1400. Moorthy G, Sallee F, Gabbita P, et al. Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistidine, in a phase 1 dose escalation study in subjects with ADHD. *Biopharm Drug Dispos*. 2015 Oct;36(7):429-39. doi: 10.1002/bdd.1955. PMID: 25904220. *Exclude-Timing*
1401. Moorthy G, Sallee F, Zemlan F, et al. Population pharmacokinetics of betahistidine in patients with attention deficit hyperactivity disorder (ADHD). *Clinical Pharmacology and Therapeutics*. 2014;95:S80. doi: 10.1038/clpt.2013.249. *Currently being assessed for management*
1402. Moreira-Maia CR, Massuti R, Tessari L, et al. Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis. *Medicine (Baltimore)*. 2018 Jun;97(24):e10923. doi: 10.1097/md.00000000000010923. PMID: 29901582. *Exclude-Intervention*
1403. Morgensterns E, Alfredsson J, Hirvikoski T. Structured skills training for adults with ADHD in an outpatient psychiatric context: an open feasibility trial. *Atten Defic Hyperact Disord*. 2016 Jun;8(2):101-11. doi: 10.1007/s12402-015-0182-1. PMID: 26410823. *Exclude-Intervention*

Excluded Publications

1404. Moritz GR, Pizutti LT, Cancian ACM, et al. Feasibility trial of the dialectical behavior therapy skills training group as add-on treatment for adults with attention-deficit/hyperactivity disorder. *J Clin Psychol*. 2021 Mar;77(3):516-24. doi: 10.1002/jclp.23049. PMID: 32880953. *Currently being assessed for management*
1405. Morkem R, Handelsman K, Queenan JA, et al. Validation of an EMR algorithm to measure the prevalence of ADHD in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). *BMC Med Inform Decis Mak*. 2020 Jul 20;20(1):166. doi: 10.1186/s12911-020-01182-2. PMID: 32690025. *Exclude-Intervention*
1406. Morley CP. The effects of patient characteristics on ADHD diagnosis and treatment: a factorial study of family physicians. *BMC Fam Pract*. 2010 Feb 8;11:11. doi: 10.1186/1471-2296-11-11. PMID: 20144184. *Exclude-Intervention*
1407. Mosholder AD, Taylor L, Mannheim G, et al. Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. *J Clin Psychopharmacol*. 2018 Oct;38(5):505-8. doi: 10.1097/jcp.0000000000000939. PMID: 30102629. *Exclude-Design*
1408. Mowinckel AM, Alnæs D, Pedersen ML, et al. Increased default-mode variability is related to reduced task-performance and is evident in adults with ADHD. *Neuroimage Clin*. 2017;16:369-82. doi: 10.1016/j.nicl.2017.03.008. PMID: 28861338. *Possible multiple publication*
1409. Mucci F, Carpita B, Pagni G, et al. Lifetime evolution of ADHD treatment. *J Neural Transm (Vienna)*. 2021 Jul;128(7):1085-98. doi: 10.1007/s00702-021-02336-w. PMID: 33993352. *Exclude-Design*
1410. Mückschel M, Roessner V, Beste C. Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study. *Eur Neuropsychopharmacol*. 2020 Jun;35:89-99. doi: 10.1016/j.euroneuro.2020.03.013. PMID: 32402650. *Exclude-Population*
1411. Muir VJ, Perry CM. Guanfacine extended-release: in attention deficit hyperactivity disorder. *Drugs*. 2010 Sep 10;70(13):1693-702. doi: 10.2165/11205940-000000000-00000. PMID: 20731476. *Exclude-Population*
1412. Muijt JJ, Bothof N, Kan CC. Pharmacotherapy of ADHD in Adults With Autism Spectrum Disorder: Effectiveness and Side Effects. *J Atten Disord*. 2020 Jan;24(2):215-25. doi: 10.1177/1087054719866255. PMID: 31625426. *Exclude-Design*
1413. Müller BW, Gimbel K, Keller-Pliessnig A, et al. Neuropsychological assessment of adult patients with attention-deficit/hyperactivity disorder. *Eur Arch Psychiatry Clin Neurosci*. 2007 Mar;257(2):112-9. doi: 10.1007/s00406-006-0688-9. PMID: 17200879. *Exclude-Intervention*
1414. Muller U. Pharmacological treatment of ADHD in adults: Implications for binge eating and obesity. *International Journal of Neuropsychopharmacology*. 2014;17:36-7. doi: 10.1017/S1461145714000741. *Currently being assessed for management*

Excluded Publications

1415. Müller U, Clark L, Lam ML, et al. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. *Psychopharmacology (Berl)*. 2005 Oct;182(2):205-13. doi: 10.1007/s00213-005-0078-4. PMID: 16078088. *Exclude-Population*
1416. Murphy K. Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. *J Clin Psychol*. 2005 May;61(5):607-19. doi: 10.1002/jclp.20123. PMID: 15723366. *Exclude-Design*
1417. Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. *J Clin Psychiatry*. 2004;65 Suppl 3:12-7. PMID: 15046530. *Exclude-Design*
1418. Muskens JB, Velders FP, Staal WG. Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. *Eur Child Adolesc Psychiatry*. 2017 Sep;26(9):1093-103. doi: 10.1007/s00787-017-1020-0. PMID: 28674760. *Exclude-Intervention*
1419. Nagatsuka Y, Nakamura D, Ota M, et al. Gaze measurements during viewing human dialogue scenes in adults with ADHD: Preliminary findings. *Neuropsychopharmacol Rep*. 2024 Mar;44(1):73-9. doi: 10.1002/npr2.12383. PMID: 38050324. *Exclude-Intervention*
1420. Naiwei F, Zhaohui Z, Wenrui D, et al. Systematic review and meta-analysis on the effectiveness of transcranial direct current stimulation (TDCS) for the treatment of attention deficit hyperactivity disorder (ADHD). 2018. PMID: CRD42018092725. *Currently being assessed for management*
1421. Najib J, Didenko E, Meleshkina D, et al. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. *Curr Med Res Opin*. 2020 Oct;36(10):1717-35. doi: 10.1080/03007995.2020.1815002. PMID: 32845786. *Exclude-Population*
1422. Nakano M, Witcher J, Sato Y, et al. Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. *Clin Drug Investig*. 2016 Nov;36(11):903-11. doi: 10.1007/s40261-016-0430-y. PMID: 27444039. *Exclude-Intervention*
1423. Nakashima M, Inada N, Tanigawa Y, et al. Efficacy of Group Cognitive Behavior Therapy Targeting Time Management for Adults with Attention Deficit/Hyperactivity Disorder in Japan: A Randomized Control Pilot Trial. *J Atten Disord*. 2022 Feb;26(3):377-90. doi: 10.1177/1087054720986939. PMID: 33472510. *Exclude-Design*
1424. Nankoo MMA, Palermo R, Bell JA, et al. Examining the Rate of Self-Reported ADHD-Related Traits and Endorsement of Depression, Anxiety, Stress, and Autistic-Like Traits in Australian University Students. *J Atten Disord*. 2019 Jun;23(8):869-86. doi: 10.1177/1087054718758901. PMID: 29502467. *Exclude-Population*
1425. Nasri B, Cassel M, Enhärje J, et al. Internet delivered cognitive behavioral therapy for adults with ADHD - A randomized controlled trial. *Internet Interv*. 2023 Sep;33:100636. doi: 10.1016/j.invent.2023.100636. PMID: 37483263. *Currently being assessed for management*

Excluded Publications

1426. Nasser A, Hull JT, Chaturvedi SA, et al. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. *CNS Drugs*. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. PMID: 35896943. *Currently being assessed for management*
1427. Nasser A, Kosheleff AR, Hull JT, et al. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2021 Apr;31(3):214-26. doi: 10.1089/cap.2020.0148. PMID: 33600233. *Exclude-Population*
1428. National Guideline C. NICE Evidence Reviews Collection. Evidence reviews for Information and support for people with ADHD: Attention deficit hyperactivity disorder: diagnosis and management: Evidence review B. London: National Institute for Health and Care Excellence (NICE)
- Copyright © NICE 2018.; 2018. *Exclude-Population*
1429. Naya N, Sakai C, Okutsu D, et al. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study. *Neuropsychopharmacol Rep*. 2021 Mar;41(1):26-39. doi: 10.1002/npr2.12152. PMID: 33305542. *Exclude-Population*
1430. Nazar BP, Bernardes C, Peachey G, et al. The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. *Int J Eat Disord*. 2016 Dec;49(12):1045-57. doi: 10.1002/eat.22643. PMID: 27859581. *Exclude-Intervention*
1431. Newbern D, Dansereau DF, Czuchry M, et al. Node-link mapping in individual counseling: treatment impact on clients with ADHD-related behaviors. *J Psychoactive Drugs*. 2005 Mar;37(1):93-103. doi: 10.1080/02791072.2005.10399752. PMID: 15916255. *Exclude-Population*
1432. Newcorn JH. Managing ADHD and comorbidities in adults. *J Clin Psychiatry*. 2009 Feb;70(2):e40. doi: 10.4088/jcp.7129br7c.e40. PMID: 19265639. *Currently being assessed for management*
1433. Newcorn JH. Risks and benefits of available treatments for adult ADHD. *J Clin Psychiatry*. 2011 Mar;72(3):e12. doi: 10.4088/JCP.9066tx2c. PMID: 21450148. *Currently being assessed for management*
1434. Newcorn JH, Ivanov I, Krone B, et al. Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement. *J Psychiatr Res*. 2024 Feb;170:19-26. doi: 10.1016/j.jpsychires.2023.11.037. PMID: 38101205. *Currently being assessed for management*

Excluded Publications

1435. Newcorn JH, Stark JG, Adcock S, et al. A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults. *Clin Ther*. 2017 Aug;39(8):1695-705. doi: 10.1016/j.clinthera.2017.07.006. PMID: 28760535. *Exclude-Population*
1436. Newcorn JH, Stein MA, Cooper KM. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. *J Child Adolesc Psychopharmacol*. 2010 Jun;20(3):187-96. doi: 10.1089/cap.2009.0102. PMID: 20578931. *Exclude-Population*
1437. Newhouse PA, Steiert JC, Prater JF, et al. A Phase IIa trial assessing the effects of AZD1446 on two cohorts of adult Attention Deficit Hyperactivity Disorder (ADHD) patients: Users and non-users of nicotine-containing products. *Biochemical Pharmacology*. 2011;82(8):1044. doi: 10.1016/j.bcp.2011.07.054. *Currently being assessed for management*
1438. Newman E, Jernigan TL, Lisdahl KM, et al. Go/No Go task performance predicts cortical thickness in the caudal inferior frontal gyrus in young adults with and without ADHD. *Brain Imaging Behav*. 2016 Sep;10(3):880-92. doi: 10.1007/s11682-015-9453-x. PMID: 26404018. *Exclude-Intervention*
1439. Ng QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *J Child Adolesc Psychopharmacol*. 2017 Mar;27(2):112-6. doi: 10.1089/cap.2016.0124. PMID: 27813651. *Exclude-Population*
1440. Ni HC, Hwang Gu SL, Lin HY, et al. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. *J Psychopharmacol*. 2016 May;30(5):459-67. doi: 10.1177/0269881116632377. PMID: 26905919. *Currently being assessed for management*
1441. Ni HC, Lin YJ, Gau SS, et al. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD. *J Atten Disord*. 2017 Jan;21(1):27-39. doi: 10.1177/1087054713476549. PMID: 23475825. *Currently being assessed for management*
1442. Ni HC, Shang CY, Gau SS, et al. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. *Int J Neuropsychopharmacol*. 2013 Oct;16(9):1959-73. doi: 10.1017/s1461145713000357. PMID: 23672818. *Currently being assessed for management*
1443. Nicoletta A, George G, Micaela MR, et al. Understanding the prescribing, efficacy, acceptability and tolerability of medications for Attention-Deficit/Hyperactivity Disorder in autistic individuals: a systematic review of non-interventional studies. 2023. PMID: CRD42023408976. *Currently being assessed for management*
1444. Niederhofer H. Tianeptine as a slightly effective therapeutic option for attention-deficit hyperactivity disorder. *Neuropsychobiology*. 2004;49(3):130-3. doi: 10.1159/000076721. PMID: 15034228. *Exclude-Design*

Excluded Publications

1445. Niederhofer H. Effectiveness of the repetitive Transcranial Magnetic Stimulation (rTMS) of 1 Hz for Attention-Deficit Hyperactivity Disorder (ADHD). *Psychiatr Danub*. 2008 Mar;20(1):91-2. PMID: 18376338. *Currently being assessed for management*
1446. Niederhofer H. Agomelatine treatment with adolescents with ADHD. *J Atten Disord*. 2012 Aug;16(6):530-2. doi: 10.1177/1087054711423631. PMID: 22668524. *Exclude-Population*
1447. Niederhofer H. Treating ADHD with agomelatine. *J Atten Disord*. 2012 May;16(4):346-8. doi: 10.1177/1087054711417400. PMID: 22491963. *Exclude-Outcome*
1448. Niederhofer H, D'Addato G. [Attention deficit hyperactivity: tianeptine open trial]. *Minerva Pediatr*. 2005 Oct;57(5):333-4. PMID: 16205621. *Exclude-Language*
1449. Nielsen NP, Wiig EH. Validation of the AQT color-form additive model for screening and monitoring pharmacological treatment of ADHD. *J Atten Disord*. 2013 Apr;17(3):187-93. doi: 10.1177/1087054711428075. PMID: 22210798. *Exclude-Intervention*
1450. Nielsen NP, Wiig EH, Bäck S, et al. Processing speed can monitor stimulant-medication effects in adults with attention deficit disorder with hyperactivity. *Nord J Psychiatry*. 2017 May;71(4):296-303. doi: 10.1080/08039488.2017.1280534. PMID: 28413936. *Exclude-Intervention*
1451. Nigg JT, Bruton A, Kozlowski MB, et al. Systematic Review and Meta-Analysis: Do White Noise or Pink Noise Help With Task Performance in Youth With Attention-Deficit/Hyperactivity Disorder or With Elevated Attention Problems? *J Am Acad Child Adolesc Psychiatry*. 2024 Feb 28. doi: 10.1016/j.jaac.2023.12.014. PMID: 38428577. *Exclude-Population*
1452. Nikles CJ, Clavarino AM, Del Mar CB. Using n-of-1 trials as a clinical tool to improve prescribing. *Br J Gen Pract*. 2005 Mar;55(512):175-80. PMID: 15808031. *Exclude-Design*
1453. NL-OMON46908. Phase shift in adult ADHD of sleep and appetite.; 2012. *Currently being assessed for management*
1454. Nobukawa S, Shirama A, Takahashi T, et al. Identification of attention-deficit hyperactivity disorder based on the complexity and symmetricity of pupil diameter. *Sci Rep*. 2021 Apr 19;11(1):8439. doi: 10.1038/s41598-021-88191-x. PMID: 33875772. *Exclude-Intervention*
1455. Nordby ES, Gjestad R, Kenter RMF, et al. The Effect of SMS Reminders on Adherence in a Self-Guided Internet-Delivered Intervention for Adults With ADHD. *Front Digit Health*. 2022;4:821031. doi: 10.3389/fdgth.2022.821031. PMID: 35651537. *Exclude-Intervention*
1456. Nordby ES, Guribye F, Schønning V, et al. A Blended Intervention Targeting Emotion Dysregulation in Adults With Attention-Deficit/Hyperactivity Disorder: Development and Feasibility Study. *JMIR Form Res*. 2024 Jan 17;8:e53931. doi: 10.2196/53931. PMID: 38231536. *Exclude-Comparator*

Excluded Publications

1457. Nordby ES, Kenter RMF, Lundervold AJ, et al. A self-guided Internet-delivered intervention for adults with ADHD: A feasibility study. *Internet Interv.* 2021 Sep;25:100416. doi: 10.1016/j.invent.2021.100416. PMID: 34401375. *Exclude-Comparator*
1458. Notzon DP, Mariani JJ, Pavlicova M, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. *Am J Addict.* 2016 Dec;25(8):666-72. doi: 10.1111/ajad.12467. PMID: 28051838. *Possible multiple publication*
1459. Nourredine M, Gering A, Fournier P, et al. Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2021 May 1;78(5):519-29. doi: 10.1001/jamapsychiatry.2020.4799. PMID: 33625499. *Exclude-Population*
1460. Nunes EV, Covey LS, Brigham G, et al. Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response. *J Clin Psychiatry.* 2013 Oct;74(10):983-90. doi: 10.4088/JCP.12m08155. PMID: 24229749. *Possible multiple publication*
1461. Nuñez NA, Jezzini-Martinez S, Ho AMC, et al. Candidate gene polymorphisms and clinical implications of the use of psychostimulants in adults with mood or attentional deficit disorders: A systematic review. *Biomarkers in Neuropsychiatry.* 2024;10. doi: 10.1016/j.bionps.2024.100092. *Currently being assessed for management*
1462. O'Connell RG, Bellgrove MA, Dockree PM, et al. Self-Alert Training: volitional modulation of autonomic arousal improves sustained attention. *Neuropsychologia.* 2008 Apr;46(5):1379-90. doi: 10.1016/j.neuropsychologia.2007.12.018. PMID: 18249419. *Exclude-Timing*
1463. O'Gorman RL, Mehta MA, Asherson P, et al. Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: a non-invasive MRI pilot study. *Neuroimage.* 2008 Aug 1;42(1):36-41. doi: 10.1016/j.neuroimage.2008.04.169. PMID: 18511306. *Exclude-Intervention*
1464. Oh Y, Yoon HJ, Kim JH, et al. Trait Anxiety as a Mediator of the Association between Attention Deficit Hyperactivity Disorder Symptom Severity and Functional Impairment. *Clin Psychopharmacol Neurosci.* 2018 Nov 30;16(4):407-14. doi: 10.9758/cpn.2018.16.4.407. PMID: 30466213. *Exclude-Intervention*
1465. Ohlmeier MD, Peters K, Kordon A, et al. Nicotine and alcohol dependence in patients with comorbid attention-deficit/hyperactivity disorder (ADHD). *Alcohol Alcohol.* 2007 Nov-Dec;42(6):539-43. doi: 10.1093/alcalc/agg069. PMID: 17766314. *Exclude-Intervention*
1466. Ohnishi T, Toda W, Itagaki S, et al. Disrupted structural connectivity and less efficient network system in patients with the treatment-naïve adult attention-deficit/hyperactivity disorder. *Front Psychiatry.* 2023;14:1093522. doi: 10.3389/fpsy.2023.1093522. PMID: 37009101. *Exclude-Intervention*

Excluded Publications

1467. Okie S. ADHD in adults. *N Engl J Med*. 2006 Jun 22;354(25):2637-41. doi: 10.1056/NEJMp068113. PMID: 16790695. *Exclude-Design*
1468. Olagunju AE, Ghoddusi F. Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2024 Aug;110(2):157-66. PMID: 39172673. *Exclude-Outcome*
1469. Olsen JL, Reimherr FW, Marchant BK, et al. The effect of personality disorder symptoms on response to treatment with methylphenidate transdermal system in adults with attention-deficit/hyperactivity disorder. *Prim Care Companion CNS Disord*. 2012;14(5). doi: 10.4088/PCC.12m01344. PMID: 23469326. *Currently being assessed for management*
1470. Oncü B, Olmez S. [Neuropsychological findings in adults with attention deficit hyperactivity disorder]. *Turk Psikiyatri Derg*. 2004 Spring;15(1):41-6. PMID: 15095114. *Exclude-Language*
1471. Oncü B, Olmez S, Sentürk V. [Validity and reliability of the Turkish version of the Wender Utah Rating Scale for attention-deficit/hyperactivity disorder in adults]. *Turk Psikiyatri Derg*. 2005 Winter;16(4):252-9. PMID: 16362844. *Exclude-Intervention*
1472. Orri M, Pingault J-B, Turecki G, et al. Contribution of birth weight to mental health, cognitive and socioeconomic outcomes: Two-sample Mendelian randomisation. United Kingdom: Cambridge University Press; 2021. p. 507-14. *Exclude-Population*
1473. Overmeyer S, Taylor E. Neuroimaging in hyperkinetic children and adults: an overview. *Pediatr Rehabil*. 2000 Apr-Jun;4(2):57-70. doi: 10.1080/13638490110039967. PMID: 11469743. *Exclude-Population*
1474. Overtom CC, Bekker EM, van der Molen MW, et al. Methylphenidate restores link between stop-signal sensory impact and successful stopping in adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2009 Apr 1;65(7):614-9. doi: 10.1016/j.biopsych.2008.10.048. PMID: 19103443. *Exclude-Timing*
1475. Palli SR, Kamble PS, Chen H, et al. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2012 Apr;22(2):139-48. doi: 10.1089/cap.2011.0028. PMID: 22364400. *Exclude-Population*
1476. Pan M, Huang F, Zhao M, et al. A comparison of efficacy between group cognitive behavioral therapy versus cognitive behavioral therapy combined with medication in adult ADHD. *ADHD Attention Deficit and Hyperactivity Disorders*. 2019;11(1):S49. doi: 10.1007/s12402-019-00295-7. *Currently being assessed for management*
1477. Pan M-R, Dong M, Zhang S-Y, et al. One-year follow-up of the effectiveness and mediators of cognitive behavioural therapy among adults with attention-deficit/hyperactivity disorder: Secondary outcomes of a randomised controlled trial. *BMC Psychiatry*. 2024;24(1). doi: 10.1186/s12888-024-05673-8. *Currently being assessed for management*
1478. Pan MR, Dong M, Zhang SY, et al. One-year follow-up of the effectiveness and mediators of cognitive behavioural therapy among adults with attention-deficit/hyperactivity

Excluded Publications

disorder: secondary outcomes of a randomised controlled trial. BMC Psychiatry. 2024 Mar 16;24(1):207. doi: 10.1186/s12888-024-05673-8. PMID: 38491411. *Possible multiple publication*

1479. Pan MR, Huang F, Zhao MJ, et al. A comparison of efficacy between cognitive behavioral therapy (CBT) and CBT combined with medication in adults with attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2019 Sep;279:23-33. doi: 10.1016/j.psychres.2019.06.040. PMID: 31280035. *Currently being assessed for management*

1480. Pan MR, Zhang SY, Qiu SW, et al. Efficacy of cognitive behavioural therapy in medicated adults with attention-deficit/hyperactivity disorder in multiple dimensions: a randomised controlled trial. Eur Arch Psychiatry Clin Neurosci. 2022 Mar;272(2):235-55. doi: 10.1007/s00406-021-01236-0. PMID: 33615398. *Currently being assessed for management*

1481. Pan MR, Zhao MJ, Liu L, et al. Cognitive behavioural therapy in groups for medicated adults with attention deficit hyperactivity disorder: protocol for a randomised controlled trial. BMJ Open. 2020 Oct 5;10(10):e037514. doi: 10.1136/bmjopen-2020-037514. PMID: 33020094. *Exclude-Design*

1482. Pancner PL. The utility of the Personality Assessment Inventory as an indicator of attention deficit/hyperactivity disorder with an adult clinical population. US: ProQuest Information & Learning; 2006. *Exclude-Comparator*

1483. Papp S, Tombor L, Kakuszi B, et al. Impaired early information processing in adult ADHD: a high-density ERP study. BMC Psychiatry. 2020 Jun 10;20(1):292. doi: 10.1186/s12888-020-02706-w. PMID: 32522183. *Exclude-Intervention*

1484. Papp S, Tombor L, Kakuszi B, et al. Electrophysiological underpinnings of dysfunctional inhibitory control in adults with attention-deficit/hyperactivity disorder: evidence for reduced NoGo anteriorization. J Neural Transm (Vienna). 2023 Jul;130(7):975-86. doi: 10.1007/s00702-023-02639-0. PMID: 37131048. *Exclude-Intervention*

1485. Pardo A, Kando JC, King TR, et al. PHARMACOKINETICS OF AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION (AMPH EROS) IN ADOLESCENTS INTERPOLATED FROM CHILDREN AND ADULTS USING POPULATION ANALYSIS. Journal of the American Academy of Child and Adolescent Psychiatry. 2020;59(10):S264. doi: 10.1016/j.jaac.2020.08.461. *Currently being assessed for management*

1486. Pardo A, King TR, Rafla E, et al. Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD. Drug Des Devel Ther. 2021;15:2979-85. doi: 10.2147/dddt.S309378. PMID: 34262263. *Exclude-Design*

1487. Park J, Kim B. Comorbidity and Factors Affecting Treatment Non-Persistence in ADHD. J Atten Disord. 2020 Jul;24(9):1276-84. doi: 10.1177/1087054715587097. PMID: 26006168. *Exclude-Population*

1488. Park Y, Lee JH. The Deficit of Early Selective Attention in Adults With Sluggish Cognitive Tempo: In Comparison With Those With Attention-Deficit/Hyperactivity Disorder.

Excluded Publications

Front Psychol. 2021;12:614213. doi: 10.3389/fpsyg.2021.614213. PMID: 33776840. *Exclude-Intervention*

1489. Parlatini V, Itahashi T, Lee Y, et al. White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis. Mol Psychiatry. 2023 Oct;28(10):4098-123. doi: 10.1038/s41380-023-02173-1. PMID: 37479785. *Exclude-Intervention*

1490. Parsons TD, Duffield T, Asbee J. A Comparison of Virtual Reality Classroom Continuous Performance Tests to Traditional Continuous Performance Tests in Delineating ADHD: a Meta-Analysis. Neuropsychol Rev. 2019 Sep;29(3):338-56. doi: 10.1007/s11065-019-09407-6. PMID: 31161465. *Exclude-Population*

1491. Paslakis G, Schredl M, Alm B, et al. [Adult attention deficit/hyperactivity disorder, associated symptoms and comorbid psychiatric disorders: diagnosis and pharmacological treatment]. Fortschr Neurol Psychiatr. 2013 Aug;81(8):444-51. doi: 10.1055/s-0033-1335657. PMID: 23864520. *Exclude-Language*

1492. Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 1999 Aug;33(4):494-502. doi: 10.1080/j.1440-1614.1999.00590.x. PMID: 10483843. *Currently being assessed for management*

1493. Patrick KS, Straughn AB. Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate. Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. PMID: 26729760. *Exclude-Design*

1494. Paucke M, Stark T, Exner C, et al. [Attention deficit-hyperactivity disorder (ADHD) and comorbid mental disorders : ADHD-specific self-rating scales in differential diagnostics]. Nervenarzt. 2018 Nov;89(11):1287-93. doi: 10.1007/s00115-018-0553-x. PMID: 29916032. *Exclude-Language*

1495. Paul S. Treatment of adult Attention Deficit Hyperactivity Disorder. 2011. PMID: CRD42011001635. *Currently being assessed for management*

1496. Paulo levi M, Gabriel Alberto Pinheiro Fernandes D, Isabel Bessa L, et al. Pharmacological approach to patients with Autism Spectrum Disorders and ADHD symptoms. 2023. PMID: CRD42023473679. *Currently being assessed for management*

1497. Pauly V, Frauger E, Lepelley M, et al. Patterns and profiles of methylphenidate use both in children and adults. Br J Clin Pharmacol. 2018 Jun;84(6):1215-27. doi: 10.1111/bcp.13544. PMID: 29512177. *Exclude-Intervention*

1498. Paz Y, Friedwald K, Levkovitz Y, et al. Deep rTMS for ADHD. Brain Stimulation. 2017;10(2):413. doi: 10.1016/j.brs.2017.01.224. *Currently being assessed for management*

1499. Paz Y, Friedwald K, Levkovitz Y, et al. Randomised sham-controlled study of high-frequency bilateral deep transcranial magnetic stimulation (dTMS) to treat adult attention

Excluded Publications

hyperactive disorder (ADHD): Negative results. *World J Biol Psychiatry*. 2018 Oct;19(7):561-6. doi: 10.1080/15622975.2017.1282170. PMID: 28090806. *Currently being assessed for management*

1500. Pazoki B, Zandi N, Assaf Z, et al. Efficacy and safety of saffron as adjunctive therapy in adults with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled clinical trial. *Advances in Integrative Medicine*. 2022;9(1):37-43. doi: 10.1016/j.aimed.2022.01.002. *Currently being assessed for management*

1501. Pedersen H, Skliarova T, Pedersen SA, et al. Psychoeducation for adult ADHD: a scoping review about characteristics, patient involvement, and content. *BMC Psychiatry*. 2024 Jan 25;24(1):73. doi: 10.1186/s12888-024-05530-8. PMID: 38273266. *Exclude-Population*

1502. Pedrero Pérez EJ, Puerta García C. [ASRS v.1.1., a tool for attention-deficit/hyperactivity disorder screening in adults treated for addictive behaviors: psychometric properties and estimated prevalence]. *Adicciones*. 2007;19(4):393-407. PMID: 18173102. *Exclude-Language*

1503. Pehlivanidis A, Papanikolaou K, Korobili K, et al. Trait-Based Dimensions Discriminating Adults with Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and, Co-occurring ADHD/ASD. *Brain Sci*. 2020 Dec 26;11(1). doi: 10.3390/brainsci11010018. PMID: 33375278. *Exclude-Intervention*

1504. Pelletier MF, Hodgetts HM, Lafleur MF, et al. Vulnerability to the Irrelevant Sound Effect in Adult ADHD. *J Atten Disord*. 2016 Apr;20(4):306-16. doi: 10.1177/1087054713492563. PMID: 23893530. *Exclude-Intervention*

1505. pellow CN. Classification of ADHD group membership using the Boston Qualitative Scoring System for the Rey-Osterrieth Complex Figure: A comparison of two methods. US: ProQuest Information & Learning; 2022. *Exclude-Intervention*

1506. Pelz R, Banaschewski T, Becker K. [Methylphenidate of retard forms in children and adolescents with ADHD - an overview]. *Klin Padiatr*. 2008 Mar-Apr;220(2):93-100. doi: 10.1055/s-2007-985864. PMID: 18157763. *Exclude-Population*

1507. Peng L, Tian L, Wang T, et al. Effects of non-invasive brain stimulation (NIBS) for executive function on subjects with ADHD: a protocol for a systematic review and meta-analysis. *BMJ Open*. 2023 Mar 6;13(3):e069004. doi: 10.1136/bmjopen-2022-069004. PMID: 36878663. *Exclude-Intervention*

1508. Pentikis HS, Simmons RD, Benedict MF, et al. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. *J Am Acad Child Adolesc Psychiatry*. 2002 Apr;41(4):443-9. doi: 10.1097/00004583-200204000-00017. PMID: 11931601. *Exclude-Timing*

1509. Pereira A, Richarte V, Fadeuilhe C, et al. ADHD Rating Scale (ADHD-RS): Validation in Spanish in adult population according to the DSM-5. *Span J Psychiatry Ment Health*. 2024 Jan-Mar;17(1):46-50. doi: 10.1016/j.sjpmh.2023.06.002. PMID: 38436988. *Exclude-Language*

Excluded Publications

1510. Perera B, Courtenay K, Solomou S, et al. Diagnosis of Attention Deficit Hyperactivity Disorder in Intellectual Disability: Diagnostic and Statistical Manual of Mental Disorder V versus clinical impression. *J Intellect Disabil Res*. 2020 Mar;64(3):251-7. doi: 10.1111/jir.12705. PMID: 31808234. *Exclude-Intervention*
1511. Perez Algorta G, Kragh CA, Arnold LE, et al. Maternal ADHD Symptoms, Personality, and Parenting Stress: Differences Between Mothers of Children With ADHD and Mothers of Comparison Children. *J Atten Disord*. 2018 Nov;22(13):1266-77. doi: 10.1177/1087054714561290. PMID: 25525155. *Exclude-Population*
1512. Perugi G, Vannucchi G. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. *Expert Opin Pharmacother*. 2015;16(14):2193-204. doi: 10.1517/14656566.2015.1079620. PMID: 26364896. *Exclude-Design*
1513. Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. *J Manag Care Pharm*. 2004 Mar-Apr;10(2):122-9. doi: 10.18553/jmcp.2004.10.2.122. PMID: 15032561. *Exclude-Population*
1514. Pettersson R, Söderström S, Edlund-Söderström K, et al. Internet-Based Cognitive Behavioral Therapy for Adults With ADHD in Outpatient Psychiatric Care. *J Atten Disord*. 2017 Apr;21(6):508-21. doi: 10.1177/1087054714539998. PMID: 24970720. *Currently being assessed for management*
1515. Pheh KS, Tan KA, Ibrahim N, et al. Effectiveness of Online Mindfulness-Based Intervention (iMBI) on Inattention, Hyperactivity-Impulsivity, and Executive Functioning in College Emerging Adults with Attention-Deficit/Hyperactivity Disorder: A Study Protocol. *Int J Environ Res Public Health*. 2021 Jan 30;18(3). doi: 10.3390/ijerph18031257. PMID: 33573341. *Exclude-Design*
1516. Philipp-Wiegmann F, Zinnow T, Retz W, et al. [Psychometric Properties of the Self- and Observer-Ratings ADHD-SR and Wender-Reimherr-Interview in the Assessment of ADHD Symptoms in Old Age]. *Psychiatr Prax*. 2017 Oct;44(7):400-5. doi: 10.1055/s-0042-111041. PMID: 27618174. *Exclude-Language*
1517. Philipsen A, Colla M, Jacob C, et al. Efficacy of psychotherapy in the treatment of adult ADHD-a randomized controlled multicentre trial. *Neuropsychiatrie de l'Enfance et de l'Adolescence*. 2012;60(5):S50-S1. doi: 10.1016/j.neurenf.2012.05.193. *Currently being assessed for management*
1518. Philipsen A, Graf E, Jans T, et al. A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample. *Atten Defic Hyperact Disord*. 2014 Mar;6(1):35-47. doi: 10.1007/s12402-013-0120-z. PMID: 24132867. *Possible multiple publication*

Excluded Publications

1519. Philipsen A, Graf E, Tebartz Van Elst L, et al. First results of the compas group (comparison of methylphenidate and psychotherapy in adult adhd study). *European Psychiatry*. 2011;26. doi: 10.1016/S0924-9338(11)73599-4. *Currently being assessed for management*
1520. Philipsen A, Graf E, Tebartz van Elst L, et al. Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial. *Atten Defic Hyperact Disord*. 2010 Dec;2(4):203-12. doi: 10.1007/s12402-010-0046-7. PMID: 21432607. *Exclude-Design*
1521. Philipsen A, Jans T, Graf E, et al. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2015 Dec;72(12):1199-210. doi: 10.1001/jamapsychiatry.2015.2146. PMID: 26536057. *Currently being assessed for management*
1522. Philipsen A, Lam AP, Breit S, et al. Early maladaptive schemas in adult patients with attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord*. 2017 Jun;9(2):101-11. doi: 10.1007/s12402-016-0211-8. PMID: 28012033. *Exclude-Intervention*
1523. Philipsen A, van Elst LT, Lesch KP, et al. [Effects and mechanisms of psychotherapy in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults]. *Psychother Psychosom Med Psychol*. 2009 Mar-Apr;59(3-4):132-40. doi: 10.1055/s-0029-1202371. PMID: 19350473. *Exclude-Population*
1524. Pilling S, Fonagy P, Allison E, et al. Long-term outcomes of psychological interventions on children and young people's mental health: A systematic review and meta-analysis. *PLoS One*. 2020;15(11):e0236525. doi: 10.1371/journal.pone.0236525. PMID: 33196654. *Exclude-Population*
1525. Pineda DA, Trujillo-Orrego N, Aguirre-Acevedo DC, et al. [Utility of the Wender-Utah rating scale and the checklists for the diagnosis of familial attention deficit hyperactivity disorder in adults. Convergent and concurrent validities]. *Rev Neurol*. 2010 Feb 16-28;50(4):207-16. PMID: 20198592. *Exclude-Language*
1526. Pingault JB, Rijdsdijk F, Schoeler T, et al. Genetic sensitivity analysis: Adjusting for genetic confounding in epidemiological associations. *PLoS Genet*. 2021 Jun;17(6):e1009590. doi: 10.1371/journal.pgen.1009590. PMID: 34115765. *Exclude-Population*
1527. Pitts M, Mangle L, Asherson P. Impairments, diagnosis and treatments associated with attention-deficit/hyperactivity disorder (ADHD) in UK adults: results from the lifetime impairment survey. *Arch Psychiatr Nurs*. 2015 Feb;29(1):56-63. doi: 10.1016/j.apnu.2014.10.001. PMID: 25634876. *Exclude-Design*
1528. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. *J Clin Psychiatry*. 1998;59 Suppl 7:50-8. PMID: 9680053. *Exclude-Design*

Excluded Publications

1529. Pollak Y, Shalit R, Aran A. Risk taking and adult attention deficit/hyperactivity disorder: A gap between real life behavior and experimental decision making. *Psychiatry Res.* 2018 Jan;259:56-62. doi: 10.1016/j.psychres.2017.10.012. PMID: 29028525. *Exclude-Intervention*
1530. Pollock B, Harrison AG, Armstrong IT. What can we learn about performance validity from TOVA response profiles? *J Clin Exp Neuropsychol.* 2021 May;43(4):412-25. doi: 10.1080/13803395.2021.1932762. PMID: 34088256. *Exclude-Intervention*
1531. Poltavski DV, Petros T. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. *Physiol Behav.* 2006 Mar 30;87(3):614-24. doi: 10.1016/j.physbeh.2005.12.011. PMID: 16466655. *Exclude-Population*
1532. Potter AS, Bucci DJ, Newhouse PA. Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. *Psychopharmacology (Berl).* 2012 Mar;220(2):331-40. doi: 10.1007/s00213-011-2476-0. PMID: 21969123. *Exclude-Intervention*
1533. Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. *Biol Psychiatry.* 2014 Feb 1;75(3):207-14. doi: 10.1016/j.biopsych.2013.06.002. PMID: 23856296. *Currently being assessed for management*
1534. Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. *Pharmacol Biochem Behav.* 2008 Feb;88(4):407-17. doi: 10.1016/j.pbb.2007.09.014. PMID: 18022679. *Exclude-Intervention*
1535. Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). *Hum Psychopharmacol.* 2009 Jun;24(4):309-17. doi: 10.1002/hup.1026. PMID: 19475630. *Exclude-Timing*
1536. Potter AS, Schaubhut G, Shipman M. Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date. *CNS Drugs.* 2014 Dec;28(12):1103-13. doi: 10.1007/s40263-014-0208-9. PMID: 25349138. *Exclude-Intervention*
1537. Poulsen AA, Horswill MS, Wetton MA, et al. A brief office-based hazard perception intervention for drivers with ADHD symptoms. *Aust N Z J Psychiatry.* 2010 Jun;44(6):528-34. doi: 10.3109/00048671003596048. PMID: 20397782. *Exclude-Population*
1538. Poulton AS, Armstrong B, Nanan RK. Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study. *CNS Drugs.* 2018 Apr;32(4):377-86. doi: 10.1007/s40263-018-0505-9. PMID: 29557079. *Exclude-Design*
1539. Poynter W, Ingram P, Minor S. Visual field asymmetries in attention vary with self-reported attention deficits. *Brain Cogn.* 2010 Apr;72(3):355-61. doi: 10.1016/j.bandc.2009.10.014. PMID: 19931966. *Exclude-Intervention*

Excluded Publications

1540. Poysoophon P, Rao AL. Neurocognitive Deficits Associated With ADHD in Athletes: A Systematic Review. *Sports Health*. 2018 Jul-Aug;10(4):317-26. doi: 10.1177/1941738117751387. PMID: 29337649. *Exclude-Intervention*
1541. Pozzi M, Bertella S, Gatti E, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). *Expert Opin Emerg Drugs*. 2020 Dec;25(4):395-407. doi: 10.1080/14728214.2020.1820481. PMID: 32938246. *Exclude-Design*
1542. Prada P, Hasler R, Baud P, et al. Distinguishing borderline personality disorder from adult attention deficit/hyperactivity disorder: a clinical and dimensional perspective. *Psychiatry Res*. 2014 Jun 30;217(1-2):107-14. doi: 10.1016/j.psychres.2014.03.006. PMID: 24656900. *Exclude-Intervention*
1543. Prada P, Nicastro R, Zimmermann J, et al. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study. *Atten Defic Hyperact Disord*. 2015 Sep;7(3):199-209. doi: 10.1007/s12402-015-0165-2. PMID: 25634471. *Exclude-Design*
1544. Pramanik P. ADHD medication proves most effective in treating symptoms, new study finds. *News Medical Life Sciences*. 2024. *Exclude-Population*
1545. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence. *Paediatr Drugs*. 2008;10(1):39-47. doi: 10.2165/00148581-200810010-00005. PMID: 18162007. *Exclude-Population*
1546. Praus P, Proctor T, Rohrmann T, et al. Female sex and burden of depressive symptoms predict insufficient response to telemedical treatment in adult attention-deficit/hyperactivity disorder: results from a naturalistic patient cohort during the COVID-19 pandemic. *Front Psychiatry*. 2023;14:1193898. doi: 10.3389/fpsy.2023.1193898. PMID: 37867771. *Exclude-Design*
1547. Price A. Working collaboratively with people with lived experience to map and co-create guidance on improving health services for people with attention deficit hyperactivity disorder (ADHD). *European Psychiatry*. 2023;66:S19. doi: 10.1192/j.eurpsy.2023.78. *Currently being assessed for management*
1548. Price MZ, Price RL. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. *CNS Drugs*. 2023 Jul;37(7):655-60. doi: 10.1007/s40263-023-01023-6. PMID: 37430151. *Exclude-Population*
1549. Primich C, Iennaco J. Diagnosing adult attention-deficit hyperactivity disorder: the importance of establishing daily life contexts for symptoms and impairments. *J Psychiatr Ment Health Nurs*. 2012 May;19(4):362-73. doi: 10.1111/j.1365-2850.2011.01845.x. PMID: 22146075. *Exclude-Outcome*

Excluded Publications

1550. Pritchard AE, Koriakin T, Jacobson LA, et al. Incremental validity of neuropsychological assessment in the identification and treatment of youth with ADHD. *Clin Neuropsychol*. 2014;28(1):26-48. doi: 10.1080/13854046.2013.863978. PMID: 24345262. *Exclude-Population*
1551. Pulver A, Kiive E, Harro J. Reward sensitivity, affective neuroscience personality, symptoms of attention-deficit/hyperactivity disorder, and TPH2-703G/T (rs4570625) genotype. *Acta Neuropsychiatr*. 2020 Oct;32(5):247-56. doi: 10.1017/neu.2020.18. PMID: 32338242. *Exclude-Intervention*
1552. Qian Y, Markowitz JS. Pharmacokinetic interaction between methylphenidate & cannabinoids. *Clinical Pharmacology in Drug Development*. 2021;10(SUPPL 1):27-8. doi: 10.1002/cpdd.1004. *Currently being assessed for management*
1553. Quaranta G, Barbuti M, Pallucchini A, et al. Relationships Among Delayed Sleep Phase Disorder, Emotional Dysregulation, and Affective Temperaments in Adults With Attention Deficit Hyperactivity Disorder and Cyclothymia. *J Nerv Ment Dis*. 2020 Nov;208(11):857-62. doi: 10.1097/nmd.0000000000001209. PMID: 32769692. *Exclude-Intervention*
1554. Quinn D. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2008 Jun;28(3 Suppl 2):S62-6. doi: 10.1097/JCP.0b013e3181744aa6. PMID: 18480679. *Exclude-Intervention*
1555. Radhoe TA, Agelink van Rentergem JA, Torenvliet C, et al. Finding Similarities in Differences Between Autistic Adults: Two Replicated Subgroups. *J Autism Dev Disord*. 2023 Jul 12. doi: 10.1007/s10803-023-06042-2. PMID: 37438586. *Exclude-Intervention*
1556. Rafał B, Ewa M, Marek K. The risk of methylphenidate pharmacotherapy in adults with attention deficit hyperactivity disorder (ADHD) – a systematic review. 2023. PMID: CRD42023422072. *Currently being assessed for management*
1557. Rafeiy-Torghabeh M, Ashraf-Ganjouei A, Moradi K, et al. Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. *Eur Child Adolesc Psychiatry*. 2021 May;30(5):799-807. doi: 10.1007/s00787-020-01562-z. PMID: 32449130. *Exclude-Population*
1558. Rahmani E, Mahvelati A, Alizadeh A, et al. Is neurofeedback effective in children with ADHD? A systematic review and meta-analysis. *Neurocase*. 2022 Feb;28(1):84-95. doi: 10.1080/13554794.2022.2027456. PMID: 35068368. *Exclude-Population*
1559. Raissa Carolina C, Su G, Cristiane Menezes de P, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol]. 2018. PMID: CRD42018096321. *Currently being assessed for management*
1560. Raj V, Haman KL, Raj SR, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. *J Neurol Neurosurg Psychiatry*. 2009 Mar;80(3):339-44. doi: 10.1136/jnnp.2008.144360. PMID: 18977825. *Exclude-Intervention*

Excluded Publications

1561. Rami B, Simona B, Alicia L, et al. Statins for Smith-Lemli-Opitz syndrome [Cochrane protocol]. 2020. PMID: CRD42020176218. *Exclude-Population*
1562. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder. *CNS Drugs*. 2008;22(7):603-11. doi: 10.2165/00023210-200822070-00005. PMID: 18547128. *Exclude-Design*
1563. Ramos-Quiroga JA, Bosch R, Richarte V, et al. Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. *Rev Psiquiatr Salud Ment*. 2012 Oct-Dec;5(4):229-35. doi: 10.1016/j.rpsm.2012.05.004. PMID: 23021295. *Exclude-Language*
1564. Ramos-Quiroga JA, Bosch-Munsó R, Castells-Cervelló X, et al. [Attention deficit hyperactivity disorder in adults: a clinical and therapeutic characterization]. *Rev Neurol*. 2006 May 16-31;42(10):600-6. PMID: 16703528. *Exclude-Language*
1565. Ramos-Quiroga JA, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. *CNS Drugs*. 2011 Jan;25(1):17-36. doi: 10.2165/11538450-000000000-00000. PMID: 21128692. *Exclude-Design*
1566. Ramos-Quiroga JA, Corominas M, Castells X, et al. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. *Expert Rev Neurother*. 2009 Aug;9(8):1121-31. doi: 10.1586/ern.09.65. PMID: 19673602. *Exclude-Design*
1567. Ramos-Quiroga JA, Corominas-Roso M, Palomar G, et al. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. *Psychopharmacology (Berl)*. 2014 Apr;231(7):1389-95. doi: 10.1007/s00213-013-3343-y. PMID: 24202115. *Exclude-Design*
1568. Ramos-Quiroga JA, Kooij S, Trott GE, et al. Predictors of treatment outcome with long-acting methylphenidate in attention deficit hyperactivity disorder in adults. *European Neuropsychopharmacology*. 2009;19:S352-S3. doi: 10.1016/S0924-977X(09)70535-8. *Currently being assessed for management*
1569. Ramos-Quiroga JA, Nasillo V, Richarte V, et al. Criteria and Concurrent Validity of DIVA 2.0: A Semi-Structured Diagnostic Interview for Adult ADHD. *J Atten Disord*. 2019 Aug;23(10):1126-35. doi: 10.1177/1087054716646451. PMID: 27125994. *Exclude-Language*
1570. Ramsay JR. Assessment and monitoring of treatment response in adult ADHD patients: current perspectives. *Neuropsychiatr Dis Treat*. 2017;13:221-32. doi: 10.2147/ndt.S104706. PMID: 28184164. *Exclude-Design*
1571. Ratner S, Laor N, Bronstein Y, et al. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2005;44(5):428-33. doi: 10.1097/01.chi.0000155327.30017.8c. *Currently being assessed for management*

Excluded Publications

1572. Reed VA, Buitelaar JK, Anand E, et al. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. *CNS Drugs*. 2016 Jul;30(7):603-28. doi: 10.1007/s40263-016-0349-0. PMID: 27290715. *Exclude-Population*
1573. Reh V, Schmidt M, Lam L, et al. Behavioral assessment of core ADHD symptoms using the Qb Test. *Journal of Attention Disorders*. 2015;19(12):1034-45. doi: 10.1177/1087054712472981. *Exclude-Intervention*
1574. Reimherr FW, Gift TE, Steans TA, et al. The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder. *J Clin Psychopharmacol*. 2022 Sep-Oct 01;42(5):445-53. doi: 10.1097/jcp.0000000000001592. PMID: 35977005. *Currently being assessed for management*
1575. Reimherr FW, Hedges DW, Strong RE, et al. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. *Neuropsychiatr Dis Treat*. 2005 Sep;1(3):245-51. PMID: 18568102. *Currently being assessed for management*
1576. Reimherr FW, Marchant BK, Gift TE, et al. ADHD and Anxiety: Clinical Significance and Treatment Implications. *Curr Psychiatry Rep*. 2017 Nov 20;19(12):109. doi: 10.1007/s11920-017-0859-6. PMID: 29152677. *Exclude-Design*
1577. Reimherr FW, Marchant BK, Gift TE, et al. Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate. *Atten Defic Hyperact Disord*. 2015 Jun;7(2):115-28. doi: 10.1007/s12402-015-0176-z. PMID: 25987323. *Exclude-Design*
1578. Reimherr FW, Marchant BK, Olsen JL, et al. Serotonin receptor genes are associated with treatment response and symptom severity in adults with ADHD. *Biological Psychiatry*. 2010;67(9):220S. doi: 10.1016/j.biopsych.2010.03.009. *Currently being assessed for management*
1579. Reimherr FW, Roesler M, Marchant BK, et al. Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis. *J Clin Psychiatry*. 2020 Mar 17;81(2). doi: 10.4088/JCP.19m13077. PMID: 32220152. *Exclude-Intervention*
1580. Reimherr FW, Wender PH, Wood DR, et al. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. *Am J Psychiatry*. 1987 Aug;144(8):1071-3. doi: 10.1176/ajp.144.8.1071. PMID: 3300376. *Exclude-Design*
1581. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. *J Clin Psychiatry*. 2007 Jan;68(1):93-101. doi: 10.4088/jcp.v68n0113. PMID: 17284136. *Currently being assessed for management*

Excluded Publications

1582. Reimherr FW, Wood DR, Wender PH. An open clinical trial of L-dopa and carbidopa in adults with minimal brain dysfunction. *Am J Psychiatry*. 1980 Jan;137(1):73-5. doi: 10.1176/ajp.137.1.73. PMID: 6986093. *Exclude-Design*
1583. Reinhardt MC, Benetti L, Victor MM, et al. Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? *J Clin Psychiatry*. 2007 Jul;68(7):1109-16. doi: 10.4088/jcp.v68n0720. PMID: 17685750. *Exclude-Intervention*
1584. Reiss F. Socioeconomic inequalities and mental health problems in children and adolescents: A systematic review. *Social Science and Medicine*. 2013;90:24-31. doi: 10.1016/j.socscimed.2013.04.026. *Currently being assessed for management*
1585. Retz W, Rösler M, Ose C, et al. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. *World J Biol Psychiatry*. 2012 Jan;13(1):48-59. doi: 10.3109/15622975.2010.540257. PMID: 21155632. *Currently being assessed for management*
1586. Retz-Junginger P, Retz W, Blocher D, et al. [Reliability and validity of the Wender-Utah-Rating-Scale short form. Retrospective assessment of symptoms for attention deficit/hyperactivity disorder]. *Nervenarzt*. 2003 Nov;74(11):987-93. doi: 10.1007/s00115-002-1447-4. PMID: 14598035. *Exclude-Language*
1587. Retz-Junginger P, Retz W, Blocher D, et al. Reliability and validity of the German short version of the Wender-Utah Rating Scale for the retrospective assessment of attention deficit/hyperactivity disorder. *Nervenarzt*. 2003;74(11):987-93. doi: 10.1007/s00115-002-1447-4. *Exclude-Duplicate*
1588. Retz-Junginger P, Retz W, Schneider M, et al. [Gender differences in self-descriptions of child psychopathology in attention deficit hyperactivity disorder]. *Nervenarzt*. 2007 Sep;78(9):1046-51. doi: 10.1007/s00115-006-2242-4. PMID: 17268790. *Exclude-Language*
1589. Reuter M, Kirsch P, Hennig J. Inferring candidate genes for attention deficit hyperactivity disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). *J Neural Transm (Vienna)*. 2006 Jul;113(7):929-38. doi: 10.1007/s00702-005-0366-5. PMID: 16362639. *Exclude-Population*
1590. Riahi F, Tehrani-Doost M, Shahrivar Z, et al. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. *Hum Psychopharmacol*. 2010 Nov;25(7-8):570-6. doi: 10.1002/hup.1158. PMID: 21312292. *Currently being assessed for management*
1591. Rianda D, Agustina R, Setiawan EA, et al. Effect of probiotic supplementation on cognitive function in children and adolescents: a systematic review of randomised trials. *Benef Microbes*. 2019 Dec 9;10(8):873-82. doi: 10.3920/bm2019.0068. PMID: 31965841. *Exclude-Population*

Excluded Publications

1592. Riccio CA, Reynolds CR. Continuous performance tests are sensitive to ADHD in adults but lack specificity. A review and critique for differential diagnosis. *Ann N Y Acad Sci.* 2001 Jun;931:113-39. doi: 10.1111/j.1749-6632.2001.tb05776.x. PMID: 11462737. *Exclude-Outcome*
1593. Riccio CA, Waldrop JJ, Reynolds CR, et al. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. *J Neuropsychiatry Clin Neurosci.* 2001 Summer;13(3):326-35. doi: 10.1176/jnp.13.3.326. PMID: 11514638. *Exclude-Population*
1594. Rice VJ, Liu B, Schroeder PJ. Impact of In-Person and Virtual World Mindfulness Training on Symptoms of Post-Traumatic Stress Disorder and Attention Deficit and Hyperactivity Disorder. *Mil Med.* 2018 Mar 1;183(suppl_1):413-20. doi: 10.1093/milmed/usx227. PMID: 29635610. *Exclude-Population*
1595. Richarte V, Corrales M, Pozuelo M, et al. Spanish validation of the adult Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS): relevance of clinical subtypes. *Rev Psiquiatr Salud Ment.* 2017 Oct-Dec;10(4):185-91. doi: 10.1016/j.rpsm.2017.06.003. PMID: 28844652. *Exclude-Language*
1596. Richarte V, Sánchez-Mora C, Corrales M, et al. Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder. *Transl Psychiatry.* 2021 Jul 8;11(1):382. doi: 10.1038/s41398-021-01504-6. PMID: 34238926. *Exclude-Intervention*
1597. Richter MM, Ehls AC, Jacob CP, et al. Cortical excitability in adult patients with attention-deficit/hyperactivity disorder (ADHD). *Neurosci Lett.* 2007 May 29;419(2):137-41. doi: 10.1016/j.neulet.2007.04.024. PMID: 17481816. *Exclude-Intervention*
1598. Richter Y, Gordon C, Vainstein G, et al. A novel intervention for treating adults with ADHD using peripheral visual stimulation. *Front Psychiatry.* 2023;14:1280440. doi: 10.3389/fpsy.2023.1280440. PMID: 37928920. *Exclude-Comparator*
1599. Rielly NE, Cunningham CE, Richards JE, et al. "Detecting attention deficit hyperactivity disorder in a communications clinic: Diagnostic utility of the Gordon Diagnostic System": Erratum. *Journal of Clinical and Experimental Neuropsychology.* 2000;22(3):435-. doi: 10.1076/1380-3395(200006)22:3;1-V;FT435. *Possible multiple publication*
1600. Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. *J Am Acad Child Adolesc Psychiatry.* 2004 Apr;43(4):420-9. doi: 10.1097/00004583-200404000-00008. PMID: 15187802. *Exclude-Population*
1601. Riordan HJ, Flashman LA, Saykin AJ, et al. Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression. *Arch Clin Neuropsychol.* 1999 Feb;14(2):217-33. PMID: 14590604. *Exclude-Intervention*
1602. Rivas-Vazquez RA, Diaz SG, Visser MM, et al. Adult ADHD: Underdiagnosis of a Treatable Condition. *J Health Serv Psychol.* 2023;49(1):11-9. doi: 10.1007/s42843-023-00077-w. PMID: 36743427. *Exclude-Design*

Excluded Publications

1603. Rivkin A, Alexander RC, Knighton J, et al. A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD. *J Atten Disord.* 2012 Nov;16(8):664-74. doi: 10.1177/1087054711423633. PMID: 22090395. *Currently being assessed for management*
1604. Robbins CA. ADHD couple and family relationships: enhancing communication and understanding through Imago Relationship Therapy. *J Clin Psychol.* 2005 May;61(5):565-77. doi: 10.1002/jclp.20120. PMID: 15723423. *Exclude-Intervention*
1605. Robeva R, Penberthy JK. Bayesian probability approach to ADHD appraisal. *Methods Enzymol.* 2009;467:357-80. doi: 10.1016/s0076-6879(09)67014-2. PMID: 19897100. *Exclude-Population*
1606. Robeva R, Penberthy JK, Loboschewski T, et al. Combined psychophysiological assessment of ADHD: a pilot study of Bayesian probability approach illustrated by appraisal of ADHD in female college students. *Appl Psychophysiol Biofeedback.* 2004 Mar;29(1):1-18. doi: 10.1023/b:apbi.0000017860.60164.66. PMID: 15077461. *Exclude-Intervention*
1607. Robinson A, Huber M, Breaux E, et al. Failing The b Test: The influence of cutoff scores and criterion group approaches in a sample of adults referred for psychoeducational evaluation. *J Clin Exp Neuropsychol.* 2022 Nov;44(9):619-26. doi: 10.1080/13803395.2022.2153805. PMID: 36727266. *Exclude-Intervention*
1608. Robinson AD, Finley J-CA, Phillips MS, et al. Examining concordance between the clinical assessment of attention deficit-adult and the barkley adult adhd rating scale-iv in a sample of adults referred for adhd. *Journal of Psychopathology and Behavioral Assessment.* 2024;No Pagination Specified-No Pagination Specified. doi: 10.1007/s10862-024-10152-1. *Exclude-Intervention*
1609. Robinson DM, Keating GM. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. *Drugs.* 2006;66(5):661-8; discussion 9-70. doi: 10.2165/00003495-200666050-00006. PMID: 16620143. *Exclude-Population*
1610. Rochdi M, González MA, Dirksen SJ. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. *Int J Clin Pharmacol Ther.* 2004 May;42(5):285-92. doi: 10.5414/cpp42285. PMID: 15176652. *Exclude-Population*
1611. Rodrigo-Yanguas M, Martín-Moratinos M, González-Tardón C, et al. Effectiveness of a Personalized, Chess-Based Training Serious Video Game in the Treatment of Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Randomized Controlled Trial. *JMIR Serious Games.* 2023 Apr 24;11:e39874. doi: 10.2196/39874. PMID: 37093628. *Exclude-Population*
1612. Rodrigues da Silva PH, Leffa DT, Luethi MS, et al. Baseline brain volume predicts home-based transcranial direct current stimulation effects on inattention in adults with attention-deficit/hyperactivity disorder. *J Psychiatr Res.* 2024 Jul 29;177:403-11. doi: 10.1016/j.jpsychires.2024.07.042. PMID: 39089118. *Exclude-Intervention*

Excluded Publications

1613. Rodrigues da Silva PH, Luethi MS, Brunoni AR, et al. Baseline brain volume predicts home-based transcranial direct current stimulation effects on inattention in adults with attention-deficit/hyperactivity disorder. *Journal of Psychiatric Research*. 2024;177:403-11. doi: 10.1016/j.jpsychires.2024.07.042. *Currently being assessed for management*
1614. Rodríguez C, García T, Areces D, et al. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: A randomized double-blind placebo-controlled trial. *Neuropsychiatric Disease and Treatment*. 2019;15. *Currently being assessed for management*
1615. Rodriguez PD, Baylis GC. Activation of brain attention systems in individuals with symptoms of ADHD. *Behav Neurol*. 2007;18(2):115-30. doi: 10.1155/2007/865717. PMID: 17538197. *Exclude-Intervention*
1616. Rodríguez-Jiménez R, Ponce G, Monasor R, et al. Validation in spanish population of the Wender-Utah Rating Scale for the retrospective evaluation in adults of attention deficit/hyperactivity disorder in early ages. *Revista de Neurologia*. 2001;33(2):138-44. doi: 10.33588/rn.3302.2001010. *Exclude-Language*
1617. Roe SA, DeSalve DS, Piper BJ. Analyzing Black Market Sales of the Second-Line ADHD Medication Atomoxetine. *Pharmacoeconomics*. 2023;2(4):320-7. PMID: doi:10.3390/pharma2040027. *Exclude-Design*
1618. Roesch B, Corcoran M, Haffey M, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. *Drugs R D*. 2013 Mar;13(1):53-61. doi: 10.1007/s40268-013-0009-5. PMID: 23519656. *Exclude-Population*
1619. Roesch B, Corcoran ME, Fetterolf J, et al. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. *Drugs R D*. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8. PMID: 23615868. *Exclude-Population*
1620. Roh SC, Park EJ, Park YC, et al. Quantitative Electroencephalography Reflects Inattention, Visual Error Responses, and Reaction Times in Male Patients with Attention Deficit Hyperactivity Disorder. *Clin Psychopharmacol Neurosci*. 2015 Aug 31;13(2):180-7. doi: 10.9758/cpn.2015.13.2.180. PMID: 26243846. *Exclude-Intervention*
1621. Roman-Urrestarazu A, Lindholm P, Moilanen I, et al. Brain structural deficits and working memory fMRI dysfunction in young adults who were diagnosed with ADHD in adolescence. *Eur Child Adolesc Psychiatry*. 2016 May;25(5):529-38. doi: 10.1007/s00787-015-0755-8. PMID: 26307356. *Exclude-Population*
1622. Romero-Martínez Á, Lila M, Moya-Albiol L. The importance of impulsivity and attention switching deficits in perpetrators convicted for intimate partner violence. *Aggress Behav*. 2019 Mar;45(2):129-38. doi: 10.1002/ab.21802. PMID: 30474120. *Exclude-Population*
1623. Roshani F, Piri R, Malek A, et al. Comparison of cognitive flexibility, appropriate risk-taking and reaction time in individuals with and without adult ADHD. *Psychiatry Res*. 2020 Feb;284:112494. doi: 10.1016/j.psychres.2019.112494. PMID: 31439404. *Exclude-Intervention*

Excluded Publications

1624. Rösler M, Fischer R, Ammer R, et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. *Eur Arch Psychiatry Clin Neurosci*. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. PMID: 19165529. *Currently being assessed for management*
1625. Rösler M, Ginsberg Y, Arngrim T, et al. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. *World J Biol Psychiatry*. 2013 May;14(4):282-90. doi: 10.3109/15622975.2011.571283. PMID: 21517701. *Possible multiple publication*
1626. Rösler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. *World J Biol Psychiatry*. 2010 Aug;11(5):709-18. doi: 10.3109/15622971003624197. PMID: 20353312. *Currently being assessed for management*
1627. Rösler M, Retz W, Retz-Junginger P, et al. [Tools for the diagnosis of attention-deficit/hyperactivity disorder in adults. Self-rating behaviour questionnaire and diagnostic checklist]. *Nervenarzt*. 2004 Sep;75(9):888-95. doi: 10.1007/s00115-003-1622-2. PMID: 15378249. *Exclude-Language*
1628. Ross RG, Olinicy A, Harris JG, et al. Smooth pursuit eye movements in schizophrenia and attentional dysfunction: adults with schizophrenia, ADHD, and a normal comparison group. *Biol Psychiatry*. 2000 Aug 1;48(3):197-203. doi: 10.1016/s0006-3223(00)00825-8. PMID: 10924662. *Exclude-Intervention*
1629. Rossiter T. The effectiveness of neurofeedback and stimulant drugs in treating AD/HD: part II. Replication. *Appl Psychophysiol Biofeedback*. 2004 Dec;29(4):233-43. doi: 10.1007/s10484-004-0383-4. PMID: 15707253. *Exclude-Design*
1630. Rössler M, Fischer R, Ammer R, et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. *European Archives of Psychiatry and Clinical Neuroscience*. 2009;259(6):368-. doi: 10.1007/s00406-009-0005-5. *Currently being assessed for management*
1631. Rostain AL. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults. *Curr Psychiatry Rep*. 2009 Oct;11(5):341-2. doi: 10.1007/s11920-009-0064-3. PMID: 19785973. *Currently being assessed for management*
1632. Rotem A, Ben-Sheetrit J, Newcorn J, et al. The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test. *J Atten Disord*. 2021 Jul;25(9):1311-20. doi: 10.1177/1087054719897819. PMID: 31965885. *Possible multiple publication*
1633. Rotem A, Danieli Y, Ben-Sheetrit J, et al. Apparent lack of practice effects in the Test of Variables of Attention (TOVA) in adult ADHD. *Atten Defic Hyperact Disord*. 2019 Mar;11(1):73-81. doi: 10.1007/s12402-018-0278-5. PMID: 30927232. *Exclude-Intervention*

Excluded Publications

1634. Rousselle L, Noël MP. The challenges of diagnosing attention/hyperactivity deficit in adults: a closer look at the sensitivity and specificity of assessment methods. *ANAE - Approche Neuropsychologique des Apprentissages chez l'Enfant*. 2024;36(190):299-307. *Exclude-Language*

1635. Roy A, Hechtman L, Arnold LE, et al. Childhood Factors Affecting Persistence and Desistence of Attention-Deficit/Hyperactivity Disorder Symptoms in Adulthood: Results From the MTA. *J Am Acad Child Adolesc Psychiatry*. 2016 Nov;55(11):937-44.e4. doi: 10.1016/j.jaac.2016.05.027. PMID: 27806861. *Exclude-Intervention*

1636. Roy-Byrne P, Scheele L, Brinkley J, et al. Adult attention-deficit hyperactivity disorder: assessment guidelines based on clinical presentation to a specialty clinic. *Compr Psychiatry*. 1997 May-Jun;38(3):133-40. doi: 10.1016/s0010-440x(97)90065-1. PMID: 9154368. *Exclude-Outcome*

1637. Rucklidge J, Johnstone J, Harrison R, et al. Micronutrients reduce stress and anxiety in adults with Attention-Deficit/Hyperactivity Disorder following a 7.1 earthquake. *Psychiatry Res*. 2011 Sep 30;189(2):281-7. doi: 10.1016/j.psychres.2011.06.016. PMID: 21802745. *Exclude-Design*

1638. Rucklidge J, Taylor M, Whitehead K. Effect of micronutrients on behavior and mood in adults With ADHD: evidence from an 8-week open label trial with natural extension. *J Atten Disord*. 2011 Jan;15(1):79-91. doi: 10.1177/1087054709356173. PMID: 20071638. *Exclude-Comparator*

1639. Rucklidge JJ, Frampton CM, Gorman B, et al. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. *Br J Psychiatry*. 2014;204:306-15. doi: 10.1192/bjp.bp.113.132126. PMID: 24482441. *Currently being assessed for management*

1640. Rucklidge JJ, Frampton CM, Gorman B, et al. Vitamin–mineral treatment of attention-deficit hyperactivity disorder in adults: Double-blind randomised placebo-controlled trial. *The British Journal of Psychiatry*. 2014;204(4):306-15. doi: 10.1192/bjp.bp.113.132126. *Currently being assessed for management*

1641. Rucklidge JJ, Frampton CM, Gorman B, et al. Vitamin-Mineral Treatment of ADHD in Adults. *J Atten Disord*. 2017 Apr;21(6):522-32. doi: 10.1177/1087054714530557. PMID: 24804687. *Possible multiple publication*

1642. Rucklidge JJ, Harrison R. Successful treatment of bipolar disorder II and ADHD with a micronutrient formula: a case study. *CNS Spectr*. 2010 May;15(5):289-95. doi: 10.1017/s1092852900027516. PMID: 20448519. *Exclude-Design*

1643. Rucklidge JJ, Harrison R, Johnstone J. Can micronutrients improve neurocognitive functioning in adults with ADHD and severe mood dysregulation? A pilot study. *J Altern Complement Med*. 2011 Dec;17(12):1125-31. doi: 10.1089/acm.2010.0499. PMID: 22112202. *Currently being assessed for management*

Excluded Publications

1644. Rucklidge JJ, Johnstone J, Gorman B, et al. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014 Apr 3;50:163-71. doi: 10.1016/j.pnpbp.2013.12.014. PMID: 24374068. *Possible multiple publication*
1645. Rucklidge JJ, Tannock R. Validity of the Brown ADD scales: an investigation in a predominantly inattentive ADHD adolescent sample with and without reading disabilities. *Journal of attention disorders*. 2002;5(3):155-64. *Exclude-Population*
1646. Rueda JR, Guillén V, Ballesteros J, et al. L-acetylcarnitine for treating fragile X syndrome. *Cochrane Database of Systematic Reviews*. 2015(5). doi: 10.1002/14651858.CD010012.pub2. PMID: CD010012. *Exclude-Intervention*
1647. Ruiz Feliu M, Cano Prous A, Iglesias Gaspar MT, et al. [Presence and influence of attention deficit hyperactivity disorder symptoms in adults with an eating disorder]. *An Sist Sanit Navar*. 2022 Apr 27;45(1). doi: 10.23938/assn.0984. PMID: 35037918. *Exclude-Language*
1648. Russell AE, Moore D, Sanders A, et al. Synthesising the existing evidence for non-pharmacological interventions targeting outcomes relevant to young people with ADHD in the school setting: systematic review protocol. *Systematic Reviews*. 2022;11(1). doi: 10.1186/s13643-022-01902-x. *Currently being assessed for management*
1649. Ryan JJ, Carruthers CA, Miller LJ, et al. The WASI matrix reasoning subtest: performance in traumatic brain injury, stroke, and dementia. *Int J Neurosci*. 2005 Jan;115(1):129-36. doi: 10.1080/00207450490512704. PMID: 15768857. *Exclude-Population*
1650. Ryan JJ, Kreiner DS, Teichner G, et al. Validity of the Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II) as an Indicator of Neurological Disease/Injury: A Pilot Study. *Brain Injury*. 2021;35(12-13):1624-9. doi: 10.1080/02699052.2021.1978547. *Exclude-Population*
1651. Rybak YE, McNeely HE, Mackenzie BE, et al. An open trial of light therapy in adult attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2006 Oct;67(10):1527-35. doi: 10.4088/jcp.v67n1006. PMID: 17107243. *Exclude-Comparator*
1652. Ryoo M, Son C. Effects of Neurofeedback Training on EEG, Continuous Performance Task (CPT), and ADHD Symptoms in ADHD-prone College Students. *J Korean Acad Nurs*. 2015 Dec;45(6):928-38. doi: 10.4040/jkan.2015.45.6.928. PMID: 26805505. *Exclude-Intervention*
1653. Sable JJ, Kyle MR, Knopf KL, et al. The Sensory Gating Inventory as a potential diagnostic tool for attention-deficit hyperactivity disorder. *Atten Defic Hyperact Disord*. 2012 Sep;4(3):141-4. doi: 10.1007/s12402-012-0079-1. PMID: 22644992. *Exclude-Intervention*
1654. Sadeghi-Bazargani H, Hasanzadeh K, Salarilak S, et al. Evaluating the relationship between adult attention-deficit/hyperactivity disorder and riding behavior of motorcyclists. *J Inj Violence Res*. 2019 Jan;11(1):45-52. doi: 10.5249/jivr.v11i1.1098. PMID: 30636000. *Exclude-Intervention*

Excluded Publications

1655. Safiri S, Haghdoost AA, Hashemi F, et al. Association Between Adult Attention Deficit Hyperactivity Disorder and Helmet Use Among Motorcycle Riders. *Trauma Mon.* 2016 May;21(2):e21066. doi: 10.5812/traumamon.21066. PMID: 27626002. *Exclude-Intervention*
1656. Safren SA. Cognitive-behavioral approaches to ADHD treatment in adulthood. *J Clin Psychiatry.* 2006;67 Suppl 8:46-50. PMID: 16961430. *Exclude-Design*
1657. Safren SA, Duran P, Yovel I, et al. Medication adherence in psychopharmacologically treated adults with ADHD. *J Atten Disord.* 2007 Feb;10(3):257-60. doi: 10.1177/1087054706292165. PMID: 17242421. *Exclude-Design*
1658. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. *Behav Res Ther.* 2005 Jul;43(7):831-42. doi: 10.1016/j.brat.2004.07.001. PMID: 15896281. *Currently being assessed for management*
1659. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. *Jama.* 2010 Aug 25;304(8):875-80. doi: 10.1001/jama.2010.1192. PMID: 20736471. *Currently being assessed for management*
1660. Sakai C, Tsuji T, Nakai T, et al. Change in Antidepressant Use After Initiation of ADHD Medication in Japanese Adults with Comorbid Depression: A Real-World Database Analysis. *Neuropsychiatr Dis Treat.* 2021;17:3097-108. doi: 10.2147/ndt.S325498. PMID: 34675521. *Exclude-Design*
1661. Saleh A, Fuchs C, Taylor WD, et al. Evaluating the consistency of scales used in adult attention deficit hyperactivity disorder assessment of college-aged adults. *J Am Coll Health.* 2018 Feb-Mar;66(2):98-105. doi: 10.1080/07448481.2017.1377206. PMID: 28915090. *Exclude-Intervention*
1662. Salmi J, Soveri A, Salmela V, et al. Working memory training restores aberrant brain activity in adult attention-deficit hyperactivity disorder. *Hum Brain Mapp.* 2020 Dec;41(17):4876-91. doi: 10.1002/hbm.25164. PMID: 32813290. *Currently being assessed for management*
1663. Salomone S, Fleming GR, Shanahan JM, et al. The effects of a Self-Alert Training (SAT) program in adults with ADHD. *Front Hum Neurosci.* 2015;9:45. doi: 10.3389/fnhum.2015.00045. PMID: 25713523. *Currently being assessed for management*
1664. Salomone S, Fleming GR, Shanahan JM, et al. The effects of a self-alert training (SAT) programme in adults with ADHD. *ADHD Attention Deficit and Hyperactivity Disorders.* 2015;7:S96. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
1665. Sami N, Carte ET, Hinshaw SP, et al. Performance of girls with ADHD and comparison girls on the Rey-Osterrieth Complex Figure: evidence for executive processing deficits. *Child Neuropsychol.* 2003 Dec;9(4):237-54. doi: 10.1076/chin.9.4.237.23514. PMID: 14972703. *Exclude-Population*

Excluded Publications

1666. Samuele C, Junhua Z, Amparo D-R. Meditation-based interventions for ADHD in children, adolescents, and adults: a systematic review and meta-analysis. 2018. PMID: CRD42018096156. *Currently being assessed for management*
1667. Sánchez XC, Montalbano S, Vaez M, et al. Associations of psychiatric disorders with sex chromosome aneuploidies in the Danish iPSYCH2015 dataset: a case-cohort study. *Lancet Psychiatry*. 2023 Feb;10(2):129-38. doi: 10.1016/s2215-0366(23)00004-4. PMID: 36697121. *Exclude-Population*
1668. Sandersleben HU, Mayer A, Ruhmann M, et al. Pharmacokinetics of a Modified-Release Dexamphetamine Sulfate Formulation Following Single and Multiple Dosing in Healthy Adults: Comparative Bioavailability with Immediate-Release Dexamphetamine Sulfate, between Strengths, Assessment of Food and Meal Composition Effects. *Scand J Child Adolesc Psychiatr Psychol*. 2023 Jan;11(1):132-42. doi: 10.2478/sjcapp-2023-0014. PMID: 38033826. *Exclude-Population*
1669. Sandra Kooij JJ, Keith Conners C, Goto T, et al. Validity of conners' adult attention-deficit/hyperactivity disorder rating Scale-investigator rated: screening version in patients from within and outside of Europe. *Psychiatry Res*. 2013 Jun 30;208(1):94-6. doi: 10.1016/j.psychres.2012.12.003. PMID: 23318025. *Possible multiple publication*
1670. Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, et al. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. *J Atten Disord*. 2008 Jan;11(4):445-58. doi: 10.1177/1087054707299367. PMID: 18083961. *Exclude-Language*
1671. Sandra Kooij JJ, Rösler M, Philipsen A, et al. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: Results from a randomized, placebo-controlled trial. *BMC Psychiatry*. 2013;13. *Currently being assessed for management*
1672. Santosh PJ, Taylor E. Stimulant drugs. *Eur Child Adolesc Psychiatry*. 2000;9 Suppl 1:I27-43. doi: 10.1007/s007870070017. PMID: 11140778. *Exclude-Design*
1673. Sarsembayeva D, Hartman CA, Cardoso Melo RD, et al. Nonlinear associations between insomnia symptoms and circadian preferences in the general population: Symptom-specific and lifespan differences in men and women. *Sleep Health*. 2024 Apr;10(2):171-81. doi: 10.1016/j.sleh.2023.10.008. PMID: 38007303. *Exclude-Population*
1674. Sarter M, Paolone G. Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. *Behav Neurosci*. 2011 Dec;125(6):825-35. doi: 10.1037/a0026227. PMID: 22122146. *Exclude-Population*
1675. Sarver DE, McCart MR, Sheidow AJ, et al. ADHD and risky sexual behavior in adolescents: conduct problems and substance use as mediators of risk. *J Child Psychol Psychiatry*. 2014 Dec;55(12):1345-53. doi: 10.1111/jcpp.12249. PMID: 24813803. *Exclude-Population*

Excluded Publications

1676. Savickaite S, Morrison C, Lux E, et al. The use of a tablet-based app for investigating the influence of autistic and ADHD traits on performance in a complex drawing task. *Behav Res Methods*. 2022 Oct;54(5):2479-501. doi: 10.3758/s13428-021-01746-8. PMID: 35018608. *Exclude-Intervention*
1677. Savulich G, Thorp E, Piercy T, et al. Improvements in Attention Following Cognitive Training With the Novel "Decoder" Game on an iPad. *Front Behav Neurosci*. 2019;13:2. doi: 10.3389/fnbeh.2019.00002. PMID: 30719000. *Exclude-Population*
1678. Sawada M, Negoro H, Iida J, et al. Pervasive developmental disorder with attention deficit hyperactivity disorder-like symptoms and mismatch negativity. *Psychiatry Clin Neurosci*. 2008 Aug;62(4):479-81. doi: 10.1111/j.1440-1819.2008.01835.x. PMID: 18778448. *Exclude-Population*
1679. Sawhney I, Perera B, Bassett P, et al. Attention-deficit hyperactivity disorder in people with intellectual disability: Statistical approach to developing a bespoke screening tool. *BJPsych Open*. 2021;7. doi: 10.1192/bjo.2021.1023. *Exclude-Intervention*
1680. Saxena A, Hartman CA, Blatt SD, et al. Reward Functioning in General and Specific Psychopathology in Children and Adults. *J Atten Disord*. 2024 Jan;28(1):77-88. doi: 10.1177/10870547231201867. PMID: 37864336. *Exclude-Population*
1681. Sayal K, Prasad V, Daley D, et al. ADHD in children and young people: prevalence, care pathways, and service provision. *Lancet Psychiatry*. 2018 Feb;5(2):175-86. doi: 10.1016/s2215-0366(17)30167-0. PMID: 29033005. *Exclude-Population*
1682. Saylor KE, Amann BH. Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *J Child Adolesc Psychopharmacol*. 2016 Feb;26(1):19-25. doi: 10.1089/cap.2015.0126. PMID: 26744906. *Exclude-Population*
1683. Schaeuble B, Buitelaar JK, Roesler M, et al. Symptomatic and functional outcomes in adults with ADHD treated with OROS methylphenidate are related as shown by partial correlation analysis. *European Journal of Neurology*. 2010;17:204. doi: 10.1111/j.1468-1331.2010.03232.x. *Currently being assessed for management*
1684. Schaeuble B, Orman C, Palumbo JM. Efficacy of prolonged-release methylphenidate in a randomized controlled trial in adults with ADHD: Secondary endpoints. *European Neuropsychopharmacology*. 2009;19:S679-S80. doi: 10.1016/S0924-977X(09)71098-3. *Currently being assessed for management*
1685. Schein J, Childress A, Cloutier M, et al. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. *BMC Psychiatry*. 2022 Jun 3;22(1):377. doi: 10.1186/s12888-022-04016-9. PMID: 35659281. *Exclude-Intervention*
1686. Schein J, Cloutier M, Bungay R, et al. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder. *J Med Econ*. 2024 Jan-Dec;27(1):653-62. doi: 10.1080/13696998.2024.2342749. PMID: 38602691. *Exclude-Intervention*

Excluded Publications

1687. Schein J, Cloutier M, Gauthier-Loiselle M, et al. Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder – A Discrete Choice Experiment. Patient Preference and Adherence. 2024;18:1651-64. doi: 10.2147/PPA.S467724. *Exclude-Intervention*
1688. Schein J, Cloutier M, Gauthier-Loiselle M, et al. CO184 A Matching-Adjusted Indirect Comparison of Centanafadine Vs Lisdexamfetamine, Methylphenidate, and Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder: Long-Term Safety and Efficacy Outcomes. 2024. p. S52. *Currently being assessed for management*
1689. Schermann H, Gurel R, Ankory R, et al. Lower risk of fractures under methylphenidate treatment for ADHD: A dose-response effect. J Orthop Res. 2018 Dec;36(12):3328-33. doi: 10.1002/jor.24129. PMID: 30129682. *Exclude-Intervention*
1690. Schermann H, Schiffmann N, Ankory R, et al. Methylphenidate use and restorative treatment needs in young adults with attention deficit hyperactivity disorder. Spec Care Dentist. 2024 Mar-Apr;44(2):556-62. doi: 10.1111/scd.12885. PMID: 37288998. *Exclude-Intervention*
1691. Schlösser C, Kovacs A, Ferrero F. Outcome of ADHD syndrome in adulthood: Epidemiological and clinical aspects. Schweizer Archiv für Neurologie und Psychiatrie. 2002;153(1):29-36. doi: 10.4414/sanp.2002.01252. *Exclude-Intervention*
1692. Schmidt H, Heidemann LS, Menrath I, et al. [Transition-oriented patient education program for adolescents and young adults with ADHD]. Z Kinder Jugendpsychiatr Psychother. 2023 Jan;51(1):28-40. doi: 10.1024/1422-4917/a000871. PMID: 35510814. *Exclude-Language*
1693. Schmidt S, Petermann F. Sensitivity and specificity of the ADHD-Screening for Adults (ADHS-E). Zeitschrift für Psychiatrie, Psychologie und Psychotherapie. 2011;59(1):73-8. doi: 10.1024/1661-4747/a000054. *Exclude-Language*
1694. Schmidt SL, Carvahó ALN, Simões EN. Effect of handedness on auditory attentional performance in ADHD students. Neuropsychiatr Dis Treat. 2017;13:2921-4. doi: 10.2147/ndt.S149454. PMID: 29238197. *Exclude-Population*
1695. Schmidt SL, Simões EDN, Novais Carvalho AL. Association Between Auditory and Visual Continuous Performance Tests in Students With ADHD. J Atten Disord. 2019 Apr;23(6):635-40. doi: 10.1177/1087054716679263. PMID: 27864429. *Exclude-Population*
1696. Schnabel R, Kydd R. Neuropsychological assessment of distractibility in mild traumatic brain injury and depression. Clin Neuropsychol. 2012;26(5):769-89. doi: 10.1080/13854046.2012.693541. PMID: 22694212. *Exclude-Population*
1697. Schneider BC, Schöttle D, Hottenrott B, et al. Assessment of Adult ADHD in Clinical Practice: Four Letters-40 Opinions. J Atten Disord. 2023 Jul;27(9):1051-61. doi: 10.1177/1087054719879498. PMID: 31625465. *Exclude-Intervention*
1698. Schneider BC, Thoering T, Cludius B, et al. Self-reported symptoms of attention-deficit/hyperactivity disorder: rate of endorsement and association with neuropsychological

Excluded Publications

performance in an adult psychiatric sample. *Arch Clin Neuropsychol*. 2015 May;30(3):186-91. doi: 10.1093/arclin/acv015. PMID: 25851625. *Exclude-Intervention*

1699. Schneider MK, Retz W, Gougleris G, et al. Effects of long-acting methylphenidate in adults with attention deficit hyperactivity disorder: a study with paired-pulse transcranial magnetic stimulation. *Neuropsychobiology*. 2011;64(4):195-201. doi: 10.1159/000326693. PMID: 21912187. *Exclude-Outcome*

1700. Schoenberg PL, Hepark S, Kan CC, et al. Effects of mindfulness-based cognitive therapy on neurophysiological correlates of performance monitoring in adult attention-deficit/hyperactivity disorder. *Clin Neurophysiol*. 2014 Jul;125(7):1407-16. doi: 10.1016/j.clinph.2013.11.031. PMID: 24374088. *Currently being assessed for management*

1701. Schoenfelder EN, Chronis-Tuscano A, Strickland J, et al. Piloting a Sequential, Multiple Assignment, Randomized Trial for Mothers with Attention-Deficit/Hyperactivity Disorder and Their At-Risk Young Children. *J Child Adolesc Psychopharmacol*. 2019 May;29(4):256-67. doi: 10.1089/cap.2018.0136. PMID: 30950637. *Possible multiple publication*

1702. Schofield F, Isotalus H, Jones M, et al. Assistive technologies and their application to sleep problems in adult ADHD: a scoping review. *Sleep Medicine*. 2024;115:404. doi: 10.1016/j.sleep.2023.11.1086. *Currently being assessed for management*

1703. Schönenberg M, Wiedemann E, Schneidt A, et al. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial. *Lancet Psychiatry*. 2017 Sep;4(9):673-84. doi: 10.1016/s2215-0366(17)30291-2. PMID: 28803030. *Currently being assessed for management*

1704. Schrantee A, Bouziane C, Bron EE, et al. Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder. *Brain Imaging Behav*. 2018 Apr;12(2):402-10. doi: 10.1007/s11682-017-9707-x. PMID: 28321605. *Exclude-Design*

1705. Schrantee A, Ferguson B, Stoffers D, et al. Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls. *Brain Imaging Behav*. 2016 Jun;10(2):548-58. doi: 10.1007/s11682-015-9419-z. PMID: 26149196. *Exclude-Population*

1706. Schrantee A, Tamminga HG, Bouziane C, et al. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2016 Sep 1;73(9):955-62. doi: 10.1001/jamapsychiatry.2016.1572. PMID: 27487479. *Currently being assessed for management*

1707. Schubert JK, Gonzalez-Trejo E, Retz W, et al. Dysfunctional cortical inhibition in adult ADHD: neural correlates in auditory event-related potentials. *J Neurosci Methods*. 2014 Sep 30;235:181-8. doi: 10.1016/j.jneumeth.2014.06.025. PMID: 25033725. *Exclude-Intervention*

Excluded Publications

1708. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications. *CNS Drugs*. 2005;19(8):643-55. doi: 10.2165/00023210-200519080-00001. PMID: 16097847. *Exclude-Intervention*
1709. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. *Exp Clin Psychopharmacol*. 2002 Aug;10(3):286-94. doi: 10.1037//1064-1297.10.3.286. PMID: 12233989. *Currently being assessed for management*
1710. Schultz MR, Rabi K, Faraone SV, et al. Efficacy of retrospective recall of attention-deficit hyperactivity disorder symptoms: A twin study. *Twin Res Hum Genet*. 2006 Apr;9(2):220-32. doi: 10.1375/183242706776382374. PMID: 16611492. *Exclude-Intervention*
1711. Schulz J, Huber F, Schlack R, et al. The Association between Low Blood Pressure and Attention-Deficit Hyperactivity Disorder (ADHD) Observed in Children/Adolescents Does Not Persist into Young Adulthood. A Population-Based Ten-Year Follow-Up Study. *Int J Environ Res Public Health*. 2021 Feb 14;18(4). doi: 10.3390/ijerph18041864. PMID: 33672943. *Exclude-Population*
1712. Schulz KP, Clerkin SM, Fan J, et al. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. *Psychopharmacology (Berl)*. 2013 Mar;226(2):261-71. doi: 10.1007/s00213-012-2893-8. PMID: 23086020. *Exclude-Population*
1713. Schulz KP, Fan J, Bédard AC, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053. PMID: 22945622. *Exclude-Population*
1714. Schulz KP, Krone B, Adler LA, et al. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018 Aug;3(8):686-93. doi: 10.1016/j.bpsc.2018.03.004. PMID: 29661516. *Currently being assessed for management*
1715. Schulz KP, Li X, Clerkin SM, et al. Prefrontal and parietal correlates of cognitive control related to the adult outcome of attention-deficit/hyperactivity disorder diagnosed in childhood. *Cortex*. 2017 May;90:1-11. doi: 10.1016/j.cortex.2017.01.019. PMID: 28292705. *Exclude-Intervention*
1716. Schweiger A, Abramovitch A, Doniger GM, et al. A clinical construct validity study of a novel computerized battery for the diagnosis of ADHD in young adults. *J Clin Exp Neuropsychol*. 2007 Jan;29(1):100-11. doi: 10.1080/13803390500519738. PMID: 17162726. *Exclude-Intervention*
1717. Schweitzer JB, Hanford RB, Medoff DR. Working memory deficits in adults with ADHD: is there evidence for subtype differences? *Behav Brain Funct*. 2006 Dec 15;2:43. doi: 10.1186/1744-9081-2-43. PMID: 17173676. *Exclude-Intervention*

Excluded Publications

1718. Schweitzer JB, Lee DO, Hanford RB, et al. A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. *Neuropsychopharmacology*. 2003 May;28(5):967-73. doi: 10.1038/sj.npp.1300110. PMID: 12700698. *Exclude-Design*
1719. Schweitzer JB, Lee DO, Hanford RB, et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. *Biol Psychiatry*. 2004 Oct 15;56(8):597-606. doi: 10.1016/j.biopsych.2004.07.011. PMID: 15476690. *Exclude-Design*
1720. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. *Am Fam Physician*. 2000 Nov 1;62(9):2077-86, 91-2. PMID: 11087189. *Exclude-Outcome*
1721. Sehlin H, Hedman Ahlström B, Andersson G, et al. Experiences of an internet-based support and coaching model for adolescents and young adults with ADHD and autism spectrum disorder -a qualitative study. *BMC Psychiatry*. 2018 Jan 18;18(1):15. doi: 10.1186/s12888-018-1599-9. PMID: 29347983. *Exclude-Design*
1722. Selander H, Strand N, Almqvist M, et al. Ready for a Learner's Permit? Clinical Neuropsychological Off-road Tests and Driving Behaviors in a Simulator among Adolescents with ADHD and ASD. *Dev Neurorehabil*. 2021 May;24(4):256-65. doi: 10.1080/17518423.2020.1869339. PMID: 33459571. *Exclude-Population*
1723. Selaskowski B, Asché LM, Wiebe A, et al. Gaze-based attention refocusing training in virtual reality for adult attention-deficit/hyperactivity disorder. *BMC Psychiatry*. 2023 Jan 26;23(1):74. doi: 10.1186/s12888-023-04551-z. PMID: 36703134. *Exclude-Outcome*
1724. Selaskowski B, Reiland M, Schulze M, et al. Chatbot-supported psychoeducation in adult attention-deficit hyperactivity disorder: randomised controlled trial. *BJPsych Open*. 2023 Oct 13;9(6):e192. doi: 10.1192/bjo.2023.573. PMID: 37827996. *Currently being assessed for management*
1725. Selaskowski B, Staerk C, Braun N, et al. Multimodal treatment efficacy differs in dependence of core symptom profiles in adult Attention-Deficit/Hyperactivity Disorder: An analysis of the randomized controlled COMPAS trial. *J Psychiatr Res*. 2022 Jul;151:225-34. doi: 10.1016/j.jpsychires.2022.03.049. PMID: 35500450. *Possible multiple publication*
1726. Selaskowski B, Steffens M, Schulze M, et al. Smartphone-assisted psychoeducation in adult attention-deficit/hyperactivity disorder: A randomized controlled trial. *Psychiatry Res*. 2022 Nov;317:114802. doi: 10.1016/j.psychres.2022.114802. PMID: 36041353. *Currently being assessed for management*
1727. Semeijn EJ, Michielsen M, Comijs HC, et al. Criterion validity of an Attention Deficit Hyperactivity Disorder (ADHD) screening list for screening ADHD in older adults aged 60-94 years. *Am J Geriatr Psychiatry*. 2013 Jul;21(7):631-5. doi: 10.1016/j.jagp.2012.08.003. PMID: 23567439. *Exclude-Language*

Excluded Publications

1728. Semeijn EJ, Michielsen M, Comijs HC, et al. Criterion validity of an attention deficit hyperactivity disorder (ADHD) screening list for screening ADHD in older adults aged 60-94 years. *American Journal of Geriatric Psychiatry*. 2013;21(7):631-5. doi: 10.1016/j.jagp.2012.08.003. *Exclude-Duplicate*
1729. Semiz UB, Basoglu C, Oner O, et al. Effects of diagnostic comorbidity and dimensional symptoms of attention-deficit-hyperactivity disorder in men with antisocial personality disorder. *Aust N Z J Psychiatry*. 2008 May;42(5):405-13. doi: 10.1080/00048670801961099. PMID: 18473259. *Exclude-Intervention*
1730. Sen B, Borle NC, Greiner R, et al. A general prediction model for the detection of ADHD and Autism using structural and functional MRI. *PLoS One*. 2018;13(4):e0194856. doi: 10.1371/journal.pone.0194856. PMID: 29664902. *Exclude-Population*
1731. Serra-Pla JF, Pozuelo M, Richarte V, et al. [Treatment of attention deficit hyperactivity disorder in adults using virtual reality through a mindfulness programme]. *Rev Neurol*. 2017 Feb 24;64(s01):S117-s22. PMID: 28256698. *Exclude-Design*
1732. Sesso G, Brancati GE, Masi G. Comorbidities in Youth with Bipolar Disorder: Clinical Features and Pharmacological Management. *Curr Neuropharmacol*. 2023;21(4):911-34. doi: 10.2174/1570159x20666220706104117. PMID: 35794777. *Exclude-Population*
1733. Sethi A, Evelyn-Rahr E, Dowell N, et al. Magnetization transfer imaging identifies basal ganglia abnormalities in adult ADHD that are invisible to conventional T1 weighted voxel-based morphometry. *Neuroimage Clin*. 2017;15:8-14. doi: 10.1016/j.nicl.2017.03.012. PMID: 28458999. *Exclude-Intervention*
1734. Sethi A, Voon V, Critchley HD, et al. A neurocomputational account of reward and novelty processing and effects of psychostimulants in attention deficit hyperactivity disorder. *Brain*. 2018 May 1;141(5):1545-57. doi: 10.1093/brain/awy048. PMID: 29547978. *Exclude-Design*
1735. Seto D, Weintraub BD. Rapid molecular diagnosis of mutations associated with generalized thyroid hormone resistance by PCR-coupled automated direct sequencing of genomic DNA: detection of two novel mutations. *Hum Mutat*. 1996;8(3):247-57. doi: 10.1002/(sici)1098-1004(1996)8:3<247::Aid-humu8>3.0.Co;2-6. PMID: 8889584. *Exclude-Population*
1736. Setyawan J, Guérin A, Hodgkins P, et al. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. *J Med Econ*. 2013 Nov;16(11):1275-89. doi: 10.3111/13696998.2013.839947. PMID: 24004347. *Exclude-Population*
1737. Setyawan J, Hodgkins P, Guérin A, et al. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults. *J Med Econ*.

Excluded Publications

2013 Oct;16(10):1203-15. doi: 10.3111/13696998.2013.832258. PMID: 23937642. *Exclude-Population*

1738. Setyawan J, Hodgkins P, Guérin A, et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ. 2013 Jul;16(7):962-75. doi: 10.3111/13696998.2013.800524. PMID: 23621503. *Exclude-Population*

1739. Sevecke K, Battel S, Dittmann RW, et al. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview]. Nervenarzt. 2006 Mar;77(3):294, 7-300, 2-4 passim. doi: 10.1007/s00115-005-1970-1. PMID: 16133434. *Exclude-Population*

1740. Seyed Sina N, Joseph C, Mario H-B, et al. Evaluate the efficacy and safety of pharmacological intervention for excessive daytime sleepiness in patients with obstructive sleep apnea syndrome. 2022. PMID: CRD42022366313. *Currently being assessed for management*

1741. Shalev H, Mizrakli Y, Zeadna A, et al. Does methylphenidate use affect sperm parameters in patients undergoing infertility investigation? A retrospective analysis of 9769 semen samples. Arch Gynecol Obstet. 2021 Aug;304(2):539-46. doi: 10.1007/s00404-020-05938-z. PMID: 33433701. *Exclude-Intervention*

1742. Shaw K, Wagner I, Eastwood H, et al. A qualitative study of Australian GPs' attitudes and practices in the diagnosis and management of attention-deficit/hyperactivity disorder (ADHD). Fam Pract. 2003 Apr;20(2):129-34. doi: 10.1093/fampra/20.2.129. PMID: 12651785. *Exclude-Intervention*

1743. Shaw KA, Mitchell GK, Wagner IJ, et al. Attitudes and practices of general practitioners in the diagnosis and management of attention-deficit/hyperactivity disorder. J Paediatr Child Health. 2002 Oct;38(5):481-6. doi: 10.1046/j.1440-1754.2002.00033.x. PMID: 12354265. *Exclude-Intervention*

1744. Shaw P, Sharp WS, Morrison M, et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am J Psychiatry. 2009 Jan;166(1):58-63. doi: 10.1176/appi.ajp.2008.08050781. PMID: 18794206. *Exclude-Population*

1745. Shaw TH, Curby TW, Satterfield K, et al. Transcranial Doppler sonography reveals sustained attention deficits in young adults diagnosed with ADHD. Exp Brain Res. 2019 Feb;237(2):511-20. doi: 10.1007/s00221-018-5432-y. PMID: 30467657. *Exclude-Intervention*

1746. Shekim WO, Antun F, Hanna GL, et al. S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull. 1990;26(2):249-53. PMID: 2236465. *Exclude-Design*

1747. Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis. 1989 May;177(5):296-9. doi: 10.1097/00005053-198905000-00008. PMID: 2651559. *Exclude-Design*

Excluded Publications

1748. Shelton CR, Hartung CM, Canu WH. Feasibility and Acceptability of an Internet-Based Intervention for Young Adults with ADHD. *J Technol Behav Sci.* 2022;7(4):428-38. doi: 10.1007/s41347-022-00256-4. PMID: 35600097. *Exclude-Intervention*
1749. Shim S-h, Woo YS, Kim JS, et al. Comparison between atomoxetine and OROS methylphenidate as an adjunctive to SSRIs in attention-deficit/hyperactivity disorder adults with comorbid partially responsive major depressive disorder: A head-to-head, 12-week, randomized, rater-blinded clinical trial. *Clinical Psychopharmacology and Neuroscience.* 2022;20(1):143-53. *Currently being assessed for management*
1750. Shim SH, Woo YS, Kim JS, et al. Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial. *Clin Psychopharmacol Neurosci.* 2022 Feb 28;20(1):143-53. doi: 10.9758/cpn.2022.20.1.143. PMID: 35078957. *Currently being assessed for management*
1751. Shura RD, Armistead-Jehle P. Base Rates of Performance and Symptom Validity Test Failures in Active Duty and Veteran Samples Referred for Attention-Deficit/Hyperactivity Disorder Evaluation. *Arch Clin Neuropsychol.* 2024 May 21;39(4):523-7. doi: 10.1093/arclin/acad092. PMID: 38073319. *Exclude-Intervention*
1752. Sibley MH. Empirically-informed guidelines for first-time adult ADHD diagnosis. *J Clin Exp Neuropsychol.* 2021 May;43(4):340-51. doi: 10.1080/13803395.2021.1923665. PMID: 33949916. *Exclude-Design*
1753. Sibley MH, Graziano PA, Kuriyan AB, et al. Parent-teen behavior therapy + motivational interviewing for adolescents with ADHD. *J Consult Clin Psychol.* 2016 Aug;84(8):699-712. doi: 10.1037/ccp0000106. PMID: 27077693. *Exclude-Population*
1754. Sibley MH, Kennedy TM, Swanson JM, et al. Characteristics and Predictors of Fluctuating Attention-Deficit/Hyperactivity Disorder in the Multimodal Treatment of ADHD (MTA) Study. *J Clin Psychiatry.* 2024 Oct 16;85(4). doi: 10.4088/JCP.24m15395. PMID: 39431909. *Currently being assessed for management*
1755. Sibley MH, Rohde LA, Swanson JM, et al. Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25. *Am J Psychiatry.* 2018 Feb 1;175(2):140-9. doi: 10.1176/appi.ajp.2017.17030298. PMID: 29050505. *Exclude-Population*
1756. Sibley MH, Rohde LA, Swanson JM, et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. *American Journal of Psychiatry.* 2018;175(2):140-9. doi: 10.1176/appi.ajp.2017.17030298. *Exclude-Duplicate*
1757. Sibley MH, Swanson JM, Arnold LE, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. *J Child Psychol Psychiatry.* 2017 Jun;58(6):655-62. doi: 10.1111/jcpp.12620. PMID: 27642116. *Exclude-Intervention*

Excluded Publications

1758. Sif-Eddine W, Ba-M'hamed S, Lefranc B, et al. Selenoprotein T, a potential treatment of attention-deficit/hyperactivity disorder and comorbid pain in neonatal 6-OHDA lesioned mice. *Exp Mol Pathol*. 2024 May 25;137:104905. doi: 10.1016/j.yexmp.2024.104905. PMID: 38797131. *Exclude-Population*
1759. Sigurdardottir HL, Kranz GS, Rami-Mark C, et al. Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. *Mol Psychiatry*. 2021 Mar;26(3):1009-18. doi: 10.1038/s41380-019-0461-x. PMID: 31383926. *Exclude-Intervention*
1760. Sigurdardottir HL, Kranz GS, Rami-Mark C, et al. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. *Hum Brain Mapp*. 2016 Mar;37(3):884-95. doi: 10.1002/hbm.23071. PMID: 26678348. *Exclude-Intervention*
1761. Sikes C, Stark JG, McMahan R, et al. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study. *Clin Ther*. 2017 Dec;39(12):2389-98. doi: 10.1016/j.clinthera.2017.10.018. PMID: 29174216. *Exclude-Population*
1762. Sikes C, Stark JG, McMahan R, et al. A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults. *J Atten Disord*. 2020 Feb;24(3):414-9. doi: 10.1177/1087054717743329. PMID: 29192549. *Exclude-Population*
1763. Silva KL, Guimarães-da-Silva PO, Grevet EH, et al. Cognitive deficits in adults with ADHD go beyond comorbidity effects. *J Atten Disord*. 2013 Aug;17(6):483-8. doi: 10.1177/1087054711434155. PMID: 22344317. *Exclude-Intervention*
1764. Siman Tov A, Halevi Hochwald I, Tesler R, et al. Weight Management for Students with Attention-Deficit Hyperactivity Disorder (ADHD): A Qualitative Study. *Healthcare (Basel)*. 2022 Nov 7;10(11). doi: 10.3390/healthcare10112225. PMID: 36360567. *Exclude-Intervention*
1765. Simon V, Czobor P, Bálint S, et al. [Detailed review of epidemiologic studies on adult Attention Deficit/Hyperactivity Disorder (ADHD)]. *Psychiatr Hung*. 2007;22(1):4-19. PMID: 17558040. *Exclude-Language*
1766. Simons L, Valentine AZ, Falconer CJ, et al. Developing mHealth Remote Monitoring Technology for Attention Deficit Hyperactivity Disorder: A Qualitative Study Eliciting User Priorities and Needs. *JMIR Mhealth Uhealth*. 2016 Mar 23;4(1):e31. doi: 10.2196/mhealth.5009. PMID: 27009498. *Exclude-Intervention*
1767. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. *CNS Drugs*. 2004;18(6):397-401. doi: 10.2165/00023210-200418060-00011. PMID: 15089111. *Exclude-Design*

Excluded Publications

1768. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. *Drugs*. 2004;64(2):205-22. doi: 10.2165/00003495-200464020-00005. PMID: 14717619. *Exclude-Design*
1769. Sinclair SJ, Walsh-Messinger J, Siefert CJ, et al. Neuropsychological functioning and profile validity on the personality assessment inventory (PAI): An investigation in multiple psychiatric settings. *Bulletin of the Menninger Clinic*. 2015;79(4):305-34. doi: 10.1521/bumc.2015.79.4.305. *Exclude-Population*
1770. Singh A, Balasundaram MK. Comment on: "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder". *CNS Drugs*. 2022 Dec;36(12):1331-2. doi: 10.1007/s40263-022-00966-6. PMID: 36331782. *Exclude-Design*
1771. Singh A, Balasundaram MK, Singh A. Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *J Cent Nerv Syst Dis*. 2022;14:11795735221092522. doi: 10.1177/11795735221092522. PMID: 35615643. *Exclude-Population*
1772. Singh MK, DelBello MP, Strakowski SM. Temperament in child offspring of parents with bipolar disorder. *J Child Adolesc Psychopharmacol*. 2008 Dec;18(6):589-93. doi: 10.1089/cap.2007.142. PMID: 19108663. *Exclude-Population*
1773. Sinnigen K, Emons B, Böhme P, et al. l-Arginine/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment. *Nitric Oxide*. 2023 Sep 1;138-139:64-9. doi: 10.1016/j.niox.2023.06.006. PMID: 37392928. *Exclude-Intervention*
1774. Sitholey P, Agarwal V, Tripathi A. Adult attention deficit/hyperactivity disorder: one year follow up. *Indian J Med Res*. 2010 May;131:692-5. PMID: 20516542. *Exclude-Intervention*
1775. Sizoo B, van den Brink W, Koeter M, et al. Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability. *Drug Alcohol Depend*. 2010 Feb 1;107(1):44-50. doi: 10.1016/j.drugalcdep.2009.09.003. PMID: 19786328. *Exclude-Intervention*
1776. Sjöwall D, Berglund M, Hirvikoski T. Computerized working memory training for adults with ADHD in a psychiatric outpatient context-a feasibility trial. *Appl Neuropsychol Adult*. 2023 Jan 13:1-9. doi: 10.1080/23279095.2022.2162900. PMID: 36639362. *Exclude-Comparator*
1777. Skeel RL, Lesica S, Fust B, et al. Validation of an adult ADHD measure of feigning in a sample including individuals with depression and anxiety symptoms. *Appl Neuropsychol Adult*. 2022 Dec 22:1-7. doi: 10.1080/23279095.2022.2158335. PMID: 36548522. *Exclude-Comparator*
1778. Skoglund C, Brandt L, Almqvist C, et al. Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. *J Clin Psychopharmacol*. 2016 Jun;36(3):222-8. doi: 10.1097/jcp.0000000000000501. PMID: 27043119. *Exclude-Intervention*

Excluded Publications

1779. Skoglund C, Brandt L, D'Onofrio B, et al. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders. *Eur Neuropsychopharmacol*. 2017 Nov;27(11):1144-52. doi: 10.1016/j.euroneuro.2017.08.435. PMID: 28935267. *Exclude-Intervention*
1780. Skott E, Yang LL, Stiernborg M, et al. Effects of a synbiotic on symptoms, and daily functioning in attention deficit hyperactivity disorder - A double-blind randomized controlled trial. *Brain Behav Immun*. 2020 Oct;89:9-19. doi: 10.1016/j.bbi.2020.05.056. PMID: 32497779. *Currently being assessed for management*
1781. Skutle A, Bu ETH, Jellestad FK, et al. Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD. Does ADHD make a difference? *Addict Behav Rep*. 2015 Dec;2:13-8. doi: 10.1016/j.abrep.2015.03.001. PMID: 29531989. *Exclude-Intervention*
1782. Skymba HV, Shields AN, Rauch AA, et al. Does comorbid depression impact executive functioning (EF) in adults diagnosed with ADHD?: a comparison of EF across diagnoses in clinically-referred individuals. *J Clin Exp Neuropsychol*. 2023 Feb;45(1):1-11. doi: 10.1080/13803395.2023.2203464. PMID: 37083506. *Exclude-Intervention*
1783. Slobodin O, Yahav I, Berger I. A machine-based prediction model of ADHD using CPT data. *Frontiers in Human Neuroscience*. 2020;14. doi: 10.3389/fnhum.2020.560021. *Exclude-Population*
1784. Smalley SL, Bailey JN, Palmer CG, et al. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. *Mol Psychiatry*. 1998 Sep;3(5):427-30. doi: 10.1038/sj.mp.4000457. PMID: 9774776. *Exclude-Population*
1785. Smith BH, Pelham WE, Gnagy E, et al. The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for attention-deficit/hyperactivity disorder. *J Consult Clin Psychol*. 2000 Jun;68(3):489-99. doi: 10.1037/0022-006x.68.3.489. PMID: 10883565. *Exclude-Population*
1786. Smith BL, McChristian CL, Smith TD, et al. The relationship of the Reynolds intellectual assessment scales and the Wechsler adult intelligence scale-third edition I. Perceptual and Motor Skills. 2009;109(1):30-40. doi: 10.2466/PMS.109.1.30-40. *Exclude-Intervention*
1787. Smith JL, Johnstone SJ, Barry RJ. Aiding diagnosis of attention-deficit/hyperactivity disorder and its subtypes: discriminant function analysis of event-related potential data. *Journal of Child Psychology and Psychiatry*. 2003;44(7):1067-75. doi: 10.1111/1469-7610.00191. *Exclude-Population*
1788. Smith TE, Samuel DB. A Multi-method Examination of the Links Between ADHD and Personality Disorder. *J Pers Disord*. 2017 Feb;31(1):26-48. doi: 10.1521/pedi_2016_30_236. PMID: 26845530. *Exclude-Intervention*

Excluded Publications

1789. Smoller JW, Kendler KK, Craddock N, et al. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. *The Lancet*. 2013;381(9875):1371-9. doi: 10.1016/S0140-6736(12)62129-1. *Exclude-Intervention*
1790. Snyder SM, Hall JR. A meta-analysis of quantitative EEG power associated with attention-deficit hyperactivity disorder. *J Clin Neurophysiol*. 2006 Oct;23(5):440-55. doi: 10.1097/01.wnp.0000221363.12503.78. PMID: 17016156. *Exclude-Intervention*
1791. Snyder SM, Quintana H, Sexson SB, et al. Blinded, multi-center validation of EEG and rating scales in identifying ADHD within a clinical sample. *Psychiatry Research*. 2008;159(3):346-58. doi: 10.1016/j.psychres.2007.05.006. *Exclude-Population*
1792. Sobanski E, Alm B, Krumm B. [Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder]. *Nervenarzt*. 2007 Mar;78(3):328-30, 33-37. doi: 10.1007/s00115-006-2068-0. PMID: 16544121. *Exclude-Language*
1793. Sobanski E, Retz W, Fischer R, et al. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate. *Eur Psychiatry*. 2014 Jun;29(5):324-30. doi: 10.1016/j.eurpsy.2013.08.004. PMID: 24176644. *Possible multiple publication*
1794. Sobanski E, Sabljic D, Alm B, et al. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. *Pharmacopsychiatry*. 2012 May;45(3):100-7. doi: 10.1055/s-0031-1291319. PMID: 22174029. *Currently being assessed for management*
1795. Sobanski E, Sabljic D, Alm B, et al. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. *Eur Psychiatry*. 2013 Aug;28(6):379-85. doi: 10.1016/j.eurpsy.2012.08.001. PMID: 23062837. *Currently being assessed for management*
1796. Sobanski E, Schredl M, Kettler N, et al. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. *Sleep*. 2008 Mar;31(3):375-81. doi: 10.1093/sleep/31.3.375. PMID: 18363314. *Exclude-Intervention*
1797. Soendergaard HM, Thomsen PH, Pedersen P, et al. Treatment dropout and missed appointments among adults with attention-deficit/hyperactivity disorder: associations with patient- and disorder-related factors. *J Clin Psychiatry*. 2016 Feb;77(2):232-9. doi: 10.4088/JCP.14m09270. PMID: 26761266. *Exclude-Intervention*
1798. Solanto M. Cognitive behaviour therapy interventions for adults with ADHD. *ADHD Attention Deficit and Hyperactivity Disorders*. 2015;7:S112. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
1799. Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. *Am J Psychiatry*. 2010 Aug;167(8):958-68. doi: 10.1176/appi.ajp.2009.09081123. PMID: 20231319. *Currently being assessed for management*

Excluded Publications

1800. Solanto MV, Surman CB, Alvir JMJ. The efficacy of cognitive-behavioral therapy for older adults with ADHD: a randomized controlled trial. *Atten Defic Hyperact Disord*. 2018 Sep;10(3):223-35. doi: 10.1007/s12402-018-0253-1. PMID: 29492784. *Exclude-Duplicate*
1801. Solanto MV, Surman CB, Alvir JMJ. The efficacy of cognitive-behavioral therapy for older adults with ADHD: a randomized controlled trial. *ADHD Attention Deficit and Hyperactivity Disorders*. 2018;10(3):223-35. doi: 10.1007/s12402-018-0253-1. *Currently being assessed for management*
1802. Solanto MV, Wasserstein J, Marks DJ, et al. Diagnosis of ADHD in adults: what is the appropriate DSM-5 symptom threshold for hyperactivity-impulsivity? *J Atten Disord*. 2012 Nov;16(8):631-4. doi: 10.1177/1087054711416910. PMID: 21976031. *Exclude-Outcome*
1803. Soliva JC, Carmona S, Fauquet J, et al. Neurobiological substrates of social cognition impairment in attention-deficit hyperactivity disorder: Gathering insights from seven structural and functional magnetic resonance imaging studies. Values, empathy, and fairness across social barriers. New York, NY, US: New York Academy of Sciences; 2009:212-20. *Exclude-Design*
1804. Solleveld MM, Schrantee A, Puts NAJ, et al. Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. *Neuroimage Clin*. 2017;15:812-8. doi: 10.1016/j.nicl.2017.06.003. PMID: 28725548. *Exclude-Outcome*
1805. Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol Psychiatry*. 2022 Jan;27(1):281-95. doi: 10.1038/s41380-021-01161-7. PMID: 34079068. *Exclude-Intervention*
1806. Someki F, Ohnishi M, Vejdemo-Johansson M, et al. Reliability, validity, factor structure, and measurement invariance of the Japanese conners' adult ADHD rating scales (CAARS). *Journal of Psychoeducational Assessment*. 2020;38(3):337-49. doi: 10.1177/0734282919842030. *Exclude-Intervention*
1807. Soncin S, Brien DC, Coe BC, et al. Contrasting emotion processing and executive functioning in attention-deficit/hyperactivity disorder and bipolar disorder. *Behav Neurosci*. 2016 Oct;130(5):531-43. doi: 10.1037/bne0000158. PMID: 27537826. *Exclude-Intervention*
1808. Song J, Park JH, Han DH, et al. Comparative study of the effects of bupropion and escitalopram on Internet gaming disorder. *Psychiatry Clin Neurosci*. 2016 Nov;70(11):527-35. doi: 10.1111/pcn.12429. PMID: 27487975. *Exclude-Population*
1809. Song P, Zha M, Yang Q, et al. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. *J Glob Health*. 2021 Feb 11;11:04009. doi: 10.7189/jogh.11.04009. PMID: 33692893. *Exclude-Intervention*
1810. Sonuga-Barke EJ, Daley D, Thompson M. Does maternal ADHD reduce the effectiveness of parent training for preschool children's ADHD? *J Am Acad Child Adolesc Psychiatry*. 2002 Jun;41(6):696-702. doi: 10.1097/00004583-200206000-00009. PMID: 12049444. *Exclude-Population*

Excluded Publications

1811. South M, Carr AW, Stephenson KG, et al. Symptom overlap on the srs-2 adult self-report between adults with asd and adults with high anxiety. *Autism Res.* 2017 Jul;10(7):1215-20. doi: 10.1002/aur.1764. PMID: 28266790. *Exclude-Population*
1812. Speirs SJ, Rinehart NJ, Robinson SR, et al. Efficacy of cognitive processes in young people with high-functioning autism spectrum disorder using a novel visual information-processing task. *J Autism Dev Disord.* 2014 Nov;44(11):2809-19. doi: 10.1007/s10803-014-2140-8. PMID: 24838123. *Exclude-Population*
1813. Spencer T, Biederman J, Wilens T. Stimulant treatment of adult attention-deficit/hyperactivity disorder. *Psychiatr Clin North Am.* 2004 Jun;27(2):361-72. doi: 10.1016/j.psc.2003.12.002. PMID: 15064002. *Exclude-Design*
1814. Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. *Psychiatr Clin North Am.* 2004 Jun;27(2):373-83. doi: 10.1016/j.psc.2003.12.001. PMID: 15064003. *Exclude-Design*
1815. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry.* 2005 Mar 1;57(5):456-63. doi: 10.1016/j.biopsych.2004.11.043. PMID: 15737659. *Currently being assessed for management*
1816. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry.* 2001 Aug;58(8):775-82. doi: 10.1001/archpsyc.58.8.775. PMID: 11483144. *Currently being assessed for management*
1817. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. *J Am Acad Child Adolesc Psychiatry.* 1996 Apr;35(4):409-32. doi: 10.1097/00004583-199604000-00008. PMID: 8919704. *Exclude-Design*
1818. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. *Am J Psychiatry.* 1998 May;155(5):693-5. doi: 10.1176/ajp.155.5.693. PMID: 9585725. *Currently being assessed for management*
1819. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. *Arch Gen Psychiatry.* 1995 Jun;52(6):434-43. doi: 10.1001/archpsyc.1995.03950180020004. PMID: 7771913. *Currently being assessed for management*
1820. Spencer TJ. Effect of an opioid receptor antagonist on stimulant treatment of adults with attention-deficit/ hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry.* 2016;55(10):S272. doi: 10.1016/j.jaac.2016.07.175. *Currently being assessed for management*
1821. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexamethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry.*

Excluded Publications

2007 Jun 15;61(12):1380-7. doi: 10.1016/j.biopsych.2006.07.032. PMID: 17137560. *Currently being assessed for management*

1822. Spencer TJ, Adler LA, Meihua Q, et al. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord. 2010 Jul;14(1):57-68. doi: 10.1177/1087054709347435. PMID: 19794135. *Exclude-Outcome*

1823. Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008 Sep;69(9):1437-48. doi: 10.4088/jcp.v69n0911. PMID: 19012813. *Currently being assessed for management*

1824. Spencer TJ, Bhide P, Zhu J, et al. Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone. J Clin Psychiatry. 2018 Jan/Feb;79(1). doi: 10.4088/JCP.16m11012. PMID: 28640990. *Currently being assessed for management*

1825. Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005 Jun 1;57(11):1293-300. doi: 10.1016/j.biopsych.2005.03.036. PMID: 15950001. *Exclude-Intervention*

1826. Spencer TJ, Biederman J, Wozniak J, et al. Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behavior disorders. Biol Psychiatry. 2001 Jun 15;49(12):1062-70. doi: 10.1016/s0006-3223(01)01155-6. PMID: 11430848. *Exclude-Population*

1827. Spencer TJ, Faraone SV, Michelson D, et al. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. doi: 10.4088/jcp.v67n0312. PMID: 16649828. *Exclude-Intervention*

1828. Spencer TJ, Landgraf JM, Adler LA, et al. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008 Nov;69(11):1766-75. doi: 10.4088/jcp.v69n1112. PMID: 19026251. *Currently being assessed for management*

1829. Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011 May;15(4):286-94. doi: 10.1177/1087054710367880. PMID: 20495161. *Currently being assessed for management*

1830. Spencer TJ, Mick E, Surman CBH, et al. A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders. 2011;15(4):286-94. doi: 10.1177/1087054710367880. *Currently being assessed for management*

Excluded Publications

1831. Spiller HA, Hays HL, Aleguas A, Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. *CNS Drugs*. 2013 Jul;27(7):531-43. doi: 10.1007/s40263-013-0084-8. PMID: 23757186. *Exclude-Design*
1832. Sprafkin J, Gadow KD, Weiss MD, et al. Psychiatric comorbidity in ADHD symptom subtypes in clinic and community adults. *J Atten Disord*. 2007 Sep;11(2):114-24. doi: 10.1177/1087054707299402. PMID: 17494828. *Exclude-Intervention*
1833. Stamatis CA, Heusser AC, Simon TJ, et al. Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01. *Transl Psychiatry*. 2024 Aug 11;14(1):328. doi: 10.1038/s41398-024-03045-0. PMID: 39128918. *Exclude-Intervention*
1834. Stamatis CA, Mercaldi C, Kollins SH. A Single-Arm Pivotal Trial to Assess the Efficacy of Akl-T01, a Novel Digital Intervention for Attention, in Adults Diagnosed With ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2023;62(10):S318. doi: 10.1016/j.jaac.2023.09.510. *Currently being assessed for management*
1835. Starck M, Grünwald J, Schlarb AA. Occurrence of ADHD in parents of ADHD children in a clinical sample. *Neuropsychiatr Dis Treat*. 2016;12:581-8. doi: 10.2147/ndt.S100238. PMID: 27042071. *Exclude-Intervention*
1836. State RC, Frye MA, Altshuler LL, et al. Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. *J Clin Psychiatry*. 2004 Aug;65(8):1057-63. doi: 10.4088/jcp.v65n0805. PMID: 15323589. *Exclude-Population*
1837. Steer C, Froelich J, Soutullo CA, et al. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. *CNS Drugs*. 2012 Aug 1;26(8):691-705. doi: 10.2165/11634340-000000000-00000. PMID: 22762726. *Exclude-Population*
1838. Stein MA. Therapeutic management. *Primary Psychiatry*. 2007;14(8):7-9. *Currently being assessed for management*
1839. Stein MA, Zulauf-McCurdy C, DelRosso LM. Attention Deficit Hyperactivity Disorder Medications and Sleep. *Child Adolesc Psychiatr Clin N Am*. 2022 Jul;31(3):499-514. doi: 10.1016/j.chc.2022.03.006. PMID: 35697398. *Exclude-Design*
1840. Steinlechner S, Brüggemann N, Sobottka V, et al. Restless legs syndrome as a possible predictor for psychiatric disorders in parents of children with ADHD. *Eur Arch Psychiatry Clin Neurosci*. 2011 Jun;261(4):285-91. doi: 10.1007/s00406-010-0140-z. PMID: 20820796. *Exclude-Intervention*
1841. Stephen F, Carlos M, Jack T, et al. Assessing the safety and efficacy of stimulant and non-stimulant medications for ADHD in patients with epilepsy. 2022. PMID: CRD42022382723. *Currently being assessed for management*

Excluded Publications

1842. Stern A, Agnew-Blais J, Danese A, et al. Associations between abuse/neglect and ADHD from childhood to young adulthood: A prospective nationally-representative twin study. *Child Abuse Negl.* 2018 Jul;81:274-85. doi: 10.1016/j.chiabu.2018.04.025. PMID: 29775871. *Exclude-Population*
1843. Stern A, Maeir A. Validating the measurement of executive functions in an occupational context for adults with attention deficit hyperactivity disorder. *Am J Occup Ther.* 2014 Nov-Dec;68(6):719-28. doi: 10.5014/ajot.2014.012419. PMID: 25397767. *Exclude-Intervention*
1844. Stern A, Malik E, Pollak Y, et al. The Efficacy of Computerized Cognitive Training in Adults With ADHD: A Randomized Controlled Trial. *J Atten Disord.* 2016 Dec;20(12):991-1003. doi: 10.1177/1087054714529815. PMID: 24756172. *Currently being assessed for management*
1845. Stern P, Kolodny T, Tsafrir S, et al. Near and Far Transfer Effects of Computerized Progressive Attention Training (CPAT) Versus Mindfulness Based Stress Reduction (MBSR) Practice Among Adults With ADHD. *J Atten Disord.* 2023 May;27(7):757-76. doi: 10.1177/10870547231155877. PMID: 36794845. *Currently being assessed for management*
1846. Stern SK, Morris MK. Discrimination of ADHD and reading disability in adults using the D-KEFS. *Arch Clin Neuropsychol.* 2013 Mar;28(2):125-34. doi: 10.1093/arclin/acs111. PMID: 23246933. *Exclude-Intervention*
1847. Stevenson CS, Stevenson RJ, Whitmont S. A self-directed psychosocial intervention with minimal therapist contact for adults with attention deficit hyperactivity disorder. *Clinical Psychology and Psychotherapy.* 2003;10(2):93-101. doi: 10.1002/cpp.356. *Currently being assessed for management*
1848. Stevenson CS, Whitmont S, Bornholt L, et al. A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. *Aust N Z J Psychiatry.* 2002 Oct;36(5):610-6. doi: 10.1046/j.1440-1614.2002.01052.x. PMID: 12225443. *Currently being assessed for management*
1849. Stewart A, Liljequist L. Specificity of the CAARS in Discriminating ADHD Symptoms in Adults From Other Axis I Symptoms. *J Atten Disord.* 2015 Dec;19(12):1007-12. doi: 10.1177/1087054712460086. PMID: 23074300. *Exclude-Intervention*
1850. Stickley A, Koyanagi A, Takahashi H, et al. Attention-deficit/hyperactivity disorder and physical multimorbidity: A population-based study. *Eur Psychiatry.* 2017 Sep;45:227-34. doi: 10.1016/j.eurpsy.2017.07.010. PMID: 28957792. *Exclude-Intervention*
1851. Støre SJ, Tillfors M, Angelhoff C, et al. A robot intervention for adults with ADHD and insomnia-A mixed-method proof-of-concept study. *PLoS One.* 2023;18(9):e0290984. doi: 10.1371/journal.pone.0290984. PMID: 37656707. *Exclude-Design*
1852. Storebø OJ, Andersen ME, Skoog M, et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. *Cochrane Database of Systematic*

Excluded Publications

Reviews. 2019;2019(6). doi: 10.1002/14651858.CD008223.pub3. *Currently being assessed for management*

1853. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015 Nov 25;2015(11):Cd009885. doi: 10.1002/14651858.CD009885.pub2. PMID: 26599576. *Exclude-Population*

1854. Stoy M, Schlagenhaut F, Schlochtermeier L, et al. Reward processing in male adults with childhood ADHD--a comparison between drug-naïve and methylphenidate-treated subjects. Psychopharmacology (Berl). 2011 Jun;215(3):467-81. doi: 10.1007/s00213-011-2166-y. PMID: 21298512. *Exclude-Population*

1855. Strajhar P, Vizeli P, Patt M, et al. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study. J Steroid Biochem Mol Biol. 2019 Feb;186:212-25. doi: 10.1016/j.jsmb.2018.10.016. PMID: 30381248. *Exclude-Population*

1856. Strålin EE, Sunnhed R, Thorell LB, et al. "It was very nice to be in a room where everyone had ADD-that's kind of VIP": Exploring clients' perceptions of group CBT for ADHD inattentive presentation. PLoS One. 2024;19(6):e0299060. doi: 10.1371/journal.pone.0299060. PMID: 38905212. *Exclude-Design*

1857. Strauß M, Petroff D, Huang J, et al. The "VIP-ADHD trial": Does brain arousal have prognostic value for predicting response to psychostimulants in adult ADHD patients? Eur Neuropsychopharmacol. 2021 Feb;43:116-28. doi: 10.1016/j.euroneuro.2020.12.003. PMID: 33388218. *Exclude-Intervention*

1858. Ströhle A, Stoy M, Wrase J, et al. Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder. Neuroimage. 2008 Feb 1;39(3):966-72. doi: 10.1016/j.neuroimage.2007.09.044. PMID: 17996464. *Exclude-Intervention*

1859. Studer P, Kratz O, Gevensleben H, et al. Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability. Front Hum Neurosci. 2014;8:555. doi: 10.3389/fnhum.2014.00555. PMID: 25104932. *Exclude-Population*

1860. Studerus E, Corbisiero S, Mazzariello N, et al. Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)? Eur Psychiatry. 2018 Aug;52:38-44. doi: 10.1016/j.eurpsy.2018.02.006. PMID: 29614390. *Exclude-Intervention*

1861. Stuhec M, Locatelli I. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study. Int J Clin Pharm. 2018 Apr;40(2):341-4. doi: 10.1007/s11096-018-0605-0. PMID: 29468526. *Exclude-Intervention*

1862. Stuhec M, Lukic P, Locatelli I. Comparative efficacy of lisdexamfetamine, mixed amphetamine salts and methylphenidate in treatment of attention deficit hyperactivity disorder in

Excluded Publications

- adults: A systematic review and meta-analysis. *European Neuropsychopharmacology*. 2016;26:S446. *Currently being assessed for management*
1863. Suarez EA, Bateman BT, Hernandez-Diaz S, et al. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. *JAMA Psychiatry*. 2024 May 1;81(5):477-88. doi: 10.1001/jamapsychiatry.2023.5073. PMID: 38265792. *Exclude-Population*
1864. Sugimoto A, Suzuki Y, Orime N, et al. Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. *J Atten Disord*. 2020 Feb;24(3):490-3. doi: 10.1177/1087054716661235. PMID: 27474159. *Exclude-Intervention*
1865. Sugimoto A, Suzuki Y, Yoshinaga K, et al. Influence of Atomoxetine on Relationship Between ADHD Symptoms and Prefrontal Cortex Activity During Task Execution in Adult Patients. *Front Hum Neurosci*. 2021;15:755025. doi: 10.3389/fnhum.2021.755025. PMID: 34899218. *Exclude-Intervention*
1866. Suhr J, Zimak E, Buelow M, et al. Self-reported childhood attention-deficit/hyperactivity disorder symptoms are not specific to the disorder. *Compr Psychiatry*. 2009 May-Jun;50(3):269-75. doi: 10.1016/j.comppsy.2008.08.008. PMID: 19374973. *Exclude-Population*
1867. Sullivan BK, May K, Galbally L. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. *Appl Neuropsychol*. 2007;14(3):189-207. doi: 10.1080/09084280701509083. PMID: 17848130. *Exclude-Intervention*
1868. Sullivan SA, Hamilton W, Tilling K, et al. Association of Primary Care Consultation Patterns With Early Signs and Symptoms of Psychosis. *JAMA Netw Open*. 2018 Nov 2;1(7):e185174. doi: 10.1001/jamanetworkopen.2018.5174. PMID: 30646393. *Exclude-Population*
1869. Sultan RS, Correll CU, Schoenbaum M, et al. National Patterns of Commonly Prescribed Psychotropic Medications to Young People. *J Child Adolesc Psychopharmacol*. 2018 Apr;28(3):158-65. doi: 10.1089/cap.2017.0077. PMID: 29376743. *Exclude-Population*
1870. Sun TH, Yeom JW, Choi KY, et al. Potential effectiveness of digital therapeutics specialized in executive functions as adjunctive treatment for clinical symptoms of attention-deficit/hyperactivity disorder: a feasibility study. *Frontiers in Psychiatry*. 2023;14. doi: 10.3389/fpsyt.2023.1169030. *Currently being assessed for management*
1871. Surman C, Boland H, Kaufman D, et al. Personalized Remote Mobile Surveys of Adult ADHD Symptoms and Function: A Pilot Study of Usability and Utility for Pharmacology Monitoring. *J Atten Disord*. 2022 May;26(7):1001-10. doi: 10.1177/10870547211044213. PMID: 34693788. *Exclude-Intervention*
1872. Surman C, Ceranoglu A, Vaudreuil C, et al. Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *J Clin Psychopharmacol*. 2019 Jan/Feb;39(1):28-38. doi: 10.1097/jcp.0000000000000990. PMID: 30566416. *Currently being assessed for management*

Excluded Publications

1873. Surman C, Hammerness P, Petty C, et al. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study. *CNS Neurosci Ther.* 2010 Spring;16(1):6-12. doi: 10.1111/j.1755-5949.2009.00124.x. PMID: 20070786. *Exclude-Design*
1874. Surman C, Vaudreuil C, Boland H, et al. L-Threonic Acid Magnesium Salt Supplementation in ADHD: An Open-Label Pilot Study. *J Diet Suppl.* 2021;18(2):119-31. doi: 10.1080/19390211.2020.1731044. PMID: 32162987. *Exclude-Comparator*
1875. Surman C, Walsh DM, Horick N, et al. 2.39 Solriamfetol for ADHD in Adults: A Double-Blind Placebo-Controlled Pilot Study. *Journal of the American Academy of Child and Adolescent Psychiatry.* 2023;62(10):S193. doi: 10.1016/j.jaac.2023.09.126. *Currently being assessed for management*
1876. Surman CB, Adamson JJ, Petty C, et al. Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study. *J Clin Psychiatry.* 2009 Nov;70(11):1523-9. doi: 10.4088/JCP.08m04514. PMID: 19646365. *Exclude-Intervention*
1877. Surman CB, Biederman J, Spencer T, et al. Neuropsychological Deficits Are Not Predictive of Deficient Emotional Self-Regulation in Adults With ADHD. *J Atten Disord.* 2015 Dec;19(12):1046-53. doi: 10.1177/1087054713476548. PMID: 23503813. *Exclude-Intervention*
1878. Surman CB, Biederman J, Spencer T, et al. Deficient emotional self-regulation and adult attention deficit hyperactivity disorder: a family risk analysis. *Am J Psychiatry.* 2011 Jun;168(6):617-23. doi: 10.1176/appi.ajp.2010.10081172. PMID: 21498464. *Exclude-Intervention*
1879. Surman CB, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. *World J Biol Psychiatry.* 2013 May;14(4):291-8. doi: 10.3109/15622975.2011.623716. PMID: 22436083. *Exclude-Design*
1880. Surman CB, Monuteaux MC, Petty CR, et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. *J Clin Psychiatry.* 2010 Dec;71(12):1612-6. doi: 10.4088/JCP.09m05344pur. PMID: 20816030. *Exclude-Intervention*
1881. Surman CB, Roth T. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. *J Clin Psychiatry.* 2011 Jul;72(7):903-8. doi: 10.4088/JCP.11m06838. PMID: 21824454. *Possible multiple publication*
1882. Surman CBH, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. *World Journal of Biological Psychiatry.* 2013;14(4):291-8. doi: 10.3109/15622975.2011.623716. *Currently being assessed for management*
1883. Surman CBH, Robertson B, Chen J, et al. Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in

Excluded Publications

Adults with Attention-Deficit/Hyperactivity Disorder. *CNS Drugs*. 2019 Jul;33(7):695-706. doi: 10.1007/s40263-019-00645-z. PMID: 31228031. *Possible multiple publication*

1884. Surman CBH, Walsh DM, Horick N, et al. Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. *J Clin Psychiatry*. 2023 Oct 9;84(6). doi: 10.4088/JCP.23m14934. PMID: 37819836. *Currently being assessed for management*

1885. Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus bupirone, or placebo in adults with ADHD. *J Clin Psychiatry*. 2012 Apr;73(4):445-50. doi: 10.4088/JCP.10m06788. PMID: 22313788. *Currently being assessed for management*

1886. Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus bupirone, or placebo in adults with ADHD. *The Journal of Clinical Psychiatry*. 2012;73(4):445-50. doi: 10.4088/JCP.10m06788. *Currently being assessed for management*

1887. Svedell LA, Holmqvist KL, Lindvall MA, et al. Feasibility and tolerability of moderate intensity regular physical exercise as treatment for core symptoms of attention deficit hyperactivity disorder: a randomized pilot study. *Front Sports Act Living*. 2023;5:1133256. doi: 10.3389/fspor.2023.1133256. PMID: 37255729. *Currently being assessed for management*

1888. Swanson JM. Role of executive function in ADHD. *J Clin Psychiatry*. 2003;64 Suppl 14:35-9. PMID: 14658934. *Exclude-Population*

1889. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. *Clin Ther*. 2007 Apr;29(4):617-25. doi: 10.1016/j.clinthera.2007.04.016. PMID: 17617285. *Exclude-Population*

1890. Swedish Council on Health Technology A. SBU Systematic Review Summaries. ADHD -- Diagnostics and Treatment, Organization of the Health Care and Patient Involvement. Stockholm: Swedish Council on Health Technology Assessment (SBU)

Copyright © 2013 by the Swedish Council on Health Technology Assessment.; 2013. *Exclude-Language*

1891. Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. *J Adolesc Health*. 2004 Oct;35(4):346.e1-9. PMID: 15830457. *Exclude-Population*

1892. Syeda Maimoona B, hifza a. effectiveness of cognitive behavioral therapy for adults with attention deficit hyperactivity disorder: A systemic review and meta analysis. 2024. PMID: CRD42024575137. *Exclude-Design*

Excluded Publications

1893. Syrjänen M, Hautamäki A, Pleshkova N, et al. Attachment and sensitivity among parents with ADHD—A multiple-case study. *Emotional & Behavioural Difficulties*. 2019;24(2):156-66. doi: 10.1080/13632752.2019.1602985. *Exclude-Intervention*
1894. Szewczuk-Bogusławska M, Flisiak-Antonijczuk H. [Will new diagnostic criteria facilitate the diagnostic process of ADHD in adults?]. *Psychiatr Pol*. 2013 Mar-Apr;47(2):293-302. PMID: 23888762. *Exclude-Language*
1895. Szobot CM, Roman T, Hutz MH, et al. Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity. *Synapse*. 2011 Feb;65(2):154-9. doi: 10.1002/syn.20829. PMID: 20593420. *Exclude-Population*
1896. Tachmazidis I, Chen T, Adamou M, et al. A hybrid AI approach for supporting clinical diagnosis of attention deficit hyperactivity disorder (ADHD) in adults. *Health Inf Sci Syst*. 2021 Dec;9(1):1. doi: 10.1007/s13755-020-00123-7. PMID: 33235709. *Exclude-Design*
1897. Takahashi M, Goto T, Takita Y, et al. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. *Asia Pac Psychiatry*. 2014 Mar;6(1):62-70. doi: 10.1111/j.1758-5872.2012.00204.x. PMID: 23857916. *Exclude-Design*
1898. Takahashi M, Takita Y, Goto T, et al. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. *Psychiatry Clin Neurosci*. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x. PMID: 21265936. *Exclude-Design*
1899. Takahashi N, Koh T, Tominaga Y, et al. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. *World J Biol Psychiatry*. 2014 Aug;15(6):488-98. doi: 10.3109/15622975.2013.868925. PMID: 24456065. *Currently being assessed for management*
1900. Takeda T, Tsuji Y, Kanazawa J, et al. Psychometric properties of the Japanese version of the Weiss Functional Impairment Rating Scale: Self-Report. *Atten Defic Hyperact Disord*. 2017 Sep;9(3):169-77. doi: 10.1007/s12402-016-0213-6. PMID: 28013402. *Exclude-Intervention*
1901. Takeda T, Tsuji Y, Kurita H. Psychometric properties of the Japanese version of the Adult Attention-deficit hyperactivity disorder (ADHD) Self-Report Scale (ASRS-J) and its short scale in accordance with DSM-5 diagnostic criteria. *Res Dev Disabil*. 2017 Apr;63:59-66. doi: 10.1016/j.ridd.2017.02.011. PMID: 28260624. *Exclude-Language*
1902. Tamburin S, Federico A, Morbioli L, et al. Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients. *Am J Addict*. 2017 Sep;26(6):610-4. doi: 10.1111/ajad.12573. PMID: 28570753. *Exclude-Intervention*
1903. Tamm L, Narad ME, Antonini TN, et al. Reaction time variability in ADHD: A review. *Neurotherapeutics*. 2012;9(3):500-8. doi: 10.1007/s13311-012-0138-5. *Exclude-Duplicate*

Excluded Publications

1904. Tamm L, Narad ME, Antonini TN, et al. Reaction time variability in ADHD: a review. *Neurotherapeutics*. 2012 Jul;9(3):500-8. doi: 10.1007/s13311-012-0138-5. PMID: 22930417. *Exclude-Design*
1905. Tamminga HGH, Reneman L, Schrantee A, et al. Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD. *Eur Neuropsychopharmacol*. 2021 May;46:1-13. doi: 10.1016/j.euroneuro.2021.02.002. PMID: 33735707. *Currently being assessed for management*
1906. Tamsin N-D, Anna P, Tamsin F, et al. A systematic review of tools and training interventions to improve management of ADHD in primary care. 2020. PMID: CRD42020166570. *Currently being assessed for management*
1907. Tanaka SC, Yahata N, Todokoro A, et al. Preliminary evidence of altered neural response during intertemporal choice of losses in adult attention-deficit hyperactivity disorder. *Sci Rep*. 2018 Apr 30;8(1):6703. doi: 10.1038/s41598-018-24944-5. PMID: 29712945. *Exclude-Intervention*
1908. Tanaka Y, Brod M, Lane JR, et al. What Is a Clinically Relevant Improvement in Quality of Life in Adults With ADHD? *J Atten Disord*. 2019 Jan;23(1):65-75. doi: 10.1177/1087054715580395. PMID: 25876607. *Exclude-Intervention*
1909. Tanaka Y, Escobar R, Upadhyaya HP. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study. *Atten Defic Hyperact Disord*. 2017 Jun;9(2):113-20. doi: 10.1007/s12402-016-0212-7. PMID: 28058589. *Possible multiple publication*
1910. Tanaka Y, Upadhyaya H. Assessment of effects of atomoxetine in adult patients with ADHD: Consistency among 3 geographic regions in a response maintenance study. *European Neuropsychopharmacology*. 2013;23:S600. doi: 10.1016/S0924-977X(13)70955-6. *Currently being assessed for management*
1911. Tang H, Zhang Z, Chen H, et al. Core items selection and psychometric properties of the adult attention-deficit hyperactivity disorder self-report scale-chinese short version (ASRS-CSV). *Asian Journal of Psychiatry*. 2024;99. doi: 10.1016/j.ajp.2024.104136. *Exclude-Comparator*
1912. Taş Dölek G, Tuğba Ozel-Kizil E, Bastug G, et al. Impaired auditory and visual time reproduction in adult patients with attention deficit-hyperactivity disorder. *J Clin Exp Neuropsychol*. 2021 Mar;43(2):176-86. doi: 10.1080/13803395.2021.1898549. PMID: 33779502. *Exclude-Intervention*
1913. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. *J Child Adolesc Psychopharmacol*. 2000 Winter;10(4):311-20. doi: 10.1089/cap.2000.10.311. PMID: 11191692. *Currently being assessed for management*

Excluded Publications

1914. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol.* 2001 Apr;21(2):223-8. doi: 10.1097/00004714-200104000-00015. PMID: 11270920. *Currently being assessed for management*
1915. Taylor MR, Boden JM, Rucklidge JJ, et al. The function of reward sensitivity and temporal discounting in the relationship between risk and ADHD in adults. *New Zealand Journal of Psychology.* 2017;46(1):36-46. *Exclude-Intervention*
1916. Taymur I, Budak E, Onen S, et al. The relationship between childhood and adult attention-deficit–hyperactivity disorder and general psychopathological features in individuals who apply for bariatric surgery. *Bariatric Surgical Practice and Patient Care.* 2016;11(3):116-22. doi: 10.1089/bari.2016.0003. *Exclude-Intervention*
1917. Tcheremissine OV, Lieving LM. Once-daily medications for the pharmacological management of ADHD in adults. *Ther Clin Risk Manag.* 2009 Apr;5(2):367-79. doi: 10.2147/tcrm.s4206. PMID: 19536322. *Exclude-Population*
1918. Tcheremissine OV, Salazar JO. Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions. *Expert Opin Pharmacother.* 2008 Jun;9(8):1299-310. doi: 10.1517/14656566.9.8.1299. PMID: 18473705. *Exclude-Design*
1919. Tebartz van Elst L, Maier S, Klöppel S, et al. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. *J Psychiatry Neurosci.* 2016 Oct;41(6):422-30. doi: 10.1503/jpn.150320. PMID: 27575717. *Exclude-Intervention*
1920. Teicher MH. Actigraphy and motion analysis: new tools for psychiatry. *Harv Rev Psychiatry.* 1995 May-Jun;3(1):18-35. doi: 10.3109/10673229509017161. PMID: 9384925. *Exclude-Intervention*
1921. Teicher MH, Polcari A, Fourligas N, et al. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. *BMC Psychiatry.* 2012 Nov 7;12:190. doi: 10.1186/1471-244x-12-190. PMID: 23134619. *Exclude-Intervention*
1922. Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). *J Atten Disord.* 2002 Sep;6(2):49-60. doi: 10.1177/108705470200600201. PMID: 12142861. *Currently being assessed for management*
1923. Teo SK, Scheffler MR, Wu A, et al. A single-dose, two-way crossover, bioequivalence study of dexamethylphenidate HCl with and without food in healthy subjects. *J Clin Pharmacol.* 2004 Feb;44(2):173-8. doi: 10.1177/0091270003261899. PMID: 14747426. *Exclude-Population*
1924. Thapar A, Cooper M. Attention deficit hyperactivity disorder. *Lancet.* 2016 Mar 19;387(10024):1240-50. doi: 10.1016/s0140-6736(15)00238-x. PMID: 26386541. *Exclude-Design*

Excluded Publications

1925. Theiling J, Petermann F. Neuropsychological Profiles on the WAIS-IV of Adults With ADHD. *J Atten Disord*. 2016 Nov;20(11):913-24. doi: 10.1177/1087054713518241. PMID: 24448224. *Exclude-Intervention*
1926. Theiling J, Petermann F, Daseking M. [Relationship between self-reported ADHD symptoms and WAIS-IV performance]. *Gesundheitswesen*. 2013 Nov;75(11):768-74. doi: 10.1055/s-0033-1357163. PMID: 24165919. *Exclude-Language*
1927. Thoma P, Edel MA, Suchan B, et al. Probabilistic reward learning in adults with Attention Deficit Hyperactivity Disorder--an electrophysiological study. *Psychiatry Res*. 2015 Jan 30;225(1-2):133-44. doi: 10.1016/j.psychres.2014.11.006. PMID: 25467706. *Exclude-Intervention*
1928. Thomason KE, Gudjonsson G, German E, et al. Sociomoral Reasoning in Adults with ADHD: A Pilot Study. *AIMS Public Health*. 2014;1(3):147-59. doi: 10.3934/publichealth.2014.3.147. PMID: 29546083. *Exclude-Intervention*
1929. Thome J, Dittmann RW, Greenhill LL, et al. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine. *Atten Defic Hyperact Disord*. 2017 Dec;9(4):219-29. doi: 10.1007/s12402-017-0227-8. PMID: 28477289. *Possible multiple publication*
1930. Thome J, Escobar R, Lipsius S, et al. Predictors of relapse or maintenance of response of Attention-Deficit/Hyperactivity Disorder symptoms after discontinuation of long-term treatment with atomoxetine. *ADHD Attention Deficit and Hyperactivity Disorders*. 2015;7:S97. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
1931. Thompson L, Thompson M. Neurofeedback combined with training in metacognitive strategies: effectiveness in students with ADD. *Appl Psychophysiol Biofeedback*. 1998 Dec;23(4):243-63. doi: 10.1023/a:1022213731956. PMID: 10457815. *Exclude-Intervention*
1932. Thorell LB, Sjöwall D, Mies GW, et al. Quick Delay Questionnaire: Reliability, validity, and relations to functional impairments in adults with attention-deficit/hyperactivity disorder (ADHD). *Psychol Assess*. 2017 Oct;29(10):1261-72. doi: 10.1037/pas0000421. PMID: 27991822. *Exclude-Language*
1933. Tinius TP. The Integrated Visual and Auditory Continuous Performance Test as a neuropsychological measure. *Arch Clin Neuropsychol*. 2003 Jul;18(5):439-54. PMID: 14591441. *Exclude-Intervention*
1934. Tinius TP. The intermediate visual and auditory continuous performance test as a neuropsychological measure. *Arch Clin Neuropsychol*. 2003 Mar;18(2):199-214. PMID: 14591471. *Exclude-Intervention*
1935. Tittel SR, Kulzer B, Warschburger P, et al. The WHO-5 well-being questionnaire in type 1 diabetes: screening for depression in pediatric and young adult subjects. *J Pediatr Endocrinol*

Excluded Publications

- Metab. 2023 Apr 25;36(4):384-92. doi: 10.1515/jpem-2023-0013. PMID: 36810205. *Exclude-Population*
1936. Tobias B, Cesar S, Alessandro Z, et al. A systematic review of quality of life and functional outcomes in randomized, placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. 2015. PMID: CRD42015027595. *Currently being assessed for management*
1937. Tockhorn A, Televantou F, Dilla T. Atomoxetine for the treatment of newly diagnosed adults with ADHD-a cost effectiveness analysis in Spain. Value in Health. 2014;17(7):A457. doi: 10.1016/j.jval.2014.08.1257. *Currently being assessed for management*
1938. Todor I, Popa A, Neag M, et al. Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Pharmacology. 2017;99(1-2):84-8. doi: 10.1159/000452223. PMID: 27816979. *Exclude-Population*
1939. Tomlinson A, Grayson B, Marsh S, et al. Putative therapeutic targets for symptom subtypes of adult ADHD: D4 receptor agonism and COMT inhibition improve attention and response inhibition in a novel translational animal model. Eur Neuropsychopharmacol. 2015 Apr;25(4):454-67. doi: 10.1016/j.euroneuro.2014.11.016. PMID: 25799918. *Exclude-Population*
1940. Torres I, Garriga M, Sole B, et al. Functional impairment in adult bipolar disorder with ADHD. J Affect Disord. 2018 Feb;227:117-25. doi: 10.1016/j.jad.2017.09.037. PMID: 29055259. *Exclude-Intervention*
1941. Torres I, Gómez N, Colom F, et al. Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. Acta Psychiatr Scand. 2015 Nov;132(5):389-99. doi: 10.1111/acps.12426. PMID: 25900393. *Exclude-Intervention*
1942. Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord. 2009 Jul;13(1):95-6. doi: 10.1177/1087054708326109. PMID: 19359667. *Exclude-Design*
1943. Tourjman SV, Potvin S, Corbalan F, et al. Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry. Atten Defic Hyperact Disord. 2019 Jun;11(2):139-47. doi: 10.1007/s12402-018-0268-7. PMID: 30225804. *Exclude-Intervention*
1944. Trantou A, Carlsen HK, Anderson C, et al. Sickness Absence Recommendation Among Outpatients With ADHD and Comorbidity: A Latent Class Analysis. J Atten Disord. 2021 Jan;25(2):209-16. doi: 10.1177/1087054718780338. PMID: 29882460. *Exclude-Intervention*
1945. Treister R, Eisenberg E, Demeter N, et al. Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). Pain Pract. 2015 Jan;15(1):4-11. doi: 10.1111/papr.12129. PMID: 24134430. *Exclude-Design*

Excluded Publications

1946. Trognon A, Richard M. Questionnaire-based computational screening of adult ADHD. BMC Psychiatry. 2022 Jun 15;22(1):401. doi: 10.1186/s12888-022-04048-1. PMID: 35706020. *Exclude-Language*
1947. Tsai CH, Gau SF. [Long-term outcome studies of hyperactive children: literature review]. Kaohsiung J Med Sci. 1999 Jun;15(6):307-14. PMID: 10441937. *Exclude-Language*
1948. Tse PKY, Finley J-C, Frick L, et al. Cross-validating the embedded performance validity indicators in the Rey Auditory Verbal Learning Test in mixed neuropsychiatric and attention-deficit/hyperactivity disorder clinical samples. Psychology & Neuroscience. 2023;16(2):125-37. doi: 10.1037/pne0000302. *Exclude-Intervention*
1949. Tseng PH, Cameron IG, Pari G, et al. High-throughput classification of clinical populations from natural viewing eye movements. J Neurol. 2013 Jan;260(1):275-84. doi: 10.1007/s00415-012-6631-2. PMID: 22926163. *Exclude-Population*
1950. Tsirmpas C, Nikolakopoulou M, Kaplow S, et al. A Digital Mental Health Support Program for Depression and Anxiety in Populations With Attention-Deficit/Hyperactivity Disorder: Feasibility and Usability Study. JMIR Form Res. 2023 Oct 11;7:e48362. doi: 10.2196/48362. PMID: 37819688. *Exclude-Intervention*
1951. Tucha L, Sontag TA, Walitza S, et al. Detection of malingered attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2009 May;1(1):47-53. doi: 10.1007/s12402-009-0007-1. PMID: 21432579. *Exclude-Intervention*
1952. Tucha O, Mecklinger L, Laufkötter R, et al. Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder. J Neural Transm (Vienna). 2006 Oct;113(10):1575-92. doi: 10.1007/s00702-005-0437-7. PMID: 16897610. *Exclude-Intervention*
1953. Turner DC, Blackwell AD, Dowson JH, et al. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2005 Mar;178(2-3):286-95. doi: 10.1007/s00213-004-1993-5. PMID: 15338103. *Exclude-Intervention*
1954. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004 May 15;55(10):1031-40. doi: 10.1016/j.biopsych.2004.02.008. PMID: 15121488. *Exclude-Timing*
1955. U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. 2023. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions>. Accessed on June 10, 2024. *Exclude-Intervention*
1956. Uebel-von Sandersleben H, Mayer A, Ruhmann M, et al. Pharmacokinetics of a modified-release dexamphetamine sulfate formulation following single and multiple dosing in healthy adults: Comparative bioavailability with immediate-release dexamphetamine sulfate, between strengths, assessment of food and meal composition effects. Scandinavian Journal of Child and

Excluded Publications

Adolescent Psychiatry and Psychology. 2023;11(1):132-42. *Currently being assessed for management*

1957. Uğurpala C, Tükel R, Ziylan EÇ, et al. Social cognition and functioning in patients with social anxiety disorder and/or attention-deficit/hyperactivity disorder. Journal of Nervous and Mental Disease. 2023;211(11):828-34. doi: 10.1097/NMD.0000000000001696. *Exclude-Intervention*

1958. Ulberstad F, Boström H, Chavanon ML, et al. Objective measurement of attention deficit hyperactivity disorder symptoms outside the clinic using the QbCheck: Reliability and validity. Int J Methods Psychiatr Res. 2020 Jun;29(2):e1822. doi: 10.1002/mpr.1822. PMID: 32100383. *Exclude-Population*

1959. Ulusoy V, Bilican I, Gormez A. Effectiveness of an online dialectical behavior therapy skills training in adults with attention-deficit/hyperactivity disorder: A randomized controlled trial. Psychother Res. 2024 Feb 15;1-17. doi: 10.1080/10503307.2024.2311773. PMID: 38359387. *Currently being assessed for management*

1960. Unal M, O'Mahony E, Dunne C, et al. The clinical utility of three visual attention tests to distinguish adults with ADHD from normal controls. Rivista di Psichiatria. 2019;54(5):211-7. doi: 10.1708/3249.32185. *Exclude-Duplicate*

1961. Upadhyaya H, Adler LA, Casas M, et al. Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine. Child Adolesc Psychiatry Ment Health. 2013 May 6;7(1):14. doi: 10.1186/1753-2000-7-14. PMID: 23648011. *Exclude-Intervention*

1962. Upadhyaya H, Ramos-Quiroga JA, Adler LA, et al. Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study. European Journal of Psychiatry. 2013;27(3):185-205. doi: 10.4321/S0213-61632013000300004. *Currently being assessed for management*

1963. Upadhyaya H, Tanaka Y, Lipsius S, et al. Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD. Postgrad Med. 2015;127(7):677-85. doi: 10.1080/00325481.2015.1083394. PMID: 26329980. *Currently being assessed for management*

1964. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007;68 Suppl 11:23-30. PMID: 18307378. *Exclude-Intervention*

1965. Upadhyaya HP, Brady KT, Sethuraman G, et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2001 Feb;21(1):116-8. doi: 10.1097/00004714-200102000-00025. PMID: 11199938. *Exclude-Comparator*

Excluded Publications

1966. Upadhyaya HP, Camporeale A, Ramos-Quiroga JA, et al. Safety and tolerability of atomoxetine hydrochloride in a placebo-controlled randomized withdrawal study in adults with attention-deficit/hyperactivity disorder. *Neuropsychopharmacology*. 2012;38:S318. doi: 10.1038/npp.2012.221. *Currently being assessed for management*
1967. Vaag JR, Lara-Cabrera ML, Hjemdal O, et al. Psychoeducational groups versus waitlist in treatment of attention-deficit hyperactivity/impulsivity disorder (ADHD) in adults: a protocol for a pilot randomized waitlist-controlled multicenter trial. *Pilot Feasibility Stud*. 2019;5:17. doi: 10.1186/s40814-019-0401-1. PMID: 30693097. *Exclude-Design*
1968. Valero S, Ramos-Quiroga A, Gomà-i-Freixanet M, et al. Personality profile of adult ADHD: the alternative five factor model. *Psychiatry Res*. 2012 Jun 30;198(1):130-4. doi: 10.1016/j.psychres.2011.11.006. PMID: 22386569. *Exclude-Intervention*
1969. van Andel E, Bijlenga D, Vogel SWN, et al. Effects of chronotherapy on circadian rhythm and ADHD symptoms in adults with attention-deficit/hyperactivity disorder and delayed sleep phase syndrome: a randomized clinical trial. *Chronobiol Int*. 2021 Feb;38(2):260-9. doi: 10.1080/07420528.2020.1835943. PMID: 33121289. *Currently being assessed for management*
1970. van Andel E, Bijlenga D, Vogel SWN, et al. Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep. *J Biol Rhythms*. 2022 Dec;37(6):673-89. doi: 10.1177/07487304221124659. PMID: 36181304. *Possible multiple publication*
1971. van de Glind G, van den Brink W, Koeter MWJ, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. *Drug and Alcohol Dependence*. 2013;132(3):587-96. doi: 10.1016/j.drugalcdep.2013.04.010. *Exclude-Duplicate*
1972. Van de Glind G, van den Brink W, Koeter MWJ, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. *Drug and Alcohol Dependence*. 2013;132(3):587-96. doi: 10.1016/j.drugalcdep.2013.04.010. *Exclude-Duplicate*
1973. van den Boogert F, Spaan P, Sizoo B, et al. Sensory Processing, Perceived Stress and Burnout Symptoms in a Working Population during the COVID-19 Crisis. *Int J Environ Res Public Health*. 2022 Feb 11;19(4). doi: 10.3390/ijerph19042043. PMID: 35206231. *Exclude-Intervention*
1974. van der Feltz-Cornelis CM, Aldenkamp AP. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. *Epilepsy Behav*. 2006 May;8(3):659-62. doi: 10.1016/j.yebeh.2006.01.015. PMID: 16504592. *Exclude-Design*
1975. Van der Oord S, Boyer BE, Van Dyck L, et al. A Randomized Controlled Study of a Cognitive Behavioral Planning Intervention for College Students With ADHD: An Effectiveness

Excluded Publications

- Study in Student Counseling Services in Flanders. *J Atten Disord.* 2020 Apr;24(6):849-62. doi: 10.1177/1087054718787033. PMID: 29998770. *Currently being assessed for management*
1976. van Emmerik-van Oortmerssen K, Blankers M, Vedel E, et al. Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial. *Addict Behav.* 2020 Apr;103:106228. doi: 10.1016/j.addbeh.2019.106228. PMID: 31838443. *Exclude-Intervention*
1977. van Emmerik-van Oortmerssen K, Vedel E, Koeter MW, et al. Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial. *BMC Psychiatry.* 2013 May 10;13:132. doi: 10.1186/1471-244x-13-132. PMID: 23663651. *Exclude-Intervention*
1978. van Emmerik-van Oortmerssen K, Vedel E, Kramer FJ, et al. Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial. *Drug Alcohol Depend.* 2019 Apr 1;197:28-36. doi: 10.1016/j.drugalcdep.2018.12.023. PMID: 30769263. *Currently being assessed for management*
1979. van Emmerik-van Oortmerssen K, Vedel E, Kramer FJ, et al. Diagnosing ADHD during active substance use: Feasible or flawed? *Drug Alcohol Depend.* 2017 Nov 1;180:371-5. doi: 10.1016/j.drugalcdep.2017.07.039. PMID: 28957778. *Exclude-Intervention*
1980. van Reekum R, Links PS. N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. *Can J Psychiatry.* 1994 Apr;39(3):186-7. doi: 10.1177/070674379403900321. PMID: 8033025. *Exclude-Design*
1981. van Rensburg R, Meyer HP, Hitchcock SA, et al. Screening for Adult ADHD in Patients with Fibromyalgia Syndrome. *Pain Med.* 2018 Sep 1;19(9):1825-31. doi: 10.1093/pm/pnx275. PMID: 29099955. *Exclude-Intervention*
1982. van Steijn DJ, Oerlemans AM, van Aken MA, et al. Match or mismatch? Influence of parental and offspring ASD and ADHD symptoms on the parent-child relationship. *J Autism Dev Disord.* 2013 Aug;43(8):1935-45. doi: 10.1007/s10803-012-1746-y. PMID: 23263787. *Exclude-Population*
1983. Vannucchi G, Medda P, Pallucchini A, et al. The relationship between attention deficit hyperactivity disorder, bipolarity and mixed features in major depressive patients: Evidence from the BRIDGE-II-Mix Study. *J Affect Disord.* 2019 Mar 1;246:346-54. doi: 10.1016/j.jad.2018.12.089. PMID: 30597295. *Exclude-Intervention*
1984. Vaughan B, Fegert J, Kratochvil CJ. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. *Expert Opin Pharmacother.* 2009 Mar;10(4):669-76. doi: 10.1517/14656560902762873. PMID: 19239401. *Exclude-Population*
1985. Vaughan BS, Wetzel MW, Kratochvil CJ. Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults. *Int Rev Psychiatry.* 2008 Apr;20(2):143-9. doi: 10.1080/09540260801887751. PMID: 18386204. *Exclude-Design*

Excluded Publications

1986. Vaziri-Harami R, Khademi M, Zolfaghari A, et al. Patterns of substance use and initiation timing in adults with substance abuse: a comparison between those with and without attention deficit hyperactivity disorder. *Ann Med Surg (Lond)*. 2024 Aug;86(8):4397-401. doi: 10.1097/ms9.0000000000002272. PMID: 39118714. *Exclude-Intervention*
1987. Vedalaveni Chowdappa S, Ravishankar V, Muralidharan K, et al. The efficacy of atomoxetine in treating adult ADHD: A meta-analysis of placebo-controlled trials. *International Journal of Neuropsychopharmacology*. 2014;17:161. doi: 10.1017/S1461145714000741. *Currently being assessed for management*
1988. Velásquez-Tirado JD, Peña JA. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder]. *Rev Neurol*. 2005 Oct 16-31;41(8):493-500. PMID: 16224736. *Exclude-Language*
1989. Verbeeck WJC. Attention deficit hyperactivity disorder in adults: Diagnostic imperatives. *South African Psychiatry Review*. 2003;6(1):7-9. *Exclude-Design*
1990. Vergara-Moragues E, González-Saiz F, Lozano Rojas O, et al. Diagnosing adult attention deficit/hyperactivity disorder in patients with cocaine dependence: discriminant validity of Barkley executive dysfunction symptoms. *Eur Addict Res*. 2011;17(6):279-84. doi: 10.1159/000329725. PMID: 21912132. *Exclude-Outcome*
1991. Verster JC, Bekker EM, de Roos M, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. *J Psychopharmacol*. 2008 May;22(3):230-7. doi: 10.1177/0269881107082946. PMID: 18308788. *Exclude-Timing*
1992. Verster JC, Bekker EM, Kooij JJ, et al. Methylphenidate significantly improves declarative memory functioning of adults with ADHD. *Psychopharmacology (Berl)*. 2010 Oct;212(2):277-81. doi: 10.1007/s00213-010-1952-2. PMID: 20645078. *Exclude-Timing*
1993. Verster JC, Bekker EM, Kooij JJS, et al. Methylphenidate significantly improves declarative memory functioning of adults with ADHD. *Psychopharmacology*. 2010;212(2):277-81. doi: 10.1007/s00213-010-1952-2. *Currently being assessed for management*
1994. Verster JC, Roth T. Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD. *J Clin Psychopharmacol*. 2014 Oct;34(5):633-6. doi: 10.1097/jcp.0000000000000174. PMID: 24978156. *Exclude-Timing*
1995. Victor MM, Grevet EH, Salgado CA, et al. Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: the role of comorbidities. *J Clin Psychopharmacol*. 2009 Dec;29(6):614-6. doi: 10.1097/JCP.0b013e3181c00b1e. PMID: 19910736. *Exclude-Intervention*
1996. Victoria W, Gashirai M, Richard C. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy [Cochrane protocol]. 2019. PMID: CRD42019146026. *Currently being assessed for management*

Excluded Publications

1997. Vidal R, Bosch R, Nogueira M, et al. Psychoeducation for adults with attention deficit hyperactivity disorder vs. cognitive behavioral group therapy: a randomized controlled pilot study. *J Nerv Ment Dis.* 2013 Oct;201(10):894-900. doi: 10.1097/NMD.0b013e3182a5c2c5. PMID: 24080677. *Currently being assessed for management*
1998. Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2015 Apr;54(4):275-82. doi: 10.1016/j.jaac.2014.12.016. PMID: 25791144. *Exclude-Population*
1999. Vidal R, Valero S, Nogueira M, et al. Emotional lability: the discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. *Compr Psychiatry.* 2014 Oct;55(7):1712-9. doi: 10.1016/j.comppsy.2014.07.001. PMID: 25088514. *Exclude-Language*
2000. Vigo R, Evans SW, Owens JS. Categorization behaviour in adults, adolescents, and attention-deficit/hyperactivity disorder adolescents: A comparative investigation. *Q J Exp Psychol (Hove).* 2015;68(6):1058-72. doi: 10.1080/17470218.2014.974625. PMID: 25311157. *Exclude-Intervention*
2001. Virta M, Hiltunen S, Mattsson M, et al. The impact of hypnotic suggestions on reaction times in continuous performance test in adults with ADHD and healthy controls. *PLoS One.* 2015;10(5):e0126497. doi: 10.1371/journal.pone.0126497. PMID: 25962151. *Exclude-Intervention*
2002. Virta M, Salakari A, Antila M, et al. Short cognitive behavioral therapy and cognitive training for adults with ADHD - a randomized controlled pilot study. *Neuropsychiatr Dis Treat.* 2010 Sep 7;6:443-53. doi: 10.2147/ndt.s11743. PMID: 20856608. *Currently being assessed for management*
2003. Virta M, Salakari A, Antila M, et al. Short cognitive behavioral therapy and cognitive training for adults with ADHD—A randomized controlled pilot study. *Neuropsychiatric Disease and Treatment.* 2010;6(1). *Currently being assessed for management*
2004. Virta M, Vedenpää A, Grönroos N, et al. Adults with ADHD benefit from cognitive-behaviorally oriented group rehabilitation: a study of 29 participants. *J Atten Disord.* 2008 Nov;12(3):218-26. doi: 10.1177/1087054707311657. PMID: 18192618. *Exclude-Design*
2005. Visens LS. [Attention deficit hyperactivity disorder (ADHD): an overview]. *Vertex.* 2012 Sep-Oct;23(105):325-30. PMID: 23269966. *Exclude-Language*
2006. Vitiello B, Perez Algorta G, Arnold LE, et al. Psychotic Symptoms in Attention-Deficit/Hyperactivity Disorder: An Analysis of the MTA Database. *J Am Acad Child Adolesc Psychiatry.* 2017 Apr;56(4):336-43. doi: 10.1016/j.jaac.2017.01.016. PMID: 28335878. *Exclude-Population*
2007. Volk HE, Todorov AA, Hay DA, et al. Simple identification of complex ADHD subtypes using current symptom counts. *J Am Acad Child Adolesc Psychiatry.* 2009 Apr;48(4):441-50. doi: 10.1097/CHI.0b013e31819996ba. PMID: 19318883. *Exclude-Population*

Excluded Publications

2008. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. *Neuroimage*. 2007 Feb 1;34(3):1182-90. doi: 10.1016/j.neuroimage.2006.10.014. PMID: 17126039. *Exclude-Intervention*
2009. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 2007 Aug;64(8):932-40. doi: 10.1001/archpsyc.64.8.932. PMID: 17679638. *Exclude-Outcome*
2010. Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. *J Neurosci*. 2012 Jan 18;32(3):841-9. doi: 10.1523/jneurosci.4461-11.2012. PMID: 22262882. *Exclude-Design*
2011. von Wallenberg Pachaly S, Isaksson J, Kouros I, et al. The WHO Adult ADHD self-report Scale used in a clinical sample of patients with overlapping symptoms - psychometric properties of and scoring methods for the Swedish translation. *Nord J Psychiatry*. 2024 May 1:1-10. doi: 10.1080/08039488.2024.2333079. PMID: 38690774. *Exclude-Language*
2012. von Wirth E, Mandler J, Breuer D, et al. The Accuracy of Retrospective Recall of Childhood ADHD: Results from a Longitudinal Study. *Journal of Psychopathology and Behavioral Assessment*. 2021;43(2):413-26. doi: 10.1007/s10862-020-09852-1. *Exclude-Intervention*
2013. Vrijen C, Hartman CA, Lodder GM, et al. Lower Sensitivity to Happy and Angry Facial Emotions in Young Adults with Psychiatric Problems. *Front Psychol*. 2016;7:1797. doi: 10.3389/fpsyg.2016.01797. PMID: 27920735. *Exclude-Intervention*
2014. Waite R. Women and attention deficit disorders: a great burden overlooked. *J Am Acad Nurse Pract*. 2007 Mar;19(3):116-25. doi: 10.1111/j.1745-7599.2006.00203.x. PMID: 17341278. *Exclude-Design*
2015. Waite R, Ramsay JR. A model for parental ADHD: help-seeking and readiness to change. *Issues Ment Health Nurs*. 2010 Dec;31(12):793-803. doi: 10.3109/01612840.2010.520406. PMID: 21142600. *Exclude-Intervention*
2016. Wakelin C, Willemse M, Munnik E. A review of recent treatments for adults living with attention-deficit/hyperactivity disorder. *South African Journal of Psychiatry*. 2023;29. doi: 10.4102/sajpsy psychiatry.v29i0.2152. *Currently being assessed for management*
2017. Waldman ID, Lilienfeld SO. Diagnostic efficiency of symptoms for oppositional defiant disorder and attention-deficit hyperactivity disorder. *Journal of Consulting and Clinical Psychology*. 1991;59(5):732-8. doi: 10.1037/0022-006X.59.5.732. *Exclude-Population*
2018. Walhovd KB, Amlien I, Schrantee A, et al. Methylphenidate Effects on Cortical Thickness in Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. *AJNR Am J Neuroradiol*. 2020 May;41(5):758-65. doi: 10.3174/ajnr.A6560. PMID: 32414901. *Currently being assessed for management*

Excluded Publications

2019. Walitza S, Melfsen S, Herhaus G, et al. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. *J Neural Transm Suppl.* 2007(72):311-5. doi: 10.1007/978-3-211-73574-9_38. PMID: 17982908. *Exclude-Population*
2020. Walker DJ, Mason O, Clemow DB, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder. *Postgrad Med.* 2015;127(7):686-701. doi: 10.1080/00325481.2015.1081046. PMID: 26343377. *Exclude-Design*
2021. Walker GJ. Personality Assessment Inventory (PAI): Can the PAI distinguish adult Attention-Deficit/Hyperactivity Disorder (ADHD) from other disorders? US: ProQuest Information & Learning; 2014. *Exclude-Outcome*
2022. Wang E-C, Sun L, Zhao X-X, et al. Working memory in patients with different early adulthood outcomes of attention-deficit/hyperactivity disorder. *Chinese Mental Health Journal.* 2014;28(6):423-8. *Exclude-Intervention*
2023. Wang P, Zhang X, Ai X, et al. Modulation of EEG Signals by Visual and Auditory Distractors in Virtual Reality-Based Continuous Performance Tests. *IEEE Transactions on Neural Systems and Rehabilitation Engineering.* 2024;32:2049-59. doi: 10.1109/TNSRE.2024.3405549. *Exclude-Intervention*
2024. Wang Y, Kessel E, Lee S, et al. Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial. *J Child Psychol Psychiatry.* 2022 Nov;63(11):1381-91. doi: 10.1111/jcpp.13585. PMID: 35141898. *Exclude-Population*
2025. Wang Z, Zuschlag ZD, Myers US, et al. Atomoxetine in comorbid ADHD/PTSD: A randomized, placebo controlled, pilot, and feasibility study. *Depress Anxiety.* 2022 Apr;39(4):286-95. doi: 10.1002/da.23248. PMID: 35312136. *Currently being assessed for management*
2026. Ware AL, Crocker N, O'Brien JW, et al. Executive function predicts adaptive behavior in children with histories of heavy prenatal alcohol exposure and attention-deficit/hyperactivity disorder. *Alcohol Clin Exp Res.* 2012 Aug;36(8):1431-41. doi: 10.1111/j.1530-0277.2011.01718.x. PMID: 22587709. *Exclude-Population*
2027. Waschbusch DA, Pelham WE, Jr., Waxmonsky J, et al. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? *J Dev Behav Pediatr.* 2009 Apr;30(2):158-68. doi: 10.1097/DBP.0b013e31819f1c15. PMID: 19363369. *Exclude-Population*
2028. Watson J, Liljequist L. Using the Personality Assessment Inventory to Identify ADHD-Like Symptoms. *J Atten Disord.* 2018 Sep;22(11):1049-55. doi: 10.1177/1087054714567133. PMID: 25630772. *Exclude-Comparator*
2029. Watters C, Adamis D, McNicholas F, et al. The impact of attention deficit hyperactivity disorder (ADHD) in adulthood: a qualitative study. *Ir J Psychol Med.* 2018 Sep;35(3):173-9. doi: 10.1017/ipm.2017.21. PMID: 30124180. *Exclude-Intervention*

Excluded Publications

2030. Waxmonsky JG, Waschbusch DA, Glatt SJ, et al. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. *J Clin Psychiatry*. 2011 Oct;72(10):1366-75. doi: 10.4088/JCP.10m05979pur. PMID: 21367347. *Exclude-Intervention*
2031. Weaver L, Rostain AL, Mace W, et al. Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study. *J ect*. 2012 Jun;28(2):98-103. doi: 10.1097/YCT.0b013e31824532c8. PMID: 22551775. *Exclude-Population*
2032. Weber DA, Reynolds CR. Clinical perspectives on neurobiological effects of psychological trauma. *Neuropsychol Rev*. 2004 Jun;14(2):115-29. doi: 10.1023/b:nerv.0000028082.13778.14. PMID: 15264712. *Exclude-Population*
2033. Weber J, Siddiqui MA. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. *CNS Drugs*. 2009;23(5):419-25. doi: 10.2165/00023210-200923050-00005. PMID: 19453202. *Exclude-Design*
2034. Weber J, Siddiqui MAA. Lisdexamfetamine dimesylate: In attention-deficit hyperactivity disorder in adults. *CNS Drugs*. 2009;23(5):419-25. doi: 10.2165/00023210-200923050-00005. *Currently being assessed for management*
2035. Wei YJ, Zhu Y, Liu W, et al. Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder. *JAMA Netw Open*. 2018 Aug 3;1(4):e181152. doi: 10.1001/jamanetworkopen.2018.1152. PMID: 30646105. *Exclude-Design*
2036. Weibel S, Nicastro R, Prada P, et al. Screening for attention-deficit/hyperactivity disorder in borderline personality disorder. *J Affect Disord*. 2018 Jan 15;226:85-91. doi: 10.1016/j.jad.2017.09.027. PMID: 28964997. *Exclude-Language*
2037. Weiler MD, Bellinger D, Simmons E, et al. Reliability and validity of a DSM-IV based ADHD screener. *Child Neuropsychology*. 2000;6(1):3-23. doi: 10.1076/0929-7049(200003)6:1;1-B;FT003. *Exclude-Population*
2038. Weinstein CS, Apfel RJ, Weinstein SR. Description of mothers with ADHD with children with ADHD. *Psychiatry*. 1998 Spring;61(1):12-9. doi: 10.1080/00332747.1998.11024815. PMID: 9595592. *Exclude-Population*
2039. Weisler R, Ginsberg L, Dirks B, et al. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study. *J Atten Disord*. 2017 Dec;21(14):1198-207. doi: 10.1177/1087054713518242. PMID: 24464328. *Currently being assessed for management*
2040. Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. *CNS Spectr*. 2009 Oct;14(10):573-85. doi: 10.1017/s1092852900024056. PMID: 20095369. *Exclude-Design*

Excluded Publications

2041. Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. *CNS Spectr*. 2005 Dec;10(12 Suppl 20):35-43. doi: 10.1017/s109285290000242x. PMID: 16344839. *Exclude-Design*
2042. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. *CNS Spectr*. 2006 Aug;11(8):625-39. doi: 10.1017/s1092852900013687. PMID: 16871129. *Currently being assessed for management*
2043. Weisler RH, Childress AC. Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications. *Prim Care Companion CNS Disord*. 2011;13(6). doi: 10.4088/PCC.11r01168. PMID: 22454805. *Exclude-Design*
2044. Weisler RH, Goodman DW. Assessment and diagnosis of adult ADHD: Clinical challenges and opportunities for improving patient care. *Primary Psychiatry*. 2008;15(11):53-64. *Exclude-Intervention*
2045. Weisler RH, Greenbaum M, Arnold V, et al. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. *CNS Drugs*. 2017 Aug;31(8):685-97. doi: 10.1007/s40263-017-0455-7. PMID: 28712074. *Currently being assessed for management*
2046. Weisler RH, Pandina GJ, Daly EJ, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. *CNS Drugs*. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000. PMID: 22519922. *Currently being assessed for management*
2047. Weisler RH, Stark JG, Sikes C. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD. *Clin Pharmacol Drug Dev*. 2018 Feb;7(2):160-7. doi: 10.1002/cpdd.361. PMID: 28544344. *Exclude-Timing*
2048. Weiss M, Childress A, Mattingly G, et al. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. *J Child Adolesc Psychopharmacol*. 2018 Oct;28(8):521-9. doi: 10.1089/cap.2017.0166. PMID: 30036076. *Exclude-Population*
2049. Weiss M, Childress A, Nordbrock E, et al. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. *J Clin Med*. 2019 Apr 5;8(4). doi: 10.3390/jcm8040461. PMID: 30959790. *Exclude-Population*
2050. Weiss M, Hechtman L. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. *J Clin Psychiatry*. 2006 Apr;67(4):611-9. PMID: 16669726. *Currently being assessed for management*

Excluded Publications

2051. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. *Cmaj*. 2003 Mar 18;168(6):715-22. PMID: 12642429. *Exclude-Design*
2052. Weiss M, Murray C, Wasdell M, et al. A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. *BMC Psychiatry*. 2012 Apr 5;12:30. doi: 10.1186/1471-244x-12-30. PMID: 22480189. *Possible multiple publication*
2053. Weiss M, Safren SA, Solanto MV, et al. Research forum on psychological treatment of adults with ADHD. *J Atten Disord*. 2008 May;11(6):642-51. doi: 10.1177/1087054708315063. PMID: 18417729. *Exclude-Design*
2054. Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. *J Atten Disord*. 2021 Aug;25(10):1417-28. doi: 10.1177/1087054719896853. PMID: 31916473. *Currently being assessed for management*
2055. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2006;67 Suppl 8:38-45. PMID: 16961429. *Exclude-Intervention*
2056. Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2010 Apr;71(4):381-90. doi: 10.4088/JCP.08m04709pur. PMID: 20361900. *Exclude-Design*
2057. Weiss MD, Wasdell M, Gadow KD, et al. Clinical correlates of oppositional defiant disorder and attention-deficit/hyperactivity disorder in adults. *Postgrad Med*. 2011 Mar;123(2):177-84. doi: 10.3810/pgm.2011.03.2276. PMID: 21474906. *Exclude-Intervention*
2058. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. *J Clin Psychiatry*. 2004;65 Suppl 3:27-37. PMID: 15046533. *Exclude-Design*
2059. Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. *J Clin Psychiatry*. 1998;59 Suppl 7:76-9. PMID: 9680056. *Exclude-Design*
2060. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. *Am J Psychiatry*. 1990 Aug;147(8):1018-20. doi: 10.1176/ajp.147.8.1018. PMID: 2115746. *Exclude-Design*
2061. Wender PH, Reimherr FW, Marchant BK, et al. A one year trial of methylphenidate in the treatment of ADHD. *J Atten Disord*. 2011 Jan;15(1):36-45. doi: 10.1177/1087054709356188. PMID: 20071637. *Currently being assessed for management*
2062. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. *Am J Psychiatry*. 1985 May;142(5):547-52. doi: 10.1176/ajp.142.5.547. PMID: 3885760. *Currently being assessed for management*

Excluded Publications

2063. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981 Apr;38(4):449-56. doi: 10.1001/archpsyc.1981.01780290083009. PMID: 7011250. *Currently being assessed for management*
2064. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001 Jun;931:1-16. PMID: 11462736. *Exclude-Design*
2065. Wender PH, Wood DR, Reimherr FW, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res. 1983 Aug;9(4):329-36. doi: 10.1016/0165-1781(83)90006-9. PMID: 6359210. *Exclude-Design*
2066. Wennberg B, Janeslätt G, Gustafsson PA, et al. Occupational performance goals and outcomes of time-related interventions for children with ADHD. Scand J Occup Ther. 2021 Feb;28(2):158-70. doi: 10.1080/11038128.2020.1820570. PMID: 32955952. *Exclude-Population*
2067. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. doi: 10.2165/00002018-200326100-00006. PMID: 12862507. *Exclude-Design*
2068. Wesemann D, Van Cleve SN. ADHD: From childhood to young adulthood. Nurse Pract. 2018 Mar 12;43(3):8-15. doi: 10.1097/01.NPR.0000530307.76316.cf. PMID: 29438181. *Exclude-Design*
2069. Westby SA. Test of Variables of Attention (TOVA) utility in differentiating Attention Deficit/Hyperactivity Disorder subtypes. US: ProQuest Information & Learning; 1999. *Exclude-Population*
2070. Wettstein R, Klabbers Y, Romijn E, et al. [Cognitive behavioral therapy in combination with pharmacotherapy for adults with ADHD]. Tijdschr Psychiatr. 2021;63(7):550-6. PMID: 34523707. *Exclude-Language*
2071. Wetzel MW, White ML, Knott NL, et al. Stimulant medications modulate frontal gamma deficits in ADHD adults during a time estimation task. Biological Psychiatry. 2011;69(9):45S. doi: 10.1016/j.biopsych.2011.03.030. *Currently being assessed for management*
2072. Weyandt LL, Oster DR, Marraccini ME, et al. Pharmacological interventions for adolescents and adults with ADHD: Stimulant and nonstimulant medications and misuse of prescription stimulants. Psychology Research and Behavior Management. 2014;7. *Currently being assessed for management*
2073. Weyandt LL, White TL, Gudmundsdottir BG, et al. Neurocognitive, Autonomic, and Mood Effects of Adderall: A Pilot Study of Healthy College Students. Pharmacy (Basel). 2018 Jun 27;6(3). doi: 10.3390/pharmacy6030058. PMID: 29954141. *Exclude-Population*
2074. Whitaker AM, Bell TS, Houskamp BM, et al. A neurodevelopmental approach to understanding memory processes among intellectually gifted youth with attention-deficit

Excluded Publications

- hyperactivity disorder. *Appl Neuropsychol Child*. 2015;4(1):31-40. doi: 10.1080/21622965.2013.790821. PMID: 24191777. *Exclude-Intervention*
2075. White DJ, Ovsiew GP, Rhoads T, et al. The Divergent Roles of Symptom and Performance Validity in the Assessment of ADHD. *J Atten Disord*. 2022 Jan;26(1):101-8. doi: 10.1177/1087054720964575. PMID: 33084457. *Exclude-Intervention*
2076. White HA, Shah P. Training attention-switching ability in adults with ADHD. *J Atten Disord*. 2006 Aug;10(1):44-53. doi: 10.1177/1087054705286063. PMID: 16840592. *Currently being assessed for management*
2077. Whyte J, Hart T, Schuster K, et al. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. *Am J Phys Med Rehabil*. 1997 Nov-Dec;76(6):440-50. doi: 10.1097/00002060-199711000-00002. PMID: 9431261. *Exclude-Population*
2078. Wiebe A, Aslan B, Brockmann C, et al. Multimodal assessment of adult attention-deficit hyperactivity disorder: A controlled virtual seminar room study. *Clin Psychol Psychother*. 2023 Sep-Oct;30(5):1111-29. doi: 10.1002/cpp.2863. PMID: 37209018. *Exclude-Intervention*
2079. Wiebe A, Aslan B, Brockmann C, et al. Multimodal assessment of adult attention-deficit hyperactivity disorder: A controlled virtual seminar room study. *Clinical Psychology & Psychotherapy*. 2023;30(5):1111-29. doi: 10.1002/cpp.2863. *Exclude-Duplicate*
2080. Wietecha L, Young J, Ruff D, et al. Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning. *Clin Neuropharmacol*. 2012 May-Jun;35(3):125-33. doi: 10.1097/WNF.0b013e3182560315. PMID: 22561876. *Currently being assessed for management*
2081. Wietecha LA, Clemow DB, Buchanan AS, et al. Atomoxetine increased effect over time in adults with attention-deficit/hyperactivity disorder treated for up to 6 months: Pooled analysis of two double-blind, placebo-controlled, randomized trials. *CNS Neuroscience & Therapeutics*. 2016;22(7):546-57. doi: 10.1111/cns.12533. *Currently being assessed for management*
2082. Wigal SB. Laboratory School Protocol Mini-Review: Use of Direct Observational and Objective Measures to Assess ADHD Treatment Response Across the Lifespan. *Front Psychol*. 2019;10:1796. doi: 10.3389/fpsyg.2019.01796. PMID: 31496966. *Exclude-Population*
2083. Wigal SB, Adjei AL, Childress A, et al. A study of methylphenidate extended-release capsules in a randomized, double-blind, placebo-controlled protocol in children and adolescents with ADHD. *CNS Spectrums*. 2015;20(1):67-8. doi: 10.1017/S1092852914000765. *Currently being assessed for management*
2084. Wigal SB, Duong S. Pharmacokinetic evaluation of eltoprazine. *Expert Opin Drug Metab Toxicol*. 2011 Jun;7(6):775-81. doi: 10.1517/17425255.2011.580275. PMID: 21548716. *Exclude-Design*

Excluded Publications

2085. Wigal SB, Raja P, Shukla A. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder. *Expert Opin Pharmacother*. 2013 Jan;14(1):137-45. doi: 10.1517/14656566.2013.754013. PMID: 23241144. *Exclude-Design*
2086. Wigal SB, Wigal T, Childress A, et al. The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. *J Atten Disord*. 2020 Feb;24(3):373-83. doi: 10.1177/1087054716672335. PMID: 27756854. *Exclude-Timing*
2087. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. *J Atten Disord*. 2006 Aug;10(1):92-111. doi: 10.1177/1087054705286049. PMID: 16840597. *Exclude-Population*
2088. Wigal T, Brams M, Frick G, et al. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. *Postgrad Med*. 2018 Jun;130(5):481-93. doi: 10.1080/00325481.2018.1481712. PMID: 29809075. *Currently being assessed for management*
2089. Wigal T, Brams M, Gasior M, et al. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. *Postgrad Med*. 2011 Mar;123(2):169-76. doi: 10.3810/pgm.2011.03.2275. PMID: 21474905. *Currently being assessed for management*
2090. Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. *Behav Brain Funct*. 2010 Jun 24;6:34. doi: 10.1186/1744-9081-6-34. PMID: 20576091. *Currently being assessed for management*
2091. Wigal T, Childress A, Frick G, et al. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. *Postgrad Med*. 2018 Jan;130(1):111-21. doi: 10.1080/00325481.2018.1389227. PMID: 29087231. *Currently being assessed for management*
2092. Wigal T, Newcorn J, Handel N, et al. A phase ii study to determine the efficacy, safety, tolerability, and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with attention-deficit/hyperactivity disorder (ADHD). *Journal of the American Academy of Child and Adolescent Psychiatry*. 2017;56(10):S169-S70. doi: 10.1016/j.jaac.2017.09.066. *Currently being assessed for management*
2093. Wigal TL, Newcorn JH, Handal N, et al. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). *CNS Drugs*. 2018 Mar;32(3):289-301. doi: 10.1007/s40263-018-0503-y. PMID: 29557078. *Currently being assessed for management*

Excluded Publications

2094. Wiggins D, Singh K, Getz HG, et al. Effects of brief group intervention for adults with attention deficit/hyperactivity disorder. *Journal of Mental Health Counseling*. 1999;21(1):82-92. *Currently being assessed for management*
2095. Wilens T, Adler L, Zhang S, et al. Safety of atomoxetine in ADHD patients with or without comorbid alcohol abuse and dependence. *American Journal on Addictions*. 2009;18(4):329. doi: 10.1080/10550490902928197. *Currently being assessed for management*
2096. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. *J Am Acad Child Adolesc Psychiatry*. 2005 Oct;44(10):1015-23. doi: 10.1097/01.chi.0000173291.28688.e7. PMID: 16175106. *Exclude-Population*
2097. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. *Drug Alcohol Depend*. 2008 Jul 1;96(1-2):145-54. doi: 10.1016/j.drugalcdep.2008.02.009. PMID: 18403134. *Currently being assessed for management*
2098. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. *Am J Psychiatry*. 1996 Sep;153(9):1147-53. doi: 10.1176/ajp.153.9.1147. PMID: 8780417. *Currently being assessed for management*
2099. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. *Annu Rev Med*. 2002;53:113-31. doi: 10.1146/annurev.med.53.082901.103945. PMID: 11818466. *Exclude-Design*
2100. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. *Am J Psychiatry*. 1999 Dec;156(12):1931-7. doi: 10.1176/ajp.156.12.1931. PMID: 10588407. *Currently being assessed for management*
2101. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 1999 Jun;19(3):257-64. doi: 10.1097/00004714-199906000-00009. PMID: 10350032. *Currently being assessed for management*
2102. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. *J Clin Psychiatry*. 2004 Oct;65(10):1301-13. doi: 10.4088/jcp.v65n1003. PMID: 15491232. *Exclude-Design*
2103. Wilens TE, Faraone SV, Biederman J. "Attention-deficit/hyperactivity disorder in adults": Comment reply. *JAMA: Journal of the American Medical Association*. 2004;292(18):2214-. doi: 10.1001/jama.292.18.2214-b. *Exclude-Design*
2104. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. *Biol Psychiatry*. 2005 Apr 1;57(7):793-801. doi: 10.1016/j.biopsych.2005.01.027. PMID: 15820237. *Currently being assessed for management*

Excluded Publications

2105. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2005 Feb;66(2):253-9. doi: 10.4088/jcp.v66n0215. PMID: 15705013. *Exclude-Comparator*
2106. Wilens TE, Klint T, Adler L, et al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. *Behav Brain Funct*. 2008 Jun 13;4:24. doi: 10.1186/1744-9081-4-24. PMID: 18554401. *Currently being assessed for management*
2107. Wilens TE, Monuteaux MC, Snyder LE, et al. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? *J Child Adolesc Psychopharmacol*. 2005 Oct;15(5):787-98. doi: 10.1089/cap.2005.15.787. PMID: 16262595. *Misuse only*
2108. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. *Biol Psychiatry*. 2003 Jul 1;54(1):9-16. doi: 10.1016/s0006-3223(02)01664-5. PMID: 12842303. *Exclude-Comparator*
2109. Wilens TE, Prince JB, Waxmonsky J, et al. An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders. *J ADHD Relat Disord*. 2010 Apr 1;1(3):25-35. PMID: 22500195. *Exclude-Design*
2110. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. *American Journal of Psychiatry*. 2001;158(2):282-8. doi: 10.1176/appi.ajp.158.2.282. *Currently being assessed for management*
2111. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. *Am J Psychiatry*. 2001 Feb;158(2):282-8. doi: 10.1176/appi.ajp.158.2.282. PMID: 11156812. *Currently being assessed for management*
2112. Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. *Biol Psychiatry*. 2006 Jun 1;59(11):1065-70. doi: 10.1016/j.biopsych.2005.10.029. PMID: 16499880. *Currently being assessed for management*
2113. Wilens TE, Waxmonsky J, Scott M, et al. An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2005 Dec;15(6):947-55. doi: 10.1089/cap.2005.15.947. PMID: 16379515. *Exclude-Population*
2114. Wilens TE, Zusman RM, Hammerness PG, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. *J Clin Psychiatry*. 2006 May;67(5):696-702. doi: 10.4088/jcp.v67n0502. PMID: 16841618. *Exclude-Intervention*
2115. Williams ED, Reimherr FW, Marchant BK, et al. Personality disorder in ADHD Part 1: Assessment of personality disorder in adult ADHD using data from a clinical trial of OROS methylphenidate. *Ann Clin Psychiatry*. 2010 May;22(2):84-93. PMID: 20445835. *Exclude-Intervention*

Excluded Publications

2116. Wilson TW, Franzen JD, Heinrichs-Graham E, et al. Broadband neurophysiological abnormalities in the medial prefrontal region of the default-mode network in adults with ADHD. *Hum Brain Mapp.* 2013 Mar;34(3):566-74. doi: 10.1002/hbm.21459. PMID: 22102400. *Exclude-Intervention*
2117. Wilson TW, Heinrichs-Graham E, White ML, et al. Estimating the passage of minutes: deviant oscillatory frontal activity in medicated and unmedicated ADHD. *Neuropsychology.* 2013 Nov;27(6):654-65. doi: 10.1037/a0034032. PMID: 24040925. *Exclude-Intervention*
2118. Wilson TW, Wetzel MW, White ML, et al. Gamma-frequency neuronal activity is diminished in adults with attention-deficit/hyperactivity disorder: a pharmaco-MEG study. *J Psychopharmacol.* 2012 Jun;26(6):771-7. doi: 10.1177/0269881111430731. PMID: 22219219. *Exclude-Intervention*
2119. Wim V, Geertruida B, Wim Van den N. Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults [Cochrane protocol]. 2017. PMID: CRD42017082816. *Currently being assessed for management*
2120. Wingo AP, Ghaemi SN. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. *J Clin Psychiatry.* 2007 Nov;68(11):1776-84. doi: 10.4088/jcp.v68n1118. PMID: 18052572. *Exclude-Population*
2121. Winhusen T, Somoza E, Singal BM, et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. *Pharmacol Biochem Behav.* 2006 Sep;85(1):29-38. doi: 10.1016/j.pbb.2006.06.023. PMID: 16916538. *Exclude-Design*
2122. Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol.* 2011 Oct;21(5):455-63. doi: 10.1089/cap.2011.0014. PMID: 22040190. *Misuse only*
2123. Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry.* 2010 Dec;71(12):1680-8. doi: 10.4088/JCP.09m05089gry. PMID: 20492837. *Currently being assessed for management*
2124. Wolf F, Heinzl-Gutenbrunner M, Becker K. [Retrospective recording of childhood ADHD symptoms : Follow-up of adults formerly diagnosed with childhood ADHD and/or childhood conduct disorder]. *Nervenarzt.* 2018 Mar;89(3):327-34. doi: 10.1007/s00115-017-0321-3. PMID: 28382487. *Exclude-Language*
2125. Wong IC, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study. *Health Technol Assess.* 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490. PMID: 19883527. *Exclude-Population*
2126. Wong ICK, Banaschewski T, Buitelaar J, et al. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder--outcome measures beyond symptom control

Excluded Publications

and clinical trials. *Lancet Psychiatry*. 2019 Jun;6(6):528-37. doi: 10.1016/s2215-0366(19)30096-3. PMID: 31122482. *Exclude-Intervention*

2127. Wood DR, Reimherr FW, Wender PH. Amino acid precursors for the treatment of attention deficit disorder, residual type. *Psychopharmacol Bull*. 1985;21(1):146-9. PMID: 3885291. *Exclude-Population*

2128. Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine. *Psychiatry Res*. 1985 Sep;16(1):21-6. doi: 10.1016/0165-1781(85)90024-1. PMID: 3903813. *Currently being assessed for management*

2129. Wood JE. Probation practice and attention-deficit hyperactivity disorder. *Crim Behav Ment Health*. 2024 Aug;34(4):373-84. doi: 10.1002/cbm.2348. PMID: 38898659. *Exclude-Intervention*

2130. Woolsey C, Smoldon J, Devney R. Initial development of an attention-deficit/hyperactivity disorder visual analog scale for rapid assessment of medication effects. *J Am Assoc Nurse Pract*. 2020 Jan;32(1):8-14. doi: 10.1097/jxx.000000000000209. PMID: 31169786. *Exclude-Design*

2131. Wu G, Zhao X, Luo X, et al. Microstate dynamics and spectral components as markers of persistent and remittent attention-deficit/hyperactivity disorder. *Clin Neurophysiol*. 2024 May;161:147-56. doi: 10.1016/j.clinph.2024.02.027. PMID: 38484486. *Exclude-Intervention*

2132. Wu JS, Nankoo MMA, Bucks RS, et al. Short form Conners' Adult ADHD Rating Scales: Factor structure and measurement invariance by sex in emerging adults. *J Clin Exp Neuropsychol*. 2023 May;45(4):345-64. doi: 10.1080/13803395.2023.2246213. PMID: 37610373. *Exclude-Intervention*

2133. Wu X-P, Sun J-H, Li Q-Q, et al. Reliability and validity of Chinese version of Conners' Adult ADHD Rating Scales Self-Report. *Chinese Mental Health Journal*. 2009;23(5):349-52, 71. *Exclude-Intervention*

2134. Wymer JH, Rayls K, Wagner MT. Utility of a clinically derived abbreviated form of the WAIS-III. *Arch Clin Neuropsychol*. 2003 Dec;18(8):917-27. doi: 10.1016/s0887-6177(02)00221-4. PMID: 14609585. *Exclude-Intervention*

2135. Wyrwich KW, Auguste P, Yu R, et al. Evaluation of Neuropsychiatric Function in Phenylketonuria: Psychometric Properties of the ADHD Rating Scale-IV and Adult ADHD Self-Report Scale Inattention Subscale in Phenylketonuria. *Value Health*. 2015 Jun;18(4):404-12. doi: 10.1016/j.jval.2015.01.008. PMID: 26091594. *Exclude-Population*

2136. Wyrwich KW, Gries KS, Al-Jassar G, et al. Assessing the content validity of the investigator-rated ADHD rating scale version IV (I-ADHD RS-IV) instrument for use in adults with phenylketonuria (PKU). *Quality of Life Research*. 2016;25(1):186. doi: 10.1007/s11136-016-1390-7. *Exclude-Population*

Excluded Publications

2137. Wyrwich KW, Shaffer S, Gries K, et al. Content validity of the ADHD rating scale (ADHD RS-IV) and adult ADHD self-report scale (ASRS) in phenylketonuria. *Journal of Inborn Errors of Metabolism and Screening*. 2016;4. doi: 10.1177/2326409816639316. *Exclude-Population*
2138. Xavier C, Ruth C, Dolors C. Pharmacological treatment of patients with attention deficit hyperactivity disorder (ADHD) and substance use disorder (SUD). 2012. PMID: CRD42012003414. *Currently being assessed for management*
2139. Xiao C, Bledsoe J, Wang S, et al. An integrated feature ranking and selection framework for ADHD characterization. *Brain Inform*. 2016 Sep;3(3):145-55. doi: 10.1007/s40708-016-0047-1. PMID: 27747592. *Exclude-Design*
2140. xinyue Y, Jing Y, Lin Z, et al. Short and Long-Term Effect of Non-pharmacotherapy for Adult with ADHD: A Systematic Review and Network Meta-Analysis. 2024. PMID: CRD42024432912. *Currently being assessed for management*
2141. Yan L, Zhang J, Yuan Y, et al. Effects of neurofeedback versus methylphenidate for the treatment of attention-deficit/hyperactivity disorder protocol for a systematic review and meta-analysis of head-to-head trials. *Medicine (Baltimore)*. 2018 Sep;97(39):e12623. doi: 10.1097/md.00000000000012623. PMID: 30278582. *Exclude-Design*
2142. Yang CC, Hinshaw SP. Associations Between Dimensional Persistence of ADHD and Adult Sleep Quality in a Prospective Study of Girls. *J Atten Disord*. 2023 May;27(7):777-85. doi: 10.1177/10870547231155439. PMID: 36799481. *Exclude-Intervention*
2143. Yang HN, Tai YM, Yang LK, et al. Prediction of childhood ADHD symptoms to quality of life in young adults: adult ADHD and anxiety/depression as mediators. *Res Dev Disabil*. 2013 Oct;34(10):3168-81. doi: 10.1016/j.ridd.2013.06.011. PMID: 23886759. *Exclude-Intervention*
2144. Yang LL, Stiernborg M, Skott E, et al. Effects of a Synbiotic on Plasma Immune Activity Markers and Short-Chain Fatty Acids in Children and Adults with ADHD-A Randomized Controlled Trial. *Nutrients*. 2023 Mar 6;15(5). doi: 10.3390/nu15051293. PMID: 36904292. *Currently being assessed for management*
2145. Yang Z, Kelly C, Castellanos FX, et al. Neural Correlates of Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2016 Aug;26(6):527-36. doi: 10.1089/cap.2015.0243. PMID: 27027541. *Exclude-Comparator*
2146. Yates WR, Lund BC, Johnson C, et al. Attention-deficit hyperactivity symptoms and disorder in eating disorder inpatients. *Int J Eat Disord*. 2009 May;42(4):375-8. doi: 10.1002/eat.20627. PMID: 19040267. *Exclude-Intervention*
2147. Yavuz BG, Yavuz M, Onal A. Examining the factors that are correlated with mindfulness with a focus on attention deficit hyperactivity symptoms. *Perspect Psychiatr Care*. 2018 Oct;54(4):596-602. doi: 10.1111/ppc.12290. PMID: 29774955. *Exclude-Intervention*

Excluded Publications

2148. Yellin AM, Hopwood JH, Greenberg LM. Adults and adolescents with attention deficit disorder: clinical and behavioral responses to psychostimulants. *J Clin Psychopharmacol*. 1982 Apr;2(2):133-6. PMID: 7076878. *Exclude-Design*
2149. Yoncheva YN, Somandepalli K, Reiss PT, et al. Mode of Anisotropy Reveals Global Diffusion Alterations in Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2016 Feb;55(2):137-45. doi: 10.1016/j.jaac.2015.11.011. PMID: 26802781. *Exclude-Outcome*
2150. Young JL, Goodman DW. Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era. *Prim Care Companion CNS Disord*. 2016 Nov 17;18(6). doi: 10.4088/PCC.16r02000. PMID: 27907271. *Exclude-Design*
2151. Young JL, Sarkis E, Qiao M, et al. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. *Clin Neuropharmacol*. 2011 Mar-Apr;34(2):51-60. doi: 10.1097/WNF.0b013e31820c00eb. PMID: 21406998. *Currently being assessed for management*
2152. Young S, Bramham J, Tyson C, et al. Inhibitory dysfunction on the Stroop in adults diagnosed with attention deficit hyperactivity disorder. *Personality and Individual Differences*. 2006;41(8):1377-84. doi: 10.1016/j.paid.2006.01.010. *Exclude-Intervention*
2153. Young S, Emilsson B, Sigurdsson JF, et al. A randomized controlled trial reporting functional outcomes of cognitive-behavioural therapy in medication-treated adults with ADHD and comorbid psychopathology. *Eur Arch Psychiatry Clin Neurosci*. 2017 Apr;267(3):267-76. doi: 10.1007/s00406-016-0735-0. PMID: 27752827. *Currently being assessed for management*
2154. Young S, Khondoker M, Emilsson B, et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. *Psychol Med*. 2015 Oct;45(13):2793-804. doi: 10.1017/s0033291715000756. PMID: 26022103. *Currently being assessed for management*
2155. Young S, Morris R, Toone B, et al. Planning ability in adults with attention-deficit/hyperactivity disorder. *Neuropsychology*. 2007 Sep;21(5):581-9. doi: 10.1037/0894-4105.21.5.581. PMID: 17784806. *Exclude-Intervention*
2156. Young S, Sedgwick O, Fridman M, et al. Co-morbid psychiatric disorders among incarcerated ADHD populations: a meta-analysis. *Psychol Med*. 2015;45(12):2499-510. doi: 10.1017/s0033291715000598. PMID: 25857258. *Exclude-Intervention*
2157. Yozwiak JA. Attention-deficit/hyperactivity disorder: Epidemiology, assessment, and treatment among children, adolescents, and adults. *International Journal on Disability and Human Development*. 2010;9(2-3):87-95. doi: 10.1515/IJDHD.2010.015. *Exclude-Intervention*
2158. Yu D. Additional brain functional network in adults with attention-deficit/hyperactivity disorder: a phase synchrony analysis. *PLoS One*. 2013;8(1):e54516. doi: 10.1371/journal.pone.0054516. PMID: 23382908. *Exclude-Intervention*

Excluded Publications

2159. Yu D, Fang JH. Using artificial intelligence methods to study the effectiveness of exercise in patients with ADHD. *Front Neurosci.* 2024;18:1380886. doi: 10.3389/fnins.2024.1380886. PMID: 38716252. *Exclude-Design*
2160. Yu-Shian C, Hsin-Yi F, Cheuk-Kwan S. A pilot meta-analysis on self-reported efficacy of neurofeedback for adolescents and adults with ADHD. 2021. PMID: CRD42021275952. *Currently being assessed for management*
2161. Yule AM, Martelon M, Faraone SV, et al. Examining the association between attention deficit hyperactivity disorder and substance use disorders: A familial risk analysis. *J Psychiatr Res.* 2017 Feb;85:49-55. doi: 10.1016/j.jpsychires.2016.10.018. PMID: 27835739. *Exclude-Population*
2162. Zaman R. The potential role of transcranial magnetic stimulation in the treatment of ADHD. *ADHD Attention Deficit and Hyperactivity Disorders.* 2015;7:S112. doi: 10.1007/s12402-015-0169-y. *Currently being assessed for management*
2163. Zamani L, Shahrivar Z, Alaghsband-Rad J, et al. Reliability, Criterion and Concurrent Validity of the Farsi Translation of DIVA-5: A Semi-Structured Diagnostic Interview for Adults With ADHD. *J Atten Disord.* 2021 Oct;25(12):1666-75. doi: 10.1177/1087054720930816. PMID: 32486881. *Exclude-Language*
2164. zeping Z, Weijing Z, Xiaolong C, et al. The effect of meditation-based mind-body therapies on symptoms and executive function in children and adults with Attention Deficit/Hyperactivity Disorder: A systematic review and meta-analysis. 2022. PMID: CRD42022353747. *Currently being assessed for management*
2165. Zhang H, Zeng W, Deng J, et al. Brain Relatively Inert Network: Taking Adult Attention Deficit Hyperactivity Disorder as an Example. *Front Neurosci.* 2021;15:771947. doi: 10.3389/fnins.2021.771947. PMID: 34924940. *Exclude-Intervention*
2166. Zhang L, Lagerberg T, Chen Q, et al. Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. *Evid Based Ment Health.* 2021 Nov;24(4):146-52. doi: 10.1136/ebmental-2020-300231. PMID: 33795353. *Exclude-Intervention*
2167. Zhang T, Sidorchuk A, Sevilla-Cermeño L, et al. Association of Cesarean Delivery With Risk of Neurodevelopmental and Psychiatric Disorders in the Offspring: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2019 Aug 2;2(8):e1910236. doi: 10.1001/jamanetworkopen.2019.10236. PMID: 31461150. *Exclude-Population*
2168. Zhang Y, Feng Y, Liu L, et al. Abnormal prefrontal cortical activation during the GO/NOGO and verbal fluency tasks in adult patients with comorbid generalized anxiety disorder and attention-deficit/hyperactivity disorder: An fNIRS study. *J Psychiatr Res.* 2024 Apr;172:281-90. doi: 10.1016/j.jpsychires.2024.02.053. PMID: 38428164. *Exclude-Outcome*

Excluded Publications

2169. Zhao X-X, Sun L, Wang E-C, et al. Working memory performance in high intelligence quotient adults with attention-deficit/ hyperactivity disorder. *Chinese Mental Health Journal*. 2014;28(6):417-22. *Exclude-Intervention*
2170. Zhou Z, Zhou ZY, Kelkar SS, et al. Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. *Curr Med Res Opin*. 2018 Apr;34(4):585-92. doi: 10.1080/03007995.2017.1411792. PMID: 29186993. *Exclude-Intervention*
2171. Zhou Z, Zhou ZY, Kellar SS, et al. Treatment patterns among adults with ADHD receiving long-acting therapy. *Am J Manag Care*. 2018 Jul;24(8 Spec No.):Sp329-sp37. PMID: 30020748. *Exclude-Intervention*
2172. Zilverstand A, Sorger B, Slaats-Willemse D, et al. fMRI Neurofeedback Training for Increasing Anterior Cingulate Cortex Activation in Adult Attention Deficit Hyperactivity Disorder. An Exploratory Randomized, Single-Blinded Study. *PLoS One*. 2017;12(1):e0170795. doi: 10.1371/journal.pone.0170795. PMID: 28125735. *Currently being assessed for management*
2173. Zimmerman M, Gorlin E, Dalrymple K, et al. A clinically useful screen for attention-deficit/hyperactivity disorder in adult psychiatric outpatients. *Ann Clin Psychiatry*. 2017 Aug;29(3):160-6. PMID: 28738095. *Exclude-Intervention*
2174. Zimmermann M, Grabemann M, Mette C, et al. The effects of acute tryptophan depletion on reactive aggression in adults with attention-deficit/hyperactivity disorder (ADHD) and healthy controls. *PLoS One*. 2012;7(3):e32023. doi: 10.1371/journal.pone.0032023. PMID: 22431971. *Exclude-Intervention*
2175. Zimovetz EA, Joseph A, Ayyagari R, et al. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. *Eur J Health Econ*. 2018 Jan;19(1):21-35. doi: 10.1007/s10198-016-0864-4. PMID: 28093662. *Exclude-Intervention*
2176. Zinnow T, Banaschewski T, Fallgatter AJ, et al. ESCAlate - Adaptive treatment approach for adolescents and adults with ADHD: study protocol for a randomized controlled trial. *Trials*. 2018 May 18;19(1):280. doi: 10.1186/s13063-018-2665-9. PMID: 29776383. *Exclude-Design*
2177. Ziqiang L, Siyuan H, Qiu hao W. A systematic review and meta-analysis of probiotics in patients with ADHD（attention deficit hyperactivity disorder）. 2021. PMID: CRD42021291534. *Currently being assessed for management*
2178. Zohar AH, Konfortes H. Diagnosing ADHD in Israeli adults: the psychometric properties of the adult ADHD Self Report Scale (ASRS) in Hebrew. *Isr J Psychiatry Relat Sci*. 2010;47(4):308-15. PMID: 21270505. *Exclude-Language*
2179. Zur M, Magnezi R, Portuguese S, et al. The Impact of Adherence to Treatment for ADHD on the Quality of Military Service - The Israeli Military Experience. *Mil Med*. 2018 Sep 1;183(9-10):e518-e24. doi: 10.1093/milmed/usy161. PMID: 30007280. *Exclude-Design*

On Order/Not Retrieved Yet

On Order/Not Retrieved Yet

This list of publications has not been received as full text.

1. Goto T, Kooij S, Conners K, et al. Validity of conners' adult attention-deficit/ hyperactivity disorder rating scale-investigator rated: Screening version in european patients with attention-deficit/hyperactivity disorder. *International Journal of Neuropsychopharmacology*. 2012;15:220-1. doi: 10.1017/S1461145712000508.
2. Silverstein MJ, Faraone SV, Alperin S, et al. Validation of the expanded versions of the adult ADHD self-report scale (ASRS) v1.1 symptom checklist and the adult ADHD investigator symptom rating scale (AISRS). *Journal of the American Academy of Child and Adolescent Psychiatry*. 2017;56(10):S275-S6. doi: 10.1016/j.jaac.2017.09.351.